"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,US,A1,US 2021/0345068 A1,021-201-293-500-001,2021-11-04,2021,US 202117307908 A,2021-05-04,US 202117307908 A;;US 202063019918 P,2020-05-04,WIRELESS CONTACT TRACKING,"A Bluetooth Low Energy (BLE) device may collect one or more resolvable public identifiers from one or more wireless devices, each of the resolvable public identifiers indicating whether a user associated with a respective one of the wireless devices is a possible virus carrier. The BLE device may generate a timestamp for each of the collected resolvable public identifiers, each timestamp indicating a time at which a corresponding resolvable public identifier was received by the BLE device. The BLE device may share the collected resolvable public identifiers and their corresponding timestamps with a paired device. The BLE device may receive, from the paired device, an indication of whether one or more of the collected resolvable public identifiers is associated with a possible virus carrier. The BLE device may be included within or attached to one of a bracelet, neckless, a belt, watch, a smartwatch, or a key fob.",ATMOSIC TECH INC,HUSTED PAUL;;YI SEUNG BAEK;;MEHTA SRENIK,ATMOSIC TECHNOLOGIES INC (2022-07-14),https://lens.org/021-201-293-500-001,Patent Application,yes,0,2,2,2,0,H04B1/385;;H04W4/029;;H04W4/80;;H04W4/029;;H04B1/385;;H04W4/80,H04W4/029;;H04B1/3827;;H04W4/80,,0,0,,,,ACTIVE
2,CN,A,CN 108513059 A,089-792-996-635-775,2018-09-07,2018,CN 201810155270 A,2018-02-23,KR 20170024824 A,2017-02-24,Image processing method and apparatus thereof and automatic drive vehicle,An image processing method and an apparatus thereof and an automatic drive vehicle are provided. The image processing method includes recognizing a target object in a first frame of an input image; adjusting an exposure of a second frame of the input image based on a brightness of the target object; and generating a synthesized image by synthesizing the first frame and the second frame.,SAMSUNG ELECTRONICS CO LTD,SEOYOUNGWAN;;PAUL BAROM JEON;;BAEK HWAN CHO,,https://lens.org/089-792-996-635-775,Patent Application,no,9,13,12,12,0,G05D1/0246;;G05D1/0088;;G01C21/26;;G01C21/34;;G01S19/47;;G06T5/50;;G06T7/74;;G06T2207/10144;;G06T2207/30252;;G06T2207/20221;;G06T2207/10016;;G06V20/56;;G06V20/584;;G06V10/141;;G06V10/25;;G06V2201/07;;H04N23/80;;H04N23/72;;H04N23/743;;H04N23/71;;H04N23/73;;H04N23/70;;H04N23/741;;H04N23/74;;G06T5/92;;G06V20/56;;G06V10/25;;G06V10/141;;G06V10/10;;G06V10/24;;H04N23/72;;H04N23/743;;H04N23/73;;H04N23/70;;H04N23/741;;H04N23/74;;G06T5/92;;G05D1/0246;;G06T7/30;;G06T7/11;;G06T7/80;;G06T7/90;;G06T2207/20221;;G06T2207/30256;;G06V20/56;;H04N23/73;;H04N23/74;;G05D1/0088;;G05D1/0246;;G01S19/47;;G01C21/34;;G01C21/26;;G06V10/25;;G06V10/141;;G06V20/56;;G06V20/584;;G06V2201/07;;H04N23/70;;H04N23/71;;H04N23/72;;H04N23/73;;H04N23/74;;H04N23/80;;H04N23/741;;H04N23/743;;G06V10/10;;G06V10/24;;G06T5/92;;G06T7/74;;G06T5/50;;G06T2207/10016;;G06T2207/10144;;G06T2207/20221;;G06T2207/30252,H04N5/232;;G01C21/16;;G01C21/26;;G01C21/34;;G01S19/47;;G06V10/141;;G06V10/25;;H04N5/235,,0,0,,,,ACTIVE
3,US,B2,US 11425534 B2,199-093-266-960-387,2022-08-23,2022,US 202117307908 A,2021-05-04,US 202117307908 A;;US 202063019918 P,2020-05-04,Wireless contact tracking,"A Bluetooth Low Energy (BLE) device may collect one or more resolvable public identifiers from one or more wireless devices, each of the resolvable public identifiers indicating whether a user associated with a respective one of the wireless devices is a possible virus carrier. The BLE device may generate a timestamp for each of the collected resolvable public identifiers, each timestamp indicating a time at which a corresponding resolvable public identifier was received by the BLE device. The BLE device may share the collected resolvable public identifiers and their corresponding timestamps with a paired device. The BLE device may receive, from the paired device, an indication of whether one or more of the collected resolvable public identifiers is associated with a possible virus carrier. The BLE device may be included within or attached to one of a bracelet, neckless, a belt, watch, a smartwatch, or a key fob.",ATMOSIC TECH INC,HUSTED PAUL;;YI SEUNG BAEK;;MEHTA SRENIK,ATMOSIC TECHNOLOGIES INC (2022-07-14),https://lens.org/199-093-266-960-387,Granted Patent,yes,6,0,2,2,0,H04B1/385;;H04W4/029;;H04W4/80;;H04W4/029;;H04B1/385;;H04W4/80,H04W4/029;;H04B1/3827;;H04W4/80,,0,0,,,,ACTIVE
4,EP,B1,EP 3367303 B1,046-033-521-551-132,2022-09-21,2022,EP 18158136 A,2018-02-22,KR 20170024824 A,2017-02-24,AUTONOMOUS DRIVING IMAGE PROCESSING METHOD AND APPARATUS THEREOF,,SAMSUNG ELECTRONICS CO LTD,SEO YOUNGWAN;;JEON PAUL BAROM;;CHO BAEK HWAN,,https://lens.org/046-033-521-551-132,Granted Patent,yes,1,0,12,12,0,G05D1/0246;;G05D1/0088;;G01C21/26;;G01C21/34;;G01S19/47;;G06T5/50;;G06T7/74;;G06T2207/10144;;G06T2207/30252;;G06T2207/20221;;G06T2207/10016;;G06V20/56;;G06V20/584;;G06V10/141;;G06V10/25;;G06V2201/07;;H04N23/80;;H04N23/72;;H04N23/743;;H04N23/71;;H04N23/73;;H04N23/70;;H04N23/741;;H04N23/74;;G06T5/92;;G06V20/56;;G06V10/25;;G06V10/141;;G06V10/10;;G06V10/24;;H04N23/72;;H04N23/743;;H04N23/73;;H04N23/70;;H04N23/741;;H04N23/74;;G06T5/92;;G05D1/0246;;G06T7/30;;G06T7/11;;G06T7/80;;G06T7/90;;G06T2207/20221;;G06T2207/30256;;G06V20/56;;H04N23/73;;H04N23/74;;G05D1/0088;;G05D1/0246;;G01S19/47;;G01C21/34;;G01C21/26;;G06V10/25;;G06V10/141;;G06V20/56;;G06V20/584;;G06V2201/07;;H04N23/70;;H04N23/71;;H04N23/72;;H04N23/73;;H04N23/74;;H04N23/80;;H04N23/741;;H04N23/743;;G06V10/10;;G06V10/24;;G06T5/92;;G06T7/74;;G06T5/50;;G06T2207/10016;;G06T2207/10144;;G06T2207/20221;;G06T2207/30252,G06T5/00;;G06V10/10;;G06V10/141;;G06V10/24;;G06V10/25;;G06V20/56;;H04N5/235,,0,0,,,,ACTIVE
5,US,B2,US 8638767 B2,143-035-534-478-224,2014-01-28,2014,US 201113026580 A,2011-02-14,US 201113026580 A,2011-02-14,Multi-communication mode packet routing mechanism for wireless communications systems,"The transmission range of a network communication device can be extended by enabling transition between legacy and non-legacy communication protocols. A communication device can receive a packet in a legacy packet format from a host device via a legacy network interface. In response to determining that the packet received via the legacy network interface is to be transmitted using one of a plurality of non-legacy communication protocols, a processing path within the communication device in accordance with which to process the packet for transmission using the non-legacy communication protocol is determined. The packet in the legacy packet format is reformatted to yield a target packet in a non-legacy packet format based, at least in part, on the non-legacy communication protocol. The target packet is provided to the destination network device in accordance with the non-legacy communication protocol.",HUSTED PAUL J;;LUTHRA MANEV;;YI SEUNG BAEK;;QUALCOMM INC,HUSTED PAUL J;;LUTHRA MANEV;;YI SEUNG BAEK,ATHEROS COMMUNICATIONS INC (2011-02-11);;QUALCOMM INCORPORATED (2011-05-24),https://lens.org/143-035-534-478-224,Granted Patent,yes,13,1,10,10,0,H04L69/08;;H04L45/52;;H04L69/08;;H04L69/08;;H04W84/12,H04L45/52;;H04W84/12;;H04W4/00,370/338;;370/328,4,0,,,"IEEE 802.11n Standard. Institute of Electrical and Electronic Engineers. Oct. 2009.;;International Search Report and Written Opinion-PCT/US2012/024928-ISA/EPO-May 16, 2012, 13 pages.;;""PCT Application No. PCT/US2012/024928 Written Opinion of the IPEA"", Mar. 1, 2013 , 7 pages.;;""PCT Application No. PCT/US2012/024928 International Preliminary Report on Patentability"", May 29, 2013 , 8 pages.",INACTIVE
6,CN,A,CN 103370918 A,007-381-642-814-628,2013-10-23,2013,CN 201280008697 A,2012-02-13,US 2012/0024928 W;;US 201113026580 A,2011-02-14,Wireless multi-communication mode packet routing mechanism,"The transmission range of a network communication device can be extended by enabling transition between legacy and non-legacy communication protocols. A communication device can receive a packet in a legacy packet format from a host device via a legacy network interface. In response to determining that the packet received via the legacy network interface is to be transmitted using one of a plurality of non-legacy communication protocols, a processing path within the communication device in accordance with which to process the packet for transmission using the non-legacy communication protocol is determined. The packet in the legacy packet format is reformatted to yield a target packet in a non-legacy packet format based, at least in part, on the non-legacy communication protocol. The target packet is provided to the destination network device in accordance with the non-legacy communication protocol.",QUALCOMM INC,HUSTED PAUL J;;LUTHRA MANEV;;YI SEUNG BAEK,,https://lens.org/007-381-642-814-628,Patent Application,no,3,1,10,10,0,H04L69/08;;H04L45/52;;H04L69/08;;H04L69/08;;H04W84/12,H04L45/52;;H04W4/18,,0,0,,,,INACTIVE
7,EP,A1,EP 3367303 A1,186-539-227-609-537,2018-08-29,2018,EP 18158136 A,2018-02-22,KR 20170024824 A,2017-02-24,AUTONOMOUS DRIVING IMAGE PROCESSING METHOD AND APPARATUS THEREOF,"A processor implemented image processing method includes recognizing a target object in a first frame of an input image; adjusting an exposure of a second frame of the input image based on a brightness of the target object; and generating a synthesized image by synthesizing the first frame and the second frame.
",SAMSUNG ELECTRONICS CO LTD,SEO YOUNGWAN;;JEON PAUL BAROM;;CHO BAEK HWAN,,https://lens.org/186-539-227-609-537,Patent Application,yes,3,0,12,12,0,G05D1/0246;;G05D1/0088;;G01C21/26;;G01C21/34;;G01S19/47;;G06T5/50;;G06T7/74;;G06T2207/10144;;G06T2207/30252;;G06T2207/20221;;G06T2207/10016;;G06V20/56;;G06V20/584;;G06V10/141;;G06V10/25;;G06V2201/07;;H04N23/80;;H04N23/72;;H04N23/743;;H04N23/71;;H04N23/73;;H04N23/70;;H04N23/741;;H04N23/74;;G06T5/92;;G06V20/56;;G06V10/25;;G06V10/141;;G06V10/10;;G06V10/24;;H04N23/72;;H04N23/743;;H04N23/73;;H04N23/70;;H04N23/741;;H04N23/74;;G06T5/92;;G05D1/0246;;G06T7/30;;G06T7/11;;G06T7/80;;G06T7/90;;G06T2207/20221;;G06T2207/30256;;G06V20/56;;H04N23/73;;H04N23/74;;G05D1/0088;;G05D1/0246;;G01S19/47;;G01C21/34;;G01C21/26;;G06V10/25;;G06V10/141;;G06V20/56;;G06V20/584;;G06V2201/07;;H04N23/70;;H04N23/71;;H04N23/72;;H04N23/73;;H04N23/74;;H04N23/80;;H04N23/741;;H04N23/743;;G06V10/10;;G06V10/24;;G06T5/92;;G06T7/74;;G06T5/50;;G06T2207/10016;;G06T2207/10144;;G06T2207/20221;;G06T2207/30252,G06T5/00;;G06V10/141;;G06V10/25;;H04N5/235,,3,3,061-048-595-006-271;;051-626-542-773-142;;015-156-610-229-239,10.1155/2007/80971;;10.1109/tip.2006.877312;;16948325;;10.1145/882262.882270,"STEFANO MARSI ET AL: ""Video Enhancement and Dynamic Range Control of HDR Sequences for Automotive Applications"", EURASIP JOURNAL ON ADVANCES IN SIGNAL PROCESSING, vol. 2007, no. 1, 27 June 2007 (2007-06-27), XP055493207, DOI: 10.1155/2007/80971;;MEYLAN L ET AL: ""High dynamic range image rendering with a retinex-based adaptive filter"", IEEE TRANSACTIONS ON IMAGE PROCESS, IEEE SERVICE CENTER, PISCATAWAY, NJ, US, vol. 15, no. 9, 1 September 2006 (2006-09-01), pages 2820 - 2830, XP009108457, ISSN: 1057-7149, DOI: 10.1109/TIP.2006.877312;;SING BING KANG ET AL: ""High dynamic range video"", ACM TRANSACTIONS ON GRAPHICS (TOG), ACM, US, vol. 22, no. 3, 1 July 2003 (2003-07-01), pages 319 - 325, XP058249526, ISSN: 0730-0301, DOI: 10.1145/882262.882270",ACTIVE
8,KR,A,KR 20130125817 A,112-916-141-220-631,2013-11-19,2013,KR 20137024422 A,2012-02-13,US 201113026580 A;;US 2012/0024928 W,2011-02-14,WIRELESS MULTI-COMMUNICATION MODE PACKET ROUTING MECHANISM,,QUALCOMM INC,HUSTED PAUL J;;LUTHRA MANEV;;YI SEUNG BAEK,,https://lens.org/112-916-141-220-631,Patent Application,no,0,0,10,10,0,H04L69/08;;H04L45/52;;H04L69/08;;H04L69/08;;H04W84/12,H04L45/52,,0,0,,,,INACTIVE
9,EP,A1,EP 2676418 A1,120-571-324-750-810,2013-12-25,2013,EP 12705753 A,2012-02-13,US 201113026580 A;;US 2012/0024928 W,2011-02-14,MULTI-COMMUNICATION MODE PACKET ROUTING MECHANISM,,QUALCOMM INC,HUSTED PAUL J;;LUTHRA MANEV;;YI SEUNG BAEK,,https://lens.org/120-571-324-750-810,Patent Application,yes,0,0,10,10,0,H04L69/08;;H04L45/52;;H04L69/08;;H04L69/08;;H04W84/12,H04L45/52;;H04W4/18,,0,0,,,,DISCONTINUED
10,WO,A1,WO 2020/142481 A1,184-980-180-448-856,2020-07-09,2020,US 2019/0069050 W,2019-12-31,US 201862786989 P,2018-12-31,QUANTUM DOT LIGHT-EMITTING DIODES COMPRISING ELECTRON SPREADING LAYER AND FABRICATION METHOD THEREOF,"Articles and methods related to quantum dot light-emitting diodes are generally provided. A quantum dot light-emitting diode may comprise a first electrode, a quantum dot light-emitting layer disposed on the first electrode, an electron transport layer disposed on the quantum dot light-emitting layer, an electron spreading layer disposed on the electron transport layer, and second electrode disposed on the electron spreading layer.",NANOPHOTONICA INC,HOLLOWAY PAUL;;KIM BAEK;;TITOV ALEXANDRE;;ACHARYA KRISHNA,,https://lens.org/184-980-180-448-856,Patent Application,yes,3,2,2,2,0,H10K50/115;;H10K50/171,H01L33/00;;H01L33/06;;H01L51/50,,0,0,,,,PENDING
11,WO,A1,WO 2020/142482 A1,041-667-490-221-01X,2020-07-09,2020,US 2019/0069051 W,2019-12-31,US 201862786972 P,2018-12-31,QUANTUM DOT LIGHT-EMITTING DIODES COMPRISING HOLE TRANSPORT LAYERS,"Articles and methods related to quantum dot light-emitting diodes are generally provided. A quantum dot light-emitting diode may comprise a first electrode, a hole injection layer disposed on the first electrode, a hole transport layer comprising ZnS disposed on the hole injection layer, a quantum dot light-emitting layer disposed on the hole transport layer, and a second electrode disposed on the quantum dot light-emitting layer. A method may comprise assembling a hole transport layer comprising ZnS with a hole injection layer, a quantum dot light-emitting layer, a first electrode, and a second electrode.",NANOPHOTONICA INC,HOLLOWAY PAUL;;KIM BAEK;;TITOV ALEXANDRE;;ACHARYA KRISHNA,,https://lens.org/041-667-490-221-01X,Patent Application,yes,3,2,2,2,0,H01L33/0083;;H01L33/343;;H10K85/1135;;H10K50/115;;H10K50/155;;H10K2102/00,H01L33/00;;H01L33/06;;H01L51/50,,1,0,,,"KATHERINE S DUNCAN; JOSEPH D TAYLOR; MARTIN JONAK; KAYLEIGH O E DERRICUTT; ALEXANDER G J TALLON; CHRISTOPHER E WILSHAW; JAMES A SM: ""Characterisation of p-type ZnS:Cu transparent conducting films fabricated by high-temperature pulsed laser deposition"", ARXIV, 20 November 2017 (2017-11-20), XP081300778, Retrieved from the Internet <URL:https://arxiv.org/pdf/1711.07579.pdf> [retrieved on 20200224]",PENDING
12,WO,A1,WO 2020/142480 A1,042-238-739-087-09X,2020-07-09,2020,US 2019/0069049 W,2019-12-31,US 201862787001 P,2018-12-31,QUANTUM DOT LIGHT-EMITTING DIODES COMPRISING DOPED ZNO ELECTRON TRANSPORT LAYER,"Articles and methods related to quantum dot light-emitting diodes are generally provided. A quantum dot light-emitting diode may comprise a first electrode, a quantum dot light-emitting layer disposed on the first electrode, an electron transport layer disposed on the quantum dot light-emitting layer, and second electrode disposed on the electron transport layer. The electron transport layer may comprise nanoparticles comprising ZnO doped with one or more dopants and/or capped with one or more ligands. The quantum dot light-emitting layer may comprise two or more electron transport layers, each of which may independently comprise ZnO doped with one or more dopants and/or capped with one or more ligands. The nanoparticles may have a number average diameter of less than or equal to 5 nm.",NANOPHOTONICA INC,HOLLOWAY PAUL;;KIM BAEK;;TITOV ALEXANDRE;;ACHARYA KRISHNA,,https://lens.org/042-238-739-087-09X,Patent Application,yes,3,3,2,2,0,H01L33/06;;H10K50/115;;H10K50/165;;H10K50/166,H01L33/00;;H01L33/06;;H01L51/50,,0,0,,,,PENDING
13,US,A1,US 2012/0207139 A1,193-071-864-457-911,2012-08-16,2012,US 201113026580 A,2011-02-14,US 201113026580 A,2011-02-14,MULTI-COMMUNICATION MODE PACKET ROUTING MECHANISM FOR WIRELESS COMMUNICATION SYSTEMS,"The transmission range of a network communication device can be extended by enabling transition between legacy and non-legacy communication protocols. A communication device can receive a packet in a legacy packet format from a host device via a legacy network interface. In response to determining that the packet received via the legacy network interface is to be transmitted using one of a plurality of non-legacy communication protocols, a processing path within the communication device in accordance with which to process the packet for transmission using the non-legacy communication protocol is determined. The packet in the legacy packet format is reformatted to yield a target packet in a non-legacy packet format based, at least in part, on the non-legacy communication protocol. The target packet is provided to the destination network device in accordance with the non-legacy communication protocol.",HUSTED PAUL J;;LUTHRA MANEV;;YI SEUNG BAEK;;ATHEROS COMM INC,HUSTED PAUL J;;LUTHRA MANEV;;YI SEUNG BAEK,ATHEROS COMMUNICATIONS INC (2011-02-11);;QUALCOMM INCORPORATED (2011-05-24),https://lens.org/193-071-864-457-911,Patent Application,yes,5,16,10,10,0,H04L69/08;;H04L45/52;;H04L69/08;;H04L69/08;;H04W84/12,H04L45/52;;H04W40/00,370/338;;370/328,1,0,,,IEEE 802.11n Standard. Institute of Electrical and Electronic Engineers. Oct 2009.,INACTIVE
14,US,B2,US 10604070 B2,092-163-763-137-78X,2020-03-31,2020,US 201715646862 A,2017-07-11,KR 20160148670 A,2016-11-09,Method and apparatus for informing pedestrian and occupant of vehicle of each other's approach,"Disclosed is a method and apparatus of detecting an object approaching a vehicle, the method includes a user from the image, extracting feature points associated with the device or a portion of the user's body from the image of the user, detecting the object using a device based on the feature point, and issuing an alert of the approaching object.",SAMSUNG ELECTRONICS CO LTD,SEO YOUNGWAN;;CHO BAEK HWAN;;JEON PAUL BAROM,SAMSUNG ELECTRONICS CO. LTD (2017-02-23),https://lens.org/092-163-763-137-78X,Granted Patent,yes,23,0,3,3,0,B60Q1/525;;B60Q5/006;;B60Q9/008;;B60R1/00;;B60R2300/307;;B60W50/14;;B60W40/02;;B60W50/16;;B60R21/34;;B60Y2400/90;;B60Y2400/902;;B60Q1/525;;B60Q5/006;;B60Q9/008;;B60R2300/307,B60Q1/00;;B60Q1/52;;B60Q5/00;;B60Q9/00;;B60R1/00,,0,0,,,,ACTIVE
15,US,A1,US 2018/0126902 A1,175-147-747-166-694,2018-05-10,2018,US 201715646862 A,2017-07-11,KR 20160148670 A,2016-11-09,METHOD AND APPARTUS FOR INFORMING PEDETRIAN AND OCCUPANT OF VEHICLE OF EACH OTHER'S APPROACH,"Disclosed is a method and apparatus of detecting an object approaching a vehicle, the method includes a user from the image, extracting feature points associated with the device or a portion of the user's body from the image of the user, detecting the object using a device based on the feature point, and issuing an alert of the approaching object.",SAMSUNG ELECTRONICS CO LTD,SEO YOUNGWAN;;CHO BAEK HWAN;;JEON PAUL BAROM,SAMSUNG ELECTRONICS CO. LTD (2017-02-23),https://lens.org/175-147-747-166-694,Patent Application,yes,12,8,3,3,0,B60Q1/525;;B60Q5/006;;B60Q9/008;;B60R1/00;;B60R2300/307;;B60W50/14;;B60W40/02;;B60W50/16;;B60R21/34;;B60Y2400/90;;B60Y2400/902;;B60Q1/525;;B60Q5/006;;B60Q9/008;;B60R2300/307,B60Q9/00;;B60Q5/00;;B60R1/00,,0,0,,,,ACTIVE
16,US,S,US D0611355 S,038-239-255-238-744,2010-03-09,2010,US 35116509 F,2009-12-01,US 35116509 F;;US 32048708 F,2008-06-27,Portable container,,PUR WATER PURIFICATION PROD,KIM CHUNSHIK;;BAEK IN HEE;;O'CONNOR PAUL FRANCIS,,https://lens.org/038-239-255-238-744,Design Right,no,0,8,5,5,0,,,0901;;D 9540;;D9/552;;D9/575;;D9/537;;D9/435,0,0,,,,ACTIVE
17,US,S,US D0610911 S,105-051-957-883-645,2010-03-02,2010,US 32048708 F,2008-06-27,US 32048708 F,2008-06-27,Portable container,,PUR WATER PURIFICATION PROD,KIM CHUNSHIK;;BAEK IN HEE;;O'CONNOR PAUL FRANCIS,THE PROCTER & GAMBLE COMPANY (2008-10-21);;PUR WATER PURIFICATION PRODUCTS INC (2008-10-21),https://lens.org/105-051-957-883-645,Design Right,no,0,2,5,5,0,,,0901;;D 9540;;D9/552;;D9/575;;D9/537,0,0,,,,EXPIRED
18,WO,A1,WO 2012/112466 A1,182-377-635-035-865,2012-08-23,2012,US 2012/0024928 W,2012-02-13,US 201113026580 A,2011-02-14,WIRELESS MULTI-COMMUNICATION MODE PACKET ROUTING MECHANISM,"The transmission range of a network communication device can be extended by enabling transition between legacy and non-legacy communication protocols. A communication device can receive a packet in a legacy packet format from a host device via a legacy network interface. In response to determining that the packet received via the legacy network interface is to be transmitted using one of a plurality of non-legacy communication protocols, a processing path within the communication device in accordance with which to process the packet for transmission using the non-legacy communication protocol is determined. The packet in the legacy packet format is reformatted to yield a target packet in a non-legacy packet format based, at least in part, on the non-legacy communication protocol. The target packet is provided to the destination network device in accordance with the non-legacy communication protocol.",QUALCOMM ATHEROS INC;;HUSTED PAUL J;;LUTHRA MANEV;;YI SEUNG BAEK,HUSTED PAUL J;;LUTHRA MANEV;;YI SEUNG BAEK,,https://lens.org/182-377-635-035-865,Patent Application,yes,7,1,10,10,0,H04L69/08;;H04L45/52;;H04L69/08;;H04L69/08;;H04W84/12,H04L45/52;;H04W4/18,,0,0,,,,PENDING
19,US,B2,US 11831109 B2,016-090-960-146-764,2023-11-28,2023,US 202017122165 A,2020-12-15,US 202017122165 A,2020-12-15,Electrical connector with integrated electronic controlled power switch or circuit breaker safety device,"In one embodiment, and apparatus includes an electrical socket for connection with an electrical plug, a sensor for identifying a secure connection between the electrical socket and the electrical plug, and an electronic controller electrically coupled to the electrical socket and comprising a power input for receiving power. The electronic controller is operable to transmit power to the electrical socket upon receiving a signal from the sensor identifying the secure connection between the electrical socket and the electrical plug and shut off or turn on power to the electrical socket upon receiving an external input to the electronic controller. A method is also disclosed herein. The apparatus and method provide an electronic controlled power switch or circuit breaker safety device.",CISCO TECH INC,ARDUINI DOUGLAS PAUL;;BAEK SUNG KEE;;GOERGEN JOEL RICHARD,CISCO TECHNOLOGY INC (2020-12-14),https://lens.org/016-090-960-146-764,Granted Patent,yes,42,0,3,3,0,H01R13/6683;;H01R13/7038;;H01R24/76;;H01R13/6666;;H01R13/6683;;H01R13/713,H02H1/00;;H01R13/66;;H01R13/713;;H02H1/04;;H02H3/22;;H02H9/06,,59,1,015-355-071-547-263,10.1109/intlec.2012.6374488,"Sager Electronics, Anderson Power Products' SAF-D-GRID® 400, Aug. 28, 2020.;;Communication Relating to the Results of the Partial International Search in counterpart International Application No. PCT/US2021/062544, dated Mar. 29, 2022, 11 pages.;;International Search Report and Written Opinion in counterpart International Application No. PCT/US2021/062544, dated May 30, 2022, 23 pages.;;Kiedaish, Jill, Popular Mechanics, https://www.popularmechanics.com/technology/infrastructure/a27557804/digital-circuit-breaker/, May 22, 2019.;;Astronics.com, CorePower Power Solutions, Astronics Advanced Electronic Systems, Product Specification 180116, 2020.;;https://new.abb.com/new/detail/18499/abb-reinvents-the-circuit-breaker-breakthrough-digital-technology-for-renewables-and-next-gen-power-grids, Hannover, Germany, Apr. 1, 2019.;;Doughty, Rani et al., Lenovo Flex Systems Higher Voltage DC Solutions, Apr. 2015.;;Anderson Power Products, Power Connector Solutions, Amperes, Safely Connect Power with Simplicity and Intelligence, LIT-PCS Rev 9, 2020-0096, 2020.;;“Product Selection Guide,” Starline Track Busway, 2017, 218 pages.;;David E. Geary, “The Transition Path to dc,” dc Fusion, LLC, 2015, 101 pages.;;“IEC 60320,” Wayback Machine, Wikipedia, https://web.archive.org/web/20201124225116/https://en.wikipedia.org/wiki/IEC_60320, Sep. 29, 2020, 12 pages.;;“IEC 62368—1:2018,” IECSTD, Version 3.4 2018, 380 pages.;;“UL 60950—Safety of Information Technology Equipment,” Underwriters Laboratories Inc. (UL), Third Edition, ISBN 0-7629-0470-4, Dec. 1, 2000, 436 pages.;;Voltserver Inc., v. Cisco Technology, Inc., “Decision Denying Institution of Post-Grant Review,” United States Patent and Trademark Office, PGR2021-00055, U.S. Pat. No. 10,735,105 B2, Aug. 19, 2021, 25 pages.;;Voltserver Inc., v. Cisco Systems, Inc., “Patent Owner's Preliminary Response to Post Grant Review Under 35 U.S.C. § 312 and 37 C.F.R. § 42.107,” United States Patent and Trademark Office, PGR2021-00055, U.S. Pat. No. 10,735,105, 2021, Jun. 2, 2021, 51 pages.;;“Effects of current on human beings and livestok—Part 1: General aspects,” Technical Specification, Basic Safety Publication, IEC/TS 60479-1, Edition 4.0, Jul. 2005, 122 pages.;;“Information technology equipment—Safety—Part 1: General requirements,” International Standard, IEC 60950-1, Edition 2.2, May 2013, pp. 1-61, 63 pages.;;“Information technology equipment—Safety—Part 1: General requirements,” International Standard, IEC 60950-1, Edition 2.2, May 2013, pp. 62-122, 61 pages.;;“Information technology equipment—Safety—Part 1: General requirements,” International Standard, IEC 60950-1, Edition 2.2, May 2013, pp. 123-181, 59 pages.;;“Information technology equipment—Safety—Part 1: General requirements,” International Standard, IEC 60950-1, Edition 2.2, May 2013, pp. 182-253, 72 pages.;;“Information technology equipment—Safety—Part 1: General requirements,” International Standard, IEC 60950-1, Edition 2.2, May 2013, pp. 254-319, 66 pages.;;“Information technology equipment—Safety—Part 1: General requirements,” International Standard, IEC 60950-1, Edition 2.2, May 2013, pp. 320-377, 58 pages.;;“Information technology equipment—Safety—Part 1: General requirements,” International Standard, IEC 60950-1, Edition 2.2, May 2013, pp. 378-433, 56 pages.;;“Information technology equipment—Safety—Part 1: General requirements,” International Standard, IEC 60950-1, Edition 2.2, May 2013, pp. 434-490, 57 pages.;;“Information technology equipment—Safety—Part 1: General requirements,” International Standard, IEC 60950-1, Edition 2.2, May 2013, pp. 491-551, 61 pages.;;“Information technology equipment—Safety—Part 1: General requirements,” International Standard, IEC 60950-1, Edition 2.2, May 2013, pp. 552-622, 71 pages.;;“Information technology equipment—Safety—Part 1: General requirements,” International Standard, IEC 60950-1, Edition 2.2, May 2013, pp. 623-644, 24 pages.;;“Low-voltage switchgear and controlgear—Part 1: General rules,” International Standard, Amendment 2, IEC 60947-1, Edition 5.0, Sep. 2014, pp. 1-63, 65 pages.;;“Low-voltage switchgear and controlgear—Part 1: General rules,” International Standard, Amendment 2, IEC 60947-1, Edition 5.0, Sep. 2014, pp. 64-102, 41 pages.;;Stephen Edelstein, “Updated 2016 Tesla Model S also gets new 75-kWhbattery option,” Internet Archive WayBack Machine, Green Car Reports, May 5, 2016, 3 pages.;;Stephen S. Eaves, “Network Remote Powering using Packet Energy Transfer,” IEEE Xplore, Proceedings of IEEE International Conference on Telecommunications Energy (INTELEC) 2012, 978-1-4673-1000, Sep. 30-Oct. 4, 2012, 4 pages.;;“Audio/video, information and communication technology equipment—Part 1: Safety requirements,” International Standard, IEC 62368-1, Edition 2.0, Feb. 2014, pp. 1-132, 134 pages.;;“Audio/video, information and communication technology equipment—Part 1: Safety requirements,” International Standard, IEC 62368-1, Edition 2.0, Feb. 2014, pp. 133-263, 131 pages.;;“Audio/video, information and communication technology equipment—Part 1: Safety requirements,” International Standard, IEC 62368-1, Edition 2.0, Feb. 2014, pp. 264-387, 124 pages.;;“Audio/video, information and communication technology equipment—Part 1: Safety requirements,” International Standard, IEC 62368-1, Edition 2.0, Feb. 2014, pp. 388-508, 121 pages.;;“Audio/video, information and communication technology equipment—Part 1: Safety requirements,” International Standard, IEC 62368-1, Edition 2.0, Feb. 2014, pp. 509-593, 85 pages.;;“Audio/video, information and communication technology equipment—Part 1: Safety requirements,” International Standard, IEC 62368-1, Edition 2.0, Feb. 2014, pp. 594-676, 85 pages.;;“National Electrical Code,” National Fire Protection Association (NFPA) 70, 2017, 881 pages.;;Voltserver Inc., v. Cisco Technology, Inc., “Declaration of David A. Durfee, Ph.D.,” United States Patent and Trademark Office, PGR2021-00055, U.S. Pat. No. 10,735,105, Feb. 16, 2021, 340 pages.;;David A. Durfee Ph.D., “Curriculum Vitae,” 4 pages.;;Adel S. Sedra, “Microelectronic Circuits,” Sedra/Smith, Oxford University Press, Seventh Edition, 2015, 38 pages.;;Charles k. Alexander, et al., “Fundamentals of Electric Circuits,” McGraw Hill Education, Indian Edition 5e, 2013, 37 pages.;;Andrew S. Tanenbaum, “Computer Networks,” Prentice Hall PTR, Third Edition, 1996, 12 pages.;;William Stallings, “Data and Computer Communications,” Macmillan Publishing Company, Fourth Edition, 1994, 14 pages.;;B.P. Lathi, et al., “Modern Digital and Analog Communication Systems,” Oxford University Press, Fourth Edition, 2009, 15 pages.;;Voltserver Inc., v. Cisco Technology, Inc., “Petition for Post Grant Review of U.S. Pat. No. 10,735,105,” United States Patent and Trademark Office, PGR2021-00055, U.S. Pat. No. 10,735,105, Feb. 16, 2021, 132 pages.;;Stephen H. Hall, et al., “High-Speed Digital System Design: A handbook of Interconnect Theory and Design Practices,”, John Wiley & Sons, Inc., 2000, 55 pages.;;“Understanding 802.3at, PoE Plus Standard Increases Available Power,” Microsemi, Jun. 2011, 7 pages.;;“Digital Electricity Gen2 Detailed Installation Manual,” Voltserver Digital Electricity, Rev B.1, Nov. 29, 2017, 68 pages.;;Berkeley Lab ETA, “Touch-Safe, High Voltage Digital Electricity Transmission using Packet Energy Transfer,” Vimeo, https://vimeo.com/172469008, Mar. 8, 2016, 8 pages.;;Voltserver Inc., v. Cisco Technology, Inc., “Decision Denying Institution of Post-Grant Review,” United States Patent and Trademark Office, PGR2021-00056, U.S. Pat. No. 10,735,105 B2, Aug. 23, 2021, 18 pages.;;Voltserver Inc., v. Cisco Systems, Inc., “Patent Owner's Preliminary Response to Post Grant Review Under 35 U.S.C. § 312 and 37 C.F.R. § 42.107,” United States Patent and Trademark Office, PGR2021-00056, U.S. Pat. No. 10,735,105, 2021, Jun. 2, 2021, 46 pages.;;Voltserver Inc., v. Cisco Technology, Inc., “Declaration of Stephens S. Eaves,” United States Patent and Trademark Office, PGR2021-00056, U.S. Pat. No. 10,735,105, Feb. 16, 2021, 7 pages.;;“Electrical—Computer Conference Proceedings,” Internet Archive WayBack Machine Search for Intelec 2012, Curran Associates, Inc., http://www.proceedings.com/electrical-computer-proceedings.html, 2012, 125 pages.;;“Part VII: A Summary of Commonly Used MARC 21 Fields,” Marc, Understanding MARC, https://www.loc.gov/marc//umb/um07to10.html, retrieved from Internet Feb. 13, 2021, 17 pages.;;LC Catalog-Browse, https://catalog.loc.gov/vwebv/searchBrowse, retrieved from the Internet Feb. 12, 2021, 1 page.;;“International Telecommunications Energy Conference: [proceedings] (Marc Tags),” Library Catalog, https://catalog.loc.gov/vwebv/staffView?searchId=3877&recPointer=0&recCount=25&searchType=1&bibId=11348322, retrieved from the Internet Feb. 12, 2021, 3 pages.;;Voltserver Inc., v. Cisco Technology, Inc., “Petition for Post Grant Review of U.S. Pat. No. 10,735,105,” United States Patent and Trademark Office, PGR2021-00056, U.S. Pat. No. 10,735,105, Feb. 16, 2021, 116 pages.;;“International Telecommunications Energy Conference: [proceedings] (Full Record),” Library Catalog, https://catalog.loc.gov/vwebv/holdingsInfo?searchId=3810&recPointer=0&recCount=25&searchType=1&bibId=11348322, retrieved from the Internet Feb. 12, 2021, 4 pages.",ACTIVE
20,US,A1,US 2020/0333796 A1,157-137-998-337-628,2020-10-22,2020,US 202016917118 A,2020-06-30,US 202016917118 A;;KR 20170024824 A;;US 201715818347 A,2017-02-24,IMAGE PROCESSING METHOD FOR AUTONOMOUS DRIVING AND APPARATUS THEREOF,A processor implemented image processing method includes recognizing a target object in a first frame of an input image; adjusting an exposure of a second frame of the input image based on a brightness of the target object; and generating a synthesized image by synthesizing the first frame and the second frame.,SAMSUNG ELECTRONICS CO LTD,SEO YOUNG WAN;;JEON PAUL BAROM;;CHO BAEK HWAN,,https://lens.org/157-137-998-337-628,Patent Application,yes,0,1,12,12,0,G05D1/0246;;G05D1/0088;;G01C21/26;;G01C21/34;;G01S19/47;;G06T5/50;;G06T7/74;;G06T2207/10144;;G06T2207/30252;;G06T2207/20221;;G06T2207/10016;;G06V20/56;;G06V20/584;;G06V10/141;;G06V10/25;;G06V2201/07;;H04N23/80;;H04N23/72;;H04N23/743;;H04N23/71;;H04N23/73;;H04N23/70;;H04N23/741;;H04N23/74;;G06T5/92;;G06V20/56;;G06V10/25;;G06V10/141;;G06V10/10;;G06V10/24;;H04N23/72;;H04N23/743;;H04N23/73;;H04N23/70;;H04N23/741;;H04N23/74;;G06T5/92;;G05D1/0246;;G06T7/30;;G06T7/11;;G06T7/80;;G06T7/90;;G06T2207/20221;;G06T2207/30256;;G06V20/56;;H04N23/73;;H04N23/74;;G05D1/0088;;G05D1/0246;;G01S19/47;;G01C21/34;;G01C21/26;;G06V10/25;;G06V10/141;;G06V20/56;;G06V20/584;;G06V2201/07;;H04N23/70;;H04N23/71;;H04N23/72;;H04N23/73;;H04N23/74;;H04N23/80;;H04N23/741;;H04N23/743;;G06V10/10;;G06V10/24;;G06T5/92;;G06T7/74;;G06T5/50;;G06T2207/10016;;G06T2207/10144;;G06T2207/20221;;G06T2207/30252,G05D1/02;;G01C21/16;;G01C21/26;;G01C21/34;;G01S19/47;;G05D1/00;;G06T5/00;;G06T5/50;;G06T7/73;;G06V10/141;;G06V10/25;;H04N5/232;;H04N5/235,,0,0,,,,ACTIVE
21,CN,A,CN 111741229 A,011-833-702-186-301,2020-10-02,2020,CN 202010776945 A,2018-02-23,KR 20170024824 A;;CN 201810155270 A,2017-02-24,Image processing method and apparatus,The invention provides an image processing method and apparatus. The image processing method comprises the following steps: identifying a road in a first frame of an input image; setting the area on the road as an identification area; scanning the identification area without scanning the entire area of the input image; identifying at least one target object in the identification area in the inputimage; and adjusting the exposure of a second frame of the input image.,SAMSUNG ELECTRONICS CO LTD,SEO YOUNG-WAN;;JEON PAUL-BAROM;;CHO BAEK-HWAN,,https://lens.org/011-833-702-186-301,Patent Application,no,9,2,12,12,0,G05D1/0246;;G05D1/0088;;G01C21/26;;G01C21/34;;G01S19/47;;G06T5/50;;G06T7/74;;G06T2207/10144;;G06T2207/30252;;G06T2207/20221;;G06T2207/10016;;G06V20/56;;G06V20/584;;G06V10/141;;G06V10/25;;G06V2201/07;;H04N23/80;;H04N23/72;;H04N23/743;;H04N23/71;;H04N23/73;;H04N23/70;;H04N23/741;;H04N23/74;;G06T5/92;;G06V20/56;;G06V10/25;;G06V10/141;;G06V10/10;;G06V10/24;;H04N23/72;;H04N23/743;;H04N23/73;;H04N23/70;;H04N23/741;;H04N23/74;;G06T5/92;;G05D1/0246;;G06T7/30;;G06T7/11;;G06T7/80;;G06T7/90;;G06T2207/20221;;G06T2207/30256;;G06V20/56;;H04N23/73;;H04N23/74;;G05D1/0088;;G05D1/0246;;G01S19/47;;G01C21/34;;G01C21/26;;G06V10/25;;G06V10/141;;G06V20/56;;G06V20/584;;G06V2201/07;;H04N23/70;;H04N23/71;;H04N23/72;;H04N23/73;;H04N23/74;;H04N23/80;;H04N23/741;;H04N23/743;;G06V10/10;;G06V10/24;;G06T5/92;;G06T7/74;;G06T5/50;;G06T2207/10016;;G06T2207/10144;;G06T2207/20221;;G06T2207/30252,H04N5/235;;G01C21/16;;G01C21/26;;G01C21/34;;G01S19/47;;G05D1/00;;G05D1/02;;G06T5/00;;G06T5/50;;G06T7/73;;G06V10/141;;G06V10/25;;H04N5/232,,0,0,,,,ACTIVE
22,US,A1,US 2022/0190528 A1,053-338-029-473-129,2022-06-16,2022,US 202017122165 A,2020-12-15,US 202017122165 A,2020-12-15,ELECTRICAL CONNECTOR WITH INTEGRATED ELECTRONIC CONTROLLED POWER SWITCH OR CIRCUIT BREAKER SAFETY DEVICE,"In one embodiment, and apparatus includes an electrical socket for connection with an electrical plug, a sensor for identifying a secure connection between the electrical socket and the electrical plug, and an electronic controller electrically coupled to the electrical socket and comprising a power input for receiving power. The electronic controller is operable to transmit power to the electrical socket upon receiving a signal from the sensor identifying the secure connection between the electrical socket and the electrical plug and shut off or turn on power to the electrical socket upon receiving an external input to the electronic controller. A method is also disclosed herein. The apparatus and method provide an electronic controlled power switch or circuit breaker safety device.",CISCO TECH INC,ARDUINI DOUGLAS PAUL;;BAEK SUNG KEE;;GOERGEN JOEL RICHARD,CISCO TECHNOLOGY INC (2020-12-14),https://lens.org/053-338-029-473-129,Patent Application,yes,6,0,3,3,0,H01R13/6683;;H01R13/7038;;H01R24/76;;H01R13/6666;;H01R13/6683;;H01R13/713,H01R13/66;;H01R13/713,,0,0,,,,ACTIVE
23,US,B2,US 10739783 B2,042-779-193-192-171,2020-08-11,2020,US 201715818347 A,2017-11-20,KR 20170024824 A,2017-02-24,Image processing method for autonomous driving and apparatus thereof,A processor implemented image processing method includes recognizing a target object in a first frame of an input image; adjusting an exposure of a second frame of the input image based on a brightness of the target object; and generating a synthesized image by synthesizing the first frame and the second frame.,SAMSUNG ELECTRONICS CO LTD,SEO YOUNG WAN;;JEON PAUL BAROM;;CHO BAEK HWAN,SAMSUNG ELECTRONICS CO. LTD (2017-11-08),https://lens.org/042-779-193-192-171,Granted Patent,yes,13,1,12,12,0,G05D1/0246;;G05D1/0088;;G01C21/26;;G01C21/34;;G01S19/47;;G06T5/50;;G06T7/74;;G06T2207/10144;;G06T2207/30252;;G06T2207/20221;;G06T2207/10016;;G06V20/56;;G06V20/584;;G06V10/141;;G06V10/25;;G06V2201/07;;H04N23/80;;H04N23/72;;H04N23/743;;H04N23/71;;H04N23/73;;H04N23/70;;H04N23/741;;H04N23/74;;G06T5/92;;G06V20/56;;G06V10/25;;G06V10/141;;G06V10/10;;G06V10/24;;H04N23/72;;H04N23/743;;H04N23/73;;H04N23/70;;H04N23/741;;H04N23/74;;G06T5/92;;G05D1/0246;;G06T7/30;;G06T7/11;;G06T7/80;;G06T7/90;;G06T2207/20221;;G06T2207/30256;;G06V20/56;;H04N23/73;;H04N23/74;;G05D1/0088;;G05D1/0246;;G01S19/47;;G01C21/34;;G01C21/26;;G06V10/25;;G06V10/141;;G06V20/56;;G06V20/584;;G06V2201/07;;H04N23/70;;H04N23/71;;H04N23/72;;H04N23/73;;H04N23/74;;H04N23/80;;H04N23/741;;H04N23/743;;G06V10/10;;G06V10/24;;G06T5/92;;G06T7/74;;G06T5/50;;G06T2207/10016;;G06T2207/10144;;G06T2207/20221;;G06T2207/30252,G05D1/02;;G01C21/16;;G01C21/26;;G01C21/34;;G01S19/47;;G05D1/00;;G06T5/00;;G06T5/50;;G06T7/73;;G06V10/141;;G06V10/25;;H04N5/232;;H04N5/235,,4,3,015-156-610-229-239;;051-626-542-773-142;;061-048-595-006-271,10.1145/882262.882270;;10.1109/tip.2006.877312;;16948325;;10.1155/2007/80971,"Kang, Sing Bing, et al. “High Dynamic Range Video.” ACM Transactions on Graphics (TOG), vol. 22,. No. 3., 2003 (pp. 319-325).;;Meylan, Laurence, et al., “High Dynamic Range Image Rendering With a Retinex-Based Adaptive Filter”, IEEE Transactions on Image Processing, vol. 15, No. 9, Sep. 2006 (pp. 2820-2830).;;Marsi, Stefano, et al. “Video Enhancement and Dynamic Range Control of HDR Sequences for Automotive Applications”, EURASIP Journal on Advances in Signal Processing, May 13, 2007 (9 pages in English).;;Extended European Search Report dated Jul. 30, 2018, in corresponding European Application No. 18158136.4 (11 pages in English).",ACTIVE
24,US,A1,US 2020/0153337 A1,102-669-987-422-466,2020-05-14,2020,US 201816191308 A,2018-11-14,US 201816191308 A,2018-11-14,MULTI-RESONANT CONVERTER POWER SUPPLY,"In one embodiment, an apparatus includes a first stage comprising a first active switch, a first resonant inductor, and a resonant capacitor and a second stage comprising a second active switch, a second resonant inductor, and a filter capacitor. The first and second stages form a non-isolated multi-resonant converter for converting a DC input voltage to a DC output voltage.",CISCO TECH INC,ARDUINI DOUGLAS PAUL;;GOERGEN JOEL RICHARD;;BAEK SUNG KEE,,https://lens.org/102-669-987-422-466,Patent Application,yes,5,1,5,5,0,H02M3/158;;Y02B70/10;;H02M1/0058;;H02M1/4241;;H02M3/1582;;H02M3/158,H02M3/158;;G06F1/28;;H02M1/42;;H02M3/335,,0,0,,,,ACTIVE
25,US,B2,US 11409303 B2,007-093-130-632-736,2022-08-09,2022,US 202016917118 A,2020-06-30,US 202016917118 A;;KR 20170024824 A;;US 201715818347 A,2017-02-24,Image processing method for autonomous driving and apparatus thereof,A processor implemented image processing method includes recognizing a target object in a first frame of an input image; adjusting an exposure of a second frame of the input image based on a brightness of the target object; and generating a synthesized image by synthesizing the first frame and the second frame.,SAMSUNG ELECTRONICS CO LTD,SEO YOUNG WAN;;JEON PAUL BAROM;;CHO BAEK HWAN,,https://lens.org/007-093-130-632-736,Granted Patent,yes,30,0,12,12,0,G05D1/0246;;G05D1/0088;;G01C21/26;;G01C21/34;;G01S19/47;;G06T5/50;;G06T7/74;;G06T2207/10144;;G06T2207/30252;;G06T2207/20221;;G06T2207/10016;;G06V20/56;;G06V20/584;;G06V10/141;;G06V10/25;;G06V2201/07;;H04N23/80;;H04N23/72;;H04N23/743;;H04N23/71;;H04N23/73;;H04N23/70;;H04N23/741;;H04N23/74;;G06T5/92;;G06V20/56;;G06V10/25;;G06V10/141;;G06V10/10;;G06V10/24;;H04N23/72;;H04N23/743;;H04N23/73;;H04N23/70;;H04N23/741;;H04N23/74;;G06T5/92;;G05D1/0246;;G06T7/30;;G06T7/11;;G06T7/80;;G06T7/90;;G06T2207/20221;;G06T2207/30256;;G06V20/56;;H04N23/73;;H04N23/74;;G05D1/0088;;G05D1/0246;;G01S19/47;;G01C21/34;;G01C21/26;;G06V10/25;;G06V10/141;;G06V20/56;;G06V20/584;;G06V2201/07;;H04N23/70;;H04N23/71;;H04N23/72;;H04N23/73;;H04N23/74;;H04N23/80;;H04N23/741;;H04N23/743;;G06V10/10;;G06V10/24;;G06T5/92;;G06T7/74;;G06T5/50;;G06T2207/10016;;G06T2207/10144;;G06T2207/20221;;G06T2207/30252,G05D1/02;;G01C21/16;;G01C21/26;;G01C21/34;;G01S19/47;;G05D1/00;;G06T5/00;;G06T5/50;;G06T7/73;;G06V10/141;;G06V10/25;;G06V20/56;;G06V20/58;;H04N5/232;;H04N5/235,,6,3,015-156-610-229-239;;051-626-542-773-142;;061-048-595-006-271,10.1145/882262.882270;;10.1109/tip.2006.877312;;16948325;;10.1155/2007/80971,"Communication dated Jul. 2, 2021, from the China National Intellectual Property Administration in Chinese Application No. 202010776945.8.;;Communication dated Sep. 11, 2020 issued by the China National Intellectual Property Administration in counterpart Chinese Application No. 201810155270.8.;;Kang, Sing Bing, et al. “High Dynamic Range Video”, 4, vol. 22, No. 3, 2003 (pp. 319-325).;;Meylan, Laurence, et al., “High Dynamic Range Image Rendering With a Retinex-Based Adaptive Filter”, IEEE Transactions on Image Processing, vol. 15, No. 9, Sep. 2006 (pp. 2820-2830).;;Marsl, Stefano, et al., “Video Enhancement and Dynamic Range Control of HDR Sequences for Automotive Applications”. EURASIP Journal on Advances in Signal Processing, May 13, 2007 (9 pages in English).;;Extended European Search Report dated Jul. 30, 2018, in corresponding European Application No. 18158136.4 (11 pages in English).",ACTIVE
26,EP,A1,EP 3881421 A1,187-932-285-893-174,2021-09-22,2021,EP 19835905 A,2019-11-04,US 201816191308 A;;US 2019/0059632 W,2018-11-14,MULTI-RESONANT CONVERTER POWER SUPPLY,,CISCO TECH INC,ARDUINI DOUGLAS PAUL;;GOERGEN JOEL RICHARD;;BAEK SUNG KEE,,https://lens.org/187-932-285-893-174,Patent Application,yes,0,0,5,5,0,H02M3/158;;Y02B70/10;;H02M1/0058;;H02M1/4241;;H02M3/1582;;H02M3/158,H02M3/158,,0,0,,,,PENDING
27,US,B2,US 10763749 B2,160-173-056-617-50X,2020-09-01,2020,US 201816191308 A,2018-11-14,US 201816191308 A,2018-11-14,Multi-resonant converter power supply,"In one embodiment, an apparatus includes a first stage comprising a first active switch, a first resonant inductor, and a resonant capacitor and a second stage comprising a second active switch, a second resonant inductor, and a filter capacitor. The first and second stages form a non-isolated multi-resonant converter for converting a DC input voltage to a DC output voltage.",CISCO TECH INC,ARDUINI DOUGLAS PAUL;;GOERGEN JOEL RICHARD;;BAEK SUNG KEE,CISCO TECHNOLOGY INC (2018-11-12),https://lens.org/160-173-056-617-50X,Granted Patent,yes,196,6,5,5,0,H02M3/158;;Y02B70/10;;H02M1/0058;;H02M1/4241;;H02M3/1582;;H02M3/158,H02M1/42;;H02M3/158,,14,3,015-355-071-547-263;;057-748-029-418-389;;078-589-609-090-910,10.1109/intlec.2012.6374488;;10.1109/pesc.2001.954206;;10.1049/ip-b.1992.0027,"https://www.fischerconnectors.com/us/en/products/fiberoptic.;;http://www.strantech.com/products/tfoca-genx-hybrid-2×2-fiber-optic-copper-connector/.;;http://www.qpcfiber.com/product/connectors/e-link-hybrid-connector/.;;https://www.lumentum.com/sites/default/files/technical-library-items/poweroverfiber-tn-pv-ae_0.pdf.;;“Network Remote Power Using Packet Energy Transfer”, Eaves et al., www.voltserver.com, Sep. 2012.;;Product Overview, “Pluribus VirtualWire Solution”, Pluribus Networks, PN-PO-VWS-05818, https://www.pluribusnetworks.com/assets/Pluribus-VirtualWire-PO-50918.pdf, May 2018, 5 pages.;;Implementation Guide, “Virtual Chassis Technology Best Practices”, Juniper Networks, 8010018-009-EN, Jan 2016, https://wwwjuniper.net/us/en/local/pdf/implementation-guides/8010018-en.pdf, 29 pages.;;Yencheck, Thermal Modeling of Portable Power Cables, 1993.;;Zang, Machine Learning-Based Temperature Prediction for Runtime Thermal Management across System Components, Mar. 2016.;;Data Center Power Equipment Thermal Guidelines and Best Practices.;;Dynamic Thermal Rating of Substation Terminal Equipment by Rambabu Adapa, 2004.;;Chen, Real-Time Termperature Estimation for Power MOSEFETs Conidering Thermal Aging Effects:, IEEE Trnasactions on Device and Materials Reliability, vol. 14, No. 1, Mar. 2014.;;JINGQUAN CHEN, MAKSIMOVIC D., ERICKSON R.: ""Buck-boost PWM converters having two independently controlled switches"", 32ND.ANNUAL IEEE POWER ELECTRONICS SPECIALISTS CONFERENCE. PESC 2001. CONFERENCE PROCEEDINGS. VANCOUVER, CANADA, JUNE 17 - 21, 2001., NEW YORK, NY : IEEE., US, vol. 2, 17 June 2001 (2001-06-17) - 21 June 2001 (2001-06-21), US, pages 736 - 741, XP010559317, ISBN: 978-0-7803-7067-8, DOI: 10.1109/PESC.2001.954206;;CHENG K. W. E., EVANS P. D.: ""CONSTANT FREQUENCY, TWO-STAGE QUASIRESONANT CONVERTOR."", IEE PROCEEDINGS B. ELECTRICAL POWER APPLICATIONS., 1271980 1, vol. 139., no. 03., 1 May 1992 (1992-05-01), pages 227 - 237., XP000292493",ACTIVE
28,US,A1,US 2018/0246521 A1,062-463-766-426-794,2018-08-30,2018,US 201715818347 A,2017-11-20,KR 20170024824 A,2017-02-24,IMAGE PROCESSING METHOD FOR AUTONOMOUS DRIVING AND APPARATUS THEREOF,A processor implemented image processing method includes recognizing a target object in a first frame of an input image; adjusting an exposure of a second frame of the input image based on a brightness of the target object; and generating a synthesized image by synthesizing the first frame and the second frame.,SAMSUNG ELECTRONICS CO LTD,SEO YOUNG WAN;;JEON PAUL BAROM;;CHO BAEK HWAN,SAMSUNG ELECTRONICS CO. LTD (2017-11-08),https://lens.org/062-463-766-426-794,Patent Application,yes,0,11,12,12,0,G05D1/0246;;G05D1/0088;;G01C21/26;;G01C21/34;;G01S19/47;;G06T5/50;;G06T7/74;;G06T2207/10144;;G06T2207/30252;;G06T2207/20221;;G06T2207/10016;;G06V20/56;;G06V20/584;;G06V10/141;;G06V10/25;;G06V2201/07;;H04N23/80;;H04N23/72;;H04N23/743;;H04N23/71;;H04N23/73;;H04N23/70;;H04N23/741;;H04N23/74;;G06T5/92;;G06V20/56;;G06V10/25;;G06V10/141;;G06V10/10;;G06V10/24;;H04N23/72;;H04N23/743;;H04N23/73;;H04N23/70;;H04N23/741;;H04N23/74;;G06T5/92;;G05D1/0246;;G06T7/30;;G06T7/11;;G06T7/80;;G06T7/90;;G06T2207/20221;;G06T2207/30256;;G06V20/56;;H04N23/73;;H04N23/74;;G05D1/0088;;G05D1/0246;;G01S19/47;;G01C21/34;;G01C21/26;;G06V10/25;;G06V10/141;;G06V20/56;;G06V20/584;;G06V2201/07;;H04N23/70;;H04N23/71;;H04N23/72;;H04N23/73;;H04N23/74;;H04N23/80;;H04N23/741;;H04N23/743;;G06V10/10;;G06V10/24;;G06T5/92;;G06T7/74;;G06T5/50;;G06T2207/10016;;G06T2207/10144;;G06T2207/20221;;G06T2207/30252,G05D1/00;;G05D1/02;;G06T5/50;;G06T7/73;;G06V10/141;;G06V10/25;;H04N5/235,,0,0,,,,ACTIVE
29,CN,A,CN 113016129 A,062-605-967-296-069,2021-06-22,2021,CN 201980074710 A,2019-11-04,US 201816191308 A;;US 2019/0059632 W,2018-11-14,MULTI-RESONANT CONVERTER POWER SUPPLY,"In one embodiment, an apparatus includes a first stage comprising a first active switch, a first resonant inductor, and a resonant capacitor and a second stage comprising a second active switch, a second resonant inductor, and a filter capacitor. The first and second stages form a non-isolated multi-resonant converter for converting a DC input voltage to a DC output voltage.",CISCO TECH INC,ARDUINI DOUGLAS PAUL;;GOERGEN JOEL RICHARD;;BAEK SUNG-KI,,https://lens.org/062-605-967-296-069,Patent Application,no,0,1,5,5,0,H02M3/158;;Y02B70/10;;H02M1/0058;;H02M1/4241;;H02M3/1582;;H02M3/158,H02M3/158,,0,0,,,,PENDING
30,WO,A1,WO 2011/149159 A1,052-323-773-741-867,2011-12-01,2011,KR 2010007491 W,2010-10-28,KR 20100049891 A,2010-05-27,REAL-TIME MARKERLESS THREE-DIMENSIONAL OBJECT TRACKING SYSTEM FOR AUGMENTED REALITY AND METHOD THEREOF,"Disclosed is a real-time markerless three-dimensional object tracking system for augmented reality and a method thereof. According to an embodiment of the present invention, the real-time markerless three-dimensional object tracking system for augmented reality comprises: a feature point extracting unit which extracts a feature point from an object image; a matching unit which matches the extracted feature point to a feature point of a reference image corresponding to preset three-dimensional position information; a rotation and movement information tracking unit which tracks rotation and movement information on the basis of a result of the matching by the matching unit.",UNIV SOGANG IND UNIV COOP FOUN;;BAEK JOONGHWAN;;MIN JAEHONG;;PAUL ANJAN KUMAR;;ISLAM MOHAMMAD KHAIRUL,BAEK JOONGHWAN;;MIN JAEHONG;;PAUL ANJAN KUMAR;;ISLAM MOHAMMAD KHAIRUL,,https://lens.org/052-323-773-741-867,Patent Application,yes,1,6,2,2,0,G06T7/246;;G06V10/50;;G06T7/246;;G06V10/50,G06T7/20;;G06V10/50,,1,0,,,"SUN-KYOO HWANG ET AL.: ""Augmented Reality by Real-time Feature Point Matching without Marker"", THE 21 ST WORKSHOP ON IMAGE PROCESSING AND IMAGE UNDERSTANDING, 18 February 2009 (2009-02-18), pages 2 - 4",PENDING
31,TW,A,TW 202032810 A,100-586-778-065-638,2020-09-01,2020,TW 108148371 A,2019-12-30,US 201862786989 P,2018-12-31,Quantum dot light-emitting diodes comprising electron spreading layer and fabrication method thereof,"Articles and methods related to quantum dot light-emitting diodes are generally provided. A quantum dot light-emitting diode may comprise a first electrode, a quantum dot light-emitting layer disposed on the first electrode, an electron transport layer disposed on the quantum dot light-emitting layer, an electron spreading layer disposed on the electron transport layer, and second electrode disposed on the electron spreading layer.",NANOPHOTONICA INC,HOLLOWAY PAUL H;;KIM BAEK-HYUN;;TITOV ALEXANDRE;;ACHARYA KRISHNA,,https://lens.org/100-586-778-065-638,Patent of Addition,no,0,0,2,2,0,H10K50/115;;H10K50/171,H01L33/04;;H01L33/00;;H01L33/14,,0,0,,,,PENDING
32,TW,A,TW 202044608 A,129-739-395-333-102,2020-12-01,2020,TW 108148373 A,2019-12-30,US 201862786972 P,2018-12-31,Quantum dot light-emitting diodes comprising hole transport layers,"Articles and methods related to quantum dot light-emitting diodes are generally provided. A quantum dot light-emitting diode may comprise a first electrode, a hole injection layer disposed on the first electrode, a hole transport layer comprising ZnS disposed on the hole injection layer, a quantum dot light-emitting layer disposed on the hole transport layer, and a second electrode disposed on the quantum dot light-emitting layer. A method may comprise assembling a hole transport layer comprising ZnS with a hole injection layer, a quantum dot light-emitting layer, a first electrode, and a second electrode.",NANOPHOTONICA INC,HOLLOWAY PAUL H;;KIM BAEK-HYUN;;TITOV ALEXANDRE;;ACHARYA KRISHNA,,https://lens.org/129-739-395-333-102,Patent of Addition,no,0,1,2,2,0,H01L33/0083;;H01L33/343;;H10K85/1135;;H10K50/115;;H10K50/155;;H10K2102/00,H01L33/00;;H01L33/06;;H01L51/50,,0,0,,,,PENDING
33,WO,A1,WO 2021/134070 A1,085-363-999-293-722,2021-07-01,2021,US 2020/0067187 W,2020-12-28,US 201962954272 P;;US 201962954306 P;;US 201962954324 P;;US 201962954292 P;;US 202016840755 A,2019-12-27,NANOBRIDGE BIOSENSOR AND MEMORY ARRAY,"Various aspects of the present disclosure provide methods, apparatus and systems for single-molecule biosensors having nanowire or nanoribbon bridges between electrodes for sequencing and information storage and reading. In various embodiments, the present disclosure provides nanofabrication of biomolecular sensing devices beginning with parallel arrangements of transferable nanowires or nanoribbons, and provides in general methods of manufacturing biosensor devices for sequencing DNA or RNA and analyzing biomolecules.",ROSWELL BIOTECHNOLOGIES INC,JIN SUNGHO;;CHOI CHULMIN;;BAEK JIHYE;;MOLA PAUL;;MERRIMAN BARRY,,https://lens.org/085-363-999-293-722,Patent Application,yes,3,0,1,4,0,B82Y15/00;;C12Q1/6869;;G01N33/48721,B82Y15/00;;B82B1/00;;B82B3/00;;B82Y40/00,,0,0,,,,PENDING
34,TW,A,TW 202036928 A,139-498-325-732-536,2020-10-01,2020,TW 108148372 A,2019-12-30,US 201862787001 P,2018-12-31,Quantum dot light-emitting diodes comprising doped ZnO electron transport layer,"Articles and methods related to quantum dot light-emitting diodes are generally provided. A quantum dot light-emitting diode may comprise a first electrode, a quantum dot light-emitting layer disposed on the first electrode, an electron transport layer disposed on the quantum dot light-emitting layer, and second electrode disposed on the electron transport layer. The electron transport layer may comprise nanoparticles comprising ZnO doped with one or more dopants and/or capped with one or more ligands. The quantum dot light-emitting layer may comprise two or more electron transport layers, each of which may independently comprise ZnO doped with one or more dopants and/or capped with one or more ligands. The nanoparticles may have a number average diameter of less than or equal to 5 nm.",NANOPHOTONICA INC,HOLLOWAY PAUL H;;KIM BAEK-HYUN;;TITOV ALEXANDRE;;ACHARYA KRISHNA,,https://lens.org/139-498-325-732-536,Patent of Addition,no,0,0,2,2,0,H01L33/06;;H10K50/115;;H10K50/165;;H10K50/166,H01L33/00;;B05D1/36;;B05D3/02;;B05D5/12;;B05D7/24;;B82Y20/00;;B82Y40/00;;H01L33/14;;H01L33/26;;H01L33/36,,0,0,,,,PENDING
35,CN,A,CN 106907202 A,126-774-015-397-695,2017-06-30,2017,CN 201610840032 A,2016-09-22,US 201562222071 P;;US 201514985136 A,2015-09-22,Method and system for electric and steam supply system,"The invention relates to a method and a system for an electric and steam supply system. An electric and steam system 100 includes an electrical generator assembly 108 configured to receive a first portion of a flow of a boil off gas (NBOG). An oxidizing unit 106 is configured to receive a second portion of the flow of the boil off gas (NBOG), the second portion being an excess of the flow of the boil off gas (NBOG) that the electrical generator can process, and a crossover duct 128 configured to receive a first flow of exhaust gas from the electrical generator assembly and a second flow of exhaust gas from the oxidizing unit 106 and channel the first and second flows to an inlet of a heat recovery steam generator 116.",GEN ELECTRIC,CHEOL PARK;;BYEONG-YEOL BAEK;;READ STAPLEY TUDDENHAM;;PAUL THOMAS MACIULEWICZ,,https://lens.org/126-774-015-397-695,Patent Application,no,3,2,9,10,0,F01K23/10;;F01K23/101;;F02C3/22;;F01D15/10;;F02G5/02;;Y02E20/16;;F01K23/10;;Y02E20/14;;F01K15/04;;F01K17/04;;B63B25/16;;B63B35/44;;B63J3/00;;F01D15/10;;B63B2035/444;;F01D15/10;;F02G5/02;;Y02E20/16;;F01K23/10;;Y02E20/14;;F01K15/04;;F01K17/04,F01K23/10;;F02C3/22,,0,0,,,,ACTIVE
36,US,B2,US 9771824 B2,187-258-436-904-503,2017-09-26,2017,US 201514985136 A,2015-12-30,US 201514985136 A;;US 201562222071 P,2015-09-22,Method and system for an electric and steam supply system,"An electric and steam system includes an electrical generator assembly configured to receive a first portion of a flow of a boil off gas (NBOG). An oxidizing unit is configured to receive a second portion of the flow of the boil off gas (NBOG), the second portion being an excess of the flow of the boil off gas (NBOG) that the electrical generator can process, and a crossover duct configured to receive a first flow of exhaust gas from the electrical generator assembly and a second flow of exhaust gas from the oxidizing unit and channel the first and second flows to an inlet of a heat recovery steam generator.",GEN ELECTRIC,PARK CHEOL;;BAEK BYEONG-YEOL;;TUDDENHAM READ STAPLEY;;MACIULEWICZ PAUL THOMAS,GENERAL ELECTRIC COMPANY (2015-12-22),https://lens.org/187-258-436-904-503,Granted Patent,yes,27,0,9,10,0,F01K23/10;;F01K23/101;;F02C3/22;;F01D15/10;;F02G5/02;;Y02E20/16;;F01K23/10;;Y02E20/14;;F01K15/04;;F01K17/04;;B63B25/16;;B63B35/44;;B63J3/00;;F01D15/10;;B63B2035/444;;F01D15/10;;F02G5/02;;Y02E20/16;;F01K23/10;;Y02E20/14;;F01K15/04;;F01K17/04,B60L1/02;;F01D15/10;;F01K15/00;;F01K17/02;;F02C6/00;;F02C6/18;;F02C7/00;;F02G5/02;;F27D17/00;;H01M2/38;;H01M8/24,,1,0,,,"MHI Develops High-Pressure Gas Supply System for Marine Engines: Bloomberg.com, Mar. 6, 2012, retrieved from website http://www.bloomberg.com/apps/news?pid=newsarchive&sid=agNxs0kW3bfQ (2pgs.).",ACTIVE
37,KR,A,KR 20170035811 A,150-005-341-352-680,2017-03-31,2017,KR 20160120548 A,2016-09-21,US 201562222071 P;;US 201514985136 A,2015-09-22,METHOD AND SYSTEM FOR AN ELECTRIC AND STEAM SUPPLY SYSTEM,"An electric and steam system (100) includes an electrical generator assembly (108) configured to receive a first portion of a flow of a boil off gas (NBOG). An oxidizing unit (106) is configured to receive a second portion of the flow of the boil off gas (NBOG), the second portion being an excess of the flow of the boil off gas (NBOG) that the electrical generator (108) can process, and a crossover duct (128) configured to receive a first flow of exhaust gas from the electrical generator assembly (108) and a second flow of exhaust gas from the oxidizing unit (106) and channel the first and second flows to an inlet of a heat recovery steam generator (116).",GEN ELECTRIC,PARK CHEOL;;BAEK BYEONG YEOL;;TUDDENHAM READ STAPLEY;;MACIULEWICZ PAUL THOMAS,,https://lens.org/150-005-341-352-680,Patent Application,no,0,0,9,10,0,F01K23/10;;F01K23/101;;F02C3/22;;F01D15/10;;F02G5/02;;Y02E20/16;;F01K23/10;;Y02E20/14;;F01K15/04;;F01K17/04;;B63B25/16;;B63B35/44;;B63J3/00;;F01D15/10;;B63B2035/444;;F01D15/10;;F02G5/02;;Y02E20/16;;F01K23/10;;Y02E20/14;;F01K15/04;;F01K17/04,B63B35/44;;B63B25/16;;B63J3/00;;F01D15/10,,0,0,,,,ACTIVE
38,DK,B1,DK 179629 B1,035-964-111-734-24X,2019-03-05,2019,DK PA201670689 A,2016-09-07,US 201562222071 P;;US 201514985136 A,2015-09-22,Fremgangsmåde og system til et elektrisk dampdrevet forsyningssystem,"An electric and steam system (100) includes an electrical generator assembly (108)configured to receive a first portion of a flow of a boil off gas (NBOG). An oxidizing unit (106)is configured to receive a second portion of the flow of the boil off gas (NBOG), the secondportion being an excess of the flow of the boil off gas (NBOG) than the electrical generator (108) can process, and a crossover duct (128) configured to receive a first flow of exhaust gas from the electrical generator assembly (108) and a second flow of exhaust gas from the oxidizing unit (106) and channel the first and second flows to an inlet of a heat recovery steam generator (116).",GEN ELECTRIC,CHEOL PARK;;BYEONG-YEOL BAEK;;PAUL THOMAS MACIULEWICZ;;READ STAPLEY TUDDENHAM,,https://lens.org/035-964-111-734-24X,Granted Patent,no,0,0,9,10,0,F01K23/10;;F01K23/101;;F02C3/22;;F01D15/10;;F02G5/02;;Y02E20/16;;F01K23/10;;Y02E20/14;;F01K15/04;;F01K17/04;;B63B25/16;;B63B35/44;;B63J3/00;;F01D15/10;;B63B2035/444;;F01D15/10;;F02G5/02;;Y02E20/16;;F01K23/10;;Y02E20/14;;F01K15/04;;F01K17/04,F01D15/10;;F02G5/02,,0,0,,,,INACTIVE
39,DE,A1,DE 102016116412 A1,141-279-823-206-514,2017-03-23,2017,DE 102016116412 A,2016-09-02,US 201562222071 P;;US 201514985136 A,2015-09-22,Verfahren und System für ein elektrisches und Dampfversorgungssystem,"Ein Strom- und Dampfsystem 100 enthält eine Stromgeneratorbaugruppe (108), die eingerichtet ist, um einen ersten Teil einer Strömung eines Boil-Off-Gases (NBOG) zu empfangen. Eine Oxidationseinheit (106) ist eingerichtet, um einen zweiten Teil der Strömung des Boil-Off-Gases (NBOG) zu empfangen, wobei der zweite Teil ein Überschuss der Strömung des Boil-Off-Gases (NBOG) ist, mehr als der Stromgenerator (108) verarbeiten kann, und ein Überleitkanal (128) ist eingerichtet, um eine erste Abgasströmung von der Stromgeneratorbaugruppe (108) und eine zweite Abgasströmung von der Oxidationseinheit (106) zu empfangen und die erste und die zweite Strömung zu einem Einlass eines Abhitzedampferzeugers (116) zu leiten.",GEN ELECTRIC,PARK CHEOL;;BAEK BYEONG-YEOL;;TUDDENHAM READ STAPLEY;;MACIULEWICZ PAUL THOMAS,,https://lens.org/141-279-823-206-514,Patent Application,no,0,0,1,10,0,F01K23/10;;F01K15/04;;F01K17/04;;Y02E20/16,F01K23/10,,0,0,,,,DISCONTINUED
40,US,A1,US 2023/0038666 A1,033-210-435-617-011,2023-02-09,2023,US 202017789512 A,2020-12-28,US 202017789512 A;;US 202016840755 A;;US 201962954272 P;;US 201962954306 P;;US 201962954324 P;;US 201962954292 P;;US 201962830231 P;;US 2020/0067187 W,2019-04-05,NANOBRIDGE BIOSENSOR AND MEMORY ARRAY,"Various aspects of the present disclosure provide methods, apparatus and systems for single-molecule biosensors having nanowire or nanoribbon bridges between electrodes for sequencing and information storage and reading. In various embodiments, the present disclosure provides nanofabrication of biomolecular sensing devices beginning with parallel arrangements of transferable nanowires or nanoribbons, and provides in general methods of manufacturing biosensor devices for sequencing DNA or RNA and analyzing biomolecules.",ROSWELL BIOTECHNOLOGIES INC,JIN SUNGHO;;CHOI CHULMIN;;BAEK JIHYE;;MOLA PAUL W;;MERRIMAN BARRY,ROSWELL BIOTECHNOLOGIES INC (2022-07-12);;ROSWELL ME INC (2023-06-22),https://lens.org/033-210-435-617-011,Patent Application,yes,0,0,1,4,0,G01N33/48721;;C12Q1/6869;;C12Q1/001;;G01N27/3275;;G01N27/3276;;G01N33/48721;;G01N27/3271;;C12Q1/6869;;C12Q1/485;;G01N27/3275,G01N33/487;;C12Q1/48;;C12Q1/6869;;G01N27/327,,0,0,,,,PENDING
41,US,A1,US 2017/0081972 A1,189-948-116-630-671,2017-03-23,2017,US 201514985136 A,2015-12-30,US 201514985136 A;;US 201562222071 P,2015-09-22,METHOD AND SYSTEM FOR AN ELECTRIC AND STEAM SUPPLY SYSTEM,"An electric and steam system includes an electrical generator assembly configured to receive a first portion of a flow of a boil off gas (NBOG). An oxidizing unit is configured to receive a second portion of the flow of the boil off gas (NBOG), the second portion being an excess of the flow of the boil off gas (NBOG) that the electrical generator can process, and a crossover duct configured to receive a first flow of exhaust gas from the electrical generator assembly and a second flow of exhaust gas from the oxidizing unit and channel the first and second flows to an inlet of a heat recovery steam generator.",GEN ELECTRIC,PARK CHEOL;;BAEK BYEONG-YEOL;;TUDDENHAM READ STAPLEY;;MACIULEWICZ PAUL THOMAS,GENERAL ELECTRIC COMPANY (2015-12-22),https://lens.org/189-948-116-630-671,Patent Application,yes,21,6,9,10,0,F01K23/10;;F01K23/101;;F02C3/22;;F01D15/10;;F02G5/02;;Y02E20/16;;F01K23/10;;Y02E20/14;;F01K15/04;;F01K17/04;;B63B25/16;;B63B35/44;;B63J3/00;;F01D15/10;;B63B2035/444;;F01D15/10;;F02G5/02;;Y02E20/16;;F01K23/10;;Y02E20/14;;F01K15/04;;F01K17/04,F01D15/10;;F02G5/02,,0,0,,,,ACTIVE
42,US,A1,US 2023/0344329 A1,058-825-693-446-815,2023-10-26,2023,US 202217724985 A,2022-04-20,US 202217724985 A,2022-04-20,MODULAR POWER SUPPLY ARCHITECTURE OPTIMIZED FOR FLAT EFFICIENCY ACROSS LOADINGS,"A control method improves the efficiency profile of a power supply across a wide range of output loading. The method includes obtaining a measure of output power for a power supply, which includes one or more output modules and an auxiliary power supply. The method determines whether a maximum power rating of the auxiliary power supply is sufficient to provide the measure of output power. Responsive to a determination that the maximum power rating of the auxiliary power supply is sufficient to provide the measure of output power, the controller of the power supply directs the auxiliary power supply to provide the output power.",CISCO TECH INC,ZHU XIQUN;;BAEK SUNG KEE;;GOERGEN JOEL;;ARDUINI DOUG PAUL;;LI RUQI,CISCO TECHNOLOGY INC (2022-04-18),https://lens.org/058-825-693-446-815,Patent Application,yes,6,0,3,3,0,H02M1/0043;;H02M1/0048;;H02M1/4208;;H02J1/102;;H02J1/109;;H02J2310/16;;H02M1/0043;;H02M1/0048,H02M1/00,,0,0,,,,ACTIVE
43,KR,A,KR 20110130309 A,197-958-939-217-377,2011-12-05,2011,KR 20100049891 A,2010-05-27,KR 20100049891 A,2010-05-27,REALTIME MARKERLESS 3D OBJECT TRACKING SYSTEM FOR AUGMENTED REALITY AND METHOD THEREFOR,PURPOSE: A real time markerless 3D object tracking system for the augmented reality is provided to extract a feature point and express the object through the extracted 3D object feature point. CONSTITUTION: A feature point extraction unit(110) extracts a feature point from an object image. A descriptor generator(120) creates expression factor of a feature vector based on the extracted feature point. A matching unit(140) matches the extracted feature point with the feature point of a reference image corresponding to a preset 3D location information. A rotation and moving information tracking unit(150) traces the rotation and moving information based on the matched result.,UNIV SOGANG IND UNIV COOP FOUN,BAEK JOONG HWAN;;MIN JAE HONG;;ANJAN KUMAR PAUL;;MOHAMMAD KHAIRUL ISLAM,,https://lens.org/197-958-939-217-377,Patent Application,no,0,4,2,2,0,G06T7/246;;G06V10/50;;G06T7/246;;G06V10/50,G06V10/50;;G06T7/20,,0,0,,,,DISCONTINUED
44,US,A1,US 2021/0408822 A1,082-447-215-191-728,2021-12-30,2021,US 202017109007 A,2020-12-01,US 202017109007 A;;US 202063046082 P,2020-06-30,METHOD AND APPARATUS FOR EFFICIENT POWER DELIVERY IN POWER SUPPLY SYSTEM,"In one embodiment, an apparatus includes a power supply operable to output power to a load along with at least one other power supply, a sensing component for identifying a load level, and a control component for switching the power supply from a full power mode to a power saving mode based on the identified load level. The power supply shares current with the other power supply at a lower current and generally the same voltage as the other power supply while in the power saving mode.",CISCO TECH INC,ARDUINI DOUGLAS PAUL;;BAEK SUNG KEE;;SMITH JONATHAN LEE;;GOERGEN JOEL RICHARD,,https://lens.org/082-447-215-191-728,Patent Application,yes,0,3,3,3,0,H02J1/08;;H02J1/12;;H02J2310/16;;G06F1/26;;G06F1/263;;G06F1/28;;G06F1/3203;;H02J9/005;;H02J2310/60;;H02J4/00,H02J4/00;;H02J9/00,,0,0,,,,ACTIVE
45,US,B2,US 11239689 B2,038-959-659-991-332,2022-02-01,2022,US 202017109007 A,2020-12-01,US 202017109007 A;;US 202063046082 P,2020-06-30,Method and apparatus for efficient power delivery in power supply system,"In one embodiment, an apparatus includes a power supply operable to output power to a load along with at least one other power supply, a sensing component for identifying a load level, and a control component for switching the power supply from a full power mode to a power saving mode based on the identified load level. The power supply shares current with the other power supply at a lower current and generally the same voltage as the other power supply while in the power saving mode.",CISCO TECH INC,ARDUINI DOUGLAS PAUL;;BAEK SUNG KEE;;SMITH JONATHAN LEE;;GOERGEN JOEL RICHARD,CISCO TECHNOLOGY INC (2020-11-25),https://lens.org/038-959-659-991-332,Granted Patent,yes,8,0,3,3,0,H02J1/08;;H02J1/12;;H02J2310/16;;G06F1/26;;G06F1/263;;G06F1/28;;G06F1/3203;;H02J9/005;;H02J2310/60;;H02J4/00,H02J9/00;;H02J4/00,,0,0,,,,ACTIVE
46,US,A1,US 2022/0094194 A1,007-273-880-864-868,2022-03-24,2022,US 202117537895 A,2021-11-30,US 202117537895 A;;US 202017109007 A;;US 202063046082 P,2020-06-30,METHOD AND APPARATUS FOR EFFICIENT POWER DELIVERY IN POWER SUPPLY SYSTEM,"In one embodiment, an apparatus includes a power supply operable to output power to a load along with at least one other power supply, a sensing component for identifying a load level, and a control component for switching the power supply from a full power mode to a power saving mode based on the identified load level. The power supply shares current with the other power supply at a lower current and generally the same voltage as the other power supply while in the power saving mode.",CISCO TECH INC,ARDUINI DOUGLAS PAUL;;BAEK SUNG KEE;;SMITH JONATHAN LEE;;GOERGEN JOEL RICHARD,CISCO TECHNOLOGY INC (2020-11-25),https://lens.org/007-273-880-864-868,Patent Application,yes,0,0,3,3,0,H02J1/08;;H02J1/12;;H02J2310/16;;G06F1/26;;G06F1/263;;G06F1/28;;G06F1/3203;;H02J9/005;;H02J2310/60;;H02J4/00,H02J9/00;;H02J4/00,,2,0,,,"Wikipedia contributors. (2023, December 23). Series and parallel circuits. In Wikipedia, The Free Encyclopedia. Retrieved 21:53, January 30, 2024, from https://en.wikipedia.org/w/index.php?title=Series_and_parallel_circuits&oldid=1191431161 (Year: 2024);;Wikipedia contributors. (2023, December 22). Power supply unit (computer). In Wikipedia, The Free Encyclopedia. Retrieved 21:54, January 30, 2024, from https://en.wikipedia.org/w/index.php?title=Power_supply_unit_(computer)&oldid=1191262338 (Year: 2024)",PENDING
47,US,B1,US 11777394 B1,013-314-827-366-11X,2023-10-03,2023,US 202217724985 A,2022-04-20,US 202217724985 A,2022-04-20,Modular power supply architecture optimized for flat efficiency across loadings,"A control method improves the efficiency profile of a power supply across a wide range of output loading. The method includes obtaining a measure of output power for a power supply, which includes one or more output modules and an auxiliary power supply. The method determines whether a maximum power rating of the auxiliary power supply is sufficient to provide the measure of output power. Responsive to a determination that the maximum power rating of the auxiliary power supply is sufficient to provide the measure of output power, the controller of the power supply directs the auxiliary power supply to provide the output power.",CISCO TECH INC,ZHU XIQUN;;BAEK SUNG KEE;;GOERGEN JOEL;;ARDUINI DOUG PAUL;;LI RUQI,CISCO TECHNOLOGY INC (2022-04-18),https://lens.org/013-314-827-366-11X,Granted Patent,yes,9,0,3,3,0,H02M1/0043;;H02M1/0048;;H02M1/4208;;H02J1/102;;H02J1/109;;H02J2310/16;;H02M1/0043;;H02M1/0048,H02M1/00,,3,2,009-139-545-974-715;;033-416-656-458-492,10.5755/j01.eie.25.3.23669;;10.1109/access.2019.2963281,"Michal Frivaldsky et al., “Dual Interleaved LLC Converter for High Power Applications and Wide Load Range”, Elektronika IR Elektrotechnika, ISSN 1392-1215, vol. 25, No. 3, Apr. 2019, 6 pages; http://dx.doi.org/10.5755/j01.eie.25.3.23669.;;Yoshiya Tada et al., “Three-Phase Interleaved LLC Asymmetric Resonant Converter with Capacitive Current Balancing and Reduced Switch Voltage Stress”, Research Gate, Dec. 2019, DOI 10.1109/ACCESS.2019.2963281, IEEE, 11 pages.;;NXP Semiconductors, “Totem-Pole Bridgeless PFC Design Using MC56F8xxxx”, Document identifier: DRM174, Rev. 1, Oct. 2020, 47 pages.",ACTIVE
48,US,A1,US 2023/0361668 A1,109-268-106-530-57X,2023-11-09,2023,US 202318353536 A,2023-07-17,US 202318353536 A;;US 202217724985 A,2022-04-20,MODULAR POWER SUPPLY ARCHITECTURE OPTIMIZED FOR FLAT EFFICIENCY ACROSS LOADINGS,"A control method improves the efficiency profile of a power supply across a wide range of output loading. The method includes obtaining a measure of output power for a power supply, which includes one or more output modules and an auxiliary power supply. The method determines whether a maximum power rating of the auxiliary power supply is sufficient to provide the measure of output power. Responsive to a determination that the maximum power rating of the auxiliary power supply is sufficient to provide the measure of output power, the controller of the power supply directs the auxiliary power supply to provide the output power.",CISCO TECH INC,ZHU XIQUN;;BAEK SUNG KEE;;GOERGEN JOEL;;ARDUINI DOUG PAUL;;LI RUQI,CISCO TECHNOLOGY INC (2022-04-18),https://lens.org/109-268-106-530-57X,Patent Application,yes,0,0,3,3,0,H02M1/0043;;H02M1/0048;;H02M1/4208;;H02J1/102;;H02J1/109;;H02J2310/16;;H02M1/0043;;H02M1/0048,H02M1/00,,0,0,,,,PENDING
49,US,B1,US 6812949 B1,029-550-070-443-106,2004-11-02,2004,US 64091003 A,2003-08-14,US 64091003 A,2003-08-14,Imaging apparatus and method for exposing a photosensitive material,"
    An imaging apparatus (  10  ) having a multiple channel image exposure device (  12  ). Improved thermal compensation is achieved by means of mounting an array of light emitting elements (  30  ) on a printed circuit board (  28  ) having at least one thermal via (  26  ) for each light emitting element to thermally control the temperature of the light emitting element. Selected microcapsules (  38  ) within a photosensitive media (  44  ) are exposed with the multiple channel image exposure device to harden the desired microcapsules. Pressure applied to the exposed photosensitive media ruptures the unexposed microcapsule (  40  ), releasing the image-forming material (  48  ) encapsulated within to form an image on the photosensitive media. 
",EASTMAN KODAK CO,SWITZER PAUL R;;KERR ROGER S;;BAEK SEUNG-HO H;;BACON WESLEY H,EASTMAN KODAK COMPANY (2003-10-03),https://lens.org/029-550-070-443-106,Granted Patent,yes,4,39,1,1,0,B41J29/377;;B41J29/377;;G03F7/002;;G03F7/002;;G03F7/70391;;G03F7/70391,B41J29/377;;G03F7/00;;G03F7/20,347/238,0,0,,,,EXPIRED
50,CN,A,CN 113508555 A,125-035-398-452-755,2021-10-15,2021,CN 202080018474 A,2020-02-28,US 201962817813 P;;US 201916380954 A;;US 2020/0020359 W,2019-03-13,MULTIPLE PHASE PULSE POWER IN A NETWORK COMMUNICATIONS SYSTEM,"In one embodiment, an apparatus comprises an input power interface for receiving input power, a power control system for transmitting DC (Direct Current) pulse power on multiple phases over a cable to a plurality of powered devices and verifying cable operation during an off-time of pulses in the DC pulse power, and a cable interface for delivery of the DC pulse power on the multiple phases and data over the cable to the powered devices. A method for transmitting multiple phase pulse power is also disclosed herein.",CISCO TECH INC,O'BRIEN RICHARD ANTHONY;;ARDUINI DOUGLAS PAUL;;BAEK SUNG-KI;;LI RUQI;;GOERGEN JOEL RICHARD,,https://lens.org/125-035-398-452-755,Patent Application,no,16,0,8,8,0,H04L12/10;;H04L12/40045;;G01R31/54;;G01R31/52;;H04L12/4641;;H04L12/10;;G01R31/085;;H04L41/0677,H04L12/10;;G01R31/08;;H04B3/54;;H04L12/40,,3,1,018-130-380-447-508,10.1109/iccct2.2017.7972239,"刘瑞，幸进，包锦辉: ""基于分支分相技术台区稽核系统的研制与应用"", 科学技术创新;;王良;宋政湘;要文波;肖佳;: ""网络通信端口的电磁脉冲防护研究"", 高压电器, no. 07;;N. MURALIDHARA; RAJESH B; RAJASHEKHAR C BIRADAR; JAYARAMAIAH G.V: ""Designing Polyphase code for Digital Pulse Compression for surveillance Radar"", 2017 2ND INTERNATIONAL CONFERENCE ON COMPUTING AND COMMUNICATIONS TECHNOLOGIES (ICCCT)",PENDING
51,US,B2,US 11456883 B2,106-486-655-287-302,2022-09-27,2022,US 201916380954 A,2019-04-10,US 201916380954 A;;US 201962817813 P,2019-03-13,Multiple phase pulse power in a network communications system,"In one embodiment, an apparatus comprises an input power interface for receiving input power, a power control system for transmitting DC (Direct Current) pulse power on multiple phases over a cable to a plurality of powered devices and verifying cable operation during an off-time of pulses in the DC pulse power, and a cable interface for delivery of the DC pulse power on the multiple phases and data over the cable to the powered devices. A method for transmitting multiple phase pulse power is also disclosed herein.",CISCO TECH INC,O'BRIEN RICHARD ANTHONY;;ARDUINI DOUGLAS PAUL;;BAEK SUNG KEE;;LI RUQI;;GOERGEN JOEL RICHARD,CISCO TECHNOLOGY INC (2019-04-09),https://lens.org/106-486-655-287-302,Granted Patent,yes,188,1,8,8,0,H04L12/10;;H04L12/40045;;G01R31/54;;G01R31/52;;H04L12/4641;;H04L12/10;;G01R31/085;;H04L41/0677,G01R31/50;;G01R31/08;;H04L12/10;;H04L41/0677,,32,4,015-355-071-547-263;;057-748-029-418-389;;078-589-609-090-910;;015-355-071-547-263,10.1109/intlec.2012.6374488;;10.1109/pesc.2001.954206;;10.1049/ip-b.1992.0027;;10.1109/intlec.2012.6374488,"“Network Remote Power Using Packet Energy Transfer”, Eaves et al., www.voltserver.com, Sep. 2012.;;https://www.fischerconnectors.com/us/en/products/fiberoptic.;;http://www.strantech.com/products/tfoca-genx-hybrid-2x2-fiber-optic-copper-connector/.;;http://www.qpcfiber.com/product/connectors/e-link-hybrid-connector/.;;https://www.lumentum.com/sites/default/files/technical-library-items/poweroverfiber-tn-pv-ae_0.pdf.;;Product Overview, “Pluribus VirtualWire Solution”, Pluribus Networks, PN-PO-VWS-05818, https://www.pluribusnetworks.com/assets/Pluribus-VirtualWire-PO-50918.pdf, May 2018, 5 pages.;;Implementation Guide, “Virtual Chassis Technology Best Practices”, Juniper Networks, 8010018-009-EN, Jan. 2016, https://wwwjuniper.net/us/en/local/pdf/implementation-guides/8010018-en.pdf, 29 pages.;;Yencheck, Thermal Modeling of Portable Power Cables, 1993.;;Zhang, Machine Learning-Based Temperature Prediction for Runtime Thermal Management across System Components, Mar. 2016.;;Data Center Power Equipment Thermal Guidelines and Best Practices.;;Dynamic Thermal Rating of Substation Terminal Equipment by Rambabu Adapa, 2004.;;Chen, Real-Time Termperature Estimation for Power MOSEFETs Conidering Thermal Aging Effects:, IEEE Trnasactions on Device and Materials Reliability, vol. 14, No. 1, Mar. 2014.;;JINGQUAN CHEN, MAKSIMOVIC D., ERICKSON R.: ""Buck-boost PWM converters having two independently controlled switches"", 32ND.ANNUAL IEEE POWER ELECTRONICS SPECIALISTS CONFERENCE. PESC 2001. CONFERENCE PROCEEDINGS. VANCOUVER, CANADA, JUNE 17 - 21, 2001., NEW YORK, NY : IEEE., US, vol. 2, 17 June 2001 (2001-06-17) - 21 June 2001 (2001-06-21), US , pages 736 - 741, XP010559317, ISBN: 978-0-7803-7067-8, DOI: 10.1109/PESC.2001.954206;;CHENG K. W. E., EVANS P. D.: ""CONSTANT FREQUENCY, TWO-STAGE QUASIRESONANT CONVERTOR."", PUBLISHED IN: IEE PROCEEDINGS B - ELECTRIC POWER APPLICATIONS, vol. 139., no. 03., 1 May 1992 (1992-05-01), pages 227 - 237., XP000292493;;Petition for Post Grant Review of U.S. Pat. No. 10,735,105 [Public], filed Feb. 16, 2021, PGR 2021-00055.;;Petition for Post Grant Review of U.S. Pat. No. 10,735,105 [Public], filed Feb. 16, 2021, PGR 2021-00056.;;Eaves, S. S., “Network Remote Powering Using Packet Energy Transfer, Proceedings of IEEE International Conference on Telecommunications Energy (INTELEC) 2012, Scottsdale, AZ, Sep. 30-Oct. 4, 2012 (IEEE 2012) (” EavesIEEE').;;Edelstein S., Updated 2016 Tesla Model S also gets new 75-kWhbattery option, (Jun. 19, 2016), archived Jun. 19, 2016 by Internet Archive Wayback machine at https://web.archive.org/web/20160619001148/https://www.greencarreports.com/news/1103 782_updated-2016-tesla-model-s-also-gets-new-7 5-kwh-battery-option (“Edelstein”).;;NFPA 70 National Electrical Code, 2017 Edition (NEC).;;International Standard IEC 62368-1 Edition 2.0 (2014), ISBN 978-2-8322-1405-3 (“IEC-62368”).;;International Standard IEC/TS 60479-1 Edition 4.0 (2005), ISBN 2-8318-8096-3 (“IEC-60479”).;;International Standard IEC 60950-1 Edition 2.2 (2013), ISBN 978-2-8322-0820-5 (“IEC-60950”).;;International Standard IEC 60947-1 Edition 5.0 (2014), ISBN 978-2-8322-1798-6 (“IEC-60947”).;;Tanenbaum, A. S., Computer Networks, Third Edition (1996) (“Tanenbaum”).;;Stallings, W., Data and Computer Communications, Fourth Edition (1994) (“Stallings”).;;Alexander, C. K., Fundamentals of Electric Circuits, Indian Edition (2013) (“Alexander”).;;Hall, S. H., High-Speed Digital System Design, A Handbook of Interconnect Theory and Design Practices (2000) (“Hall”).;;Sedra, A. S., Microelectronic Circuits, Seventh Edition (2014) (“Sedra”).;;Lathi, B. P., Modem Digital and Analog Communication Systems, Fourth Edition (2009) (“Lathi”).;;Understanding 802.3at PoE Plus Standard Increases Available Power (Jun. 2011) (“Microsemi”).;;International Search Report and Written Opinion in counterpart International Application No. PCT/US2020/020359, dated May 27, 2020, 10 pages.;;International Preliminary Report on Patentability in counterpart International Application No. PCT/US2020/020359, dated Sep. 23, 2021, 9 pages.",ACTIVE
52,US,B2,US 11442271 B2,075-403-220-528-374,2022-09-13,2022,US 201816609066 A,2018-06-05,US 201816609066 A;;US 201762519597 P;;US 2018/0036143 W,2017-06-14,Display illumination systems,An electronic device may have a reflective display with a pixel array that generates images. The reflective display may be illuminated by an illumination system. Light from the illumination system may be reflected by the pixel array as image light. The image light may be provided to a viewer using a waveguide with diffractive input and output couplers. The illumination system may have a waveguide. The illumination system may also have a light source such as one or more light-emitting diodes. Light from the light source may be coupled into the waveguide of the illumination system by a diffractive coupler such as volume hologram that serves as an input coupler. Light from the light source may be routed to the display to illuminate the display using the waveguide in the illumination system and a diffractive coupler such as a volume hologram that serves as an output coupler.,APPLE INC,CHOI HYUNGRYUL;;HANSOTTE ERIC J;;PENG GUOLIN;;GELSINGER-AUSTIN PAUL J;;OH SE BAEK,APPLE INC (2018-03-06),https://lens.org/075-403-220-528-374,Granted Patent,yes,22,0,5,5,0,G02B27/0103;;G02B27/0101;;G02B5/32;;G02B6/0026;;G02B6/005;;G02B27/0172;;G02B2027/0174;;G03H1/0248;;G03H2222/31,G02B27/01;;F21V8/00;;G02B5/32;;G03H1/02,,0,0,,,,ACTIVE
53,US,A1,US 2022/0116238 A1,000-404-754-525-315,2022-04-14,2022,US 202117560424 A,2021-12-23,US 202117560424 A;;US 201916380954 A;;US 201962817813 P,2019-03-13,MULTIPLE PHASE PULSE POWER IN A NETWORK COMMUNICATIONS SYSTEM,"In one embodiment, an apparatus comprises an input power interface for receiving input power, a power control system for transmitting DC (Direct Current) pulse power on multiple phases over a cable to a plurality of powered devices and verifying cable operation during an off-time of pulses in the DC pulse power, and a cable interface for delivery of the DC pulse power on the multiple phases and data over the cable to the powered devices. A method for transmitting multiple phase pulse power is also disclosed herein.",CISCO TECH INC,O'BRIEN RICHARD ANTHONY;;ARDUINI DOUGLAS PAUL;;BAEK SUNG KEE;;LI RUQI;;GOERGEN JOEL RICHARD,CISCO TECHNOLOGY INC (2019-04-09),https://lens.org/000-404-754-525-315,Patent Application,yes,2,0,8,8,0,H04L12/10;;H04L12/40045;;G01R31/54;;G01R31/52;;H04L12/4641;;H04L12/10;;G01R31/085;;H04L41/0677,H04L12/10;;G01R31/08;;H04L41/0677,,0,0,,,,PENDING
54,US,A1,US 2020/0057308 A1,085-880-841-856-594,2020-02-20,2020,US 201816609066 A,2018-06-05,US 201816609066 A;;US 201762519597 P;;US 2018/0036143 W,2017-06-14,Display Illumination Systems,An electronic device may have a reflective display with a pixel array that generates images. The reflective display may be illuminated by an illumination system. Light from the illumination system may be reflected by the pixel array as image light. The image light may be provided to a viewer using a waveguide with diffractive input and output couplers. The illumination system may have a waveguide. The illumination system may also have a light source such as one or more light-emitting diodes. Light from the light source may be coupled into the waveguide of the illumination system by a diffractive coupler such as volume hologram that serves as an input coupler. Light from the light source may be routed to the display to illuminate the display using the waveguide in the illumination system and a diffractive coupler such as a volume hologram that serves as an output coupler.,APPLE INC,CHOI HYUNGRYUL;;HANSOTTE ERIC J;;PENG GUOLIN;;GELSINGER-AUSTIN PAUL J;;OH SE BAEK,APPLE INC (2018-03-06),https://lens.org/085-880-841-856-594,Patent Application,yes,0,4,5,5,0,G02B27/0103;;G02B27/0101;;G02B5/32;;G02B6/0026;;G02B6/005;;G02B27/0172;;G02B2027/0174;;G03H1/0248;;G03H2222/31,G02B27/01;;F21V8/00;;G02B5/32;;G03H1/02,,0,0,,,,ACTIVE
55,EP,B1,EP 3939203 B1,096-039-701-051-419,2023-11-01,2023,EP 20714427 A,2020-02-28,US 201962817813 P;;US 201916380954 A;;US 2020/0020359 W,2019-03-13,MULTIPLE PHASE PULSE POWER IN A NETWORK COMMUNICATIONS SYSTEM,,CISCO TECH INC,O'BRIEN RICHARD ANTHONY;;ARDUINI DOUGLAS PAUL;;BAEK SUNG KEE;;LI RUQI;;GOERGEN JOEL RICHARD,,https://lens.org/096-039-701-051-419,Granted Patent,yes,3,0,8,8,0,H04L12/10;;H04L12/40045;;G01R31/54;;G01R31/52;;H04L12/4641;;H04L12/10;;G01R31/085;;H04L41/0677,H04L12/10;;G01R31/52;;G01R31/54;;H04L12/40,,0,0,,,,ACTIVE
56,CA,A1,CA 3127083 A1,051-278-494-189-882,2020-09-17,2020,CA 3127083 A,2020-02-28,US 201962817813 P;;US 201916380954 A;;US 2020/0020359 W,2019-03-13,MULTIPLE PHASE PULSE POWER IN A NETWORK COMMUNICATIONS SYSTEM,"In one embodiment, an apparatus comprises an input power interface for receiving input power, a power control system for transmitting DC (Direct Current) pulse power on multiple phases over a cable to a plurality of powered devices and verifying cable operation during an off-time of pulses in the DC pulse power, and a cable interface for delivery of the DC pulse power on the multiple phases and data over the cable to the powered devices. A method for transmitting multiple phase pulse power is also disclosed herein.",CISCO TECH INC,O'BRIEN RICHARD ANTHONY;;ARDUINI DOUGLAS PAUL;;BAEK SUNG KEE;;LI RUQI;;GOERGEN JOEL RICHARD,,https://lens.org/051-278-494-189-882,Patent Application,no,0,0,8,8,0,H04L12/10;;H04L12/40045;;G01R31/54;;G01R31/52;;H04L12/4641;;H04L12/10;;G01R31/085;;H04L41/0677,H04L12/10;;G01R31/08;;H04B3/54;;H04L12/40,,0,0,,,,PENDING
57,WO,A1,WO 2020/185422 A1,040-642-597-566-651,2020-09-17,2020,US 2020/0020359 W,2020-02-28,US 201916380954 A;;US 201962817813 P,2019-03-13,MULTIPLE PHASE PULSE POWER IN A NETWORK COMMUNICATIONS SYSTEM,"In one embodiment, an apparatus comprises an input power interface for receiving input power, a power control system for transmitting DC (Direct Current) pulse power on multiple phases over a cable to a plurality of powered devices and verifying cable operation during an off-time of pulses in the DC pulse power, and a cable interface for delivery of the DC pulse power on the multiple phases and data over the cable to the powered devices. A method for transmitting multiple phase pulse power is also disclosed herein.",CISCO TECH INC,O'BRIEN RICHARD ANTHONY;;ARDUINI DOUGLAS PAUL;;BAEK SUNG KEE;;LI RUQI;;GOERGEN JOEL RICHARD,,https://lens.org/040-642-597-566-651,Patent Application,yes,5,0,8,8,0,H04L12/10;;H04L12/40045;;G01R31/54;;G01R31/52;;H04L12/4641;;H04L12/10;;G01R31/085;;H04L41/0677,H04L12/10;;G01R31/08;;H04B3/54;;H04L12/40,,0,0,,,,PENDING
58,EP,A1,EP 3939203 A1,176-822-797-196-595,2022-01-19,2022,EP 20714427 A,2020-02-28,US 201962817813 P;;US 201916380954 A;;US 2020/0020359 W,2019-03-13,MULTIPLE PHASE PULSE POWER IN A NETWORK COMMUNICATIONS SYSTEM,,CISCO TECH INC,O'BRIEN RICHARD ANTHONY;;ARDUINI DOUGLAS PAUL;;BAEK SUNG KEE;;LI RUQI;;GOERGEN JOEL RICHARD,,https://lens.org/176-822-797-196-595,Patent Application,yes,0,0,8,8,0,H04L12/10;;H04L12/40045;;G01R31/54;;G01R31/52;;H04L12/4641;;H04L12/10;;G01R31/085;;H04L41/0677,H04L12/10;;G01R31/08;;H04B3/54;;H04L12/40,,0,0,,,,ACTIVE
59,US,A1,US 2020/0295955 A1,006-665-158-206-83X,2020-09-17,2020,US 201916380954 A,2019-04-10,US 201916380954 A;;US 201962817813 P,2019-03-13,MULTIPLE PHASE PULSE POWER IN A NETWORK COMMUNICATIONS SYSTEM,"In one embodiment, an apparatus comprises an input power interface for receiving input power, a power control system for transmitting DC (Direct Current) pulse power on multiple phases over a cable to a plurality of powered devices and verifying cable operation during an off-time of pulses in the DC pulse power, and a cable interface for delivery of the DC pulse power on the multiple phases and data over the cable to the powered devices. A method for transmitting multiple phase pulse power is also disclosed herein.",CISCO TECH INC,O'BRIEN RICHARD ANTHONY;;ARDUINI DOUGLAS PAUL;;BAEK SUNG KEE;;LI RUQI;;GOERGEN JOEL RICHARD,CISCO TECHNOLOGY INC (2019-04-09),https://lens.org/006-665-158-206-83X,Patent Application,yes,0,15,8,8,0,H04L12/10;;H04L12/40045;;G01R31/54;;G01R31/52;;H04L12/4641;;H04L12/10;;G01R31/085;;H04L41/0677,H04L12/10;;G01R31/08;;H04L12/24,,0,0,,,,ACTIVE
60,US,B2,US 7755649 B2,042-735-707-235-905,2010-07-13,2010,US 69534307 A,2007-04-02,US 69534307 A;;US 15035502 A;;US 5161202 A;;US 29008601 P;;US 29008701 P;;US 29014301 P;;US 31305401 P;;US 31113801 P;;US 31295501 P;;US 31294601 P;;US 31462201 P;;US 31812901 P,2001-05-09,Methods and systems for sub-pixel rendering with gamma adjustment,"Sub-pixel rendering with gamma adjustment allows the luminance for the sub-pixel arrangement to match the non-linear gamma response of the human eye's luminance channel, while the chrominance can match the linear response of the human eye's chrominance channels. The gamma correction allows the sub-pixel rendering to operate independently of the actual gamma of a display device. The sub-pixel rendering techniques with gamma adjustment may be optimized for the gamma transfer curve of a display device in order to improve response time, dot inversion balance, and contrast.",SAMSUNG ELECTRONICS CO LTD,BROWN ELLIOTT CANDICE HELLEN;;HAN SEOKJIN;;IM MOONHWAN;;BAEK INCHUL;;HIGGINS MICHAEL FRANCIS;;HIGGINS PAUL,SAMSUNG DISPLAY CO. LTD (2012-09-04);;CLAIRVOYANTE INC (2004-03-02);;SAMSUNG ELECTRONICS CO. LTD (2018-08-29),https://lens.org/042-735-707-235-905,Granted Patent,yes,101,13,26,81,0,G09G3/20;;G09G3/2003;;G09G5/005;;G09G5/006;;G09G5/02;;G09G2300/0452;;G09G2320/0276;;G09G2340/0407;;G09G2340/0414;;G09G2340/0421;;G09G2340/0457;;G09G2340/0492;;G09G3/20;;G09G3/36;;G09G5/00;;H04N5/202;;G09G5/006;;G09G2320/0276;;G09G3/2003;;G09G2340/0457;;G09G2340/0492;;G09G2300/0452;;G09G5/02;;G09G2340/0407;;G09G2340/0414;;G09G2340/0421;;G09G3/20;;G09G5/005,G09G3/36;;G09G3/20;;G09G5/10;;G09G5/00;;G09G5/02;;H04N5/202,345/690;;345/214;;345/589;;345/596;;345/597;;345/598;;345/613;;345/643;;348/254;;358/519;;382/167,58,9,007-151-325-367-760;;023-674-219-621-625;;006-822-786-531-074;;046-426-201-860-46X;;041-151-136-226-363;;011-751-663-448-890;;077-426-158-712-625;;039-897-388-399-796;;005-585-106-580-591,10.1889/1.1832941;;10.5594/m001004;;10.1889/1.1830224;;10.1889/1.1831775;;10.1117/12.952646;;10.1889/1.1830225;;10.1889/1.1832505;;10.1109/icip.2002.1038102;;10.1109/97.847362,"""Subpixel rendering."" Wikipedia, The Free Encyclopedia. Oct. 18, 2009, 00:37 UTC. Nov. 6, 2009 .;;""How Sub-Pixel Rendering Works."" Gibson Research Corporation. Last Edit: Oct. 6, 2003 at 13:31 Accessed: Nov. 6, 2009 .;;Adobe Systems, Inc. website http://www.adobe.com/products/acrobat/cooltype.html.;;Betrisey, C., et al., Displaced Filtering for Patterned Displays, SID Symp. Digest 1999, pp. 296-299.;;Brown Elliott, C., ""Active Matrix Display . . . "", IDMC 2000, 185-189, Aug. 2000.;;Brown Elliott, C., ""Color Subpixel Rendering Projectors and Flat Panel Displays,"" SMPTE, Feb. 27-Mar. 1, 2003, Seattle, WA pp. 1-4.;;Brown Elliott, C, ""Co-Optimization of Color AMLCD Subpixel Architecture and Rendering Algorithms,"" SID 2002 Proceedings Paper, May 30, 2002 pp. 172-175.;;Brown Elliott, C, ""Development of the PenTile Matrix(TM) Color AMLCD Subpixel Architecture and Rendering Algorithms"", SID 2003, Journal Article.;;Brown Elliott, C, ""New Pixel Layout for PenTile Matrix(TM) Architecture"", IDMC 2002, pp. 115-117.;;Brown Elliott, C, ""Pentile Matrix(TM) Displays and Drivers"" ADEAC Proceedings Paper, Portland OR., Oct. 2005.;;Brown Elliott, C, ""Reducing Pixel Count Without Reducing Image Quality"", Information Display Dec. 1999, vol. 1, pp. 22-25.;;Carvajal, D., ""Big Publishers Looking Into Digital Books,"" The NY Times, Apr. 3, 2000, Business/ Financial Desk.;;""ClearType magnified"", Wired Magazine, Nov. 8, 1999, Microsoft Typography, article posted Nov. 8, 1999, last updated Jan. 27, 1999 1 page.;;Credelle, Thomas, ""P-00: MTF of High-Resolution PenTile Matrix Displays"", Eurodisplay 02 Digest, 2002 pp. 1-4.;;Daly, Scott, ""Analysis of Subtriad Addressing Algorithms by Visual System Models"",SID Symp. Digest, Jun. 2001 pp. 1200-1203.;;E-Reader Devices and Software, Jan. 1, 2001, Syllabus, http://www.campus-technology.com/article.asp?id=419.;;Feigenblatt, R.I., Full-color imaging on amplitude-quantized color mosaic displays, SPIE, 1989, pp. 199-204.;;Feigenblatt, Ron, ""Remarks on Microsoft ClearType(TM)"", http://www.geocities.com/SiliconVallev/Ridge/6664/ClearType.html, Dec. 5, 1998, Dec. 7, 1998, Dec. 12, 1999, Dec. 26, 1999, Dec. 30, 1999 and Jun. 19, 2000, 30 pages.;;Gibson, S., ""Sub-Pixel Rendering; How it works,"" Gibson Research Corp., http://www.grc.com/ctwhat.html.;;Johnston, Stuart, ""An Easy Read: Microsoft's ClearType,"" InformationWeek Online, Redmond WA, Nov. 23, 1998. 3 pages.;;Johnston, Stuart, ""Clarifying ClearType,"" InformationWeek Online, Redmond WA, Jan. 4, 1999, 4 pages.;;Just Outta Beta, Wired Magazine, Dec. 1999 Issue 7-12, 3 pages.;;Klompenhouwer, Michiel, Subpixel Image Scaling for Color Matrix Displays, SID Symp. Digest, May 2002, pp. 176-179.;;Krantz, John et al., Color Matrix Display Image Quality: The Effects of Luminance . . . SID 90 Digest, pp. 29-32.;;Lee, Baek-woon et al., 40.5L: Late-News Paper: TFT-LCD with RGBW Color system, SID 03 Digest, 2003, pp. 1212-1215.;;Markoff, John, Microsoft's Cleartype Sets Off Debate on Originality, NY Times, Dec. 7, 1998, 5 pages.;;Martin, R., et al., ""Detectability of Reduced Blue-Pixel Count in Projection Displays,"" SID Symp. Digest, May 1993, pp. 606-609.;;Messing, Dean et al., Improved Display Resolution of Subsampled Colour Images Using Subpixel Addressing, IEEE ICIP 2002, vol. 1, pp. 625-628.;;Messing, Dean et al., Subpixel Rendering on Non-Striped Colour Matrix Displays, 2003 International Conf on Image Processing, Sep. 2003, Barcelona, Spain, 4 pages.;;""Microsoft ClearType,"" website, Mar. 26, 2003, 4 pages.;;Microsoft Corp. website, http://www.microsoft.com/typography/cleartype, 7 pages.;;Microsoft press release, Microsoft Research Announces Screen Display Breakthrough at COMDEX/Fall '98; . . . Nov. 15, 1998.;;Murch, M., ""Visual Perception Basics,"" SID Seminar, 1987, Tektronix Inc, Beaverton Oregon.;;Okumura et al., ""A New Flicker-Reduction Drive Method for High Resolution LCTVs"", SID Digest,pp. 551-554, 2001.;;Platt, John, Optimal Filtering for Patterned Displays, IEEE Signal Processing Letters, 2000, 4 pages.;;Poor, Alfred, ""LCDs: The 800-pound Gorilla,"" Information Display, Sep. 2002, pp. 18-21.;;Wandell, Brian A., Stanford University, ""Fundamentals of Vision: Behavior . . . ,"" Jun. 12, 1994, Society for Information Display (SID) Short Course S-2, Fairmont Hotel, San Jose, California.;;Werner, Ken, ""OLEDS, OLEDS, Everywhere . . . ,"" Information Display, Sep. 2002, pp. 12-15.;;USPTO, Non-Final Office Action, dated Feb. 7, 2005 in US Patent No. 7,123,277 (U.S. Appl. No. 10/051,612).;;Clairvoyante Inc, Response to Non-Final Office, dated Jul. 7, 2005 in US Patent No. 7,123,277 (U.S. Appl. No. 10/051,612).;;USPTO, Final Office Action dated, Aug. 31, 2005 in US Patent No. 7,123,277 (U.S. Appl. No. 10/051,612).;;Clairvoyante Inc, Response to Final Office, dated Sep. 19, 2005 in US Patent No. 7,123,277 (U.S. Appl. No. 10/051,612).;;USPTO, Non-Final Office Action dated, Dec. 15, 2005 in US Patent No. 7,123,277 (U.S. Appl. No. 10/051,612).;;Clairvoyante Inc, Response to Non-Final Office, dated Feb. 8, 2006 in US Patent No. 7,123,277 (U.S. Appl. No. 10/051,612).;;USPTO, Notice of Allowance, dated May 4, 2006 in US Patent No. 7,123,277 (U.S. Appl. No. 10/051,612).;;USPTO, Non-Final Office Action, dated Mar. 24, 2005 in US Patent No. 7,184,066 (U.S. Appl. No. 10/215,843).;;Clairvoyante Inc, Response to Non-Final Office Action, dated Sep. 26, 2005 in US Patent No. 7,184,066 (U.S. Appl. No. 10/215,843).;;USPTO, Final Office Action, dated Jan. 25, 2006 in US Patent No. 7,184,066 (U.S. Appl. No. 10/215,843).;;Clairvoyante Inc, Response to Non-Final Office Action, dated Jun. 26, 2006 in US Patent No. 7,184,066 (U.S. Appl. No. 10/215,843).;;USPTO, Non-Final Office Action, dated Nov. 16, 2004 in US Patent Publication No. 2003/0128225, (U.S. Appl. No. 10/278,353).;;Clairvoyante Inc, Response to Non-Final Office Action, dated Apr. 15, 2005 in US Patent Publication No. 2003/0128225, (U.S. Appl. No. 10/278,353).;;USPTO, Non-Final Office Action, dated Jul. 12, 2005 in US Patent Publication No. 2003/0128225, (U.S. Appl. No. 10/278,353).;;Clairvoyante Inc, Response to Non-Final Office Action, dated Jan. 12, 2006 in US Patent Publication No. 2003/0128225, (U.S. Appl. No. 10/278,353).;;USPTO, Final Office Action, dated Apr. 18, 2006 in US Patent Publication No. 2003/0128225, (U.S. Appl. No. 10/278,353).;;USPTO, Non-Final Office Action, dated Nov. 16, 2004 in US Patent Publication No. 2003/0128179, (U.S. Appl. No. 10/278,352).;;Clairvoyante Inc, Response to Non-Final Office Action, dated Apr. 15, 2005 in US Patent Publication No. 2003/0128179, (U.S. Appl. No. 10/278,352).;;USPTO, Non-Final Office Action, dated Jul. 12, 2005 in US Patent Publication No. 2003/0128179, (U.S. Appl. No. 10/278,352).;;Clairvoyante Inc, Response to Non-Final Office Action, dated Jan. 12, 2006 in US Patent Publication No. 2003/0128179, (U.S. Appl. No. 10/278,352).",EXPIRED
61,US,B2,US 10645694 B2,112-632-689-415-659,2020-05-05,2020,US 201715647915 A,2017-07-12,US 201715647915 A;;US 201715397206 A,2017-01-03,Over the air signaling of dynamic frequency selection (DFS) operating parameters to client devices,"Over the air signaling of dynamic frequency selection operating parameters to client devices is disclosed. In an embodiment, a multi-channel master device determines a maximum range value of a radar detection umbrella associated with the multi-channel master device based on a first range representing a range at which the multi-channel master device detects a first radar transmission transmitted by a radar device at a defined transmission power; determines a compliance range value based on a second range representing a range at which the multi-channel master device detects a second radar transmission transmitted by the radar device at a dynamic frequency selection (DFS) compliance threshold transmission power; and determines a margin range value based on a third range representing a range at which the multi-channel master device detects a third radar transmission transmitted by the radar device at a transmission power that is lower than the dynamic frequency selection compliance threshold transmission power.",NETWORK PERFORMANCE RES GROUP LLC,YI SEUNG BAEK;;TSAI KUN TING;;YEE PAUL V;;NGO TERRY F K;;KURNIAWAN ERICK,CHENGDU SK SPRUCE TECHNOLOGIES CO. LTD (2023-07-04);;NETWORK PERFORMANCE RESEARCH GROUP LLC (2017-01-02),https://lens.org/112-632-689-415-659,Granted Patent,yes,51,0,3,3,0,H04W16/14;;H04W74/08;;H04W72/04;;H04W72/044;;H04W74/0808;;G01S7/021;;H04W72/0453;;H04W16/14,H04W72/04;;G01S7/02;;G01S13/00;;H04W16/14;;H04W74/08,,1,0,,,"Office Action for U.S. Appl. No. 15/397,206 dated Feb. 3, 2017, 283 pages.",ACTIVE
62,US,B2,US 7623141 B2,040-025-806-783-035,2009-11-24,2009,US 74739807 A,2007-05-11,US 74739807 A;;US 15035502 A;;US 5161202 A;;US 29008601 P;;US 29008701 P;;US 29014301 P;;US 31305401 P;;US 31113801 P;;US 31295501 P;;US 31294601 P;;US 31462201 P;;US 31812901 P,2001-05-09,Methods and systems for sub-pixel rendering with gamma adjustment,"Sub-pixel rendering with gamma adjustment allows the luminance of the sub-pixel arrangement to match the non-linear gamma response of the human eye's luminance channel. For each of a subset of input sampled data indicating a region of an input image, a gamma-adjusted data value is generated for each input image data value in the subset using a local average of at least two input image data values. A sub-pixel rendering operation uses the subset of gamma-adjusted data values and the subset of input image data values to produce an output data value for each sub-pixel element on the display panel. A plurality of output data values collectively indicates an output image. The gamma adjustment allows the sub-pixel rendering to operate independently of the actual gamma of a display device. The sub-pixel rendering techniques with gamma adjustment may improve image contrast in high spatial frequency portions of an image.",SAMSUNG ELECTRONICS CO LTD,BROWN ELLIOTT CANDICE HELLEN;;HAN SEOKJIN;;IM MOONHWAN;;BAEK INCHUL;;HIGGINS MICHAEL FRANCIS;;HIGGINS PAUL,SAMSUNG DISPLAY CO. LTD (2012-09-04);;CLAIRVOYANTE INC (2004-03-02);;SAMSUNG ELECTRONICS CO. LTD (2018-08-29),https://lens.org/040-025-806-783-035,Granted Patent,yes,103,15,26,81,0,G09G3/20;;G09G3/2003;;G09G5/005;;G09G5/006;;G09G5/02;;G09G2300/0452;;G09G2320/0276;;G09G2340/0407;;G09G2340/0414;;G09G2340/0421;;G09G2340/0457;;G09G2340/0492;;G09G3/20;;G09G3/36;;G09G5/00;;H04N5/202;;G09G5/006;;G09G2320/0276;;G09G3/2003;;G09G2340/0457;;G09G2340/0492;;G09G2300/0452;;G09G5/02;;G09G2340/0407;;G09G2340/0414;;G09G2340/0421;;G09G3/20;;G09G5/005,G09G3/20;;G09G3/36;;G09G5/00;;G09G5/10;;G09G5/02;;H04N5/202,345/690;;345/214;;345/589;;345/596;;345/597;;345/613;;382/167;;382/272;;382/274;;348/254;;358/519,53,9,007-151-325-367-760;;023-674-219-621-625;;006-822-786-531-074;;046-426-201-860-46X;;041-151-136-226-363;;011-751-663-448-890;;077-426-158-712-625;;039-897-388-399-796;;005-585-106-580-591,10.1889/1.1832941;;10.5594/m001004;;10.1889/1.1830224;;10.1889/1.1831775;;10.1117/12.952646;;10.1889/1.1830225;;10.1889/1.1832505;;10.1109/icip.2002.1038102;;10.1109/97.847362,"Betrisey, C., et al., Displaced Filtering for Patterned Displays, SID Symp. Digest 1999, pp. 296-299.;;Brown Elliott, C., ""Active Matrix Display . . . "", IDMC 2000, 185-189, Aug. 2000.;;Brown Elliott, C., ""Color Subpixel Rendering Projectors and Flat Panel Displays,"" SMPTE, Feb. 27-Mar. 1, 2003, Seattle, WA pp. 1-4.;;Brown Elliott, C, ""Co-Optimization of Color AMLCD Subpixel Architecture and Rendering Algorithms,"" SID 2002 Proceedings Paper, May 30, 2002 pp. 172-175.;;Brown Elliott, C, ""Development of the PenTile Matrix(TM) Color AMLCD Subpixel Architecture and Rendering Algorithms"", SID 2003, Journal Article.;;Brown Elliott, C, ""New Pixel Layout for PenTile Matrix(TM) Architecture"", IDMC 2002, pp. 115-117.;;Brown Elliott, C, ""Pentile Matrix(TM) Displays and Drivers"" ADEAC Proceedings Paper, Portland OR., Oct. 2005.;;Brown Elliott, C, ""Reducing Pixel Count Without Reducing Image Quality"", Information Display Dec. 1999, vol. 1, pp. 22-25.;;Carvajal, D., ""Big Publishers Looking Into Digital Books,"" The NY Times, Apr. 3, 2000, Business/ Financial Desk.;;""ClearType magnified"", Wired Magazine, Nov. 8, 1999, Microsoft Typography, article posted Nov. 8, 1999, last updated Jan. 27, 1999 1 page.;;Credelle, Thomas, ""P-00: MTF of High-Resolution PenTile Matrix Displays"", Eurodisplay 02 Digest, 2002 pp. 1-4.;;Daly, Scott, ""Analysis of Subtriad Addressing Algorithms by Visual System Models"",SID Symp. Digest, Jun. 2001 pp. 1200-1203.;;E-Reader Devices and Software, Jan. 1, 2001, Syllabus, http://www.campus-technology.com/article.asp?id=419.;;Feigenblatt, R.I., Full-color imaging on amplitude-quantized color mosaic displays, SPIE, 1989, pp. 199-204.;;Feigenblatt, Ron, ""Remarks on Microsoft ClearType(TM)"", http://www.geocities.com/SiliconValley/Ridge/6664/ClearType.html, Dec. 5, 1998, Dec. 7, 1998, Dec. 12, 1999, Dec. 26, 1999, Dec. 30, 1999 and Jun. 19, 2000, 30 pages.;;Johnston, Stuart, ""An Easy Read: Microsoft's ClearType,"" InformationWeek Online, Redmond WA, Nov. 23, 1998. 3 pages.;;Johnston, Stuart, ""Clarifying ClearType,"" InformationWeek Online, Redmond WA, Jan. 4, 1999, 4 pages.;;Just Outta Beta, Wired Magazine, Dec. 1999 Issue 7-12, 3 pages.;;Klompenhouwer, Michiel, Subpixel Image Scaling for Color Matrix Displays, SID Symp. Digest, May 2002, pp. 176-179.;;Krantz, John et al., Color Matrix Display Image Quality: The Effects of Luminance . . . SID 90 Digest, pp. 29-32.;;Lee, Baek-woon et al., 40.5L: Late-News Paper: TFT-LCD with RGBW Color system, SID 03 Digest, 2003, pp. 1212-1215.;;Markoff, John, Microsoft's Cleartype Sets Off Debate on Originality, NY Times, Dec. 7, 1998, 5 pages.;;Martin, R., et al., ""Detectability of Reduced Blue-Pixel Count in Projection Displays,"" SID Symp. Digest, May 1993, pp. 606-609.;;Messing, Dean et al., Improved Display Resolution of Subsampled Colour Images Using Subpixel Addressing, IEEE ICIP 2002, vol. 1, pp. 625-628.;;Messing, Dean et al., Subpixel Rendering on Non-Striped Colour Matrix Displays, 2003 International Conf on Image Processing, Sep. 2003, Barcelona, Spain, 4 pages.;;""Microsoft ClearType,"" website, Mar. 26, 2003, 4 pages.;;Microsoft press release, Microsoft Research Announces Screen Display Breakthrough at COMDEX/Fall '98; . . . Nov. 15, 1998.;;Murch, M., ""Visual Perception Basics,"" SID Seminar, 1987, Tektronix Inc, Beaverton Oregon.;;Okumura et al., ""A New Flicker-Reduction Drive Method for High Resolution LCTVs"", SID Digest,pp. 551-554, 2001.;;Platt, John, Optimal Filtering for Patterned Displays, IEEE Signal Processing Letters, 2000, 4 pages.;;Poor, Alfred, ""LCDs: The 800-pound Gorilla,"" Information Display, Sep. 2002, pp. 18-21.;;Wandell, Brian A., Stanford University, ""Fundamentals of Vision: Behavior . . . ,"" Jun. 12, 1994, Society for Information Display (SID) Short Course S-2, Fairmont Hotel, San Jose, California.;;Werner, Ken, ""OLEDS, OLEDS, Everywhere . . . ,"" Information Display, Sep. 2002, pp. 12-15.;;USPTO, Non-Final Office Action, dated Feb. 7, 2005 in US Patent No. 7,123,277 (U.S. Appl. No. 10/051,612).;;Clairvoyante Inc, Response to Non-Final Office, dated Jul. 7, 2005 in US Patent No. 7,123,277 (U.S. Appl. No. 10/051,612).;;USPTO, Final Office Action dated, Aug. 31, 2005 in US Patent No. 7,123,277 (U.S. Appl. No. 10/051,612).;;Clairvoyante Inc, Response to Final Office, dated Sep. 19, 2005 in US Patent No. 7,123,277 (U.S. Appl. No. 10/051,612).;;USPTO, Non-Final Office Action dated, Dec. 15, 2005 in US Patent No. 7,123,277 (U.S. Appl. No. 10/051,612).;;Clairvoyante Inc, Response to Non-Final Office, dated Feb. 8, 2006 in US Patent No. 7,123,277 (U.S. Appl. No. 10/051,612).;;USPTO, Notice of Allowance, dated May 4, 2006 in US Patent No. 7,123,277 (U.S. Appl. No. 10/051,612).;;USPTO, Non-Final Office Action, dated Mar. 24, 2005 in US Patent No. 7,184,066 (U.S. Appl. No. 10/215,843).;;Clairvoyante Inc, Response to Non-Final Office Action, dated Sep. 26, 2005 in US Patent No. 7,184,066 (U.S. Appl. No. 10/215,843).;;USPTO, Final Office Action, dated Jan. 25, 2006 in US Patent No. 7,184,066 (U.S. Appl. No. 10/215,843).;;Clairvoyante Inc, Response to Non-Final Office Action, dated Jun. 26, 2006 in US Patent No. 7,184,066 (U.S. Appl. No. 10/215,843).;;USPTO, Non-Final Office Action, dated Nov. 16, 2004 in US Patent Publication No. 2003/0128225, (U.S. Appl. No. 10/278,353).;;Clairvoyante Inc, Response to Non-Final Office Action, dated Apr. 15, 2005 in US Patent Publication No. 2003/0128225, (U.S. Appl. No. 10/278,353).;;USPTO, Non-Final Office Action, dated Jul. 12, 2005 in US Patent Publication No. 2003/0128225, (U.S. Appl. No. 10/278,353).;;Clairvoyante Inc, Response to Non-Final Office Action, dated Jan. 12, 2006 in US Patent Publication No. 2003/0128225, (U.S. Appl. No. 10/278,353).;;USPTO, Final Office Action, dated Apr. 18, 2006 in US Patent Publication No. 2003/0128225, (U.S. Appl. No. 10/278,353).;;USPTO, Non-Final Office Action, dated Nov. 16, 2004 in US Patent Publication No. 2003/0128179, (U.S. Appl. No. 10/278,352).;;Clairvoyante Inc, Response to Non-Final Office Action, dated Apr. 15, 2005 in US Patent Publication No. 2003/0128179, (U.S. Appl. No. 10/278,352).;;USPTO, Non-Final Office Action, dated Jul. 12, 2005 in US Patent Publication No. 2003/0128179, (U.S. Appl. No. 10/278,352).;;Clairvoyante Inc, Response to Non-Final Office Action, dated Jan. 12, 2006 in US Patent Publication No. 2003/0128179, (U.S. Appl. No. 10/278,352).",EXPIRED
63,US,A1,US 2018/0192422 A1,198-897-932-666-372,2018-07-05,2018,US 201715647915 A,2017-07-12,US 201715647915 A;;US 201715397206 A,2017-01-03,OVER THE AIR SIGNALING OF DYNAMIC FREQUENCY SELECTION (DFS) OPERATING PARAMETERS TO CLIENT DEVICES,"Over the air signaling of dynamic frequency selection operating parameters to client devices is disclosed. In an embodiment, a multi-channel master device determines a maximum range value of a radar detection umbrella associated with the multi-channel master device based on a first range representing a range at which the multi-channel master device detects a first radar transmission transmitted by a radar device at a defined transmission power; determines a compliance range value based on a second range representing a range at which the multi-channel master device detects a second radar transmission transmitted by the radar device at a dynamic frequency selection (DFS) compliance threshold transmission power; and determines a margin range value based on a third range representing a range at which the multi-channel master device detects a third radar transmission transmitted by the radar device at a transmission power that is lower than the dynamic frequency selection compliance threshold transmission power.",NETWORK PERFORMANCE RES GROUP LLC,YI SEUNG BAEK;;TSAI KUN TING;;YEE PAUL V;;NGO TERRY F K;;KURNIAWAN ERICK,CHENGDU SK SPRUCE TECHNOLOGIES CO. LTD (2023-07-04);;NETWORK PERFORMANCE RESEARCH GROUP LLC (2017-01-02),https://lens.org/198-897-932-666-372,Patent Application,yes,29,5,3,3,0,H04W16/14;;H04W74/08;;H04W72/04;;H04W72/044;;H04W74/0808;;G01S7/021;;H04W72/0453;;H04W16/14,H04W72/04;;G01S7/02;;H04W74/08,,0,0,,,,ACTIVE
64,US,B1,US 9736845 B1,079-599-569-392-433,2017-08-15,2017,US 201715397206 A,2017-01-03,US 201715397206 A,2017-01-03,Over the air signaling of dynamic frequency selection (DFS) operating parameters to client devices,"Over the air signaling of dynamic frequency selection operating parameters to client devices is disclosed. In an embodiment, a multi-channel master device determines a maximum range value of a radar detection umbrella associated with the multi-channel master device based on a first range representing a range at which the multi-channel master device detects a first radar transmission transmitted by a radar device at a defined transmission power; determines a compliance range value based on a second range representing a range at which the multi-channel master device detects a second radar transmission transmitted by the radar device at a dynamic frequency selection (DFS) compliance threshold transmission power; and determines a margin range value based on a third range representing a range at which the multi-channel master device detects a third radar transmission transmitted by the radar device at a transmission power that is lower than the dynamic frequency selection compliance threshold transmission power.",NETWORK PERFORMANCE RES GROUP LLC,YI SEUNG BAEK;;TSAI KUN TING;;YEE PAUL V;;NGO TERRY F K;;KURNIAWAN ERICK,CHENGDU SK SPRUCE TECHNOLOGIES CO. LTD (2023-07-04);;NETWORK PERFORMANCE RESEARCH GROUP LLC (2017-01-02),https://lens.org/079-599-569-392-433,Granted Patent,yes,22,15,3,3,0,H04W16/14;;H04W74/08;;H04W72/04;;H04W72/044;;H04W74/0808;;G01S7/021;;H04W72/0453;;H04W16/14,G01S7/40;;G01S7/00;;G01S7/02;;H04W72/04;;H04W74/08,,0,0,,,,ACTIVE
65,CN,A,CN 109416470 A,089-388-055-304-523,2019-03-01,2019,CN 201780020762 A,2017-06-06,US 201662352754 P;;US 2017/0036205 W,2016-06-21,OPTICAL SYSTEMS FOR DISPLAYS,An electronic device may include a display system for presenting images close to a user's eyes. The display system may include a display unit that directs light and an optical system that redirects the light from the display unit towards a user's eyes. The optical system may include an input coupler and an output coupler formed on a waveguide. The input coupler may redirect light from the displayunit so that it propagates in the waveguide towards the output coupler. The output coupler may redirect the light from the input coupler so that it exits the waveguide towards the user's eyes. A light-redirecting element may be used to redirect edge light that would otherwise be outside of the user' s field of view towards the user's eyes.,APPLE INC,MYHRE GRAHAM B;;HANSOTTE ERIC J;;PENG GUOLIN;;CHOI HYUNGRYUL;;OH SE BAEK;;GELSINGER-AUSTIN PAUL,,https://lens.org/089-388-055-304-523,Patent Application,no,5,2,10,10,0,G02B27/017;;G02B2027/0123;;G02B2027/0178;;G02B27/0172;;G02B2027/0123;;G02B2027/0178;;G02B6/0023;;G02B6/0035;;G02B27/0172;;G02B2027/0123;;G02B2027/0174;;G02B2027/0178,G02B27/01,,0,0,,,,PENDING
66,WO,A1,WO 2017/222808 A1,122-101-105-784-777,2017-12-28,2017,US 2017/0036205 W,2017-06-06,US 201662352754 P,2016-06-21,OPTICAL SYSTEMS FOR DISPLAYS,An electronic device may include a display system for presenting images close to a user's eyes. The display system may include a display unit that directs light and an optical system that redirects the light from the display unit towards a user's eyes. The optical system may include an input coupler and an output coupler formed on a waveguide. The input coupler may redirect light from the display unit so that it propagates in the waveguide towards the output coupler. The output coupler may redirect the light from the input coupler so that it exits the waveguide towards the user's eyes. A light-redirecting element may be used to redirect edge light that would otherwise be outside of the user' s field of view towards the user's eyes.,APPLE INC,MYHRE GRAHAM B;;HANSOTTE ERIC J;;PENG GUOLIN;;CHOI HYUNGRYUL;;OH SE BAEK;;GELSINGER-AUSTIN PAUL,,https://lens.org/122-101-105-784-777,Patent Application,yes,2,19,10,10,0,G02B27/017;;G02B2027/0123;;G02B2027/0178;;G02B27/0172;;G02B2027/0123;;G02B2027/0178;;G02B6/0023;;G02B6/0035;;G02B27/0172;;G02B2027/0123;;G02B2027/0174;;G02B2027/0178,G02B27/01,,0,0,,,,PENDING
67,EP,A1,EP 3420395 A1,102-198-700-986-70X,2019-01-02,2019,EP 17731027 A,2017-06-06,US 201662352754 P;;US 2017/0036205 W,2016-06-21,OPTICAL SYSTEMS FOR DISPLAYS,,APPLE INC,MYHRE GRAHAM B;;HANSOTTE ERIC J;;PENG GUOLIN;;CHOI HYUNGRYUL;;OH SE BAEK;;GELSINGER-AUSTIN PAUL,,https://lens.org/102-198-700-986-70X,Patent Application,yes,0,0,10,10,0,G02B27/017;;G02B2027/0123;;G02B2027/0178;;G02B27/0172;;G02B2027/0123;;G02B2027/0178;;G02B6/0023;;G02B6/0035;;G02B27/0172;;G02B2027/0123;;G02B2027/0174;;G02B2027/0178,G02B27/01,,0,0,,,,PENDING
68,US,A1,US 2019/0377181 A1,013-009-629-510-132,2019-12-12,2019,US 201716089006 A,2017-06-06,US 201716089006 A;;US 201662352754 P;;US 2017/0036205 W,2016-06-21,Optical Systems for Displays,An electronic device may include a display system for presenting images close to a user's eyes. The display system may include a display unit that directs light and an optical system that redirects the light from the display unit towards a user's eyes. The optical system may include an input coupler and an output coupler formed on a waveguide. The input coupler may redirect light from the display unit so that it propagates in the waveguide towards the output coupler. The output coupler may redirect the light from the input coupler so that it exits the waveguide towards the user's eyes. A light-redirecting element may be used to redirect edge light that would otherwise be outside of the user's field of view towards the user's eyes.,APPLE INC,MYHRE GRAHAM B;;HANSOTTE ERIC J;;PENG GUOLIN;;CHOI HYUNGRYUL;;OH SE BAEK;;GELSINGER-AUSTIN PAUL,,https://lens.org/013-009-629-510-132,Patent Application,yes,1,3,10,10,0,G02B27/017;;G02B2027/0123;;G02B2027/0178;;G02B27/0172;;G02B2027/0123;;G02B2027/0178;;G02B6/0023;;G02B6/0035;;G02B27/0172;;G02B2027/0123;;G02B2027/0174;;G02B2027/0178,G02B27/01;;F21V8/00,,0,0,,,,PENDING
69,JP,A,JP 2020201496 A,075-860-531-643-672,2020-12-17,2020,JP 2020131863 A,2020-08-03,US 201662352754 P,2016-06-21,OPTICAL SYSTEM FOR DISPLAY,"To provide a novel display system to display an image near user's eyes.SOLUTION: A display system can include a display unit that guides light, and an optical system that changes a direction of the light from the display unit to user's eyes. The optical system can include an input coupler 30 and an output coupler 32 formed in a waveguide 28. The input coupler can change the direction of the light from the display unit so that the light propagates in the waveguide to the output coupler. The output coupler can change the direction of the light from the input coupler so that the light is output from the waveguide to the user's eyes. The edge light, which would be out of user's sight if not changed in direction, can be directed to the user's eyes by using a light direction changing element.SELECTED DRAWING: Figure 2B",APPLE INC,GRAHAM B MYHRE;;ERIC J HANSOTTE;;PENG GUOLIN;;CHOI HYUNGRYUL;;OH SE BAEK;;PAUL GELSINGER-AUSTIN,,https://lens.org/075-860-531-643-672,Patent Application,no,3,0,10,10,0,G02B27/017;;G02B2027/0123;;G02B2027/0178;;G02B27/0172;;G02B2027/0123;;G02B2027/0178;;G02B6/0023;;G02B6/0035;;G02B27/0172;;G02B2027/0123;;G02B2027/0174;;G02B2027/0178,G02B27/02;;G02B5/32,,0,0,,,,ACTIVE
70,KR,A,KR 20180115311 A,174-910-485-550-273,2018-10-22,2018,KR 20187027391 A,2017-06-06,US 201662352754 P;;US 2017/0036205 W,2016-06-21,디스플레이용 광학 시스템,"전자 디바이스는 사용자의 눈 가까이에 이미지들을 제공하기 위한 디스플레이 시스템을 포함할 수 있다. 디스플레이 시스템은 광을 지향시키는 디스플레이 유닛 및 디스플레이 유닛으로부터의 광을 사용자의 눈을 향해 방향전환하는 광학 시스템을 포함할 수 있다. 광학 시스템은 도파관 상에 형성된 입력 커플러 및 출력 커플러를 포함할 수 있다. 입력 커플러는 디스플레이 유닛으로부터의 광을, 그것이 출력 커플러를 향해 도파관 내에서 전파되도록 방향전환할 수 있다. 출력 커플러는 입력 커플러로부터의 광을, 그것이 사용자의 눈을 향해 도파관을 빠져나가도록 방향전환할 수 있다. 광-방향전환 요소는 그렇지 않으면 사용자의 시야 외부에 있을 에지 광을, 사용자의 눈을 향해 방향전환하기 위해 사용될 수 있다.",APPLE INC,MYHRE GRAHAM B;;HANSOTTE ERIC J;;PENG GUOLIN;;CHOI HYUNGRYUL;;OH SE BAEK;;GELSINGER AUSTIN PAUL,,https://lens.org/174-910-485-550-273,Patent Application,no,3,2,10,10,0,G02B27/017;;G02B2027/0123;;G02B2027/0178;;G02B27/0172;;G02B2027/0123;;G02B2027/0178;;G02B6/0023;;G02B6/0035;;G02B27/0172;;G02B2027/0123;;G02B2027/0174;;G02B2027/0178,G02B27/01,,0,0,,,,ACTIVE
71,US,A1,US 2023/0223988 A1,156-294-149-616-692,2023-07-13,2023,US 202318187006 A,2023-03-21,US 202318187006 A;;US 202117171723 A;;US 201916671508 A,2019-11-01,FAULT MANAGED POWER WITH DYNAMIC AND ADAPTIVE FAULT SENSOR,"Techniques are provided for detecting a fault across a pair of lines. Pulse power is applied across the pair of lines. The pulse power comprises alternating pulse on-time intervals and pulse off-time intervals. During a pulse off-time interval, a resistor is connected across the pair of lines and then disconnected when a voltage across the pair of lines reaches a first droop percentage in a first period of time. After disconnecting the resistor, it is determined whether the voltage across the pair of lines droops at least a second droop percentage within a second period of time that begins after the first period of time. Occurrence of a line-to-line fault across the pair of lines is determined when the voltage across the pair of lines droops by at least the second droop percentage or more within the second period of time.",CISCO TECH INC,ARDUINI DOUGLAS PAUL;;LI RUQI;;JONES CHAD M;;BAEK SUNG KEE;;POTTERF JASON DEWAYNE;;GOERGEN JOEL RICHARD,CISCO TECHNOLOGY INC (2023-03-16),https://lens.org/156-294-149-616-692,Patent Application,yes,0,1,1,14,0,H02J13/00032;;H02J13/00;;H04B3/54;;G01R31/086;;H04L12/10;;H04L12/40045;;H02J13/00032;;G01R31/50;;G01R31/083;;G05B9/02;;G06F1/305;;H02J13/00;;H04B3/54;;H04L12/10;;H04L12/40045,G06F1/30,,0,0,,,,PENDING
72,CN,A,CN 112075053 A,199-891-074-473-652,2020-12-11,2020,CN 201980030126 A,2019-04-19,US 201815971729 A;;US 2019/0028251 W,2018-05-04,HIGH POWER AND DATA DELIVERY IN A COMMUNICATIONS NETWORK WITH SAFETY AND FAULT PROTECTION,"In one embodiment, a method includes receiving power at an optical transceiver module at a remote network device on a cable delivering power and data from a central network device, operating the remote network device in a low voltage startup mode during fault sensing at the remote network device, transmitting on the cable, a data signal to the central network device, the data signal indicating anoperating status based on the fault sensing, and receiving high voltage power from the central network device on the cable at the remote network device upon transmitting an indication of a safe operating status at the remote network device, wherein the remote network device is powered by the high voltage power. An apparatus is also disclosed herein.",CISCO TECH INC,GOERGEN JOEL;;JONES CHAD M;;ARDUINI DOUGLAS PAUL;;O'BRIEN RICHARD ANTHONY;;BARSOTTI DANIEL LEE;;BAEK SUNG-KI,,https://lens.org/199-891-074-473-652,Patent Application,no,12,1,14,14,0,H04L12/10;;H04L12/40032;;H02H1/0007;;H04B10/0779;;H04B10/808;;H04B10/07;;H04L12/10,H04L12/10;;H04L12/40,,0,0,,,,ACTIVE
73,US,B2,US 8159511 B2,127-527-245-498-465,2012-04-17,2012,US 82525010 A,2010-06-28,US 82525010 A;;US 69534307 A;;US 15035502 A;;US 5161202 A;;US 31113801 P;;US 31295501 P;;US 31294601 P;;US 31462201 P;;US 31812901 P;;US 29008601 P;;US 29008701 P;;US 29014301 P;;US 31305401 P,2001-05-09,Methods and systems for sub-pixel rendering with gamma adjustment,"Sub-pixel rendering with gamma adjustment allows the luminance for the sub-pixel arrangement to match the non-linear gamma response of the human eye's luminance channel, while the chrominance can match the linear response of the human eye's chrominance channels. The gamma correction allows the sub-pixel rendering to operate independently of the actual gamma of a display device. The sub-pixel rendering techniques with gamma adjustment may be optimized for the gamma transfer curve of a display device in order to improve response time, dot inversion balance, and contrast.",BROWN ELLIOTT CANDICE HELLEN;;HAN SEOK JIN;;IM MOON HWAN;;BAEK IN CHUL;;HIGGINS MICHAEL FRANCIS;;HIGGINS PAUL;;SAMSUNG ELECTRONICS CO LTD,BROWN ELLIOTT CANDICE HELLEN;;HAN SEOK JIN;;IM MOON HWAN;;BAEK IN CHUL;;HIGGINS MICHAEL FRANCIS;;HIGGINS PAUL,SAMSUNG DISPLAY CO. LTD (2012-09-04);;SAMSUNG ELECTRONICS CO. LTD (2018-08-29),https://lens.org/127-527-245-498-465,Granted Patent,yes,101,6,26,81,0,G09G3/20;;G09G3/2003;;G09G5/005;;G09G5/006;;G09G5/02;;G09G2300/0452;;G09G2320/0276;;G09G2340/0407;;G09G2340/0414;;G09G2340/0421;;G09G2340/0457;;G09G2340/0492;;G09G3/20;;G09G3/36;;G09G5/00;;H04N5/202;;G09G5/006;;G09G2320/0276;;G09G3/2003;;G09G2340/0457;;G09G2340/0492;;G09G2300/0452;;G09G5/02;;G09G2340/0407;;G09G2340/0414;;G09G2340/0421;;G09G3/20;;G09G5/005,G09G3/20;;G09G3/36;;G09G5/00;;G09G5/10;;G09G5/02;;H04N5/202,345/690;;345/55;;345/214;;345/589;;345/613;;348/254,33,9,041-151-136-226-363;;007-151-325-367-760;;023-674-219-621-625;;006-822-786-531-074;;046-426-201-860-46X;;011-751-663-448-890;;077-426-158-712-625;;005-585-106-580-591;;039-897-388-399-796,10.1117/12.952646;;10.1889/1.1832941;;10.5594/m001004;;10.1889/1.1830224;;10.1889/1.1831775;;10.1889/1.1830225;;10.1889/1.1832505;;10.1109/97.847362;;10.1109/icip.2002.1038102,"E-Reader Devices and Software, Jan. 1, 2001, Syllabus, http://www.campus-technology.com/article.asp?id=419.;;Brown Elliott, C. ""Pentile Matrix TM Displays and Drivers"" ADEAC Proceedings Paper, Portland OR, Oct. 2005.;;Feigenblatt, R.I., ""Full-color imaging on amplitude-quantized color mosaic displays,"" SPIE, 1989, pp. 199-204.;;Wikipedia, The Free Encyclopedia ""Subpixel rendering"" Oct. 18, 2009, 0037 UTC. Nov. 6, 2009 .;;Betrisey, C., et al., Displaced Filtering for Patterned Displays, SID Symp. Digest 1999, pp. 296-299.;;Brown Elliott, C., ""Active Matrix Display . . . "", IDMC 2000, 185-189, Aug. 2000.;;Brown Elliott, C., ""Color Subpixel Rendering Projectors and Flat Panel Displays,"" SMPTE, Feb. 27-Mar. 1, 2003, Seattle, WA pp. 1-4.;;Brown Elliott, C., ""Co-Optimization of Color AMLCD Subpixel Architecture and Rendering Algorithms,"" SID 2002 Proceedings Paper, May 30, 2002 pp. 172-175.;;Brown Elliott, C., ""Development of the PenTile Matrix Color AMLCD Subpixel Architecture and Rendering Algorithms"", SID 2003, Journal Article.;;Brown Elliott, C., ""New Pixel Layout for PenTile Matrix Architecture"", IDMC 2002, pp. 115-117.;;Brown Elliott C., ""Reducing Pixel Count Without Reducing Image Quality"", Information Display Dec. 1999, vol. 1, pp. 22-25.;;Caravajal, D., ""Big Publishers Looking Into Digital Books,"" The NY Times, Apr. 3, 2000, Business/Finalcial Desk.;;""ClearType magnified"", Wired Magazine, Nov. 8, 1999, Microsoft Typography, article posted Nov. 8, 1999, last updated Jan. 27, 1999, 1 page.;;Credelle, Thomas, ""P-00: MTF of High-Resolution PenTile Matrix Displays"", Eurodisplay 02 Digest, 2002, pp. 1-4.;;Daly, Scott, ""Analysis of Subtriad Addressing Algorithms by Visual System Models"", SID Symp. Digest, Jun. 2001, pp. 1200-1203.;;Feigenblatt, Ron, ""rearks on Microsoft ClearType"", http://www.geocities.com/SiliconValley/Ridge/6664/ClearType.html Dec. 5, 1998, Dec. 7, 1998, Dec. 12, 1999, Dec. 26, 1999, Dec. 30, 1999 and Jun. 19, 2000, 30 pages.;;Johnston, Stuart, ""An Easy Read: Microsoft's ClearType,"" InformationWeek ONline, REdmond WA, Nov. 23, 1998. 3 pages.;;Johnston, Stuart, ""Clarifying ClearType,"" InfomationWeek Online, Redmond WA, Jan. 4, 1999, 4 pages.;;""Just Outta Beta"", Wired Magazine, Dec. 1999 Issue 7-12, 3 pages.;;Klompenhouwer, Michiel, Subpizel Image Scaling for Color Matrix Displays, SID Symp. Digest, May 2002, pp. 176-179.;;Lee, Baek-Woon, et al., 40.5L Late-News Paper TFT-LCD with RGBW Color System, SID 03 Digest, 2003, pp. 1212-1215.;;Markoff, John, ""Microsoft's Cleartype Sets Off Debate on Originality"", NY Times, Dec. 7, 1998, 5 pages.;;Martin, R., et al., ""Detectability of Reduced Blue-Pixel Count in Projection Displays,"" SID Symp. Digest, May 1993, pp. 606-609.;;""Microsoft ClearType,"" website, Mar. 26, 2003, 4 pages.;;Murch, M., ""Visual Perception Basics,"" SID Seminar, 1987, Tektronix Inc., Beaverton Oregon.;;Okumura, et al., ""A New Flicker-Reduction Drive Method for High Resolution LCTVs"", SID Digest, pp. 551-554, 2001.;;Plat, John, Optimal Filtering for Patterned Displays, IEEE Signal Processing Letters, 2000, 4 pages.;;Poor, Alfred, ""LCDs: The 800-pound Gorilla,"" Information Display, Sep. 2002, pp. 18-21.;;Wandell, Brian A., Stanford University, ""Fundamentals of Vision: Behavior . . . "", Jun. 12, 1994, Society for Informaiton Display (SID) Short Course S-2, Fairmont Hotel, San Jose, California.;;Werner, Ken., ""OLEDS, OLEDS, Everywhere . . . ,"" Information Display, Sep. 2002, pp. 12-15.;;Microsoft press release, Microsoft Research Announces Screen Display Breakthrough at COMDEX/Fall'98, Nov. 15, 1998.;;Messing, Dean, et al. Subpixel Rendering on Non-Striped Colour Matrix Displays, 2003 International Conf. on Image Processing, Sep. 2003, Barcelona, Spain, 4 pages.;;Messing, Dean, et al., ""Improved Display Resolution of Subsampled Colour Images Using Subpixel Addressing"", IEEE ICIP 2002, vol. 1, pp. 625-628.",EXPIRED
74,US,A1,US 2023/0036460 A1,180-653-917-862-696,2023-02-02,2023,US 202217964471 A,2022-10-12,US 202217964471 A;;US 202117560446 A;;US 202016913792 A;;US 201815971729 A,2018-05-04,HIGH POWER AND DATA DELIVERY IN A COMMUNICATIONS NETWORK WITH SAFETY AND FAULT PROTECTION,"In one embodiment, a method includes receiving at a remote network device, power and data from a central network device, wherein the power is used to power the remote network device, performing auto-negotiation with the central network device, wherein the auto-negotiation includes operating the remote network device in a low voltage mode during fault sensing of a power circuit at the remote network device, and selecting a power operating mode, wherein selecting the power operating mode includes selecting a high voltage mode if no fault is detected during the fault sensing, the high voltage mode comprising DC (direct current) pulse power. An apparatus is also disclosed herein.",CISCO TECH INC,GOERGEN JOEL RICHARD;;JONES CHAD M;;ARDUINI DOUGLAS PAUL;;O'BRIEN RICHARD ANTHONY;;BARSOTTI DANIEL LEE;;BAEK SUNG KEE,CISCO TECHNOLOGY INC (2018-05-03),https://lens.org/180-653-917-862-696,Patent Application,yes,10,0,14,14,0,H04L12/10;;H04L12/40032;;H02H1/0007;;H04B10/0779;;H04B10/808;;H04B10/07;;H04L12/10,H04L12/10;;H02H1/00;;H04B10/07;;H04B10/077;;H04B10/80,,0,0,,,,PENDING
75,US,B2,US 10735105 B2,163-549-546-767-254,2020-08-04,2020,US 201815971729 A,2018-05-04,US 201815971729 A,2018-05-04,High power and data delivery in a communications network with safety and fault protection,"In one embodiment, a method includes receiving power at an optical transceiver module at a remote network device on a cable delivering power and data from a central network device, operating the remote network device in a low voltage startup mode during fault sensing at the remote network device, transmitting on the cable, a data signal to the central network device, the data signal indicating an operating status based on the fault sensing, and receiving high voltage power from the central network device on the cable at the remote network device upon transmitting an indication of a safe operating status at the remote network device, wherein the remote network device is powered by the high voltage power. An apparatus is also disclosed herein.",CISCO TECH INC,GOERGEN JOEL RICHARD;;JONES CHAD M;;ARDUINI DOUGLAS PAUL;;O'BRIEN RICHARD ANTHONY;;BARSOTTI DANIEL LEE;;BAEK SUNG KEE,CISCO TECHNOLOGY INC (2018-05-03),https://lens.org/163-549-546-767-254,Granted Patent,yes,140,42,14,14,0,H04L12/10;;H04L12/40032;;H02H1/0007;;H04B10/0779;;H04B10/808;;H04B10/07;;H04L12/10,H04B10/07;;H02H1/00;;H02J1/00;;H04B10/077;;H04B10/80,,12,1,015-355-071-547-263,10.1109/intlec.2012.6374488,"“Network Remote Power Using Packet Energy Transfer”, Eaves et al., www.voltserver.com, Sep. 2012.;;https://www.fischerconnectors.com/us/en/products/fiberoptic.;;http://www.strantech.com/products/tfoca-genx-hybrid-2x2-fiber-optic-copper-connector/.;;http://www.qpcfiber.com/product/connectors/e-link-hybrid-connector/.;;hittps://www.lumentum.com/sites/default/files/technical-library-items/poweroverfiber-tn-pv-ae_0.pdf.;;Chen, Real-Time Termperature Estimation for Power MOSEFETs Conidering Thermal Aging Effects:, IEEE Trnasactions on Device and Materials Reliability, vol. 14, No. 1, Mar. 2014.;;Product Overview, “Pluribus VirtualWire Solution”, Pluribus Networks, PN-PO-VWS-05818, https://www.pluribusnetworks.com/assets/Pluribus-VirtualWire-PO-50918.pdf, May 2018, 5 pages.;;Implementation Guide, “Virtual Chassis Technology Best Practices”, Juniper Networks, 8010018-009-EN, Jan. 2016, https://wwwjuniper.net/us/en/local/pdf/implementation-guides/8010018-en.pdf, 29 pages.;;Yencheck, Thermal Modeling of Portable Power Cables, 1993.;;Zhang, Machine Learning-Based Temperature Prediction for Runtime Thermal Management across System Components, Mar. 2016.;;Data Center Power Equipment Thermal Guidelines and Best Practices.;;Dynamic Thermal Rating of Substation Terminal Equipment by Rambabu Adapa, 2004.",ACTIVE
76,US,A1,US 2019/0342011 A1,090-597-597-983-205,2019-11-07,2019,US 201815971729 A,2018-05-04,US 201815971729 A,2018-05-04,HIGH POWER AND DATA DELIVERY IN A COMMUNICATIONS NETWORK WITH SAFETY AND FAULT PROTECTION,"In one embodiment, a method includes receiving power at an optical transceiver module at a remote network device on a cable delivering power and data from a central network device, operating the remote network device in a low voltage startup mode during fault sensing at the remote network device, transmitting on the cable, a data signal to the central network device, the data signal indicating an operating status based on the fault sensing, and receiving high voltage power from the central network device on the cable at the remote network device upon transmitting an indication of a safe operating status at the remote network device, wherein the remote network device is powered by the high voltage power. An apparatus is also disclosed herein.",CISCO TECH INC,GOERGEN JOEL RICHARD;;JONES CHAD M;;ARDUINI DOUGLAS PAUL;;O'BRIEN RICHARD ANTHONY;;BARSOTTI DANIEL LEE;;BAEK SUNG KEE,CISCO TECHNOLOGY INC (2018-05-03),https://lens.org/090-597-597-983-205,Patent Application,yes,15,35,14,14,0,H04L12/10;;H04L12/40032;;H02H1/0007;;H04B10/0779;;H04B10/808;;H04B10/07;;H04L12/10,H04B10/80;;H02H1/00;;H02J1/00;;H04B10/077,,0,0,,,,ACTIVE
77,US,A1,US 2022/0116122 A1,095-824-120-073-086,2022-04-14,2022,US 202117560446 A,2021-12-23,US 202117560446 A;;US 202016913792 A;;US 201815971729 A,2018-05-04,HIGH POWER AND DATA DELIVERY IN A COMMUNICATIONS NETWORK WITH SAFETY AND FAULT PROTECTION,"In one embodiment, a method includes receiving at a remote network device, power and data from a central network device, wherein the power is used to power the remote network device, performing auto-negotiation with the central network device, wherein the auto-negotiation includes operating the remote network device in a low voltage mode during fault sensing of a power circuit at the remote network device, and selecting a power operating mode, wherein selecting the power operating mode includes selecting a high voltage mode if no fault is detected during the fault sensing, the high voltage mode comprising DC (direct current) pulse power. An apparatus is also disclosed herein.",CISCO TECH INC,GOERGEN JOEL RICHARD;;JONES CHAD M;;ARDUINI DOUGLAS PAUL;;O'BRIEN RICHARD ANTHONY;;BARSOTTI DANIEL LEE;;BAEK SUNG KEE,CISCO TECHNOLOGY INC (2018-05-03),https://lens.org/095-824-120-073-086,Patent Application,yes,14,2,14,14,0,H04L12/10;;H04L12/40032;;H02H1/0007;;H04B10/0779;;H04B10/808;;H04B10/07;;H04L12/10,H04B10/80;;H02H1/00;;H02J1/00;;H04B10/07;;H04B10/077,,0,0,,,,DISCONTINUED
78,EP,B1,EP 3788743 B1,005-940-844-469-901,2023-05-10,2023,EP 19723560 A,2019-04-19,US 201815971729 A;;US 2019/0028251 W,2018-05-04,HIGH POWER AND DATA DELIVERY IN A COMMUNICATIONS NETWORK WITH SAFETY AND FAULT PROTECTION,,CISCO TECH INC,GOERGEN JOEL RICHARD;;JONES CHAD M;;ARDUINI DOUGLAS PAUL;;O'BRIEN RICHARD ANTHONY;;BARSOTTI DANIEL LEE;;BAEK SUNG KEE,,https://lens.org/005-940-844-469-901,Granted Patent,yes,4,0,14,14,0,H04L12/10;;H04L12/40032;;H02H1/0007;;H04B10/0779;;H04B10/808;;H04B10/07;;H04L12/10,H04L12/10;;H04L12/40,,0,0,,,,ACTIVE
79,EP,A1,EP 4221093 A1,002-637-116-830-569,2023-08-02,2023,EP 23166210 A,2019-04-19,US 201815971729 A;;EP 19723560 A;;US 2019/0028251 W,2018-05-04,HIGH POWER AND DATA DELIVERY IN A COMMUNICATIONS NETWORK WITH SAFETY AND FAULT PROTECTION,"In one embodiment, a method includes receiving power at an optical transceiver module at a remote network device on a cable delivering power and data from a central network device, operating the remote network device in a low voltage startup mode during fault sensing at the remote network device, transmitting on the cable, a data signal to the central network device, the data signal indicating an operating status based on the fault sensing, and receiving high voltage power from the central network device on the cable at the remote network device upon transmitting an indication of a safe operating status at the remote network device, wherein the remote network device is powered by the high voltage power. An apparatus is also disclosed herein.
",CISCO TECH INC,GOERGEN JOEL RICHARD;;JONES CHAD M;;ARDUINI DOUGLAS PAUL;;O'BRIEN RICHARD ANTHONY;;BARSOTTI DANIEL LEE;;BAEK SUNG KEE,,https://lens.org/002-637-116-830-569,Patent Application,yes,10,0,14,14,0,H04L12/10;;H04L12/40032;;H02H1/0007;;H04B10/0779;;H04B10/808;;H04B10/07;;H04L12/10,H04L12/10;;H04L12/40,,0,0,,,,PENDING
80,US,B2,US 7221381 B2,023-641-507-075-592,2007-05-22,2007,US 15035502 A,2002-05-17,US 15035502 A;;US 5161202 A;;US 29008601 P;;US 29008701 P;;US 29014301 P;;US 31305401 P;;US 31113801 P;;US 31295501 P;;US 31294601 P;;US 31462201 P;;US 31812901 P,2001-05-09,Methods and systems for sub-pixel rendering with gamma adjustment,"The gamma adjustment allows the luminance for the sub-pixel arrangement to match the non-linear gamma response of the human eye's luminance channel, while the chrominance can match the linear response of the human eye's chrominance channels. The gamma correction allows the algorithms to operate independently of the actual gamma of a display device. The sub-pixel rendering techniques disclosed with gamma adjustment can be optimized for a display device gamma to improve response time, dot inversion balance, and contrast because gamma correction and compensation of the sub-pixel rendering algorithm provides the desired gamma through sub-pixel rendering. These techniques can adhere to any specified gamma transfer curve.",CLAIRVOYANTE INC,BROWN ELLIOTT CANDICE HELLEN;;HAN SEOK JIN;;IM MOON HWAN;;BAEK IN CHUL;;HIGGINS MICHAEL FRANCIS;;HIGGINS PAUL,SAMSUNG DISPLAY CO. LTD (2012-09-04);;CLAIRVOYANTE INC (2004-03-02);;SAMSUNG ELECTRONICS CO. LTD (2018-08-29),https://lens.org/023-641-507-075-592,Granted Patent,yes,102,49,26,81,0,G09G3/20;;G09G3/2003;;G09G5/005;;G09G5/006;;G09G5/02;;G09G2300/0452;;G09G2320/0276;;G09G2340/0407;;G09G2340/0414;;G09G2340/0421;;G09G2340/0457;;G09G2340/0492;;G09G3/20;;G09G3/36;;G09G5/00;;H04N5/202;;G09G5/006;;G09G2320/0276;;G09G3/2003;;G09G2340/0457;;G09G2340/0492;;G09G2300/0452;;G09G5/02;;G09G2340/0407;;G09G2340/0414;;G09G2340/0421;;G09G3/20;;G09G5/005,G09G3/20;;G09G3/36;;G09G5/00;;G09G5/10;;G09G5/02;;H04N5/202,345/690;;345/12;;345/55;;345/214;;345/589;;345/596;;345/597;;345/598;;345/643;;382/167;;382/169;;382/272;;382/274,49,10,039-897-388-399-796;;046-426-201-860-46X;;023-674-219-621-625;;006-822-786-531-074;;041-151-136-226-363;;011-751-663-448-890;;005-585-106-580-591;;077-426-158-712-625;;006-822-786-531-074;;039-897-388-399-796,10.1109/icip.2002.1038102;;10.1889/1.1831775;;10.5594/m001004;;10.1889/1.1830224;;10.1117/12.952646;;10.1889/1.1830225;;10.1109/97.847362;;10.1889/1.1832505;;10.1889/1.1830224;;10.1109/icip.2002.1038102,"Krantz, John H. et al., ""Color Matrix Display Image Quality: The Effects of Luminance and Spatial Sampling,"" SID International Symposium, Digest of Technical Papers, 1990, pp. 29-32.;;Messing, Dean S. et al., ""Improved Display Resolution of Subsampled Colour Images Using Subpixel Addressing,"" Proc. Int. Conf. Image Processing (ICIP '02), Rochester, N.Y., IEEE Signal Processing Society, 2002, vol. 1, pp. 625-628.;;Messing, Dean S. et al., ""Subpixel Rendering on Non-Striped Colour Matrix Displays,"" International Conference on Image Processing, Barcelona, Spain, Sep. 2003, 4 pages.;;""ClearType magnified,"" Wired Magazine, Nov. 8, 1999, Microsoft Typography, article posted Nov. 8, 1999, and last updated Jan. 27, 1999, (C) 1999 Microsoft Corporation, 1 page.;;Credelle, Thomas L. et al., ""P-00: MTF of High-Resolution PenTile Matrix(TM) Displays,"" Eurodisplay 02 Digest, 2002, pp. 1-4.;;Daly, Scott, ""Analysis of Subtriad Addressing Algorithms by Visual System Models,"" SID Symp. Digest, Jun. 2001, pp. 1200-1203.;;Elliott, Candice H. Brown et al., ""Color Subpixel Rendering Projectors and Flat Panel Displays,"" New Initiatives in Motion Imaging, SMPTE Advanced Motion Imaging Conference, Feb. 27-Mar. 1, 2003, Seattle, Washington, pp. 1-4.;;Elliott, Candice H. Brown et al., ""Co-optimization of Color AMLCD Subpixel Architecture and Rendering Algorithms,"" SID Symp. Digest, May 2002, pp. 172-175.;;Feigenblatt, R.I., ""Full-color imaging on amplitude-quantized color mosaic displays,"" SPIE, vol. 1075, Digital Image Processing Applications, 1989, pp. 199-204.;;Johnston, Stuart J., ""An Easy Read: Microsoft's ClearType,"" InformationWeek Online, Redmond, WA, Nov. 23, 1998, 3 pages.;;Johnston, Stuart J., ""Clarifying ClearType,"" InformationWeek Online, Redmond, WA, Jan. 4, 1999, 4 pages.;;""Just Outta Beta,"" Wired Magazine, Dec. 1999, Issue 7.12, 3 pages.;;Klompenhouwer, Michiel A. et al., ""Subpixel Image Scaling for Color Matrix Displays,"" SID Symp. Digest, May 2002, pp. 176-179.;;Markoff, John, ""Microsoft's Cleartype Sets Off Debate on Originality,"" New York Times, Dec. 7, 1998, 5 pages.;;""Microsoft ClearType,"" http://www.microsoft.com/opentype/cleartype, Sep. 26, 2002, 4 pages.;;Platt, John C., ""Optimal Filtering for Patterned Displays,"" Microsoft Research, IEEE Signal Processing Letters, 2000, 4 pages.;;Poor, Alfred, ""LCDs: The 800-pound Gorilla,"" Information Display, Sep. 2002, pp. 18-21.;;""Ron Feigenblatt's remarks on Microsoft Cleartype(TM),"" http://www.geocities.com/SiliconValley/Ridge/6664/ClearType.html, Dec. 5, 1998, Dec. 7, 1998, Dec. 12, 1999, Dec. 26, 1999, Dec. 30, 1999, and Jun. 19, 2000, 30 pages.;;""Sub-Pixel Font Rendering Technology,"" (C) 2003 Gibson Research Corporation, Laguna Hills, CA, 2 pages.;;Werner, Ken, ""OLEDs, OLEDs, Everywhere . . . ,"" Information Display, Sep. 2002, pp. 12-15.;;Lee, Baek-woon et al., ""40.5L: Late-News Paper: TFT-LCD with RGBW Color System,"" SID 03 Digest, 2003, pp. 1212-1215.;;Adobe Systems, Inc., website, 2002, http://www.adobe.com/products/acrobat/cooltype.html.;;Betrisey, C., et al., ""Displaced Filtering for Patterned Displays,"" 2000, Society for Information Display (SID) 00 Digest, pp. 296-299.;;Carvajal, D., ""Big Publishers Looking Into Digital Books,"" Apr. 3, 2000, The New York Times, Business/Financial Desk.;;Elliott, C., ""Active Matrix Display Layout Optimization for Sub-pixel Image Rendering,"" Sep. 2000, Proceedings of the 1<SUP>st </SUP>International Display Manufacturing Conference, pp. 185-189.;;Elliott, C., ""New Pixel Layout for PenTile Matrix,"" Jan. 2002, Proceedings of the International Display Manufacturing Conference, pp. 115-117.;;Elliott, C., ""Reducing Pixel Count without Reducing Image Quality,"" Dec. 1999, Information Display, vol. 15, pp. 22-25.;;Gibson Research Corporation, website, ""Sub-Pixel Font Rendering Technology, How It Works,"" 2002, http://www.grc.com/ctwhat.html.;;Martin, R., et al., ""Detectability of Reduced Blue Pixel Count in Projection Displays,"" May 1993, Society for Information Display (SID) 93 Digest, pp. 606-609.;;Microsoft Corporation, website, 2002, http://www.microsoft.com/reader/ppc/product/cleartype.hmtl.;;Microsoft Press Release, Nov. 15, 1998, Microsoft Research Announces Screen Display Breakthrough at COMDEX/Fall '98, PR Newswire.;;Murch, M., ""Visual Perception Basics,"" 1987, SID, Seminar 2, Tektronix, Inc., Beaverton, Oregon.;;Okumura, H., et al., ""A New Flicker-Reduction Drive Method for High-Resolution LCTVs,"" May 1991, Society for Information Displays (SID) International Symposium Digest of Technical Papers, pp. 551-554.;;Wandell, Brian A., Stanford University, ""Fundamentals of Vision: Behavior, Neuroscience and Computation,"" Jun. 12, 1994, Society for Information Display (SID) Short Course S-2, Fairmont Hotel, San Jose, California.;;Brown Elliott, C, ""Co-Optimization of Color AMLCD Subpixel Architecture and Rendering Algorithms,"" SID 2002 Proceedings Paper, May 30, 2002 pp. 172-175.;;Brown Elliot, C, ""Development of the PenTile Matrix(TM) Color AMLCD Subpixel Architecture and Rendering Algorithms"", SID 2003, Journal Article.;;Brown Elliott, C, ""New Pixel Layout for PenTile Matrix(TM) Architecture"", IDMC 2002, pp. 115-117.;;Brown Elliott, C, ""Reducing Pixel Count Without Reducing Image Quality"", Information Display Dec. 1999, vol. 1, pp. 22-25.;;E-Reader Devices and Software, Jan. 1, 2001, Syllabus, http://www.campus-technology.com/article.asp?id=419.;;Feigenblatt, Ron, ""Remarks on Microsoft ClearType(TM)"", http://www.geocities.com/SiliconValley/Ridge/6664/ClearType.html, Dec. 5, 1998, Dec. 7, 1998, Dec. 12, 1999, Dec. 26, 1999, Dec. 30, 1999 and Jun. 19, 2000, 30 pages.;;Krantz, John et al., Color matrix Display Image Quality: The Effects of Luminance . . . SID 90 Digest, pp. 29-32.;;Messing, Dean et al., improved Display Resolution of Subsampled Colour Images Using Subpixel Addressing, IEEE ICIP 2002, vol. 1, pp. 625-628.;;Messing, Dean et al., Subpixel Rendering on Non-Striped Colour Matrix Displays, 2003 International Conf on Image Processing, Sep. 2003, Barcelona, Spain, 4 pages.;;Poor, Alfred, ""LCDs: The 800-pound Gorilla,"" Information Display, Sep. 2002, pp. 18-21.;;Wandell, Brian A., Stanford University, ""Fundamentals of Vision: Behavior . . . ,"" Jun. 12, 1994, Society for Information Display (SID) Short Course S-2, Fairmont Hotel, San Jose, California.;;Brown Elliott, C, ""Pentile Matrix(TM) Displays and Drivers"" ADEAC Proceedings Paper, Portland OR., Oct. 2005.;;Clairvoyante Inc, Response to Final Office, dated Sep. 19, 2005 in U.S. Patent Publication No. 10/051,612 (U.S. Appl. No. 10/051,612).;;Clairvoyante Inc, Response to Non-Final Office, dated Feb. 8, 2006 in U.S. Patent Publication No. 10/051,612 (U.S. Appl. No. 10/051,612).;;USPTO, Notice of Allowance, dated May 4, 2006 in U.S. Patent Publication No. 10/051,612 (U.S. Appl. No. 10/051,612).",EXPIRED
81,US,A1,US 2003/0103058 A1,042-490-262-448-680,2003-06-05,2003,US 15035502 A,2002-05-17,US 15035502 A;;US 5161202 A;;US 29008601 P;;US 29008701 P;;US 29014301 P;;US 31305401 P;;US 31113801 P;;US 31295501 P;;US 31294601 P;;US 31462201 P;;US 31812901 P,2001-05-09,Methods and systems for sub-pixel rendering with gamma adjustment,"
   Thus, methods and systems for sub-pixel rendering with gamma adjustment are disclosed. The gamma adjustment allows the luminance for the sub-pixel arrangement to match the non-linear gamma response of the human eye's luminance channel, while the chrominance can match the linear response of the human eye's chrominance channels. The gamma correction allows the algorithms to operate independently of the actual gamma of a display device. The sub-pixel rendering techniques disclosed with gamma adjustment can be optimized for a display device gamma to improve response time, dot inversion balance, and contrast because gamma correction and compensation of the sub-pixel rendering algorithm provides the desired gamma through sub-pixel rendering. These techniques can adhere to any specified gamma transfer curve. 
",HELLEN BROWN ELLIOTT CANDICE;;JIN HAN SEOK;;HWAN IM MOON;;BAEK IN CHUL;;HIGGINS MICHAEL FRANCIS;;HIGGINS PAUL,HELLEN BROWN ELLIOTT CANDICE;;JIN HAN SEOK;;HWAN IM MOON;;BAEK IN CHUL;;HIGGINS MICHAEL FRANCIS;;HIGGINS PAUL,SAMSUNG DISPLAY CO. LTD (2012-09-04);;CLAIRVOYANTE INC (2004-03-02);;SAMSUNG ELECTRONICS CO. LTD (2018-08-29),https://lens.org/042-490-262-448-680,Patent Application,yes,67,122,26,81,0,G09G3/20;;G09G3/2003;;G09G5/005;;G09G5/006;;G09G5/02;;G09G2300/0452;;G09G2320/0276;;G09G2340/0407;;G09G2340/0414;;G09G2340/0421;;G09G2340/0457;;G09G2340/0492;;G09G3/20;;G09G3/36;;G09G5/00;;H04N5/202;;G09G5/006;;G09G2320/0276;;G09G3/2003;;G09G2340/0457;;G09G2340/0492;;G09G2300/0452;;G09G5/02;;G09G2340/0407;;G09G2340/0414;;G09G2340/0421;;G09G3/20;;G09G5/005,G09G3/20;;G09G3/36;;G09G5/00;;G09G5/02;;H04N5/202,345/589,0,0,,,,EXPIRED
82,US,A1,US 2007/0206013 A1,046-677-386-629-470,2007-09-06,2007,US 74739807 A,2007-05-11,US 74739807 A;;US 15035502 A;;US 5161202 A;;US 29008601 P;;US 29008701 P;;US 29014301 P;;US 31305401 P;;US 31113801 P;;US 31295501 P;;US 31294601 P;;US 31462201 P;;US 31812901 P,2001-05-09,Methods and Systems For Sub-Pixel Rendering With Gamma Adjustment,"Sub-pixel rendering with gamma adjustment allows the luminance of the sub-pixel arrangement to match the non-linear gamma response of the human eye's luminance channel. For each of a subset of input sampled data indicating a region of an input image, a gamma-adjusted data value is generated for each input image data value in the subset using a local average of at least two input image data values. A sub-pixel rendering operation uses the subset of gamma-adjusted data values and the subset of input image data values to produce an output data value for each sub-pixel element on the display panel. A plurality of output data values collectively indicates an output image. The gamma adjustment allows the sub-pixel rendering to operate independently of the actual gamma of a display device. The sub-pixel rendering techniques with gamma adjustment may improve image contrast in high spatial frequency portions of an image.",CLAIRVOYANTE INC,BROWN ELLIOTT CANDICE H;;HAN SEOK JIN;;IM MOON HWAN;;BAEK IN CHUL;;HIGGINS MICHAEL F;;HIGGINS PAUL,SAMSUNG DISPLAY CO. LTD (2012-09-04);;CLAIRVOYANTE INC (2004-03-02);;SAMSUNG ELECTRONICS CO. LTD (2018-08-29),https://lens.org/046-677-386-629-470,Patent Application,yes,4,13,26,81,0,G09G3/20;;G09G3/2003;;G09G5/005;;G09G5/006;;G09G5/02;;G09G2300/0452;;G09G2320/0276;;G09G2340/0407;;G09G2340/0414;;G09G2340/0421;;G09G2340/0457;;G09G2340/0492;;G09G3/20;;G09G3/36;;G09G5/00;;H04N5/202;;G09G5/006;;G09G2320/0276;;G09G3/2003;;G09G2340/0457;;G09G2340/0492;;G09G2300/0452;;G09G5/02;;G09G2340/0407;;G09G2340/0414;;G09G2340/0421;;G09G3/20;;G09G5/005,G06T11/20;;G09G3/20;;G09G3/36;;G09G5/00;;G09G5/02;;H04N5/202,345/441,0,0,,,,EXPIRED
83,US,A1,US 2007/0182756 A1,134-794-194-697-404,2007-08-09,2007,US 69534307 A,2007-04-02,US 69534307 A;;US 15035502 A;;US 5161202 A;;US 29008601 P;;US 29008701 P;;US 29014301 P;;US 31305401 P;;US 31113801 P;;US 31295501 P;;US 31294601 P;;US 31462201 P;;US 31812901 P,2001-05-09,Methods and Systems For Sub-Pixel Rendering With Gamma Adjustment,"Sub-pixel rendering with gamma adjustment allows the luminance for the sub-pixel arrangement to match the non-linear gamma response of the human eye's luminance channel, while the chrominance can match the linear response of the human eye's chrominance channels. The gamma correction allows the sub-pixel rendering to operate independently of the actual gamma of a display device. The sub-pixel rendering techniques with gamma adjustment may be optimized for the gamma transfer curve of a display device in order to improve response time, dot inversion balance, and contrast.",CLAIRVOYANTE INC,BROWN ELLIOTT CANDICE H;;HAN SEOK J;;IM MOON H;;BAEK IN C;;HIGGINS MICHAEL F;;HIGGINS PAUL,SAMSUNG DISPLAY CO. LTD (2012-09-04);;CLAIRVOYANTE INC (2004-03-02);;SAMSUNG ELECTRONICS CO. LTD (2018-08-29),https://lens.org/134-794-194-697-404,Patent Application,yes,99,6,26,81,0,G09G3/20;;G09G3/2003;;G09G5/005;;G09G5/006;;G09G5/02;;G09G2300/0452;;G09G2320/0276;;G09G2340/0407;;G09G2340/0414;;G09G2340/0421;;G09G2340/0457;;G09G2340/0492;;G09G3/20;;G09G3/36;;G09G5/00;;H04N5/202;;G09G5/006;;G09G2320/0276;;G09G3/2003;;G09G2340/0457;;G09G2340/0492;;G09G2300/0452;;G09G5/02;;G09G2340/0407;;G09G2340/0414;;G09G2340/0421;;G09G3/20;;G09G5/005,G09G3/20;;G09G3/36;;G09G5/02;;G09G5/00;;H04N5/202,345/613,0,0,,,,EXPIRED
84,EP,A1,EP 3788743 A1,051-536-592-366-554,2021-03-10,2021,EP 19723560 A,2019-04-19,US 201815971729 A;;US 2019/0028251 W,2018-05-04,HIGH POWER AND DATA DELIVERY IN A COMMUNICATIONS NETWORK WITH SAFETY AND FAULT PROTECTION,,CISCO TECH INC,GOERGEN JOEL RICHARD;;JONES CHAD M;;ARDUINI DOUGLAS PAUL;;O'BRIEN RICHARD ANTHONY;;BARSOTTI DANIEL LEE;;BAEK SUNG KEE,,https://lens.org/051-536-592-366-554,Patent Application,yes,0,3,14,14,0,H04L12/10;;H04L12/40032;;H02H1/0007;;H04B10/0779;;H04B10/808;;H04B10/07;;H04L12/10,H04L12/10;;H04L12/40,,0,0,,,,ACTIVE
85,US,A1,US 2010/0026709 A1,147-778-228-357-419,2010-02-04,2010,US 57845209 A,2009-10-13,US 57845209 A;;US 74739807 A;;US 15035502 A;;US 5161202 A;;US 31113801 P;;US 31295501 P;;US 31294601 P;;US 31462201 P;;US 31812901 P;;US 29008601 P;;US 29008701 P;;US 29014301 P;;US 31305401 P,2001-05-09,METHODS AND SYSTEMS FOR SUB-PIXEL RENDERING WITH GAMMA ADJUSTMENT,"Sub-pixel rendering with gamma adjustment allows the luminance of the sub-pixel arrangement to match the non-linear gamma response of the human eye's luminance channel. For each of a subset of input sampled data indicating a region of an input image, a gamma-adjusted data value is generated for each input image data value in the subset using a local average of at least two input image data values. A sub-pixel rendering operation uses the subset of gamma-adjusted data values and the subset of input image data values to produce an output data value for each sub-pixel element on the display panel. A plurality of output data values collectively indicates an output image. The gamma adjustment allows the sub-pixel rendering to operate independently of the actual gamma of a display device. The sub-pixel rendering techniques with gamma adjustment may improve image contrast in high spatial frequency portions of an image.",BROWN ELLIOTT CANDICE HELLEN;;HAN SEOK JIN;;IM MOON HWAN;;BAEK IN CHUL;;HIGGINS MICHAEL FRANCIS;;HIGGINS PAUL,BROWN ELLIOTT CANDICE HELLEN;;HAN SEOK JIN;;IM MOON HWAN;;BAEK IN CHUL;;HIGGINS MICHAEL FRANCIS;;HIGGINS PAUL,SAMSUNG DISPLAY CO. LTD (2012-09-04);;SAMSUNG ELECTRONICS CO. LTD (2018-08-29),https://lens.org/147-778-228-357-419,Patent Application,yes,99,3,26,81,0,G09G3/20;;G09G3/2003;;G09G5/005;;G09G5/006;;G09G5/02;;G09G2300/0452;;G09G2320/0276;;G09G2340/0407;;G09G2340/0414;;G09G2340/0421;;G09G2340/0457;;G09G2340/0492;;G09G3/20;;G09G3/36;;G09G5/00;;H04N5/202;;G09G5/006;;G09G2320/0276;;G09G3/2003;;G09G2340/0457;;G09G2340/0492;;G09G2300/0452;;G09G5/02;;G09G2340/0407;;G09G2340/0414;;G09G2340/0421;;G09G3/20;;G09G5/005,G09G3/20;;G09G3/36;;G09G5/00;;G09G5/02;;H04N5/202,345/600;;345/522,0,0,,,,EXPIRED
86,US,B2,US 11258520 B2,159-872-468-802-485,2022-02-22,2022,US 202016913792 A,2020-06-26,US 202016913792 A;;US 201815971729 A,2018-05-04,High power and data delivery in a communications network with safety and fault protection,"In one embodiment, a method includes receiving at a remote network device, power and data from a central network device, wherein the power is used to power the remote network device, performing auto-negotiation with the central network device, wherein the auto-negotiation includes operating the remote network device in a low voltage mode during fault sensing of a power circuit at the remote network device, and selecting a power operating mode, wherein selecting the power operating mode includes selecting a high voltage mode if no fault is detected during the fault sensing, the high voltage mode comprising DC (direct current) pulse power. An apparatus is also disclosed herein.",CISCO TECH INC,GOERGEN JOEL RICHARD;;JONES CHAD M;;ARDUINI DOUGLAS PAUL;;O'BRIEN RICHARD ANTHONY;;BARSOTTI DANIEL LEE;;BAEK SUNG KEE,CISCO TECHNOLOGY INC (2018-05-03),https://lens.org/159-872-468-802-485,Granted Patent,yes,151,2,14,14,0,H04L12/10;;H04L12/40032;;H02H1/0007;;H04B10/0779;;H04B10/808;;H04B10/07;;H04L12/10,H04B10/07;;H02H1/00;;H02J1/00;;H04B10/077;;H04B10/80,,30,2,015-355-071-547-263;;015-355-071-547-263,10.1109/intlec.2012.6374488;;10.1109/intlec.2012.6374488,"PTAB Decision on Voltserver Inc. v. Cisco Technology, Inc., PGR2021-00055, U.S. Pat. No. 10,745,105 (Year: 2021).;;PTAB Decision on Voltserver Inc. v. Cisco Technology, Inc., PGR2021-00056, U.S. Pat. No. 10,745,105 (Year: 2021).;;“Network Remote Power Using Packet Energy Transfer”, Eaves et al., www.voltserver.com, Sep. 2012.;;https://www.fischerconnectors.com/us/en/products/fiberoptic.;;http://www.strantech.com/products/tfoca-genx-hybrid-2x2-fiber-optic-copper-connector/.;;http://www.qpcfiber.com/product/connectors/e-link-hybrid-connector/.;;https://www.lumentum.com/sites/default/files/technical-library-items/poweroverfiber-tn-pv-ae_0.pdf.;;Chen, Real-Time Termperature Estimation for Power MOSEFETs Conidering Thermal Aging Effects:, IEEE Trnasactions on Device and Materials Reliability, vol. 14, No. 1, Mar. 2014.;;Product Overview, “Pluribus VirtualWire Solution”, Pluribus Networks, PN-PO-VWS-05818, https://www.pluribusnetworks.com/assets/Pluribus-VirtualWire-PO-50918.pdf, May 2018, 5 pages.;;Implementation Guide, “Virtual Chassis Technology Best Practices”, Juniper Networks, 8010018-009-EN, Jan. 2016, https://wwwjuniper.net/us/en/local/pdf/implementation-guides/8010018-en.pdf, 29 pages.;;Yencheck, Thermal Modeling of Portable Power Cables, 1993.;;Zhang, Machine Learning-Based Temperature Prediction for Runtime Thermal Management across System Components, Mar. 2016.;;Data Center Power Equipment Thermal Guidelines and Best Practices.;;Dynamic Thermal Rating of Substation Terminal Equipment by Rambabu Adapa, 2004.;;Petition for Post Grant Review of U.S. Pat. No. 10,735,105 [Public] with Exhibits, filed Feb. 16, 2021, PGR 2021-00055.;;Petition for Post Grant Review of U.S. Pat. No. 10,735,105 [Public] with Exhibits, filed Feb. 16, 2021, PGR 2021-00056.;;Eaves, S. S., Network Remote Powering Using Packet Energy Transfer, Proceedings of IEEE International Conference on Telecommunications Energy (INTELEC) 2012, Scottsdale, AZ, Sep. 30-Oct. 4, 2012 (IEEE 2012) (EavesIEEE).;;Edelstein S., Updated 2016 Tesla Model S also gets new 75-kWhbattery option, (Jun. 19, 2016), archived Jun. 19, 2016 by Internet Archive Wayback machine at https://web.archive.org/web/20160619001148/https://www.greencarreports.com/news/1103 782_updated-2016-tesla-model-s-also-gets-new-7 5-kwh-battery-option (“Edelstein”).;;NFPA 70 National Electrical Code, 2017 Edition (NEC).;;International Standard IEC 62368-1 Edition 2.0 (2014), ISBN 978-2-8322-1405-3 (“IEC-62368”).;;International Standard IEC/TS 60479-1 Edition 4.0 (2005), ISBN 2-8318-8096-3 (“IEC-60479”).;;International Standard IEC 60950-1 Edition 2.2 (2013), ISBN 978-2-8322-0820-5 (“IEC-60950”).;;International Standard IEC 60947-1 Edition 5.0 (2014), ISBN 978-2-8322-1798-6 (“IEC-60947”).;;Tanenbaum, A. S., Computer Networks, Third Edition (1996) (“Tanenbaum”).;;Stallings, W., Data and Computer Communications, Fourth Edition (1994) (“Stallings”).;;Alexander, C. K., Fundamentals of Electric Circuits, Indian Edition (2013) (“Alexander”).;;Hall, S. H., High-Speed Digital System Design, A Handbook of Interconnect Theory and Design Practices (2000) (“Hall”).;;Sedra, A. S., Microelectronic Circuits, Seventh Edition (2014) (“Sedra”).;;Lathi, B. P., Modem Digital and Analog Communication Systems, Fourth Edition (2009) (“Lathi”).;;Understanding 802.3at PoE Plus Standard Increases Available Power (Jun. 2011) (“Microsemi”).",ACTIVE
87,US,B2,US 7911487 B2,014-236-594-047-120,2011-03-22,2011,US 57845209 A,2009-10-13,US 57845209 A;;US 74739807 A;;US 15035502 A;;US 5161202 A;;US 31113801 P;;US 31295501 P;;US 31294601 P;;US 31462201 P;;US 31812901 P;;US 29008601 P;;US 29008701 P;;US 29014301 P;;US 31305401 P,2001-05-09,Methods and systems for sub-pixel rendering with gamma adjustment,"Sub-pixel rendering with gamma adjustment allows the luminance of the sub-pixel arrangement to match the non-linear gamma response of the human eye's luminance channel. For each of a subset of input sampled data indicating a region of an input image, a gamma-adjusted data value is generated for each input image data value in the subset using a local average of at least two input image data values. A sub-pixel rendering operation uses the subset of gamma-adjusted data values and the subset of input image data values to produce an output data value for each sub-pixel element on the display panel. A plurality of output data values collectively indicates an output image. The gamma adjustment allows the sub-pixel rendering to operate independently of the actual gamma of a display device. The sub-pixel rendering techniques with gamma adjustment may improve image contrast in high spatial frequency portions of an image.",SAMSUNG ELECTRONICS CO LTD,BROWN ELLIOTT CANDICE HELEN;;HAN SEOK JIN;;IM MOON HWAN;;BAEK IN CHUL;;HIGGINS MICHAEL FRANCIS;;HIGGINS PAUL,SAMSUNG DISPLAY CO. LTD (2012-09-04);;SAMSUNG ELECTRONICS CO. LTD (2018-08-29),https://lens.org/014-236-594-047-120,Granted Patent,yes,101,4,26,81,0,G09G3/20;;G09G3/2003;;G09G5/005;;G09G5/006;;G09G5/02;;G09G2300/0452;;G09G2320/0276;;G09G2340/0407;;G09G2340/0414;;G09G2340/0421;;G09G2340/0457;;G09G2340/0492;;G09G3/20;;G09G3/36;;G09G5/00;;H04N5/202;;G09G5/006;;G09G2320/0276;;G09G3/2003;;G09G2340/0457;;G09G2340/0492;;G09G2300/0452;;G09G5/02;;G09G2340/0407;;G09G2340/0414;;G09G2340/0421;;G09G3/20;;G09G5/005,G09G3/20;;G09G3/36;;G09G5/00;;G09G5/10;;G09G5/02;;H04N5/202,345/690;;345/214;;345/589;;345/596;;345/597;;345/613;;345/644;;382/167;;382/272;;348/254;;358/519,53,9,007-151-325-367-760;;023-674-219-621-625;;006-822-786-531-074;;046-426-201-860-46X;;041-151-136-226-363;;011-751-663-448-890;;077-426-158-712-625;;039-897-388-399-796;;005-585-106-580-591,10.1889/1.1832941;;10.5594/m001004;;10.1889/1.1830224;;10.1889/1.1831775;;10.1117/12.952646;;10.1889/1.1830225;;10.1889/1.1832505;;10.1109/icip.2002.1038102;;10.1109/97.847362,"Betrisey, C., et al., Displaced Filtering for Patterned Displays, SID Symp. Digest 1999, pp. 296-299.;;Brown Elliott, C., ""Active Matrix Display . . . "", IDMC 2000, 185-189, Aug. 2000.;;Brown Elliott, C., ""Color Subpixel Rendering Projectors and Flat Panel Displays,"" SMPTE, Feb. 27-Mar. 1, 2003, Seattle, WA pp. 1-4.;;Brown Elliott, C, ""Co-Optimization of Color AMLCD Subpixel Architecture and Rendering Algorithms,"" SID 2002 Proceedings Paper, May 30, 2002 pp. 172-175.;;Brown Elliott, C, ""Development of the PenTile Matrix(TM) Color AMLCD Subpixel Architecture and Rendering Algorithms"", SID 2003, Journal Article.;;Brown Elliott, C, ""New Pixel Layout for PenTile Matrix(TM) Architecture"", IDMC 2002, pp. 115-117.;;Brown Elliott, C, ""Pentile Matrix(TM) Displays and Drivers"" ADEAC Proceedings Paper, Portland OR., Oct. 2005.;;Brown Elliott, C, ""Reducing Pixel Count Without Reducing Image Quality"", Information Display Dec. 1999, vol. 1, pp. 22-25.;;Carvajal, D., ""Big Publishers Looking Into Digital Books,"" The NY Times, Apr. 3, 2000, Business/ Financial Desk.;;""ClearType magnified"", Wired Magazine, Nov. 8, 1999, Microsoft Typography, article posted Nov. 8, 1999, last updated Jan. 27, 1999 1 page.;;Credelle, Thomas, ""P-00: MTF of High-Resolution PenTile Matrix Displays"", Eurodisplay 02 Digest, 2002 pp. 1-4.;;Daly, Scott, ""Analysis of Subtriad Addressing Algorithms by Visual System Models"",SID Symp. Digest, Jun. 2001 pp. 1200-1203.;;E-Reader Devices and Software, Jan. 1, 2001, Syllabus, http://www.campus-technology.com/article.asp?id=419.;;Feigenblatt, R.I., Full-color imaging on amplitude-quantized color mosaic displays, SPIE, 1989, pp. 199-204.;;Feigenblatt, Ron, ""Remarks on Microsoft ClearType(TM)"", http://www.geocities.com/SiliconValley/Ridge/6664/ClearType.html, Dec. 5, 1998, Dec. 7, 1998, Dec. 12, 1999, Dec. 26, 1999, Dec. 30, 1999 and Jun. 19, 2000, 30 pages.;;Johnston, Stuart, ""An Easy Read: Microsoft's ClearType,"" InformationWeek Online, Redmond WA, Nov. 23, 1998. 3 pages.;;Johnston, Stuart, ""Clarifying ClearType,"" InformationWeek Online, Redmond WA, Jan. 4, 1999, 4 pages.;;Just Outta Beta, Wired Magazine, Dec. 1999 Issue 7-12, 3 pages.;;Klompenhouwer, Michiel, Subpixel Image Scaling for Color Matrix Displays, SID Symp. Digest, May 2002, pp. 176-179.;;Krantz, John et al., Color Matrix Display Image Quality: The Effects of Luminance . . . SID 90 Digest, pp. 29-32.;;Lee, Baek-woon et al., 40.5L: Late-News Paper: TFT-LCD with RGBW Color system, SID 03 Digest, 2003, pp. 1212-1215.;;Markoff, John, Microsoft's Cleartype Sets Off Debate on Originality, NY Times, Dec. 7, 1998, 5 pages.;;Martin, R., et al., ""Detectability of Reduced Blue-Pixel Count in Projection Displays,"" SID Symp. Digest, May 1993, pp. 606-609.;;Messing, Dean et al., Improved Display Resolution of Subsampled Colour Images Using Subpixel Addressing, IEEE ICIP 2002, vol. 1, pp. 625-628.;;Messing, Dean et al., Subpixel Rendering on Non-Striped Colour Matrix Displays, 2003 International Conf on Image Processing, Sep. 2003, Barcelona, Spain, 4 pages.;;""Microsoft ClearType,"" website, Mar. 26, 2003, 4 pages.;;Microsoft press release, Microsoft Research Announces Screen Display Breakthrough at COMDEX/Fall '98; . . . Nov. 15, 1998.;;Murch, M., ""Visual Perception Basics,"" SID Seminar, 1987, Tektronix Inc, Beaverton Oregon.;;Okumura et al., ""A New Flicker-Reduction Drive Method for High Resolution LCTVs"", SID Digest,pp. 551-554, 2001.;;Platt, John, Optimal Filtering for Patterned Displays, IEEE Signal Processing Letters, 2000, 4 pages.;;Poor, Alfred, ""LCDs: The 800-pound Gorilla,"" Information Display, Sep. 2002, pp. 18-21.;;Wandell, Brian A., Stanford University, ""Fundamentals of Vision: Behavior . . . ,"" Jun. 12, 1994, Society for Information Display (SID) Short Course S-2, Fairmont Hotel, San Jose, California.;;Werner, Ken, ""OLEDS, OLEDS, Everywhere . . . ,"" Information Display, Sep. 2002, pp. 12-15.;;USPTO, Non-Final Office Action, dated Feb. 7, 2005 in US Patent No. 7,123,277 (U.S. Appl. No. 10/051,612).;;Clairvoyante Inc, Response to Non-Final Office, dated Jul. 7, 2005 in US Patent No. 7,123,277 (U.S. Appl. No. 10/051,612).;;USPTO, Final Office Action dated, Aug. 31, 2005 in US Patent No. 7,123,277 (U.S. Appl. No. 10/051,612).;;Clairvoyante Inc, Response to Final Office, dated Sep. 19, 2005 in US Patent No. 7,123,277 (U.S. Appl. No. 10/051,612).;;USPTO, Non-Final Office Action dated, Dec. 15, 2005 in US Patent No. 7,123,277 (U.S. Appl. No. 10/051,612).;;Clairvoyante Inc, Response to Non-Final Office, dated Feb. 8, 2006 in US Patent No. 7,123,277 (U.S. Appl. No. 10/051,612).;;USPTO, Notice of Allowance, dated May 4, 2006 in US Patent No. 7,123,277 (U.S. Appl. No. 10/051,612).;;USPTO, Non-Final Office Action, dated Mar. 24, 2005 in US Patent No. 7,184,066 (U.S. Appl. No. 10/215,843).;;Clairvoyante Inc, Response to Non-Final Office Action, dated Sep. 26, 2005 in US Patent No. 7,184,066 (U.S. Appl. No. 10/215,843).;;USPTO, Final Office Action, dated Jan. 25, 2006 in US Patent No. 7,184,066 (U.S. Appl. No. 10/215,843).;;Clairvoyante Inc, Response to Non-Final Office Action, dated Jun. 26, 2006 in US Patent No. 7,184,066 (U.S. Appl. No. 10/215,843).;;USPTO, Non-Final Office Action, dated Nov. 16, 2004 in US Patent Publication No. 2003/0128225, (U.S. Appl. No. 10/278,353).;;Clairvoyante Inc, Response to Non-Final Office Action, dated Apr. 15, 2005 in US Patent Publication No. 2003/0128225, (U.S. Appl. No. 10/278,353).;;USPTO, Non-Final Office Action, dated Jul. 12, 2005 in US Patent Publication No. 2003/0128225, (U.S. Appl. No. 10/278,353).;;Clairvoyante Inc, Response to Non-Final Office Action, dated Jan. 12, 2006 in US Patent Publication No. 2003/0128225, (U.S. Appl. No. 10/278,353).;;USPTO, Final Office Action, dated Apr. 18, 2006 in US Patent Publication No. 2003/0128225, (U.S. Appl. No. 10/278,353).;;USPTO, Non-Final Office Action, dated Nov. 16, 2004 in US Patent Publication No. 2003/0128179, (U.S. Appl. No. 10/278,352).;;Clairvoyante Inc, Response to Non-Final Office Action, dated Apr. 15, 2005 in US Patent Publication No. 2003/0128179, (U.S. Appl. No. 10/278,352).;;USPTO, Non-Final Office Action, dated Jul. 12, 2005 in US Patent Publication No. 2003/0128179, (U.S. Appl. No. 10/278,352).;;Clairvoyante Inc, Response to Non-Final Office Action, dated Jan. 12, 2006 in US Patent Publication No. 2003/0128179, (U.S. Appl. No. 10/278,352).",EXPIRED
88,US,A1,US 2011/0157217 A1,009-577-580-657-977,2011-06-30,2011,US 82525010 A,2010-06-28,US 82525010 A;;US 69534307 A;;US 15035502 A;;US 5161202 A;;US 31113801 P;;US 31295501 P;;US 31294601 P;;US 31462201 P;;US 31812901 P;;US 29008601 P;;US 29008701 P;;US 29014301 P;;US 31305401 P,2001-05-09,METHODS AND SYSTEMS FOR SUB-PIXEL RENDERING WITH GAMMA ADJUSTMENT,"Sub-pixel rendering with gamma adjustment allows the luminance for the sub-pixel arrangement to match the non-linear gamma response of the human eye's luminance channel, while the chrominance can match the linear response of the human eye's chrominance channels. The gamma correction allows the sub-pixel rendering to operate independently of the actual gamma of a display device. The sub-pixel rendering techniques with gamma adjustment may be optimized for the gamma transfer curve of a display device in order to improve response time, dot inversion balance, and contrast.",BROWN ELLIOTT CANDICE HELLEN;;HAN SEOK JIN;;IM MOON HWAN;;BAEK IN CHUL;;HIGGINS MICHAEL FRANCIS;;HIGGINS PAUL,BROWN ELLIOTT CANDICE HELLEN;;HAN SEOK JIN;;IM MOON HWAN;;BAEK IN CHUL;;HIGGINS MICHAEL FRANCIS;;HIGGINS PAUL,SAMSUNG DISPLAY CO. LTD (2012-09-04);;SAMSUNG ELECTRONICS CO. LTD (2018-08-29),https://lens.org/009-577-580-657-977,Patent Application,yes,2,13,26,81,0,G09G3/20;;G09G3/2003;;G09G5/005;;G09G5/006;;G09G5/02;;G09G2300/0452;;G09G2320/0276;;G09G2340/0407;;G09G2340/0414;;G09G2340/0421;;G09G2340/0457;;G09G2340/0492;;G09G3/20;;G09G3/36;;G09G5/00;;H04N5/202;;G09G5/006;;G09G2320/0276;;G09G3/2003;;G09G2340/0457;;G09G2340/0492;;G09G2300/0452;;G09G5/02;;G09G2340/0407;;G09G2340/0414;;G09G2340/0421;;G09G3/20;;G09G5/005,G09G3/20;;G09G3/36;;G09G5/00;;G09G5/02;;H04N5/202,345/605,0,0,,,,EXPIRED
89,US,A1,US 2020/0328819 A1,156-827-788-171-000,2020-10-15,2020,US 202016913792 A,2020-06-26,US 202016913792 A;;US 201815971729 A,2018-05-04,HIGH POWER AND DATA DELIVERY IN A COMMUNICATIONS NETWORK WITH SAFETY AND FAULT PROTECTION,"In one embodiment, a method includes receiving at a remote network device, power and data from a central network device, wherein the power is used to power the remote network device, performing auto-negotiation with the central network device, wherein the auto-negotiation includes operating the remote network device in a low voltage mode during fault sensing of a power circuit at the remote network device, and selecting a power operating mode, wherein selecting the power operating mode includes selecting a high voltage mode if no fault is detected during the fault sensing, the high voltage mode comprising DC (direct current) pulse power. An apparatus is also disclosed herein.",CISCO TECH INC,GOERGEN JOEL RICHARD;;JONES CHAD M;;ARDUINI DOUGLAS PAUL;;O'BRIEN RICHARD ANTHONY;;BARSOTTI DANIEL LEE;;BAEK SUNG KEE,CISCO TECHNOLOGY INC (2018-05-03),https://lens.org/156-827-788-171-000,Patent Application,yes,0,0,14,14,0,H04L12/10;;H04L12/40032;;H02H1/0007;;H04B10/0779;;H04B10/808;;H04B10/07;;H04L12/10,H04B10/80;;H02H1/00;;H02J1/00;;H04B10/07;;H04B10/077,,0,0,,,,ACTIVE
90,US,B2,US 11916614 B2,037-935-998-804-535,2024-02-27,2024,US 202117171785 A,2021-02-09,US 202117171785 A;;US 201916671508 A,2019-11-01,Initialization and synchronization for pulse power in a network system,"In one embodiment, a method includes identifying at a first powered device in communication with power sourcing equipment, a second powered device in communication with the first powered device, wherein the first powered device is receiving high voltage pulse power from the power sourcing equipment, notifying the power sourcing equipment of the second powered device at the first powered device, and performing a low voltage power initialization at the first powered device with the second powered device before passing the high voltage pulse power to the second powered device.",CISCO TECH INC,ARDUINI DOUGLAS PAUL;;BAEK SUNG KEE;;O'BRIEN RICHARD ANTHONY;;GOERGEN JOEL RICHARD;;JONES CHAD M;;POTTERF JASON DEWAYNE;;LI RUQI,CISCO TECHNOLOGY INC (2019-10-31),https://lens.org/037-935-998-804-535,Granted Patent,yes,300,0,13,14,0,H04L12/10;;H04B3/54;;G01R31/52;;G01R31/58;;G01R29/16;;H04L12/10;;H04L12/10;;H02J13/00032;;G05B9/02;;G06F1/305;;G01R31/083;;G01R31/50;;H02J13/00032;;G01R31/50;;G01R31/083;;G05B9/02;;G06F1/305;;H02J13/00;;H04B3/54;;H04L12/10;;H04L12/40045,G06F1/30;;G01R31/08;;G01R31/50;;G05B9/02;;H02J13/00;;H04B3/54;;H04L12/10;;H04L12/40,,85,0,,,"English Translation of Office Action in counterpart Japanese Application No. 2022-507587, dated May 16, 2023, 3 pages.;;Inntemational Search Report and Written Opinion in counterpart International Application No. PCT/US2020/055532, dated Mar. 15, 2021, 15 pages.;;https://www.fischerconnectors.com/us/en/products/fiberoptic.;;http://www.strantech.com/products/tfoca-genx-hybrid-2x2-fiber-optic-copper-connector/.;;http://www.qpcfiber.com/product/connectors/e-link-hybrid-connector/.;;https://www.lumentum.com/sites/default/files/technical-library-items/poweroverfiber-tn-pv-ae_0.pdf.;;“Network Remote Power Using Packet Energy Transfer”, Eaves et al., www.voltserver.com, Sep. 2012.;;Product Overview, “Pluribus VirtualWire Solution”, Pluribus Networks, PN-PO-VWS-05818, https://www.pluribusnetworks.com/assets/Pluribus-VirtualWire-PO-50918.pdf, May 2018, 5 pages.;;Implementation Guide, “Virtual Chassis Technology Best Practices”, Juniper Networks, 8010018-009-EN, Jan. 2016, https://wwwjuniper.net/us/en/local/pdf/implementation-guides/8010018-en.pdf, 29 pages.;;Yencheck, Thermal Modeling of Portable Power Cables, 1993.;;Zhang, Machine Learning-Based Temperature Prediction for Runtime Thermal Management across System Components, Mar. 2016.;;Data Center Power Equipment Thermal Guidelines and Best Practices.;;Dynamic Thermal Rating of Substation Terminal Equipment by Rambabu Adapa, 2004.;;Chen, Real-Time Termperature Estimation for Power MOSEFETs Conidering Thermal Aging Effects:, IEEE Trnasactions on Device and Materials Reliability, vol. 14, No. 1, Mar. 2014.;;Jingquan Chen et al: “Buck-boost PWM converters having two independently controlled switches”, 32nd Annual IEEE Power Electronics Specialists Conference. PESC 2001. Conference Proceedings, Vancouver, Canada, Jun. 17-21, 2001; [Annual Power Electronics Specialists Conference], New York, Ny: IEEE, US, vol. 2,Jun. 17, 2001 (Jun. 17, 2001), pp. 736-741, XP010559317, DOI: 10.1109/PESC.2001.954206, ISBN 978-0-7803-7067-8 paragraph [SectionII]; figure 3.;;Cheng K W E et al: “Constant Frequency, Two-Stage Quasiresonant Convertor”, IEE Proceedings B. Electrical Power Applications, 1271980 1, vol. 139, No. 3, May 1, 1992 (May 1, 1992), pp. 227-237, XP000292493, the whole document.;;UPOE-2400G, 7 pages (Year: 2016).;;Hirshmann, 8 pages, (Year: 2011).;;Selecting Cables for Power over Ethernet , Hitachi Cable America Inc. Aug. 12, 2017, 7 pages (Year: 2017).;;How Cable Temperature Impacts Cable Reach, Belden, Sep. 29, 2017, 2 pages (Year: 2017).;;NCP1095, PoE-PD Interface Controller, IEEE 802.3bt, 17 pages, Jun. 2019 (Year: 2019).;;IEEE 802.3af PoE Powered Device Controllers With Auto-Retry, Texas Instruments, Apr. 2008, 28 pages (Year: 2008).;;Petition for Post Grant Review of U.S. Pat. No. 10,735,105 [Public] with Exhibits, filed Feb. 16, 2021, PGR 2021-00055.;;Petition for Post Grant Review of U.S. Pat. No. 10,735,105 [Public] with Exhibits, filed Feb. 16, 2021, PGR 2021-00056.;;Eaves, S. S., Network Remote Powering Using Packet Energy Transfer, Proceedings of IEEE International Conference on Telecommunications Energy (INTELEC) 2012, Scottsdale, AZ, Sep. 30-Oct. 4, 2012 (IEEE 2012) (EavesIEEE).;;Edelstein S., Updated 2016 Tesla Model S also gets new 75-kWhbattery option, (Jun. 19, 2016), archived Jun. 19, 2016 by Internet Archive Wayback machine at https://web.archive.org/web/20160619001148/https://www.greencarreports.com/news/1103 782_updated-2016-tesla-model-s-also-gets-new-7 5-kwh-battery-option (“Edelstein”).;;NFPA 70 National Electrical Code, 2017 Edition (NEC).;;International Standard IEC 62368-1 Edition 2.0 (2014), ISBN 978-2-8322-1405-3 (“IEC-62368”).;;International Standard IEC/TS 60479-1 Edition 4.0 (2005), ISBN 2-8318-8096-3 (“IEC-60479”).;;International Standard IEC 60950-1 Edition 2.2 (2013), ISBN 978-2-8322-0820-5 (“IEC-60950”).;;International Standard IEC 60947-1 Edition 5.0 (2014), ISBN 978-2-8322-1798-6 (“IEC-60947”).;;Tanenbaum, A. S., Computer Networks, Third Edition (1996) (“Tanenbaum”).;;Stallings, W., Data and Computer Communications, Fourth Edition ( 1994) (“Stallings”).;;Alexander, C. K., Fundamentals of Electric Circuits, Indian Edition (2013) (“Alexander”).;;Hall, S. H., High-Speed Digital System Design, A Handbook of Interconnect Theory and Design Practices (2000) (“Hall”).;;Bedra, A. S., Microelectronic Circuits, Seventh Edition (2014) (“Sedra”).;;Lathi, B. P., Modem Digital and Analog Communication Systems, Fourth Edition (2009) (“Lathi”).;;Understanding 802.3at PoE Plus Standard Increases Available Power (Jun. 2011) (“Microsemi”).;;Voltserver Inc., v. Cisco Technology, Inc., “Decision Denying Institution of Post-Grant Review,” United States Patent and Trademark Office, PGR2021-00055, U.S. Pat. No. 10,735,105 B2, Aug. 19, 2021, 25 pages.;;Voltserver Inc., v. Cisco Systems, Inc., “Patent Owner's Preliminary Response to Post Grant Review Under 35 U.S.C. § 312 and 37 C.F.R. § 42.107,” United States Patent and Trademark Office, PGR2021-00055, U.S. Pat. No. 10,735,105, 2021, Jun. 2, 2021, 51 pages.;;“Effects of current on human beings and livestok—Part 1: General aspects,” Technical Specification, Basic Safety Publication, IEC/TS 60479-1, Edition 4.0, Jul. 2005, 122 pages.;;“Information technology equipment13 Safety—Part 1: General requirements,” International Standard, IEC 60950-1, Edition 2.2, May 2013, pp. 1-61, 63 pages.;;“Information technology equipment13 Safety—Part 1: General requirements,” International Standard, IEC 60950-1, Edition 2.2, May 2013, pp. 62-122, 61 pages.;;“Information technology equipment13 Safety—Part 1: General requirements,” International Standard, IEC 60950-1, Edition 2.2, May 2013, pp. 123-181, 59 pages.;;“Information technology equipment13 Safety—Part 1: General requirements,” International Standard, IEC 60950-1, Edition 2.2, May 2013, pp. 182-253, 72 pages.;;“Information technology equipment13 Safety—Part 1: General requirements,” International Standard, IEC 60950-1, Edition 2.2, May 2013, pp. 254-319, 66 pages.;;“Information technology equipment13 Safety—Part 1: General requirements,” International Standard, IEC 60950-1, Edition 2.2, May 2013, pp. 320-377, 58 pages.;;“Information technology equipment13 Safety—Part 1: General requirements,” International Standard, IEC 60950-1, Edition 2.2, May 2013, pp. 378-433, 56 pages.;;“Information technology equipment13 Safety—Part 1: General requirements,” International Standard, IEC 60950-1, Edition 2.2, May 2013, pp. 434-490, 57 pages.;;“Information technology equipment13 Safety—Part 1: General requirements,” International Standard, IEC 60950-1, Edition 2.2, May 2013, pp. 491-551, 61 pages.;;“Information technology equipment13 Safety—Part 1: General requirements,” International Standard, IEC 60950-1, Edition 2.2, May 2013, pp. 552-622, 71 pages.;;“Information technology equipment13 Safety—Part 1: General requirements,” International Standard, IEC 60950-1, Edition 2.2, May 2013, pp. 623-644, 24 pages.;;“Low-voltage switchgear and controlgear—Part 1: General rules,” International Standard, Amendment 2, IEC 60947-1, Edition 5.0, Sep. 2014, pp. 1-63, 65 pages.;;“Low-voltage switchgear and controlgear—Part 1: General rules,” International Standard, Amendment 2, IEC 60947-1, Edition 5.0, Sep. 2014, pp. 64-102, 41 pages.;;Stephen Edelstein, “Updated 2016 Tesla Model S also gets new 75-kWhbattery option,” Internet Archive WayBack Machine, Green Car Reports, May 5, 2016, 3 pages.;;Stephen S. Eaves, “Network Remote Powering using Packet Energy Transfer,” IEEE Xplore, Proceedings of IEEE International Conference on Telecommunications Energy (INTELEC) 2012, 978-1-4673-1000, Sep. 30-Oct. 4, 2012, 4 pages.;;“Audio/video, information and communication technology equipment—Part 1: Safety requirements,” International Standard, IEC 62368-1, Edition 2.0, Feb. 2014, pp. 1-132, 134 pages.;;“Audio/video, information and communication technology equipment—Part 1: Safety requirements,” International Standard, IEC 62368-1, Edition 2.0, Feb. 2014, pp. 133-263, 131 pages.;;“Audio/video, information and communication technology equipment—Part 1: Safety requirements,” International Standard, IEC 62368-1, Edition 2.0, Feb. 2014, pp. 264-387, 124 pages.;;“Audio/video, information and communication technology equipment—Part 1: Safety requirements,” International Standard, IEC 62368-1, Edition 2.0, Feb. 2014, pp. 388-508, 121 pages.;;“Audio/video, information and communication technology equipment—Part 1: Safety requirements,” International Standard, IEC 62368-1, Edition 2.0, Feb. 2014, pp. 509-593, 85 pages.;;“Audio/video, information and communication technology equipment—Part 1: Safety requirements,” International Standard, IEC 62368-1, Edition 2.0, Feb. 2014, pp. 594-676, 85 pages.;;“National Electrical Code,” National Fire Protection Association (NFPA) 70, 2017, 881 pages.;;Voltserver Inc., v. Cisco Technology, Inc., “Declaration of David A. Durfee, Ph.D.,” United States Patent and Trademark Office, PGR2021-00055, U.S. Pat. No. 10,735,105, Feb. 16, 2021, 340 pages.;;David A. Durfee Ph.D., “Curriculum Vitae,” 4 pages.;;Adel S. Sedra, “Microelectronic Circuits,” Sedra/Smith, Oxford University Press, Seventh Edition, 2015, 38 pages.;;Charles k. Alexander, et al., “Fundamentals of Electric Circuits,” McGraw Hill Education, Indian Edition 5e, 2013, 37 pages.;;Andrew S. Tanenbaum, “Computer Networks,” Prentice Hall PTR, Third Edition, 1996, 12 pages.;;William Stallings, “Data and Computer Communications,” Macmillan Publishing Company, Fourth Edition, 1994, 14 pages.;;B.P. Lathi, et al., “Modern Digital and Analog Communication Systems,” Oxford University Press, Fourth Edition, 2009, 15 pages.;;Voltserver Inc., v. Cisco Technology, Inc., “Petition for Post Grant Review of U.S. Pat. No. 10,735,105,” United States Patent and Trademark Office, PGR2021-00055, U.S. Pat. No. 10,735,105, Feb. 16, 2021, 132 pages.;;Stephen H. Hall, et al., “High-Speed Digital System Design: A handbook of Interconnect Theory and Design Practices,” , John Wiley & Sons, Inc., 2000, 55 pages.;;“Understanding 802.3at, PoE Plus Standard Increases Available Power,” Microsemi, Jun. 2011, 7 pages.;;“Digital Electricity Gen2 Detailed Installation Manual,” Voltserver Digital Electricity, Rev B.1, Nov. 29, 2017, 68 pages.;;Berkeley Lab ETA, “Touch-Safe, High Voltage Digital Electricity Transmission using Packet Energy Transfer,” Vimeo, https://vimeo.com/172469008, Mar. 8, 2016, 8 pages.;;Voltserver Inc., v. Cisco Technology, Inc., “Decision Denying Institution of Post-Grant Review,” United States Patent and Trademark Office, PGR2021-00056, U.S. Pat. No. 10,735,105 B2, Aug. 23, 2021, 18 pages.;;Voltserver Inc., v. Cisco Systems, Inc., “Patent Owner's Preliminary Response to Post Grant Review Under 35 U.S.C. § 312 and 37 C.F.R. § 42.107,” United States Patent and Trademark Office, PGR2021-00056, U.S. Pat. No. 10,735,105, 2021, Jun. 2, 2021, 46 pages.;;Voltserver Inc., v. Cisco Technology, Inc., “Declaration of Stephens S. Eaves,” United States Patent and Trademark Office, PGR2021-00056, U.S. Pat. No. 10,735,105, Feb. 16, 2021, 7 pages.;;“Electrical—Computer Conference Proceedings,” Internet Archive WayBack Machine Search for Intelec 2012, Curran Associates, Inc., http://www.proceedings.com/electrical-computer-proceedings.html, 2012, 125 pages.;;“Part VII: A Summary of Commonly Used MARC 21 Fields,” Marc, Understanding MARC, https://www.loc.gov/marc//umb/um07to10.html, retrieved from Internet Feb. 13, 2021, 17 pages.;;LC Catalog-Browse, https://catalog.loc.gov/vwebv/searchBrowse, retrieved from the Internet Feb. 12, 2021, 1 page.;;“International Telecommunications Energy Conference: [proceedings] (Marc Tags),” Library Catalog, https://catalog.loc.gov/vwebv/staffView?searchId=3877&recPointer=0&recCount=25&searchType=1&bibld=11348322, retrieved from the Internet Feb. 12, 2021, 3 pages.;;Voltserver Inc., v. Cisco Technology, Inc., “Petition for Post Grant Review of U.S. Pat. No. 10,735,105,” United States Patent and Trademark Office, PGR2021-00056, U.S. Pat. No. 10,735,105, Feb. 16, 2021, 116 pages.;;“International Telecommunications Energy Conference: [proceedings] (Full Record),” Library Catalog, https://catalog.loc.gov/vwebv/holdingsInfo?searchId=3810&recPointer=0&recCount=25&searchType=1&bibId=11348322, retrieved rom the Internet Feb. 12, 2021, 4 pages.;;Office Action in counterpart Chinese Application No. 202080070369.3, dated Nov. 8, 2023, 18 pages.",ACTIVE
91,EP,A1,EP 4052418 A1,103-150-631-820-696,2022-09-07,2022,EP 20800518 A,2020-10-14,US 201916671508 A;;US 2020/0055532 W,2019-11-01,INITIALIZATION AND SYNCHRONIZATION FOR PULSE POWER IN A NETWORK SYSTEM,,CISCO TECH INC,ARDUINI DOUGLAS PAUL;;BAEK SUNG KEE;;O'BRIEN RICHARD ANTHONY;;GOERGEN JOEL RICHARD;;JONES CHAD M;;POTTERF JASON DEWAYNE;;LI RUQI,,https://lens.org/103-150-631-820-696,Patent Application,yes,0,0,13,14,0,H04L12/10;;H04B3/54;;G01R31/52;;G01R31/58;;G01R29/16;;H04L12/10;;H04L12/10;;H02J13/00032;;G05B9/02;;G06F1/305;;G01R31/083;;G01R31/50;;H02J13/00032;;G01R31/50;;G01R31/083;;G05B9/02;;G06F1/305;;H02J13/00;;H04B3/54;;H04L12/10;;H04L12/40045,H04L12/10,,0,0,,,,PENDING
92,KR,A,KR 20220093153 A,045-055-903-779-045,2022-07-05,2022,KR 20227017997 A,2020-10-14,US 201916671508 A;;US 2020/0055532 W,2019-11-01,네트워크 시스템에서의 펄스 전력을 위한 초기화 및 동기화,"일 실시예에서, 방법은, 통신 네트워크에서 전력 소싱 장비로부터 급전되는 디바이스로 저전압 펄스 전력을 전송하는 단계, 안전 테스트를 수행하는 단계, 안전 테스트를 통과할 시에 전력 소싱 장비에서 고전압 펄스 전력 동작을 인에이블하는 단계, 및 전력 소싱 장비로부터 급전되는 디바이스로 고전압 펄스 전력을 전송하는 단계를 포함한다. 급전되는 디바이스는 저전압 펄스 전력의 파형과 동기화한다.",CISCO TECH INC,ARDUINI DOUGLAS PAUL;;BAEK SUNG KEE;;O'BRIEN RICHARD ANTHONY;;GOERGEN JOEL RICHARD;;JONES CHAD M;;POTTERF JASON DEWAYNE;;LI RUQI,,https://lens.org/045-055-903-779-045,Patent Application,no,0,0,13,14,0,H04L12/10;;H04B3/54;;G01R31/52;;G01R31/58;;G01R29/16;;H04L12/10;;H04L12/10;;H02J13/00032;;G05B9/02;;G06F1/305;;G01R31/083;;G01R31/50;;H02J13/00032;;G01R31/50;;G01R31/083;;G05B9/02;;G06F1/305;;H02J13/00;;H04B3/54;;H04L12/10;;H04L12/40045,H04L12/10;;G01R31/08;;G01R31/50;;G05B9/02;;G06F1/30;;H02J13/00,,0,0,,,,PENDING
93,WO,A1,WO 2021/086609 A1,148-043-935-243-663,2021-05-06,2021,US 2020/0055532 W,2020-10-14,US 201916671508 A,2019-11-01,INITIALIZATION AND SYNCHRONIZATION FOR PULSE POWER IN A NETWORK SYSTEM,"In one embodiment, a method includes transmitting from power sourcing equipment, low voltage pulse power to a powered device in a communications network, performing a safety test, enabling high voltage pulse power operation at the power sourcing equipment upon passing the safety test, and transmitting high voltage pulse power from the power sourcing equipment to the powered device. The powered device synchronizes with a waveform of the low voltage pulse power.",CISCO TECH INC,ARDUINI DOUGLAS PAUL;;BAEK SUNG KEE;;O'BRIEN RICHARD ANTHONY;;GOERGEN JOEL RICHARD;;JONES CHAD M;;POTTERF JASON DEWAYNE;;LI RUQI,,https://lens.org/148-043-935-243-663,Patent Application,yes,13,0,13,14,0,H04L12/10;;H04B3/54;;G01R31/52;;G01R31/58;;G01R29/16;;H04L12/10;;H04L12/10;;H02J13/00032;;G05B9/02;;G06F1/305;;G01R31/083;;G01R31/50;;H02J13/00032;;G01R31/50;;G01R31/083;;G05B9/02;;G06F1/305;;H02J13/00;;H04B3/54;;H04L12/10;;H04L12/40045,H04L12/10,,0,0,,,,PENDING
94,US,B2,US 11063630 B2,061-399-838-053-596,2021-07-13,2021,US 201916671508 A,2019-11-01,US 201916671508 A,2019-11-01,Initialization and synchronization for pulse power in a network system,"In one embodiment, a method includes transmitting from power sourcing equipment, low voltage pulse power to a powered device in a communications network, performing a safety test, enabling high voltage pulse power operation at the power sourcing equipment upon passing the safety test, and transmitting high voltage pulse power from the power sourcing equipment to the powered device. The powered device synchronizes with a waveform of the low voltage pulse power.",CISCO TECH INC,ARDUINI DOUGLAS PAUL;;BAEK SUNG KEE;;O'BRIEN RICHARD ANTHONY;;GOERGEN JOEL RICHARD;;JONES CHAD M;;POTTERF JASON DEWAYNE;;LI RUQI,CISCO TECHNOLOGY INC (2019-10-31),https://lens.org/061-399-838-053-596,Granted Patent,yes,208,2,13,14,0,H04L12/10;;H04B3/54;;G01R31/52;;G01R31/58;;G01R29/16;;H04L12/10;;H04L12/10;;H02J13/00032;;G05B9/02;;G06F1/305;;G01R31/083;;G01R31/50;;H02J13/00032;;G01R31/50;;G01R31/083;;G05B9/02;;G06F1/305;;H02J13/00;;H04B3/54;;H04L12/10;;H04L12/40045,H04B3/54;;G01R31/08;;G01R31/50;;G05B9/02;;G06F1/30;;H02J13/00;;H04L12/10,,28,2,015-355-071-547-263;;015-355-071-547-263,10.1109/intlec.2012.6374488;;10.1109/intlec.2012.6374488,"https://www.fischerconnectors.com/us/en/products/fiberoptic.;;http://www.strantech.com/products/tfoca-genx-hybrid-2×2-fiber-optic-copper-connector/.;;http://www.qpcfiber.com/product/connectors/e-link-hybrid-connector/.;;https://www.lumentum.com/sites/default/files/technical-library-items/poweroverfiber-tn-pv-ae_0.pdf.;;“Network Remote Power Using Packet Energy Transfer”, Eaves et al., www.voltserver.com, Sep. 2012.;;Product Overview, “Pluribus VirtualWire Solution”, Pluribus Networks, PN-PO-VWS-05818, https://www.pluribusnetworks.com/assets/Pluribus-VirtualWire-PO-50918.pdf, May 2018, 5 pages.;;Implementation Guide, “Virtual Chassis Technology Best Practices”, Juniper Networks, 8010018-009-EN, Jan. 2016, https://wwwjuniper.net/us/en/local/pdf/implementation-guides/8010018-en.pdf, 29 pages.;;Yencheck, Thermal Modeling of Portable Power Cables, 1993.;;Zhang, Machine Learning-Based Temperature Prediction for Runtime Thermal Management across System Components, Mar. 2016.;;Data Center Power Equipment Thermal Guidelines and Best Practices.;;Dynamic Thermal Rating of Substation Terminal Equipment by Rambabu Adapa, 2004.;;Chen, Real-Time Termperature Estimation for Power MOSEFETs Conidering Thermal Aging Effects:, IEEE Trnasactions on Device and Materials Reliability, vol. 14, No. 1, Mar. 2014.;;Petition for Post Grant Review of U.S. Pat. No. 10,735,105 [Public], filed Feb. 16, 2021, PGR 2021-00055.;;Petition for Post Grant Review of U.S. Pat. No. 10,735,105 [Public], filed Feb. 16, 2021, PGR 2021-00056.;;Eaves, S. S., Network Remote Powering Using Packet Energy Transfer, Proceedings of IEEE International Conference on Telecommunications Energy (INTELEC) 2012, Scottsdale, AZ, Sep. 30-Oct. 4, 2012 (IEEE 2012) (EavesIEEE).;;Edelstein S., Updated 2016 Tesla Model S also gets new 75-kWhbattery option, (Jun. 19, 2016), archived Jun. 19, 2016 by Internet Archive Wayback machine at https://web.archive.org/web/20160619001148/https://www.greencarreports.com/news/1103 782_updated-2016-tesla-model-s-also-gets-new-7 5-kwh-battery-option (“Edelstein”).;;NFPA 70 National Electrical Code, 2017 Edition (NEC').;;International Standard IEC 62368-1 Edition 2.0 (2014), ISBN 978-2-8322-1405-3 (“IEC-62368”).;;International Standard IEC/TS 60479-1 Edition 4.0 (2005), ISBN 2-8318-8096-3 (“IEC-60479”).;;International Standard IEC 60950-1 Edition 2.2 (2013), ISBN 978-2-8322-0820-5 (“IEC-60950”).;;International Standard IEC 60947-1 Edition 5.0 (2014), ISBN 978-2-8322-1798-6 (“IEC-60947”).;;Tanenbaum, A. S., Computer Networks, Third Edition (1996) (“Tanenbaum”).;;Stallings, W., Data and Computer Communications, Fourth Edition ( 1994) (“Stallings”).;;Alexander, C. K., Fundamentals of Electric Circuits, Indian Edition (2013) (“Alexander”).;;Hall, S. H., High-Speed Digital System Design, A Handbook of Interconnect Theory and Design Practices (2000) (“Hall”).;;Sedra, A. S., Microelectronic Circuits, Seventh Edition (2014) (“Sedra”).;;Lathi, B. R, Modem Digital and Analog Communication Systems, Fourth Edition (2009) (“Lathi”).;;Understanding 802.3at PoE Plus Standard Increases Available Power (Jun. 2011) (“Microsemi”).",ACTIVE
95,US,A1,US 2023/0308134 A1,104-659-997-685-263,2023-09-28,2023,US 202318186301 A,2023-03-20,US 202318186301 A;;US 202117171723 A;;US 201916671508 A,2019-11-01,INITIALIZATION AND SYNCHRONIZATION FOR PULSE POWER IN A NETWORK SYSTEM,"In one embodiment, a method includes receiving low voltage pulse power from power sourcing equipment at a powered device, synchronizing the powered device with a waveform of the low voltage pulse power received from the power sourcing equipment, and operating the powered device with high voltage pulse power received from the power sourcing equipment.",CISCO TECH INC,ARDUINI DOUGLAS PAUL;;BAEK SUNG KEE;;O'BRIEN RICHARD ANTHONY;;GOERGEN JOEL RICHARD;;JONES CHAD M;;POTTERF JASON DEWAYNE;;LI RUQI,CISCO TECHNOLOGY INC (2019-10-31),https://lens.org/104-659-997-685-263,Patent Application,yes,5,1,13,14,0,H04L12/10;;H04B3/54;;G01R31/52;;G01R31/58;;G01R29/16;;H04L12/10;;H04L12/10;;H02J13/00032;;G05B9/02;;G06F1/305;;G01R31/083;;G01R31/50;;H02J13/00032;;G01R31/50;;G01R31/083;;G05B9/02;;G06F1/305;;H02J13/00;;H04B3/54;;H04L12/10;;H04L12/40045,H04B3/54;;G01R31/08;;G01R31/50;;G05B9/02;;G06F1/30;;H02J13/00;;H04L12/10;;H04L12/40,,0,0,,,,PENDING
96,US,A1,US 2021/0167813 A1,109-670-220-030-734,2021-06-03,2021,US 202117171723 A,2021-02-09,US 202117171723 A;;US 201916671508 A,2019-11-01,INITIALIZATION AND SYNCHRONIZATION FOR PULSE POWER IN A NETWORK SYSTEM,"In one embodiment, a method includes receiving low voltage pulse power from power sourcing equipment at a powered device, synchronizing the powered device with a waveform of the low voltage pulse power received from the power sourcing equipment, and operating the powered device with high voltage pulse power received from the power sourcing equipment.",CISCO TECH INC,ARDUINI DOUGLAS PAUL;;BAEK SUNG KEE;;O'BRIEN RICHARD ANTHONY;;GOERGEN JOEL RICHARD;;JONES CHAD M;;POTTERF JASON DEWAYNE;;LI RUQI,CISCO TECHNOLOGY INC (2019-10-31),https://lens.org/109-670-220-030-734,Patent Application,yes,3,2,13,14,0,H04L12/10;;H04B3/54;;G01R31/52;;G01R31/58;;G01R29/16;;H04L12/10;;H04L12/10;;H02J13/00032;;G05B9/02;;G06F1/305;;G01R31/083;;G01R31/50;;H02J13/00032;;G01R31/50;;G01R31/083;;G05B9/02;;G06F1/305;;H02J13/00;;H04B3/54;;H04L12/10;;H04L12/40045,H04B3/54;;G01R31/08;;G01R31/50;;G05B9/02;;G06F1/30;;H02J13/00;;H04L12/10,,0,0,,,,PENDING
97,US,A1,US 2021/0167814 A1,026-506-776-035-561,2021-06-03,2021,US 202117171785 A,2021-02-09,US 202117171785 A;;US 201916671508 A,2019-11-01,INITIALIZATION AND SYNCHRONIZATION FOR PULSE POWER IN A NETWORK SYSTEM,"In one embodiment, a method includes identifying at a first powered device in communication with power sourcing equipment, a second powered device in communication with the first powered device, wherein the first powered device is receiving high voltage pulse power from the power sourcing equipment, notifying the power sourcing equipment of the second powered device at the first powered device, and performing a low voltage power initialization at the first powered device with the second powered device before passing the high voltage pulse power to the second powered device.",CISCO TECH INC,ARDUINI DOUGLAS PAUL;;BAEK SUNG KEE;;O'BRIEN RICHARD ANTHONY;;GOERGEN JOEL RICHARD;;JONES CHAD M;;POTTERF JASON DEWAYNE;;LI RUQI,CISCO TECHNOLOGY INC (2019-10-31),https://lens.org/026-506-776-035-561,Patent Application,yes,2,1,13,14,0,H04L12/10;;H04B3/54;;G01R31/52;;G01R31/58;;G01R29/16;;H04L12/10;;H04L12/10;;H02J13/00032;;G05B9/02;;G06F1/305;;G01R31/083;;G01R31/50;;H02J13/00032;;G01R31/50;;G01R31/083;;G05B9/02;;G06F1/305;;H02J13/00;;H04B3/54;;H04L12/10;;H04L12/40045,H04B3/54;;G01R31/08;;G01R31/50;;G05B9/02;;G06F1/30;;H02J13/00;;H04L12/10,,0,0,,,,ACTIVE
98,US,A1,US 2021/0135890 A1,155-605-253-560-405,2021-05-06,2021,US 201916671508 A,2019-11-01,US 201916671508 A,2019-11-01,INITIALIZATION AND SYNCHRONIZATION FOR PULSE POWER IN A NETWORK SYSTEM,"In one embodiment, a method includes transmitting from power sourcing equipment, low voltage pulse power to a powered device in a communications network, performing a safety test, enabling high voltage pulse power operation at the power sourcing equipment upon passing the safety test, and transmitting high voltage pulse power from the power sourcing equipment to the powered device. The powered device synchronizes with a waveform of the low voltage pulse power.",CISCO TECH INC,ARDUINI DOUGLAS PAUL;;BAEK SUNG KEE;;O'BRIEN RICHARD ANTHONY;;GOERGEN JOEL RICHARD;;JONES CHAD M;;POTTERF JASON DEWAYNE;;LI RUQI,CISCO TECHNOLOGY INC (2019-10-31),https://lens.org/155-605-253-560-405,Patent Application,yes,0,5,13,14,0,H04L12/10;;H04B3/54;;G01R31/52;;G01R31/58;;G01R29/16;;H04L12/10;;H04L12/10;;H02J13/00032;;G05B9/02;;G06F1/305;;G01R31/083;;G01R31/50;;H02J13/00032;;G01R31/50;;G01R31/083;;G05B9/02;;G06F1/305;;H02J13/00;;H04B3/54;;H04L12/10;;H04L12/40045,H04L12/10;;G01R31/08;;G05B9/02;;H02J13/00,,0,0,,,,ACTIVE
99,US,A1,US 2022/0385334 A1,109-885-923-077-713,2022-12-01,2022,US 202217884124 A,2022-08-09,US 202217884124 A;;US 202016999754 A;;US 201916704502 A;;US 201916255657 A,2019-01-23,TRANSMISSION OF PULSE POWER AND DATA IN A COMMUNICATIONS NETWORK,"In one embodiment, a method includes transmitting pulse power on two wire pairs, the pulse power comprising a plurality of high voltage pulses with the high voltage pulses on the wire pairs offset between the wire pairs to provide continuous power, performing low voltage fault detection on each of the wire pairs between the high voltage pulses, and transmitting data on at least one of the wire pairs during transmittal of the high voltage pulses. Data transmittal is suspended during the low voltage fault detection.",CISCO TECH INC,JONES CHAD M;;GOERGEN JOEL RICHARD;;ZIMMERMAN GEORGE ALLAN;;O'BRIEN RICHARD ANTHONY;;ARDUINI DOUGLAS PAUL;;POTTERF JASON DEWAYNE;;BAEK SUNG KEE,CISCO TECHNOLOGY INC (2019-12-05),https://lens.org/109-885-923-077-713,Patent Application,yes,3,0,12,23,0,H04B3/54;;H03M13/03;;H03M13/1515;;H03M13/373;;Y04S40/00;;H04L12/40045;;H04L12/10;;H04L12/10;;H03M13/03;;H04B2203/542;;H04B3/54;;H04L41/12;;H04W80/02;;H03M13/1515;;H03M13/373,H04B3/54;;H03M13/37;;H04L12/10,,0,0,,,,ACTIVE
100,US,B2,US 10790997 B2,019-011-597-980-906,2020-09-29,2020,US 201916704502 A,2019-12-05,US 201916704502 A;;US 201916255657 A,2019-01-23,Transmission of pulse power and data in a communications network,"In one embodiment, a method includes transmitting data on two wire pairs carrying pulse power, wherein the pulse power comprises a plurality of voltage pulses with the voltage pulses on the wire pairs offset between the wire pairs to provide continuous power and identifying transitions between at least one of a pulse-on time and a pulse-off time, and a pulse-off time and a pulse-on time on at least one of the wire pairs. Data transmission on the wire pair is controlled during the identified transitions on the wire pair to prevent interference between the pulse power and the data.",CISCO TECH INC,JONES CHAD M;;GOERGEN JOEL RICHARD;;ZIMMERMAN GEORGE ALLAN;;O'BRIEN RICHARD ANTHONY;;ARDUINI DOUGLAS PAUL;;POTTERF JASON DEWAYNE;;BAEK SUNG KEE,CISCO TECHNOLOGY INC (2019-12-05),https://lens.org/019-011-597-980-906,Granted Patent,yes,195,10,12,23,0,H04B3/54;;H03M13/03;;H03M13/1515;;H03M13/373;;Y04S40/00;;H04L12/40045;;H04L12/10;;H04L12/10;;H03M13/03;;H04B2203/542;;H04B3/54;;H04L41/12;;H04W80/02;;H03M13/1515;;H03M13/373,H03M13/00;;H03M13/03;;H04B3/54;;H04L12/10;;H04L12/24;;H04W80/02,,12,1,015-355-071-547-263,10.1109/intlec.2012.6374488,"https://www.fischerconnectors.com/us/en/products/fiberoptic.;;http://www.strantech.com/products/tfoca-genx-hybrid-2x2-fiber-optic-copper-connector/.;;http://www.qpcfiber.com/product/connectors/e-link-hybrid-connector/.;;https://www.lumentum.com/sites/default/files/technical-library-items/poweroverfiber-tn-pv-ae_0.pdf.;;“Network Remote Power Using Packet Energy Transfer”, Eaves et al., www.voltserver.com, Sep. 2012.;;Product Overview, “Pluribus VirtualWire Solution”, Pluribus Networks, PN-PO-VWS-05818, https://www.pluribusnetworks.com/assets/Pluribus-VirtualWire-PO-50918.pdf, May 2018, 5 pages.;;Implementation Guide, “Virtual Chassis Technology Best Practices”, Juniper Networks, 8010018-009-EN, Jan. 2016, https://wwwjuniper.net/us/en/local/pdf/implementation-guides/8010018-en.pdf, 29 pages.;;Yencheck, Thermal Modeling of Portable Power Cables, 1993.;;Zhang, Machine Learning-Based Temperature Prediction for Runtime Thermal Management across System Components, Mar. 2016.;;Data Center Power Equipment Thermal Guidelines and Best Practices.;;Dynamic Thermal Rating of Substation Terminal Equipment by Rambabu Adapa, 2004.;;Chen, Real-Time Termperature Estimation for Power MOSEFETs Conidering Thermal Aging Effects:, IEEE Trnasactions on Device and Materials Reliability, vol. 14, No. 1, Mar. 2014.",ACTIVE
101,CA,A1,CA 3125024 A1,167-190-414-662-845,2020-07-30,2020,CA 3125024 A,2020-01-08,US 201916255657 A;;US 201916704502 A;;US 2020/0012801 W,2019-01-23,TRANSMISSION OF PULSE POWER AND DATA IN A COMMUNICATIONS NETWORK,"In one embodiment, a method includes transmitting data on two wire pairs carrying pulse power, wherein the pulse power comprises a plurality of voltage pulses with the voltage pulses on the wire pairs offset between the wire pairs to provide continuous power and identifying transitions between at least one of a pulse-on time and a pulse-off time, and a pulse-off time and a pulse-on time on at least one of the wire pairs. Data transmission on the wire pair is controlled during the identified transitions on the wire pair to prevent interference between the pulse power and the data.",CISCO TECH INC,JONES CHAD M;;GOERGEN JOEL RICHARD;;ZIMMERMAN GEORGE ALLAN;;O'BRIEN RICHARD ANTHONY;;ARDUINI DOUGLAS PAUL;;POTTERF JASON DEWAYNE;;BAEK SUNG KEE,,https://lens.org/167-190-414-662-845,Patent Application,no,0,0,12,23,0,H04B3/54;;H03M13/03;;H03M13/1515;;H03M13/373;;Y04S40/00;;H04L12/40045;;H04L12/10;;H04L12/10;;H03M13/03;;H04B2203/542;;H04B3/54;;H04L41/12;;H04W80/02;;H03M13/1515;;H03M13/373,H04L12/40;;H04L12/10,,0,0,,,,PENDING
102,US,B2,US 11444791 B2,125-825-073-389-66X,2022-09-13,2022,US 202016999754 A,2020-08-21,US 202016999754 A;;US 201916704502 A;;US 201916255657 A,2019-01-23,Transmission of pulse power and data in a communications network,"In one embodiment, a method includes transmitting pulse power on two wire pairs, the pulse power comprising a plurality of high voltage pulses with the high voltage pulses on the wire pairs offset between the wire pairs to provide continuous power, performing low voltage fault detection on each of the wire pairs between the high voltage pulses, and transmitting data on at least one of the wire pairs during transmittal of the high voltage pulses. Data transmittal is suspended during the low voltage fault detection.",CISCO TECH INC,JONES CHAD M;;GOERGEN JOEL RICHARD;;ZIMMERMAN GEORGE ALLAN;;O'BRIEN RICHARD ANTHONY;;ARDUINI DOUGLAS PAUL;;POTTERF JASON DEWAYNE;;BAEK SUNG KEE,CISCO TECHNOLOGY INC (2019-12-05),https://lens.org/125-825-073-389-66X,Granted Patent,yes,263,2,12,23,0,H04B3/54;;H03M13/03;;H03M13/1515;;H03M13/373;;Y04S40/00;;H04L12/40045;;H04L12/10;;H04L12/10;;H03M13/03;;H04B2203/542;;H04B3/54;;H04L41/12;;H04W80/02;;H03M13/1515;;H03M13/373,H03M13/00;;H03M13/03;;H04B3/54;;H04L12/10;;H04L41/12;;H04W80/02,,38,4,015-355-071-547-263;;015-355-071-547-263;;078-589-609-090-910;;057-748-029-418-389,10.1109/intlec.2012.6374488;;10.1109/intlec.2012.6374488;;10.1049/ip-b.1992.0027;;10.1109/pesc.2001.954206,"https://www.fischerconnectors.com/us/en/products/fiberoptic.;;http://www.strantech.com/products/tfoca-genx-hybrid-2x2-fiber-optic-copper-connector/.;;http://www.qpcfiber.com/product/connectors/e-link-hybrid-connector/.;;https://www.lumentum.com/sites/default/files/technical-library-items/poweroverfiber-tn-pv-ae_0.pdf.;;“Network Remote Power Using Packet Energy Transfer”, Eaves et al., www.voltserver.com, Sep. 2012.;;Product Overview, “Pluribus VirtualWire Solution”, Pluribus Networks, PN-PO-VWS-05818, https://www.pluribusnetworks.com/assets/Pluribus-VirtualWire-PO-50918.pdf, May 2018, 5 pages.;;Implementation Guide, “Virtual Chassis Technology Best Practices”, Juniper Networks, 8010018-009-EN, Jan. 2016, https://wwwjuniper.net/us/en/local/pdf/implementation-guides/8010018-en.pdf, 29 pages.;;Yencheck, Thermal Modeling of Portable Power Cables, 1993.;;Zhang, Machine Learning-Based Temperature Prediction for Runtime Thermal Management across System Components, Mar. 2016.;;Data Center Power Equipment Thermal Guidelines and Best Practices.;;Dynamic Thermal Rating of Substation Terminal Equipment by Rambabu Adapa, 2004.;;Chen, Real-Time Termperature Estimation for Power MOSEFETs Conidering Thermal Aging Effects:, IEEE Trnasactions on Device and Materials Reliability, vol. 14, No. 1, Mar. 2014.;;Petition for Post Grant Review of U.S. Pat. No. 10,735,105 [Public], filed Feb. 16, 2021, PGR 2021-00055.;;Petition for Post Grant Review of U.S. Pat. No. 10,735,105 [Public], filed Feb. 16, 2021, PGR 2021-00056.;;Eaves, S. S., Network Remote Powering Using Packet Energy Transfer, Proceedings of IEEE International Conference on Telecommunications Energy (INTELEC) 2012, Scottsdale, AZ, Sep. 30-Oct. 4, 2012 (IEEE 2012) (EavesIEEE).;;Edelstein S., Updated 2016 Tesla Model S also gets new 75-kWhbattery option, (Jun. 19, 2016), archived Jun. 19, 2016 by Internet Archive Wayback machine at https://web.archive.org/web/20160619001148/https://www.greencarreports.com/news/1103 782_updated-2016-tesla-model-s-also-gets-new-7 5-kwh-battery-option (“Edelstein”).;;NFPA 70 National Electrical Code, 2017 Edition (NEC).;;International Standard IEC 62368-1 Edition 2.0 (2014), ISBN 978-2-8322-1405-3 (“IEC-62368”).;;International Standard IEC/TS 60479-1 Edition 4.0 (2005), ISBN 2-8318-8096-3 (“IEC-60479”).;;International Standard IEC 60950-1 Edition 2.2 (2013), ISBN 978-2-8322-0820-5 (“IEC-60950”).;;International Standard IEC 60947-1 Edition 5.0 (2014), ISBN 978-2-8322-1798-6 (“IEC-60947”).;;Tanenbaum, A. S., Computer Networks, Third Edition (1996) (“Tanenbaum”).;;Stallings, W., Data and Computer Communications, Fourth Edition (1994) (“Stallings”).;;Alexander, C. K., Fundamentals of Electric Circuits, Indian Edition (2013) (“Alexander”).;;Hall, S. H., High-Speed Digital System Design, A Handbook of Interconnect Theory and Design Practices (2000) (“Hall”).;;Sedra, A. S., Microelectronic Circuits, Seventh Edition (2014) (“Sedra”).;;Lathi, B. P., Modem Digital and Analog Communication Systems, Fourth Edition (2009) (“Lathi”).;;Understanding 802.3at PoE Plus Standard Increases Available Power (Jun. 2011) (“Microsemi”).;;CHENG K. W. E., EVANS P. D.: ""CONSTANT FREQUENCY, TWO-STAGE QUASIRESONANT CONVERTOR."", PUBLISHED IN: IEE PROCEEDINGS B - ELECTRIC POWER APPLICATIONS, vol. 139., no. 03., 1 May 1992 (1992-05-01), pages 227 - 237., XP000292493;;International Preliminary Report on Patentability for International Application No. PCT/US2020/012758, dated Aug. 5, 2021,10 Pages.;;International Preliminary Report on Patentability for International Application No. PCT/US2020/012801, dated Aug. 5, 2021, 9 Pages.;;International Preliminary Report on Patentability for International Application No. PCT/US2020/020359, dated Sep. 23, 2021, 9 Pages.;;International Search Report and Written Opinion for International Application No. PCT/US2020/012758, dated Apr. 8, 2020, 11 Pages.;;International Search Report and Written Opinion for International Application No. PCT/US2020/012801, dated Apr. 15, 2020, 10 Pages.;;International Search Report and Written Opinion for International Application No. PCT/US2020/020359, dated May 27, 2020, 10 Pages.;;JINGQUAN CHEN, MAKSIMOVIC D., ERICKSON R.: ""Buck-boost PWM converters having two independently controlled switches"", 32ND.ANNUAL IEEE POWER ELECTRONICS SPECIALISTS CONFERENCE. PESC 2001. CONFERENCE PROCEEDINGS. VANCOUVER, CANADA, JUNE 17 - 21, 2001., NEW YORK, NY : IEEE., US, vol. 2, 17 June 2001 (2001-06-17) - 21 June 2001 (2001-06-21), US , pages 736 - 741, XP010559317, ISBN: 978-0-7803-7067-8, DOI: 10.1109/PESC.2001.954206;;English Translation of Office Action in counterpart Chinese Application No. 202080010019.8, dated Mar. 3, 2022, 11 pages.;;English Translation of Office Action in counterpart Chinese Application No. 202080010020.0, dated Mar. 3, 2022, 15 pages.",ACTIVE
103,US,A1,US 2020/0235949 A1,012-319-343-277-467,2020-07-23,2020,US 201916704502 A,2019-12-05,US 201916704502 A;;US 201916255657 A,2019-01-23,TRANSMISSION OF PULSE POWER AND DATA IN A COMMUNICATIONS NETWORK,"In one embodiment, a method includes transmitting data on two wire pairs carrying pulse power, wherein the pulse power comprises a plurality of voltage pulses with the voltage pulses on the wire pairs offset between the wire pairs to provide continuous power and identifying transitions between at least one of a pulse-on time and a pulse-off time, and a pulse-off time and a pulse-on time on at least one of the wire pairs. Data transmission on the wire pair is controlled during the identified transitions on the wire pair to prevent interference between the pulse power and the data.",CISCO TECH INC,JONES CHAD M;;GOERGEN JOEL RICHARD;;ZIMMERMAN GEORGE ALLAN;;O'BRIEN RICHARD ANTHONY;;ARDUINI DOUGLAS PAUL;;POTTERF JASON DEWAYNE;;BAEK SUNG KEE,CISCO TECHNOLOGY INC (2019-12-05),https://lens.org/012-319-343-277-467,Patent Application,yes,2,14,12,23,0,H04B3/54;;H03M13/03;;H03M13/1515;;H03M13/373;;Y04S40/00;;H04L12/40045;;H04L12/10;;H04L12/10;;H03M13/03;;H04B2203/542;;H04B3/54;;H04L41/12;;H04W80/02;;H03M13/1515;;H03M13/373,H04L12/10;;H03M13/03;;H04B3/54;;H04L12/24;;H04W80/02,,0,0,,,,ACTIVE
104,EP,B1,EP 3915229 B1,098-678-392-300-840,2023-09-13,2023,EP 20703636 A,2020-01-08,US 201916255657 A;;US 201916704502 A;;US 2020/0012801 W,2019-01-23,TRANSMISSION OF PULSE POWER AND DATA IN A COMMUNICATIONS NETWORK,,CISCO TECH INC,JONES CHAD M;;GOERGEN JOEL RICHARD;;ZIMMERMAN GEORGE ALLAN;;O'BRIEN RICHARD ANTHONY;;ARDUINI DOUGLAS PAUL;;POTTERF JASON DEWAYNE;;BAEK SUNG KEE,,https://lens.org/098-678-392-300-840,Granted Patent,yes,3,0,12,23,0,H04B3/54;;H03M13/03;;H03M13/1515;;H03M13/373;;Y04S40/00;;H04L12/40045;;H04L12/10;;H04L12/10;;H03M13/03;;H04B2203/542;;H04B3/54;;H04L41/12;;H04W80/02;;H03M13/1515;;H03M13/373,H04L12/40;;H04L12/10,,0,0,,,,ACTIVE
105,US,B2,US 11848790 B2,050-889-741-512-701,2023-12-19,2023,US 202217884124 A,2022-08-09,US 202217884124 A;;US 202016999754 A;;US 201916704502 A;;US 201916255657 A,2019-01-23,Transmission of pulse power and data in a communications network,"In one embodiment, a method includes transmitting pulse power on two wire pairs, the pulse power comprising a plurality of high voltage pulses with the high voltage pulses on the wire pairs offset between the wire pairs to provide continuous power, performing low voltage fault detection on each of the wire pairs between the high voltage pulses, and transmitting data on at least one of the wire pairs during transmittal of the high voltage pulses. Data transmittal is suspended during the low voltage fault detection.",CISCO TECH INC,JONES CHAD M;;GOERGEN JOEL RICHARD;;ZIMMERMAN GEORGE ALLAN;;O'BRIEN RICHARD ANTHONY;;ARDUINI DOUGLAS PAUL;;POTTERF JASON DEWAYNE;;BAEK SUNG KEE,CISCO TECHNOLOGY INC (2019-12-05),https://lens.org/050-889-741-512-701,Granted Patent,yes,283,0,12,23,0,H04B3/54;;H03M13/03;;H03M13/1515;;H03M13/373;;Y04S40/00;;H04L12/40045;;H04L12/10;;H04L12/10;;H03M13/03;;H04B2203/542;;H04B3/54;;H04L41/12;;H04W80/02;;H03M13/1515;;H03M13/373,H03M13/00;;H03M13/03;;H03M13/15;;H03M13/37;;H04B3/54;;H04L12/10;;H04L41/12;;H04W80/02,,95,0,,,"Voltserver Inc., v. Cisco Technology, Inc., “Decision Denying Institution of Post-Grant Review,” United States Patent and Trademark Office, PGR2021-00055, U.S. Pat. No. 10,735,105 B2, Aug. 19, 2021, 25 pages.;;Voltserver Inc., v. Cisco Systems, Inc., “Patent Owner's Preliminary Response to Post Grant Review Under 35 U.S.C. § 312 and 37 C.F.R. § 42.107,” United States Patent and Trademark Office, PGR2021-00055, U.S. Pat. No. 10,735,105, 2021, Jun. 2, 2021, 51 pages.;;“Effects of current on human beings and livestok—Part 1: General aspects,” Technical Specification, Basic Safety Publication, IEC/TS 60479-1, Edition 4.0, Jul. 2005, 122 pages.;;“Information technology equipment—Safety—Part 1: General requirements,” International Standard, IEC 60950-1, Edition 2.2, May 2013, pp. 1-61, 63 pages.;;“Information technology equipment—Safety—Part 1: General requirements,” International Standard, IEC 60950-1, Edition 2.2, May 2013, pp. 62-122, 61 pages.;;“Information technology equipment—Safety—Part 1: General requirements,” International Standard, IEC 60950-1, Edition 2.2, May 2013, pp. 123-181, 59 pages.;;“Information technology equipment—Safety—Part 1: General requirements,” International Standard, IEC 60950-1, Edition 2.2, May 2013, pp. 182-253, 72 pages.;;“Information technology equipment—Safety—Part 1: General requirements,” International Standard, IEC 60950-1, Edition 2.2, May 2013, pp. 254-319, 66 pages.;;“Information technology equipment—Safety—Part 1: General requirements,” International Standard, IEC 60950-1, Edition 2.2, May 2013, pp. 320-377, 58 pages.;;“Information technology equipment—Safety—Part 1: General requirements,” International Standard, IEC 60950-1, Edition 2.2, May 2013, pp. 378-433, 56 pages.;;“Information technology equipment—Safety—Part 1: General requirements,” International Standard, IEC 60950-1, Edition 2.2, May 2013, pp. 434-490, 57 pages.;;“Information technology equipment—Safety—Part 1: General requirements,” International Standard, IEC 60950-1, Edition 2.2, May 2013, pp. 491-551, 61 pages.;;“Information technology equipment—Safety—Part 1: General requirements,” International Standard, IEC 60950-1, Edition 2.2, May 2013, pp. 552-622, 71 pages.;;“Information technology equipment—Safety—Part 1: General requirements,” International Standard, IEC 60950-1, Edition 2.2, May 2013, pp. 623-644, 24 pages.;;“Low-voltage switchgear and controlgear—Part 1: General rules,” International Standard, Amendment 2, IEC 60947-1, Edition 5.0, Sep. 2014, pp. 1-63, 65 pages.;;“Low-voltage switchgear and controlgear—Part 1: General rules,” International Standard, Amendment 2, IEC 60947-1, Edition 5.0, Sep. 2014, pp. 64-102, 41 pages.;;Stephen Edelstein, “Updated 2016 Tesla Model S also gets new 75-kWhbattery option,” Internet Archive WayBack Machine, Green Car Reports, May 5, 2016, 3 pages.;;Stephen S. Eaves, “Network Remote Powering using Packet Energy Transfer,” IEEE Xplore, Proceedings of IEEE International Conference on Telecommunications Energy (INTELEC) 2012, 978-1-4673-1000, Sep. 30-Oct. 4, 2012, 4 pages.;;“Audio/video, information and communication technology equipment—Part 1: Safety requirements,” International Standard, IEC 62368-1, Edition 2.0, Feb. 2014, pp. 1-132, 134 pages.;;“Audio/video, information and communication technology equipment—Part 1: Safety requirements,” International Standard, IEC 62368-1, Edition 2.0, Feb. 2014, pp. 133-263, 131 pages.;;“Audio/video, information and communication technology equipment—Part 1: Safety requirements,” International Standard, IEC 62368-1, Edition 2.0, Feb. 2014, pp. 264-387, 124 pages.;;“Audio/video, information and communication technology equipment—Part 1: Safety requirements,” International Standard, IEC 62368-1, Edition 2.0, Feb. 2014, pp. 388-508, 121 pages.;;“Audio/video, information and communication technology equipment—Part 1: Safety requirements,” International Standard, IEC 62368-1, Edition 2.0, Feb. 2014, pp. 509-593, 85 pages.;;“Audio/video, information and communication technology equipment—Part 1: Safety requirements,” International Standard, IEC 62368-1, Edition 2.0, Feb. 2014, pp. 594-676, 85 pages.;;“National Electrical Code,” National Fire Protection Association (NFPA) 70, 2017, 881 pages.;;Voltserver Inc., v. Cisco Technology, Inc., “Declaration of David A. Durfee, Ph.D.,” United States Patent and Trademark Office, PGR2021-00055, Patent No. 10,735,105, Feb. 16, 2021, 340 pages.;;David A. Durfee Ph.D., “Curriculum Vitae,” 4 pages.;;Adel S. Sedra, “Microelectronic Circuits,” Sedra/Smith, Oxford University Press, Seventh Edition, 2015, 38 pages.;;Charles k. Alexander, et al., “Fundamentals of Electric Circuits,” McGraw Hill Education, Indian Edition 5e, 2013, 37 pages.;;Andrew S. Tanenbaum, “Computer Networks,” Prentice Hall PTR, Third Edition, 1996, 12 pages.;;William Stallings, “Data and Computer Communications,” Macmillan Publishing Company, Fourth Edition, 1994, 14 pages.;;B.P. Lathi, et al., “Modern Digital and Analog Communication Systems,” Oxford University Press, Fourth Edition, 2009, 15 pages.;;Voltserver Inc., v. Cisco Technology, Inc., “Petition for Post Grant Review of U.S. Pat. No. 10,735,105,” United States Patent and Trademark Office, PGR2021-00055, U.S. Pat. No. 10,735,105, Feb. 16, 2021, 132 pages.;;Stephen H. Hall, et al., “High-Speed Digital System Design: A handbook of Interconnect Theory and Design Practices,” , John Wiley & Sons, Inc., 2000, 55 pages.;;“Understanding 802.3at, PoE Plus Standard Increases Available Power,” Microsemi, Jun. 2011, 7 pages.;;“Digital Electricity Gen2 Detailed Installation Manual,” Voltserver Digital Electricity, Rev B.1, Nov. 29, 2017, 68 pages.;;Berkeley Lab ETA, “Touch-Safe, High Voltage Digital Electricity Transmission using Packet Energy Transfer,” Vimeo, https://vimeo.com/172469008, Mar. 8, 2016, 8 pages.;;Voltserver Inc., v. Cisco Technology, Inc., “Decision Denying Institution of Post-Grant Review,” United States Patent and Trademark Office, PGR2021-00056, U.S. Pat. No. 10,735,105 B2, Aug. 23, 2021, 18 pages.;;Voltserver Inc., v. Cisco Systems, Inc., “Patent Owner's Preliminary Response to Post Grant Review Under 35 U.S.C. § 312 and 37 C.F.R. § 42.107,” United States Patent and Trademark Office, PGR2021-00056, U.S. Pat. No. 10,735,105, 2021, Jun. 2, 2021, 46 pages.;;Voltserver Inc., v. Cisco Technology, Inc., “Declaration of Stephens S. Eaves,” United States Patent and Trademark Office, PGR2021-00056, U.S. Pat. No. 10,735,105, Feb. 16, 2021, 7 pages.;;“Electrical—Computer Conference Proceedings,” Internet Archive WayBack Machine Search for Intelec 2012, Curran Associates, Inc., http://www.proceedings.com/electrical-computer-proceedings.html, 2012, 125 pages.;;“Part VII: A Summary of Commonly Used MARC 21 Fields,” Marc, Understanding MARC, https://www.loc.gov/marc//umb/um07to10.html, retrieved from Internet Feb. 13, 2021, 17 pages.;;LC Catalog-Browse, https://catalog.loc.gov/vwebv/searchBrowse, retrieved from the Internet Feb. 12, 2021, 1 page.;;“International Telecommunications Energy Conference: [proceedings] (Marc Tags),” Library Catalog, https://catalog.loc.gov/vwebv/staffView?searchId=3877&recPointer=0&recCount=25&searchType=1&bibId=11348322, retrieved from the Internet Feb. 12, 2021, 3 pages.;;Voltserver Inc., v. Cisco Technology, Inc., “Petition for Post Grant Review of U.S. Pat. No. 10,735,105,” United States Patent and Trademark Office, PGR2021-00056, U.S. Pat. No. 10,735,105, Feb. 16, 2021, 116 pages.;;“International Telecommunications Energy Conference: [proceedings] (Full Record),” Library Catalog, https://catalog.loc.gov/vwebv/holdingsInfo?searchId=3810&recPointer=0&recCount=25&searchType=1&bibId=11348322, retrieved from the Internet Feb. 12, 2021, 4 pages.;;Fischer Connectors SA, “Fiberoptic Cable and Connector Solutions,” retrieved from https://www.fischerconnectors.com/us/en/products/fiberoptic, on Dec. 21, 2017, 5 pages.;;Stran Technologies, http://www.strantech.com/products/tfoca-genx-hybrid-2x2-fiber-optic-copper-connector/, Dec. 2017, 2 pages.;;QPC Engineered Fiber Optic Soloutions, http://www.qpcfiber.com/product/connectors/e-link-hybrid-connector/ retrieved Dec. 21, 2017, 4 pages.;;Lumentum, https://www.lumentum.com/sites/default/files/technical-library-items/poweroverfiber-tn-pv-ae_0.pdf, Sep. 25, 2020, 8 pages.;;Eaves et al. “Network Remote Power Using Packet Energy Transfer”, www.voltserver.com, Sep. 2012, 4 pages.;;Product Overview, “Pluribus VirtualWire Solution”, Pluribus Networks, PN-PO-VWS-05818, https://www.pluribusnetworks.com/assets/Pluribus-VirtualWire-PO-50918.pdf, May 2018, 5 pages.;;Implementation Guide, “Virtual Chassis Technology Best Practices”, Juniper Networks, 8010018-009-EN, Jan. 2016, https://wwwjuniper.net/us/en/local/pdf/implementation-guides/8010018-en.pdf, 29 pages.;;Yencheck, “Thermal Modeling of Portable Power Cables,” Jan. 1993, 19 pages.;;Zhang, Machine Learning-Based Temperature Prediction for Runtime Thermal Management across System Components, Mar. 2016, 15 pages.;;Rabe, et al. “Data Center Power Equipment Thermal Guidelines and Best Practices,” ASHRAE Technical Committee 9.9 Mission Critical Facilities, Data Centers, Technology Spaces, and Electronic Equipment, Jun. 2016, 60 pages.;;Adapa, R. “Dynamic Thermal Rating of Substation Terminal Equipment,” Jan. 2004, 8 pages.;;Chen, Real-Time Termperature Estimation for Power MOSEFETs Conidering Thermal Aging Effects:, IEEE Trnasactions on Device and Materials Reliability, vol. 14, No. 1, Mar. 2014, 9 pages.;;Petition for Post Grant Review of U.S. Pat. No. 10,735,105 [Public], filed Feb. 16, 2021, PGR 2021-00055, 116 pages.;;Goergen, et al. Petition for Post Grant Review of U.S. Pat. No. 10,735,105 [Public], filed Feb. 16, 2021, PGR 2021-00056, 132 pages.;;Edelstein S., Updated 2016 Tesla Model S also gets new 75-kWhbattery option, (Jun. 19, 2016), archived Jun. 19, 2016 by Internet Archive Wayback machine at https://web.archive.org/web/20160619001148/https://www.greencarreports.com/news/1103 782_updated-2016-tesla-model-s-also-gets-new-7 5-kwh-battery-option (“Edelstein”), 3 pages.;;NFPA 70, “National Electrical Code,” retrieved Dec. 2017, Edition (NEC), 881 pages.;;International Standard IEC 62368-1 Edition 2.0 (Feb. 2014), ISBN 978-2-8322-1405-3 (“IEC-62368”), 680 pages.;;International Standard IEC/TS 60479-1 Edition 4.0 (Jul. 2005), ISBN 2-8318-8096-3 (“IEC-60479”), 122 pages.;;International Standard IEC 60950-1 Edition 2.2 (May 2013), ISBN 978-2-8322-0820-5 (“IEC-60950”), 648 pages.;;International Standard IEC 60947-1 Edition 5.0 (Sep. 2014), ISBN 978-2-8322-1798-6 (“IEC-60947”), 106 pages.;;Tanenbaum, A. S., “Computer Networks,” Third Edition, Mar. 6, 1996, 12 pages.;;Stallings, W., Data and Computer Communications, Fourth Edition, published Jan. 1, 1994. (“Stallings”), 14 pages.;;Alexander, C. K., Fundamentals of Electric Circuits, Indian Edition (Jul. 2013) (“Alexander”), 37 pages.;;Hall, S. H., High-Speed Digital System Design, A Handbook of Interconnect Theory and Design Practices, Aug. 25, 2000. (“Hall”), 55 pages.;;Sedra, A. S., Microelectronic Circuits, Seventh Edition, Nov. 14, 2014. (“Sedra”), 38 pages.;;Lathi, B. P., Modern Digital and Analog Communication Systems, Fourth Edition Jan. 23, 2009 (“Lathi”), 15 pages.;;Understanding 802.3at PoE Plus Standard Increases Available Power (Jun. 2011) (“Microsemi”), 7 pages.;;Cheng K.W.E., et al., “Constant Frequency, Two-Stage Quasiresonant Convertor,” Published in: IEE Proceedings B—Electric Power Applications, May 1, 1992, vol. 139, No. 03, XP000292493, pp. 227-237.;;International Preliminary Report on Patentability for International Application No. PCT/US2020/012758, dated Aug. 5, 2021, 10 Pages.;;International Preliminary Report on Patentability for International Application No. PCT/US2020/012801, dated Aug. 5, 2021, 9 Pages.;;International Preliminary Report on Patentability for International Application No. PCT/US2020/020359, dated Sep. 23, 2021, 9 Pages.;;International Search Report and Written Opinion for International Application No. PCT/US2020/012758, dated Apr. 8, 2020, 11 Pages.;;International Search Report and Written Opinion for International Application No. PCT/US2020/012801, dated Apr. 15, 2020, 10 Pages.;;International Search Report and Written Opinion for International Application No. PCT/US2020/020359, dated May 27, 2020, 10 Pages.;;Jingquan C., et al., “Buck-Boost PWM Converters Having Two Independently Controlled Switches,” 32nd Annual IEEE Power Electronics Specialists Conference, PESC 2001, Conference Proceedings, Vancouver, Canada, New York, NY : IEEE., US, US, Jun. 17-21, 2001, vol. 2, pp. 736-741, DOI:10.1109/PESC.2001.954206, ISBN 978-0-7803-7067-8, XP010559317.;;English Translation of Office Action in Chinese Application No. 202080010019.8, dated Mar. 3, 2022, 11 pages.;;English Translation of Office Action in Chinese Application No. 202080010020.0, dated Mar. 3, 2022, 15 pages.;;Palm Intranet, “Inventor Name Search Result—Chad Jones,” May 12, 2022, 3 pages.;;Palm Intranet, “Inventor Name Search Result—Joel Goergen,” May 12, 2022, 3 pages.;;Palm Intranet, “Inventor Name Search Result—George Zimmerman,” May 12, 2022, 2 pages.;;Palm Intranet, “Inventor Name Search Result—Jason Potterf,” May 12, 2022, 1 page.;;Palm Intranet, “Inventor Name Search Result—Douglas Arduini,” May 12, 2022, 2 pages.;;Palm Intranet, “Inventor Name Search Result—Sung Baek,” May 12, 2022, 3 pages.;;Google, “data power pulse transition edge suspended patents,” retrieved May 12, 2022, 3 pages.;;Palm Intranet, “Inventor Name Search Result—Richard O'Brien,” May 12, 2022, 3 pages.;;Google, “transmitting power voltage pulses sequence alternating on-time off-time transition low-state high-state superimposing modulated data patents,” Jan. 18, 2022, 3 pages.;;Google, “data pulses transition multiphase patents,” Jan. 19, 2022, 3 pages.;;Examination Report in counterpart Indian Application No. 202147024800, dated Jan. 11, 2023, 6 pages.;;Examination Report in counterpart Indian Application No. 202127029265, dated May 1, 2023, 5 pages.",ACTIVE
106,CN,A,CN 114514728 A,081-607-555-891-636,2022-05-17,2022,CN 202080070369 A,2020-10-14,US 201916671508 A;;US 2020/0055532 W,2019-11-01,Initialization and synchronization of pulse power in network system,"In one embodiment, a method includes transmitting low voltage pulsed power from a power supply device to a powered device in a communication network, performing a security test, enabling high voltage pulsed power operation at the power supply device after passing the security test, and transmitting high voltage pulsed power from the power supply device to the powered device. The powered device is synchronized with the waveform of the low-voltage pulse power.",SQUARE TECH COMPANY,ARDUINI DOUGLAS PAUL;;BAEK SUNG-KI;;O 'BRIEN RICHARD ANTHONY;;GOERGEN JOEL RICHARD;;JONES CHAD M;;BOTTORFF JASON DWAYNE;;LI RUQI,,https://lens.org/081-607-555-891-636,Patent Application,no,5,0,13,14,0,H04L12/10;;H04B3/54;;G01R31/52;;G01R31/58;;G01R29/16;;H04L12/10;;H04L12/10;;H02J13/00032;;G05B9/02;;G06F1/305;;G01R31/083;;G01R31/50;;H02J13/00032;;G01R31/50;;G01R31/083;;G05B9/02;;G06F1/305;;H02J13/00;;H04B3/54;;H04L12/10;;H04L12/40045,H04L12/10;;G01R29/16;;G01R31/52;;G01R31/58;;H04B3/54,,0,0,,,,PENDING
107,EP,A1,EP 3915229 A1,143-817-240-964-610,2021-12-01,2021,EP 20703636 A,2020-01-08,US 201916255657 A;;US 201916704502 A;;US 2020/0012801 W,2019-01-23,TRANSMISSION OF PULSE POWER AND DATA IN A COMMUNICATIONS NETWORK,,CISCO TECH INC,JONES CHAD M;;GOERGEN JOEL RICHARD;;ZIMMERMAN GEORGE ALLAN;;O'BRIEN RICHARD ANTHONY;;ARDUINI DOUGLAS PAUL;;POTTERF JASON DEWAYNE;;BAEK SUNG KEE,,https://lens.org/143-817-240-964-610,Patent Application,yes,0,0,12,23,0,H04B3/54;;H03M13/03;;H03M13/1515;;H03M13/373;;Y04S40/00;;H04L12/40045;;H04L12/10;;H04L12/10;;H03M13/03;;H04B2203/542;;H04B3/54;;H04L41/12;;H04W80/02;;H03M13/1515;;H03M13/373,H04L12/40;;H04L12/10,,0,0,,,,ACTIVE
108,CN,A,CN 113330718 A,152-323-297-558-142,2021-08-31,2021,CN 202080010020 A,2020-01-08,US 201916255657 A;;US 201916704502 A;;US 2020/0012801 W,2019-01-23,TRANSMISSION OF PULSE POWER AND DATA IN A COMMUNICATIONS NETWORK,"In one embodiment, a method includes transmitting data on two wire pairs carrying pulse power, wherein the pulse power comprises a plurality of voltage pulses with the voltage pulses on the wire pairs offset between the wire pairs to provide continuous power and identifying transitions between at least one of a pulse-on time and a pulse-off time, and a pulse-off time and a pulse-on time on at least one of the wire pairs. Data transmission on the wire pair is controlled during the identified transitions on the wire pair to prevent interference between the pulse power and the data.",CISCO TECH INC,JONES CHAD M;;GOERGEN JOEL RICHARD;;ZIMMERMAN GEORGE ALLAN;;O'BRIEN RICHARD ANTHONY;;ARDUINI DOUGLAS PAUL;;POTTERF JASON DEWAYNE;;BAEK SUNG-KI,,https://lens.org/152-323-297-558-142,Patent Application,no,6,0,12,23,0,H04B3/54;;H03M13/03;;H03M13/1515;;H03M13/373;;Y04S40/00;;H04L12/40045;;H04L12/10;;H04L12/10;;H03M13/03;;H04B2203/542;;H04B3/54;;H04L41/12;;H04W80/02;;H03M13/1515;;H03M13/373,H04L12/40;;H04L12/10,,0,0,,,,ACTIVE
109,US,A1,US 2020/0389329 A1,195-873-151-286-582,2020-12-10,2020,US 202016999754 A,2020-08-21,US 202016999754 A;;US 201916704502 A;;US 201916255657 A,2019-01-23,TRANSMISSION OF PULSE POWER AND DATA IN A COMMUNICATIONS NETWORK,"In one embodiment, a method includes transmitting pulse power on two wire pairs, the pulse power comprising a plurality of high voltage pulses with the high voltage pulses on the wire pairs offset between the wire pairs to provide continuous power, performing low voltage fault detection on each of the wire pairs between the high voltage pulses, and transmitting data on at least one of the wire pairs during transmittal of the high voltage pulses. Data transmittal is suspended during the low voltage fault detection.",CISCO TECH INC,JONES CHAD M;;GOERGEN JOEL RICHARD;;ZIMMERMAN GEORGE ALLAN;;O'BRIEN RICHARD ANTHONY;;ARDUINI DOUGLAS PAUL;;POTTERF JASON DEWAYNE;;BAEK SUNG KEE,CISCO TECHNOLOGY INC (2019-12-05),https://lens.org/195-873-151-286-582,Patent Application,yes,0,5,12,23,0,H04B3/54;;H03M13/03;;H03M13/1515;;H03M13/373;;Y04S40/00;;H04L12/40045;;H04L12/10;;H04L12/10;;H03M13/03;;H04B2203/542;;H04B3/54;;H04L41/12;;H04W80/02;;H03M13/1515;;H03M13/373,H04L12/10;;H03M13/03;;H04B3/54;;H04L12/24;;H04W80/02,,0,0,,,,ACTIVE
110,WO,A2,WO 2023/230573 A2,073-071-180-281-854,2023-11-30,2023,US 2023/0067496 W,2023-05-25,US 202263345765 P,2022-05-25,COMPOSITIONS AND METHODS FOR MODULATION OF IMMUNE RESPONSES,"The disclosure provides, in various embodiments, compositions, such as polypeptides, polynucleotides, gene editing system, small molecules, vectors or host cells, that comprises and/or modulate expression or activity of immune regulation-associated proteins. The disclosure also provides, in various embodiments, methods of treating aging, senescence, fibrosis, autoimmunity, cancer, an infection, and/or an immunological disease using an agent that comprises and/or modulates expression or activity of an immune regulation-associated protein and methods of identifying said agent.",FLAGSHIP PIONEERING INNOVATIONS VII LLC,MANI VINIDHRA;;WEINSTEIN ERICA;;ECHELARD YANN PAUL GUY RÉGIS;;KAHVEJIAN AVAK;;PENDERGRAST PATRICK;;OUSPENSKAIA TAMARA;;BILLINGS GABRIEL HUMPHREY;;GRISHKEVICH VLAD;;BAEK SUNGMIN,,https://lens.org/073-071-180-281-854,Patent Application,yes,53,0,1,1,38393,G01N33/574;;C12Q1/6883;;C12Q2600/158;;A61K38/00;;G01N33/6893;;G01N33/564;;G01N2800/52;;G01N2800/085;;G01N2800/24,,,62,44,114-614-901-357-69X;;066-084-560-669-796;;000-561-429-722-656;;032-728-154-591-070;;085-764-009-624-439;;006-890-776-895-725;;004-176-377-330-048;;019-874-354-250-515;;025-211-251-924-855;;142-880-622-315-822;;031-430-982-956-209;;084-184-482-643-478;;012-027-156-925-460;;000-403-821-848-233;;085-179-098-214-767;;020-157-016-684-103;;032-301-857-006-63X;;148-672-936-761-042;;148-672-936-761-042;;016-910-630-941-045;;010-721-055-957-022;;030-128-775-006-207;;006-398-707-250-46X;;065-151-944-314-653;;077-126-414-891-278;;057-246-430-371-10X;;026-541-422-040-535;;058-996-110-425-454;;025-993-072-057-29X;;125-980-003-853-48X;;029-409-793-996-772;;007-036-211-301-786;;013-140-777-961-318;;022-147-642-693-596;;066-494-081-508-460;;071-466-701-306-791;;018-040-257-391-327;;045-516-489-704-249;;060-564-874-788-725;;031-202-782-365-493;;029-945-971-289-536;;003-616-876-741-191;;024-253-670-428-580;;007-285-616-513-629,30914442;;10.1124/pr.118.016790;;pmc2686540;;18948278;;10.1093/nar/gkn728;;32494050;;10.1038/s41573-020-0062-z;;10.1016/0022-2836(70)90057-4;;5420325;;10.1073/pnas.85.8.2444;;pmc280013;;3162770;;pmc3498134;;23166701;;10.1371/journal.pone.0049535;;24280701;;pmc3816645;;10.3390/ph5090991;;22735943;;10.1007/978-1-61779-921-1_1;;pmc6988726;;14744438;;10.1016/s0092-8674(04)00045-5;;10.1016/s1097-2765(02)00541-5;;12086629;;12600936;;pmc195999;;10.1101/gad.1064703;;10.1038/ng1798;;16736023;;10.1038/nature03315;;15685193;;16489337;;10.1038/nmeth854;;10.1016/j.cell.2015.02.029;;pmc4359748;;25768907;;10.1016/s1525-0016(16)33740-6;;26050989;;10.1038/mt.2015.103;;pmc4817881;;10.1007/978-1-60761-657-3_16;;10.1007/978-1-60761-657-3_29;;20387164;;10.1007/978-1-60761-657-3_25;;20387167;;20387145;;10.1007/978-1-60761-657-3_7;;10.1007/978-1-60761-657-3_26;;10.1007/978-1-60761-657-3;;20394129;;pmc5485616;;28655327;;10.1186/s13073-017-0450-0;;pmc5485616;;28655327;;10.1186/s13073-017-0450-0;;10.1093/nar/gkv1393;;10.1038/nbt.3301;;pmc4532950;;26237515;;10.1016/j.jconrel.2015.08.051;;26342664;;10.1093/nar/gkx135;;28334758;;pmc5449617;;10.1261/rna.5430403;;pmc1370475;;12923259;;10.1016/j.bbrc.2005.12.105;;16403444;;pmc4297522;;25533786;;10.1016/j.cell.2014.11.052;;10.1021/acs.nanolett.5b02497;;26469188;;pmc5245883;;26889757;;10.1002/adma.201505822;;10.1016/j.cell.2013.06.044;;pmc3770145;;23849981;;10.1126/science.1231143;;pmc3795411;;23287718;;24157548;;10.1038/nprot.2013.143;;pmc3969860;;10.1038/cr.2013.122;;pmc3790238;;23979020;;25307932;;pmc4253859;;10.1016/j.cell.2014.09.029;;pmc4252608;;25307933;;10.1016/j.cell.2014.09.039;;pmc4420636;;10.1038/nature14136;;25494202;;10.1038/nmeth.3312;;pmc4393883;;25730490;;pmc5094855;;27661255;;10.7554/elife.19760;;pmc4927356;;10.1038/nmeth.3871;;27214048;;10.1021/acsnano.6b07600;;28129503;;pmc5848212;;21493687;;pmc3130266;;pmc3130291;;21385827;;10.1093/nar/gkr086;;10.1093/nar/gkr218;;10.1016/s1359-6446(01)02087-6;;11790603;;11738971;;10.1016/s1359-6446(01)02070-0;;pmc4951582;;10.1016/j.apsb.2016.02.001;;27471669;;25075903;;10.1101/006726;;pmc4486245;;10.1038/nmeth.3047,"KENAKIN, T.: ""Biased Receptor Signaling in Drug Discovery"", PHARMACOL REV, vol. 71, April 2019 (2019-04-01), pages 267 - 315;;HARMAR, A.J. ET AL.: ""IUPHAR-DB: the IUPHAR database of G protein-coupled receptors and ion channels"", NUCLEIC ACIDS RESEARCH, vol. 37, 2009;;DAVENPORT APSCULLY CCGGRAAF CBROWN AJHMAGUIRE JJ.: ""Advances in therapeutic peptides targeting G protein-coupled receptors"", NAT REV DRUG DISCOV., vol. 19, no. 6, June 2020 (2020-06-01), pages 389 - 413, XP037154924, DOI: 10.1038/s41573-020-0062-z;;SMITHWATERMAN, ADV. APPL. MATH., vol. 2, 1981, pages 482;;NEEDLEMANWUNSCH, J. MOL. BIOL., vol. 48, 1970, pages 443;;PEARSONLIPMAN, PROC. NAT'L. ACAD. SCI. USA, vol. 85, 1988, pages 2444;;AUSUBEL ET AL., CURRENT PROTOCOLS IN MOLECULAR BIOLOGY;;GREENWUTS: ""Protecting Groups in Organic Synthesis"", 1991, JOHN WILEY AND SONS;;""Therapeutic Monoclonal Antibodies: From Bench to Clinic"", 2009;;PHARMACEUTICAL BIOTECHNOLOGY: FUNDAMENTALS AND APPLICATIONS, 2013;;FERRARA ET AL.: ""Using Phage and Yeast Display to Select Hundreds of Monoclonal Antibodies: Application to Antigen 85, a Tuberculosis Biomarker"", PLOS ONE, vol. 7, no. 11, 2012, pages e49535, XP055152096, DOI: 10.1371/journal.pone.0049535;;REGBERG ET AL.: ""Applications of cell-penetrating peptides for tumor targeting and future cancer therapies"", PHARMACEUTICALS, vol. 5, no. 9, 2012, pages 991 - 1007;;THERAPEUTIC PROTEINS: METHODS AND PROTOCOLS, 2005;;BARTEL, CELL, vol. 116, 2004, pages 281 - 97;;ZENG ET AL., MOL CELL, vol. 9, 2002, pages 1327 - 33;;DOENCH ET AL., GENES DEV, vol. 17, 2003, pages 438 - 42;;WU ET AL., PROC NATL ACAD SCI USA, vol. 103, 2006, pages 4034 - 39;;RAJEWSKY, NAT GENET, vol. 38, 2006, pages 8 - 13;;LIM ET AL., NATURE, vol. 433, 2005, pages 769 - 73;;BIRMINGHAM ET AL., NAT METHODS, vol. 3, 2006, pages 199 - 204;;PRESNYAK ET AL., CELL., vol. 160, no. 6, 2015, pages 1111 - 24;;THESS ET AL., MOL THER., vol. 23, no. 9, 2015, pages 1456 - 64;;RNA THERAPEUTICS: FUNCTION, DESIGN, AND DELIVERY, 2010;;KACZMAREK ET AL.: ""Advances in the delivery of RNA therapeutics: from concept to clinical reality"", GENOME MEDICINE, vol. 9, 2017, pages 60, XP055464283, DOI: 10.1186/s13073-017-0450-0;;KACZMAREK ET AL., GENOME MEDICINE, vol. 9, 2017, pages 60;;STRENKOWSKA ET AL., NUCLEIC ACIDS RES., vol. 44, 2016, pages 9578 - 90;;WROBLEWSKA ET AL., NATBIOTECHNOL, vol. 33, 2015, pages 839 - 41;;ANDRIES ET AL., J CONTROL RELEASE, vol. 217, 2015, pages 337 - 44;;SVITKIN ET AL., NUCLEIC ACIDS RES., vol. 45, 2017, pages 6023 - 36;;JEMIELITY ET AL., RNA, vol. 9, no. 9, 2003, pages 1108 - 22;;MOCKEY ET AL., BIOCHEM BIOPHYS RES COMMUN., vol. 340, 2006, pages 1062 - 88;;PRESNYAK ET AL.: ""Engineering complex synthetic transcriptional programs with CRISPR RNA scaffolds"", CELL, vol. 160, 2015, pages 1111 - 50;;KAUFFMAN ET AL., NANO LETT., vol. 15, 2015, pages 7300 - 6;;FENTON ET AL., ADV MATER., vol. 28, 2016, pages 2939 - 43;;GILBERT ET AL.: ""CRISPR-Mediated Modular RNA-Guided Regulation of Transcription in Eukaryotes"", CELL, vol. 154, 2013, pages 1380 - 51;;CONG ET AL., SCIENCE, vol. 339, 2013, pages 819 - 23;;RAN ET AL., NATURE PROTOCOLS, vol. 8, 2013, pages 2281 - 308;;HENDEL ET AL., NATURE BIOTECHNOL., 2015, pages 985 - 91;;CHENG ET AL.: ""Multiplexed activation of endogenous genes by CRISPR-on, an RNA-guided transcriptional activator system"", CELL RES., vol. 23, 2013, pages 1163 - 71;;GILBERT ET AL.: ""Genome-Scale CRISPRMediated Control of Gene Repression and Activation,"", CELL, vol. 159, 2014, pages 647 - 61;;TANENBAUM ET AL.: ""A protein-tagging system for signal amplification in gene expression and fluorescence imaging"", CELL, vol. 159, 2014, pages 635 - 46, XP029084861, DOI: 10.1016/j.cell.2014.09.039;;KONERMANN ET AL.: ""Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex"", NATURE, vol. 517, 2015, pages 583 - 88, XP055585957, DOI: 10.1038/nature14136;;CHAVEZ ET AL.: ""Highly efficient Cas9-mediated transcriptional programming"", NAT. METHODS., vol. 12, 2015, pages 326 - 28, XP055694813, DOI: 10.1038/nmeth.3312;;HORLBECK ET AL.: ""Compact and highly active next-generation libraries for CRISPR-mediated gene repression and activation"", ELIFE., vol. 5, 2016, pages 19760, XP055610557, DOI: 10.7554/eLife.19760;;CHAVEZ ET AL.: ""Comparison of Cas9 activators in multiple species"", NAT METHODS., vol. 7, 2016, pages 563 - 67;;JO ET AL., BIOMED RES. INT., vol. 2015, 2015, pages 305716;;MOUT ET AL., ACS NANO, vol. 11, no. 3, 2017, pages 2452 - 58;;CERMAK ET AL.: ""Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting"", NUCLEIC ACIDS RES, vol. 39, no. 12, 2011, pages 82, XP055130093, DOI: 10.1093/nar/gkr218;;GANESAN, DRUG DISCOV. TODAY, vol. 7, no. 1, January 2002 (2002-01-01), pages 47 - 55;;LOU, DRUG DISCOV. TODAY, vol. 6, no. 24, December 2001 (2001-12-01), pages 1288 - 1294;;""Therapeutic Protein Drug Products: Practical Approaches to formulation in the Laboratory, Manufacturing, and the Clinic"", 2012;;SHI ET AL., PNAS, vol. 111, no. 28, 2014, pages 10131 - 36;;""Protein Biotechnology: Isolation, Characterization, and Stabilization"", 2013;;""Protein Purification Protocols"", 2010;;""Remington's Pharmaceutical Sciences"", 1980;;SPUCHNAVARRO, J DRUG DELIV., vol. 2011, 2011, pages 469679 - 843;;TEMPLETON ET AL., NATURE BIOTECH, vol. 15, 1997, pages 647 - 52;;LI ET AL., NANOMATERIALS, vol. 7, no. 6, 2017, pages 122;;HA ET AL., ACTA PHARM SIN B., vol. 6, no. 4, 2016, pages 287 - 96;;HUANG ET AL., NATURE COMMUNICATIONS, vol. 8, 2017, pages 423;;SANJANA NESHALEM OZHANG F., NAT. METHODS., vol. 11, no. 8, August 2014 (2014-08-01), pages 783 - 4;;LI WKOSTER JXU HCHEN CHXIAO TBROWN MLIU S., GENOME BIOLOGY, no. 281, 2015",PENDING
111,WO,A3,WO 2023/230566 A3,160-238-441-459-063,2024-02-01,2024,US 2023/0067486 W,2023-05-25,US 202263345778 P,2022-05-25,COMPOSITIONS AND METHODS FOR MODULATING CYTOKINES,"The disclosure provides, in various embodiments, compositions, such as polypeptides, polynucleotides, gene editing systems, small molecules, vectors or host cells, that comprise and/or modulate expression or activity of immune regulation-associated proteins, such as cytokines. The disclosure also provides, in various embodiments, methods of treating inflammation, aging, senescence, fibrosis, autoimmunity, cancer, an infection, and/or an immunological disease using an agent that comprises and/or modulates expression or activity of an immune regulation-associated protein, and methods of identifying said agent.",FLAGSHIP PIONEERING INNOVATIONS VII LLC,MANI VINIDHRA;;WEINSTEIN ERICA GABRIELLE;;ECHELARD YANN PAUL GUY RÉGIS;;KAHVEJIAN AVAK;;PENDERGRAST PATRICK SHANNON;;OUSPENSKAIA TAMARA;;BILLINGS GABRIEL HUMPHREY;;BAEK SUNGMIN,,https://lens.org/160-238-441-459-063,Search Report,yes,7,0,2,2,0,C12Q1/6883;;C12Q1/6886;;C12Q2600/158;;A61K38/00;;G01N33/6893;;G01N33/6863,C12Q1/6883;;A61K38/00;;C12Q1/6886;;G01N33/53;;G01N33/574,,1,1,011-543-438-498-879,pmc6409483;;30262890;;10.1038/nrd.2018.135,"CAMPBELL ADRIAN P. ET AL: ""Targeting G protein-coupled receptor signalling by blocking G proteins"", NATURE REVIEWS DRUG DISCOVERY, vol. 17, no. 11, 11 March 2019 (2019-03-11), GB, pages 789 - 803, XP093084090, ISSN: 1474-1776, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6409483/pdf/nihms-1010373.pdf> DOI: 10.1038/nrd.2018.135",PENDING
112,WO,A2,WO 2023/230566 A2,103-055-431-653-701,2023-11-30,2023,US 2023/0067486 W,2023-05-25,US 202263345778 P,2022-05-25,COMPOSITIONS AND METHODS FOR MODULATING CYTOKINES,"The disclosure provides, in various embodiments, compositions, such as polypeptides, polynucleotides, gene editing systems, small molecules, vectors or host cells, that comprise and/or modulate expression or activity of immune regulation-associated proteins, such as cytokines. The disclosure also provides, in various embodiments, methods of treating inflammation, aging, senescence, fibrosis, autoimmunity, cancer, an infection, and/or an immunological disease using an agent that comprises and/or modulates expression or activity of an immune regulation-associated protein, and methods of identifying said agent.",FLAGSHIP PIONEERING INNOVATIONS VII LLC,MANI VINIDHRA;;WEINSTEIN ERICA GABRIELLE;;ECHELARD YANN PAUL GUY RÉGIS;;KAHVEJIAN AVAK;;PENDERGRAST PATRICK SHANNON;;OUSPENSKAIA TAMARA;;BILLINGS GABRIEL HUMPHREY;;BAEK SUNGMIN,,https://lens.org/103-055-431-653-701,Patent Application,yes,53,0,2,2,6520,C12Q1/6883;;C12Q1/6886;;C12Q2600/158;;A61K38/00;;G01N33/6893;;G01N33/6863,,,58,42,114-614-901-357-69X;;066-084-560-669-796;;000-561-429-722-656;;032-728-154-591-070;;085-764-009-624-439;;025-993-072-057-29X;;006-890-776-895-725;;004-176-377-330-048;;012-027-156-925-460;;025-211-251-924-855;;142-880-622-315-822;;031-430-982-956-209;;084-184-482-643-478;;000-403-821-848-233;;057-246-430-371-10X;;020-157-016-684-103;;032-301-857-006-63X;;148-672-936-761-042;;148-672-936-761-042;;016-910-630-941-045;;010-721-055-957-022;;030-128-775-006-207;;006-398-707-250-46X;;065-151-944-314-653;;077-126-414-891-278;;026-541-422-040-535;;058-996-110-425-454;;125-980-003-853-48X;;029-409-793-996-772;;007-036-211-301-786;;013-140-777-961-318;;022-147-642-693-596;;066-494-081-508-460;;071-466-701-306-791;;018-040-257-391-327;;045-516-489-704-249;;060-564-874-788-725;;031-202-782-365-493;;029-945-971-289-536;;003-616-876-741-191;;069-562-312-580-621;;024-253-670-428-580,30914442;;10.1124/pr.118.016790;;pmc2686540;;18948278;;10.1093/nar/gkn728;;32494050;;10.1038/s41573-020-0062-z;;10.1016/0022-2836(70)90057-4;;5420325;;10.1073/pnas.85.8.2444;;pmc280013;;3162770;;10.1016/j.cell.2013.06.044;;pmc3770145;;23849981;;pmc3498134;;23166701;;10.1371/journal.pone.0049535;;24280701;;pmc3816645;;10.3390/ph5090991;;10.1038/nature03315;;15685193;;14744438;;10.1016/s0092-8674(04)00045-5;;10.1016/s1097-2765(02)00541-5;;12086629;;12600936;;pmc195999;;10.1101/gad.1064703;;10.1038/ng1798;;16736023;;16489337;;10.1038/nmeth854;;pmc4297522;;25533786;;10.1016/j.cell.2014.11.052;;10.1016/s1525-0016(16)33740-6;;26050989;;10.1038/mt.2015.103;;pmc4817881;;10.1007/978-1-60761-657-3_16;;10.1007/978-1-60761-657-3_29;;20387164;;10.1007/978-1-60761-657-3_25;;20387167;;20387145;;10.1007/978-1-60761-657-3_7;;10.1007/978-1-60761-657-3_26;;10.1007/978-1-60761-657-3;;20394129;;pmc5485616;;28655327;;10.1186/s13073-017-0450-0;;pmc5485616;;28655327;;10.1186/s13073-017-0450-0;;10.1093/nar/gkv1393;;10.1038/nbt.3301;;pmc4532950;;26237515;;10.1016/j.jconrel.2015.08.051;;26342664;;10.1093/nar/gkx135;;28334758;;pmc5449617;;10.1261/rna.5430403;;pmc1370475;;12923259;;10.1016/j.bbrc.2005.12.105;;16403444;;10.1021/acs.nanolett.5b02497;;26469188;;pmc5245883;;26889757;;10.1002/adma.201505822;;10.1126/science.1231143;;pmc3795411;;23287718;;24157548;;10.1038/nprot.2013.143;;pmc3969860;;10.1038/cr.2013.122;;pmc3790238;;23979020;;25307932;;pmc4253859;;10.1016/j.cell.2014.09.029;;pmc4252608;;25307933;;10.1016/j.cell.2014.09.039;;pmc4420636;;10.1038/nature14136;;25494202;;10.1038/nmeth.3312;;pmc4393883;;25730490;;pmc5094855;;27661255;;10.7554/elife.19760;;pmc4927356;;10.1038/nmeth.3871;;27214048;;10.1021/acsnano.6b07600;;28129503;;pmc5848212;;21493687;;pmc3130266;;pmc3130291;;21385827;;10.1093/nar/gkr086;;10.1093/nar/gkr218;;10.1016/s1359-6446(01)02087-6;;11790603;;11738971;;10.1016/s1359-6446(01)02070-0;;24258145;;10.1007/978-3-642-54050-9;;10.1007/10_2013_255;;pmc4951582;;10.1016/j.apsb.2016.02.001;;27471669,"KENAKIN, T.: ""Biased Receptor Signaling in Drug Discovery"", PHARMACOL REV, vol. 71, April 2019 (2019-04-01), pages 267 - 315;;HARMAR, A.J. ET AL.: ""IUPHAR-DB: the IUPHAR database of G protein-coupled receptors and ion channels"", NUCLEIC ACIDS RESEARCH, vol. 37, 2009;;DAVENPORT APSCULLY CCGDE GRAAF CBROWN AJHMAGUIRE JJ: ""Advances in therapeutic peptides targeting G protein-coupled receptors"", NAT REV DRUG DISCOV, no. 6, 19 June 2020 (2020-06-19), pages 389 - 413, XP037154924, DOI: 10.1038/s41573-020-0062-z;;SMITHWATERMAN, ADV. APPL. MATH., vol. 2, 1981, pages 482;;NEEDLEMANWUNSCH, J. MOL. BIOL., vol. 48, 1970, pages 443;;PEARSONLIPMAN, PROC. NAT'L. ACAD. SCI. USA, vol. 85, 1988, pages 2444;;AUSUBEL ET AL., CURRENT PROTOCOLS IN MOLECULAR BIOLOGY;;GREENWUTS: ""Protecting Groups in Organic Synthesis"", 1991, JOHN WILEY AND SONS;;""Therapeutic Monoclonal Antibodies: From Bench to Clinic"", 2009;;GILBERT ET AL.: ""CRISPR-Mediated Modular RNA-Guided Regulation of Transcription in Eukaryotes"", CELL, vol. 154, 2013, pages 1380 - 51;;FERRARA ET AL.: ""Using Phage and Yeast Display to Select Hundreds of Monoclonal Antibodies: Application to Antigen 85, a Tuberculosis Biomarker"", PLOS ONE, vol. 7, no. 11, 2012, pages e49535, XP055152096, DOI: 10.1371/journal.pone.0049535;;REGBERG ET AL.: ""Applications of cell-penetrating peptides for tumor targeting and future cancer therapies"", PHARMACEUTICALS, vol. 5, no. 9, 2012, pages 991 - 1007;;LIM ET AL., NATURE, vol. 433, 2005, pages 769 - 73;;BARTEL, CELL, vol. 116, 2004, pages 281 - 97;;ZENG ET AL., MOL CELL, vol. 9, 2002, pages 1327 - 33;;DOENCH ET AL., GENES DEV, vol. 17, 2003, pages 438 - 42;;WU ET AL., PROC NATL ACAD SCI USA, vol. 103, 2006, pages 4034 - 39;;RAJEWSKY, NAT GENET, vol. 38, 2006, pages S8 - 13;;BIRMINGHAM ET AL., NAT METHODS, vol. 3, 2006, pages 199 - 204;;PRESNYAK ET AL.: ""Engineering complex synthetic transcriptional programs with CRISPR RNA scaffolds"", CELL, vol. 160, no. 6, 2015, pages 1111 - 50;;THESS ET AL., MOL THER, vol. 23, no. 9, 2015, pages 1456 - 64;;""RNA Therapeutics: Function, Design, and Delivery"", 2010;;KACZMAREK ET AL.: ""Advances in the delivery of RNA therapeutics: from concept to clinical reality"", GENOME MEDICINE, vol. 9, 2017, pages 60, XP055464283, DOI: 10.1186/s13073-017-0450-0;;KACZMAREK ET AL., GENOME MEDICINE, vol. 9, 2017, pages 60;;STRENKOWSKA ET AL., NUCLEIC ACIDS RES, vol. 44, 2016, pages 9578 - 90;;WROBLEWSKA ET AL., NATBIOTECHNOL, vol. 33, 2015, pages 839 - 41;;ANDRIES ET AL., J CONTROL RELEASE, vol. 217, 2015, pages 337 - 44;;SVITKIN ET AL., NUCLEIC ACIDS RES, vol. 45, 2017, pages 6023 - 36;;JEMIELITY ET AL., RNA, vol. 9, no. 9, 2003, pages 1108 - 22;;MOCKEY ET AL., BIOCHEM BIOPHYS RES COMMUN, vol. 340, 2006, pages 1062 - 88;;KAUFFMAN ET AL., NANO LETT, vol. 15, 2015, pages 7300 - 6;;FENTON ET AL., ADV MATER, vol. 28, 2016, pages 2939 - 43;;CONG ET AL., SCIENCE, vol. 339, 2013, pages 819 - 23;;RAN ET AL., NATURE PROTOCOLS, vol. 8, 2013, pages 2281 - 308;;HENDEL ET AL., NATURE BIOTECHNOL, 2015, pages 985 - 91;;CHENG ET AL.: ""Multiplexed activation of endogenous genes by CRISPR-on, an RNA-guided transcriptional activator system"", CELL RES, vol. 23, 2013, pages 1163 - 71;;GILBERT ET AL.: ""Genome-Scale CRISPRMediated Control of Gene Repression and Activation"", CELL, vol. 159, 2014, pages 647 - 61;;TANENBAUM ET AL.: ""A protein-tagging system for signal amplification in gene expression andfluorescence imaging"", CELL, vol. 159, 2014, pages 635 - 46, XP029084861, DOI: 10.1016/j.cell.2014.09.039;;KONERMANN ET AL.: ""Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex"", NATURE, vol. 517, 2015, pages 583 - 88, XP055585957, DOI: 10.1038/nature14136;;CHAVEZ ET AL.: ""Highly efficient Cas9-mediated transcriptional programming"", NAT. METHODS., vol. 12, 2015, pages 326 - 28, XP055694813, DOI: 10.1038/nmeth.3312;;HORLBECK ET AL.: ""Compact and highly active next-generation libraries for CRISPR-mediated gene repression and activation"", ELIFE, vol. 5, 2016, pages e19760, XP055610557, DOI: 10.7554/eLife.19760;;CHAVEZ ET AL.: ""Comparison of Cas9 activators in multiple species"", NAT METHODS, vol. 7, 2016, pages 563 - 67;;JO ET AL., BIOMED RES. INT., vol. 2015, 2015, pages 305716;;MOUT ET AL., ACS NANO, vol. 11, no. 3, 2017, pages 2452 - 58;;CERMAK ET AL.: ""Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting"", NUCLEIC ACIDS RES, vol. 39, no. 12, 2011, pages e82, XP055130093, DOI: 10.1093/nar/gkr218;;GANESAN, DRUG DISCOV. TODAY, vol. 7, no. 1, January 2002 (2002-01-01), pages 47 - 55;;LOU, DRUG DISCOV. TODAY, vol. 6, no. 24, December 2001 (2001-12-01), pages 1288 - 1294;;""Therapeutic Protein Drug Products: Practical Approaches to formulation in the Laboratory, Manufacturing, and the Clinic"", 2012;;MAMMALIAN CELL CULTURES FOR BIOLOGICS MANUFACTURING, 2014;;""Protein Biotechnology: Isolation, Characterization, and Stabilization"", 2013;;""Remington's Pharmaceutical Sciences"", 1980;;COFFIN JM ET AL.: ""Fundamental Virology"", 1996, LIPPINCOTT-RAVEN PUBLISHERS, article ""Retroviridae: The viruses and their replication"", pages: 763 - 843;;SPUCHNAVARRO, J DRUG DELIV, vol. 2011, 2011, pages 469679;;TEMPLETON ET AL., NATURE BIOTECH, vol. 15, 1997, pages 647 - 52;;LI ET AL., NANOMATERIALS, vol. 7, no. 6, 2017, pages 122;;HA ET AL., ACTA PHARM SIN B., vol. 6, no. 4, 2016, pages 287 - 96;;SHI ET AL., PNAS, vol. 111, no. 28, 2014, pages 10131 - 36;;HUANG ET AL., NATURE COMMUNICATIONS, vol. 8, 2017, pages 423",PENDING
113,TW,A,TW 202342484 A,067-447-896-190-283,2023-11-01,2023,TW 112103921 A,2023-02-03,US 202263306443 P;;US 202263308456 P,2022-02-03,Methods of preparing and crystalline forms of CFTR modulators,"Processes and methods of preparing Compound I are disclosed. Crystalline forms of Compound I, pharmaceutically acceptable salts, solvates, hydrates, and cocrystals thereof, pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.",VERTEX PHARMA,ANGELL PAUL TIMOTHY;;BAEK MINSON;;GAGNON KEVIN;;MACK DANIEL JAMES;;MEDEK ALES;;PERESYPKIN ANDREY;;ROEPER STEFANIE;;SHRESTHA MUNA;;SIESEL DAVID A;;ZHOU JINGLAN,,https://lens.org/067-447-896-190-283,Patent of Addition,no,0,0,2,2,0,C07D498/14;;A61K31/437;;A61P11/00;;C07D413/04;;C07D213/81;;A61K45/06,C07D498/18;;A61K31/438;;A61P11/00;;C07D413/04,,0,0,,,,PENDING
114,WO,A1,WO 2023/150236 A1,091-455-912-879-487,2023-08-10,2023,US 2023/0012229 W,2023-02-02,US 202263306443 P;;US 202263308456 P,2022-02-03,"METHODS OF PREPARING AND CRYSTALLINE FORMS OF (6A,12A)-17-AMINO-12-METHYL-6,15-BIS(TRIFLUOROMETHYL)-13,19-DIOXA-3,4,18-TRIAZATRICYCLO[ 12.3.1.12,5]NONADECA-1(18),2,4,14,16-PENTAEN-6-OL","Processes and methods of preparing Compound (I) are disclosed. Crystalline forms of Compound (I), pharmaceutically acceptable salts, solvates, hydrates, and cocrystals thereof, pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.",VERTEX PHARMA,ANGELL PAUL TIMOTHY;;BAEK MINSON;;GAGNON KEVIN;;MACK DANIEL JAMES;;MEDEK ALES;;PERESYPKIN ANDREY;;ROEPER STEFANIE;;SHRESTHA MUNA;;SIESEL DAVID A;;ZHOU JINGLAN,,https://lens.org/091-455-912-879-487,Patent Application,yes,51,0,2,2,0,C07D498/14;;A61K31/437;;A61P11/00;;C07D413/04;;C07D213/81;;A61K45/06,C07D498/14;;A61K31/437;;A61P11/00;;C07D213/81;;C07D413/04,,21,15,027-495-322-764-618;;062-658-814-888-724;;115-252-470-991-090;;147-561-926-460-635;;077-295-491-167-117;;007-364-858-655-289;;060-421-717-880-984;;003-435-046-077-014;;046-328-268-422-852;;036-319-355-441-595;;094-562-500-767-254;;034-163-404-619-281;;056-530-308-246-913;;019-819-339-794-141;;089-386-545-524-511,1695717;;10.1038/346366a0;;10.1016/0092-8674(90)90196-l;;2344617;;10.1126/science.2570460;;2570460;;2236053;;pmc54973;;10.1073/pnas.87.21.8447;;10.1002/0471220574;;10.1002/jps.2600660104;;833720;;10.1016/j.jcf.2018.05.010;;pmc6436558;;29903467;;32128418;;10.1126/sciadv.aay9669;;pmc7034990;;pmc6881293;;31776420;;10.1038/s41598-019-54158-2;;10.1016/j.jcf.2019.12.009;;31902693;;pmc7052731;;32376628;;10.1124/jpet.120.265595;;31800572;;10.1371/journal.pone.0223954;;pmc6892560;;10.4155/ppa-2017-0009;;28696180;;pmc6362895;;10.3389/fphar.2019.00003;;30761000;;pmc7744356;;33092904;;10.1016/j.ejmech.2020.112888,"CUTTING, G. R. ET AL., NATURE, vol. 346, 1990, pages 366 - 369;;DEAN, M. ET AL., CELL, vol. 61, no. 863, 1990, pages 870;;KEREM, B-S. ET AL., SCIENCE, vol. 245, 1989, pages 1073 - 1080;;KEREM, B-S., PROC. NATL. ACAD. SCI. USA, vol. 87, 1990, pages 8447 - 8451;;GHELANISCHNEIDER-FUTSCHIK, ACS PHARMACOL. TRANSL. SCI., vol. 3, 2020, pages 4 - 10;;P. J. KOCIENSKI: ""Remington: The Science and Practice of Pharmacy"", 2005, LIPPINCOTT WILLIAMS & WILKINS;;GREENEWUTS: ""Protective Groups in Organic Synthesis"", 2007, JOHN WILEY & SONS;;S. M. BERGE ET AL., J. PHARM. SCI., vol. 66, 1977, pages 1 - 19;;PHUAN, P.-W. ET AL., J. CYST. FIBROS., vol. 17, no. 5, 2018, pages 595 - 606;;PEDEMONTE, N. ET AL., SCI. ADV., vol. 6, no. 8, 2020, pages eaay9669;;PHUAN, P.-W. ET AL., SCI. REP., vol. 9, no. 1, 2019, pages 17640;;BOSE, S. ET AL., J. CYST. FIBROS., vol. 19, 2020, pages S25 - S32;;CRAWFORD, D.K., J. PHARMACOL. EXP. THER., vol. 374, no. 2, 2020, pages 264 - 272;;BRASELL, E.J. ET AL., PLOS ONE, vol. 14, no. 12, 2019, pages e0223954;;SMITH, N.JSOLOVAY, C.F., PHARM. PAT. ANAL., vol. 6, no. 4, 2017, pages 179 - 188;;KUNZELMANN, K. ET AL., FRONT. PHARMACOL., vol. 10, 2019, pages 3;;SON, J.-H. ET AL., EUR. J. OF MED. CHEM., 2020, pages 112888;;PEDEMONTE, N. ET AL., SCI. ADV, vol. 6, no. 8, 2020, pages eaay9669;;""Encyclopedia of Pharmaceutical Technology"", 1988, MARCEL DEKKER;;SON, J.-H. ET AL., EUR. J. OF MED., 2020, pages 112888;;SHELDRICK, G.M., ACTA CRYST., vol. A64, 2008, pages 112 - 122",PENDING
115,US,A1,US 2013/0116570 A1,174-842-592-435-48X,2013-05-09,2013,US 201213655962 A,2012-10-19,US 201213655962 A;;US 201161549352 P,2011-10-20,LOCAL COMPRESSION DURING AUTOMATED ULTRASOUND SCANNING AND METHODS OF ACOUSTIC COUPLING,"A system for imaging a portion of a body, such as a human breast. The system comprises a first scanning system that ultrasonically scans a portion of a body while a compression system applies a compressing force to the portion of the body being scanned. A device is used for containing an acoustic coupling gel for enhanced acoustic coupling with the portion of body.",UNIV MICHIGAN;;UNIV MICHIGAN,CARSON PAUL L;;LECARPENTIER GERALD L;;LASHBROOK CHRISTINE R;;LEE WON-MEAN;;GOODSITT MITCHELL M;;SAITOU KAZUHIRO;;WANG BOYUN;;BAEK SEUNGHUN;;FOWLKES J BRIAN,THE REGENTS OF THE UNIVERSITY OF MICHIGAN (2012-12-11),https://lens.org/174-842-592-435-48X,Patent Application,yes,4,30,1,1,0,A61B8/0825;;A61B8/587;;A61B8/582;;A61B6/4417;;A61B6/502;;A61B8/4281;;A61B8/403;;A61B8/4416;;A61B8/4281;;A61B8/403;;A61B8/4416;;A61B8/0825;;A61B8/582;;A61B8/587;;A61B6/4417;;A61B6/502,A61B8/00,600/459,4,2,038-483-504-496-475;;052-002-380-361-786,10.7863/jum.2010.29.7.1075;;pmc3098001;;20587431;;18002210;;10.1109/iembs.2007.4352544,"Li et al. ""Effect of a Gel Retainment Dam on Automated Ultrasound Coverage in a Dual-Modality Breast Imaging System."" 01 July 2010. J Ultrasound Med. 29:1075-1081;;Sinha et al. ""Machine Learning for Noise Removal on Breast Ultrasound Images."" 11 October 2010. IEEE International Ultrasonics Symposium Proceedings;;Carson et al. ""Local Compression in Automated Breast Ultrasound in the Mammographic Geometry."" 11 October 2010. IEEE International Ultrasonics Symposium Proceedings;;Sinha et al. ""Multi-modality 3D breast imaging with X-Ray tomosynthesis and automated ultrasound."" 23 August 2007. Proceedings of the 29th Annual International Conference of the IEEE EMBS",DISCONTINUED
116,US,B2,US 11803056 B2,116-205-727-844-710,2023-10-31,2023,US 201916546157 A,2019-08-20,US 201916546157 A;;US 201862731309 P,2018-09-14,Waveguided display systems,"An electronic device may have a display that emits image light, a waveguide, and an input coupler that couples the image light into the waveguide. Beam splitter structures may be embedded within the waveguide. The beam splitter structures may partially reflect the image light multiple times and may serve to generate replicated beams of light that are coupled out of the waveguide by an output coupler. The beam splitter structures may replicate the beams across two dimensions to provide an eye box with uniform-intensity light from the display across its area. The beam splitter structures may include stacked partially reflective beam splitter layers, sandwiched transparent substrate layers having different indices of refraction, a thick volume hologram interposed between substrate layers, or combinations of these or other structures. The reflectivity of the beam splitter structures may vary discretely or continuously across the lateral area of the waveguide.",APPLE INC,PENG GUOLIN;;HANSOTTE ERIC J;;AIETA FRANCESCO;;MYHRE GRAHAM B;;CHOI HYUNGRYUL;;ZHU NAN;;GELSINGER-AUSTIN PAUL J;;OH SE BAEK;;DELAPP SCOTT M;;STEELE BRADLEY C,APPLE INC (2019-08-07),https://lens.org/116-205-727-844-710,Granted Patent,yes,56,0,4,4,0,G02B27/0101;;G02B27/0172;;G02B27/0172;;G02B2027/0174;;G02B27/1086;;G02B27/142;;G02B6/34;;G02B27/14;;G02B27/0172;;G02B27/12;;G02B2027/0174,G02B27/01;;G02B27/12;;G02B27/14,,1,0,,,Wikipedia webpage “Beam splitter” (Year: 2018).,ACTIVE
117,US,A1,US 2020/0089014 A1,100-010-931-457-047,2020-03-19,2020,US 201916546157 A,2019-08-20,US 201916546157 A;;US 201862731309 P,2018-09-14,Waveguided Display Systems,"An electronic device may have a display that emits image light, a waveguide, and an input coupler that couples the image light into the waveguide. Beam splitter structures may be embedded within the waveguide. The beam splitter structures may partially reflect the image light multiple times and may serve to generate replicated beams of light that are coupled out of the waveguide by an output coupler. The beam splitter structures may replicate the beams across two dimensions to provide an eye box with uniform-intensity light from the display across its area. The beam splitter structures may include stacked partially reflective beam splitter layers, sandwiched transparent substrate layers having different indices of refraction, a thick volume hologram interposed between substrate layers, or combinations of these or other structures. The reflectivity of the beam splitter structures may vary discretely or continuously across the lateral area of the waveguide.",APPLE INC,PENG GUOLIN;;HANSOTTE ERIC J;;AIETA FRANCESCO;;MYHRE GRAHAM B;;CHOI HYUNGRYUL;;ZHU NAN;;GELSINGER-AUSTIN PAUL J;;OH SE BAEK;;DELAPP SCOTT M;;STEELE BRADLEY C,APPLE INC (2019-08-07),https://lens.org/100-010-931-457-047,Patent Application,yes,0,7,4,4,0,G02B27/0101;;G02B27/0172;;G02B27/0172;;G02B2027/0174;;G02B27/1086;;G02B27/142;;G02B6/34;;G02B27/14;;G02B27/0172;;G02B27/12;;G02B2027/0174,G02B27/14;;G02B27/01;;G02B27/12,,0,0,,,,ACTIVE
118,CN,A,CN 110908113 A,091-186-587-866-937,2020-03-24,2020,CN 201910830440 A,2019-09-04,US 201862731309 P;;US 201916546157 A,2018-09-14,WAVEGUIDED DISPLAY SYSTEMS,"The invention relates to a waveguide display system. An electronic device may have a display that emits image light, a waveguide, and an input coupler that couples the image light into the waveguide.Beam splitter structures may be embedded within the waveguide. The beam splitter structures may partially reflect the image light multiple times and may serve to generate replicated beams of light that are coupled out of the waveguide by an output coupler. The beam splitter structures may replicate the beams across two dimensions to provide an eye box with uniform-intensity light from the displayacross its area. The beam splitter structures may include stacked partially reflective beam splitter layers, sandwiched transparent substrate layers having different indices of refraction, a thick volume hologram interposed between substrate layers, or combinations of these or other structures. The reflectivity of the beam splitter structures may vary discretely or continuously across the lateralarea of the waveguide.",APPLE INC,PENG GUOLIN;;HANSOTTE ERIC J;;AIETA FRANCESCO;;MYHRE GRAHAM B;;CHOI HYUNGRYUL;;ZHU NAN;;GELSINGER-AUSTIN PAUL J;;OH SE BAEK;;DELAPP SCOTT M;;STEELE BRADLEY C,,https://lens.org/091-186-587-866-937,Patent Application,no,35,3,4,4,0,G02B27/0101;;G02B27/0172;;G02B27/0172;;G02B2027/0174;;G02B27/1086;;G02B27/142;;G02B6/34;;G02B27/14;;G02B27/0172;;G02B27/12;;G02B2027/0174,G02B27/01,,0,0,,,,ACTIVE
119,WO,A2,WO 2023/230578 A2,167-769-133-252-21X,2023-11-30,2023,US 2023/0067505 W,2023-05-25,US 202263345771 P,2022-05-25,COMPOSITIONS AND METHODS FOR MODULATING CIRCULATING FACTORS,"The disclosure provides, in various embodiments, compositions, such as polypeptides, polynucleotides, gene editing system, small molecules, vectors or host cells, that comprises and/or modulate expression or activity of immune regulation-associated proteins. The disclosure also provides, in various embodiments, methods of treating aging, senescence, fibrosis, a metabolic disease, a cardiovascular disease, an endocrine-associated disorder, a genetic disease, cancer, an infection, an immunological disease, an indication treated with hormone, growth factor and/or protein replacement, or a combination thereof using an agent that comprises and/or modulates expression or activity of an immune regulation-associated protein and methods of identifying said agent.",FLAGSHIP PIONEERING INNOVATIONS VII LLC,MANI VINIDHRA;;WEINSTEIN ERICA;;ECHELARD YANN PAUL GUY;;KAHVEJIAN AVAK;;PENDERGRAST PATRICK;;OUSPENSKAIA TAMARA;;BILLINGS GABRIEL;;NICOD CHARLOTTE;;GRISHKEVICH VLAD;;BAEK SUNGMIN;;LABER SAMANTHA;;DAI SHUJIA;;ROSENBERGER GEORGE;;FANG TAO;;HAMSANATHAN SHURUTHI,,https://lens.org/167-769-133-252-21X,Patent Application,yes,53,0,2,2,75353,C12Q1/6883;;C12Q1/6886;;C12Q2600/158;;A61K38/05;;A61K38/06;;G01N2500/00;;G01N33/57484;;G01N33/6893,,,61,44,114-614-901-357-69X;;066-084-560-669-796;;000-561-429-722-656;;032-728-154-591-070;;085-764-009-624-439;;025-993-072-057-29X;;006-890-776-895-725;;004-176-377-330-048;;012-027-156-925-460;;025-211-251-924-855;;142-880-622-315-822;;031-430-982-956-209;;084-184-482-643-478;;000-403-821-848-233;;057-246-430-371-10X;;020-157-016-684-103;;032-301-857-006-63X;;148-672-936-761-042;;148-672-936-761-042;;016-910-630-941-045;;010-721-055-957-022;;030-128-775-006-207;;006-398-707-250-46X;;065-151-944-314-653;;077-126-414-891-278;;026-541-422-040-535;;058-996-110-425-454;;125-980-003-853-48X;;029-409-793-996-772;;007-036-211-301-786;;013-140-777-961-318;;022-147-642-693-596;;066-494-081-508-460;;071-466-701-306-791;;018-040-257-391-327;;045-516-489-704-249;;060-564-874-788-725;;031-202-782-365-493;;029-945-971-289-536;;003-616-876-741-191;;024-253-670-428-580;;041-203-844-428-443;;020-655-723-137-741;;049-362-025-986-141,30914442;;10.1124/pr.118.016790;;pmc2686540;;18948278;;10.1093/nar/gkn728;;32494050;;10.1038/s41573-020-0062-z;;10.1016/0022-2836(70)90057-4;;5420325;;10.1073/pnas.85.8.2444;;pmc280013;;3162770;;10.1016/j.cell.2013.06.044;;pmc3770145;;23849981;;pmc3498134;;23166701;;10.1371/journal.pone.0049535;;24280701;;pmc3816645;;10.3390/ph5090991;;10.1038/nature03315;;15685193;;14744438;;10.1016/s0092-8674(04)00045-5;;10.1016/s1097-2765(02)00541-5;;12086629;;12600936;;pmc195999;;10.1101/gad.1064703;;10.1038/ng1798;;16736023;;16489337;;10.1038/nmeth854;;pmc4297522;;25533786;;10.1016/j.cell.2014.11.052;;10.1016/s1525-0016(16)33740-6;;26050989;;10.1038/mt.2015.103;;pmc4817881;;10.1007/978-1-60761-657-3_16;;10.1007/978-1-60761-657-3_29;;20387164;;10.1007/978-1-60761-657-3_25;;20387167;;20387145;;10.1007/978-1-60761-657-3_7;;10.1007/978-1-60761-657-3_26;;10.1007/978-1-60761-657-3;;20394129;;pmc5485616;;28655327;;10.1186/s13073-017-0450-0;;pmc5485616;;28655327;;10.1186/s13073-017-0450-0;;10.1093/nar/gkv1393;;10.1038/nbt.3301;;pmc4532950;;26237515;;10.1016/j.jconrel.2015.08.051;;26342664;;10.1093/nar/gkx135;;28334758;;pmc5449617;;10.1261/rna.5430403;;pmc1370475;;12923259;;10.1016/j.bbrc.2005.12.105;;16403444;;10.1021/acs.nanolett.5b02497;;26469188;;pmc5245883;;26889757;;10.1002/adma.201505822;;10.1126/science.1231143;;pmc3795411;;23287718;;24157548;;10.1038/nprot.2013.143;;pmc3969860;;10.1038/cr.2013.122;;pmc3790238;;23979020;;25307932;;pmc4253859;;10.1016/j.cell.2014.09.029;;pmc4252608;;25307933;;10.1016/j.cell.2014.09.039;;pmc4420636;;10.1038/nature14136;;25494202;;10.1038/nmeth.3312;;pmc4393883;;25730490;;pmc5094855;;27661255;;10.7554/elife.19760;;pmc4927356;;10.1038/nmeth.3871;;27214048;;10.1021/acsnano.6b07600;;28129503;;pmc5848212;;21493687;;pmc3130266;;pmc3130291;;21385827;;10.1093/nar/gkr086;;10.1093/nar/gkr218;;10.1016/s1359-6446(01)02087-6;;11790603;;11738971;;10.1016/s1359-6446(01)02070-0;;pmc4951582;;10.1016/j.apsb.2016.02.001;;27471669;;10.1016/j.cels.2016.02.015;;27135364;;27560178;;pmc5223290;;10.1038/nprot.2016.105;;25724909;;pmc4563722;;10.1074/mcp.m114.046813,"KENAKIN, T: ""Biased Receptor Signaling in Drug Discovery"", PHARMACOL REV, vol. 71, April 2019 (2019-04-01), pages 267 - 315;;HARMAR, A.J. ET AL.: ""IUPHAR-DB: the IUPHAR database of G protein-coupled receptors and ion channels"", NUCLEIC ACIDS RESEARCH, vol. 37, 2009;;DAVENPORT APSCULLY CCGDE GRAAF CBROWN AJHMAGUIRE JJ: ""Advances in therapeutic peptides targeting G protein-coupled receptors"", NAT REV DRUG DISCOV, no. 6, 19 June 2020 (2020-06-19), pages 389 - 413, XP037154924, DOI: 10.1038/s41573-020-0062-z;;SMITHWATERMAN, ADV. APPL. MATH., vol. 2, 1981, pages 482;;NEEDLEMANWUNSCH, J. MOL. BIOL., vol. 48, 1970, pages 443;;PEARSONLIPMAN, PROC. NAT'L. ACAD. SCI. USA, vol. 85, 1988, pages 2444;;AUSUBEL ET AL., CURRENT PROTOCOLS IN MOLECULAR BIOLOGY;;GREENWUTS: ""Protecting Groups in Organic Synthesis"", 1991, JOHN WILEY AND SONS;;""Therapeutic Monoclonal Antibodies: From Bench to Clinic"", 2009;;GILBERT ET AL.: ""CRISPR-Mediated Modular RNA-Guided Regulation of Transcription in Eukaryotes"", CELL, vol. 154, 2013, pages 1380 - 51;;FERRARA ET AL.: ""Using Phage and Yeast Display to Select Hundreds of Monoclonal Antibodies: Application to Antigen 85, a Tuberculosis Biomarker"", PLOS ONE, vol. 7, no. 11, 2012, pages 49535, XP055152096, DOI: 10.1371/journal.pone.0049535;;REGBERG ET AL.: ""Applications of cell-penetrating peptides for tumor targeting and future cancer therapies"", PHARMACEUTICALS, vol. 5, no. 9, 2012, pages 991 - 1007;;LIM ET AL., NATURE, vol. 433, 2005, pages 769 - 73;;BARTEL, CELL, vol. 116, 2004, pages 281 - 97;;ZENG ET AL., MOL CELL, vol. 9, 2002, pages 1327 - 33;;DOENCH ET AL., GENES DEV, vol. 17, 2003, pages 438 - 42;;WU ET AL., PROC NATL ACAD SCI USA, vol. 103, 2006, pages 4034 - 39;;RAJEWSKY, NAT GENET, vol. 38, 2006, pages 8 - 13;;BIRMINGHAM ET AL., NAT METHODS, vol. 3, 2006, pages 199 - 204;;PRESNYAK ET AL.: ""Engineering complex synthetic transcriptional programs with CRISPR RNA scaffolds"", CELL, vol. 160, no. 6, 2015, pages 1111 - 50;;THESS ET AL., MOL THER, vol. 23, no. 9, 2015, pages 1456 - 64;;""RNA Therapeutics: Function, Design, and Delivery"", 2010;;KACZMAREK ET AL.: ""Advances in the delivery of RNA therapeutics: from concept to clinical reality"", GENOME MEDICINE, vol. 9, 2017, pages 60, XP055464283, DOI: 10.1186/s13073-017-0450-0;;KACZMAREK ET AL., GENOME MEDICINE, vol. 9, 2017, pages 60;;STRENKOWSKA ET AL., NUCLEIC ACIDS RES., vol. 44, 2016, pages 9578 - 90;;WROBLEWSKA ET AL., NATBIOTECHNOL, vol. 33, 2015, pages 839 - 41;;ANDRIES ET AL., J CONTROL RELEASE, vol. 217, 2015, pages 337 - 44;;SVITKIN ET AL., NUCLEIC ACIDS RES., vol. 45, 2017, pages 6023 - 36;;JEMIELITY ET AL., RNA, vol. 9, no. 9, 2003, pages 1108 - 22;;MOCKEY ET AL., BIOCHEM BIOPHYS RES COMMUN, vol. 340, 2006, pages 1062 - 88;;KAUFFMAN ET AL., NANO LETT, vol. 15, 2015, pages 7300 - 6;;FENTON ET AL., ADV MATER, vol. 28, 2016, pages 2939 - 43;;CONG ET AL., SCIENCE, vol. 339, 2013, pages 819 - 23;;RAN ET AL., NATURE PROTOCOLS, vol. 8, 2013, pages 2281 - 308;;HENDEL ET AL., NATURE BIOTECHNOL., 2015, pages 985 - 91;;CHENG ET AL.: ""Multiplexed activation of endogenous genes by CRISPR-on, an RNA-guided transcriptional activator system"", CELL RES, vol. 23, 2013, pages 1163 - 71;;GILBERT ET AL.: ""Genome-Scale CRISPRMediated Control of Gene Repression and Activation"", CELL, vol. 159, 2014, pages 647 - 61;;TANENBAUM ET AL.: ""A protein-tagging system for signal amplification in gene expression and fluorescence imaging"", CELL, vol. 159, 2014, pages 635 - 46, XP029084861, DOI: 10.1016/j.cell.2014.09.039;;KONERMANN ET AL.: ""Genome- scale transcriptional activation by an engineered CRISPR-Cas9 complex"", NATURE, vol. 517, 2015, pages 583 - 88, XP055585957, DOI: 10.1038/nature14136;;CHAVEZ ET AL.: ""Highly efficient Cas9-mediated transcriptional programming"", NAT. METHODS., vol. 12, 2015, pages 326 - 28, XP055694813, DOI: 10.1038/nmeth.3312;;HORLBECK ET AL.: ""Compact and highly active next-generation libraries for CRISPR-mediated gene repression and activation"", ELIFE, vol. 5, 2016, pages 19760, XP055610557, DOI: 10.7554/eLife.19760;;CHAVEZ ET AL.: ""Comparison of Cas9 activators in multiple species"", NAT METHODS, vol. 7, 2016, pages 563 - 67;;JO ET AL., BIOMED RES. INT., vol. 2015, 2015, pages 305716;;MOUT ET AL., ACS NANO, vol. 11, no. 3, 2017, pages 2452 - 58;;CERMAK ET AL.: ""Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting"", NUCLEIC ACIDS RES, vol. 39, no. 12, 2011, pages 82, XP055130093, DOI: 10.1093/nar/gkr218;;GANESAN, DRUG DISCOV. TODAY, vol. 7, no. 1, January 2002 (2002-01-01), pages 47 - 55;;LOU, DRUG DISCOV. TODAY, vol. 6, no. 24, December 2001 (2001-12-01), pages 1288 - 1294;;""Therapeutic Protein Drug Products: Practical Approaches to formulation in the Laboratory, Manufacturing, and the Clinic"", 2012;;SHI ET AL., PNAS, vol. 111, no. 28, 2014, pages 10131 - 36;;""Protein Biotechnology: Isolation, Characterization, and Stabilization"", 2013;;""Remington's Pharmaceutical Sciences"", 1980;;COFFIN JM ET AL.: ""Fundamental Virology"", vol. 1996, LIPPINCOTT-RAVEN PUBLISHERS, article ""Retroviridae: The viruses and their replication"", pages: 763 - 843;;SPUCHNAVARRO, J DRUG DELIV, vol. 2011, 2011, pages 469679;;TEMPLETON ET AL., NATURE BIOTECH, vol. 15, 1997, pages 647 - 52;;LI ET AL., NANOMATERIALS, vol. 7, no. 6, 2017, pages 122;;HA ET AL., ACTA PHARM SIN B, vol. 6, no. 4, 2016, pages 287 - 96;;HUANG ET AL., NATURE COMMUNICATIONS, vol. 8, 2017, pages 423;;GEYER ET AL., CELL SYST, vol. 2, 2016, pages 185 - 195;;BRAY ET AL., NAT. PROTOC., vol. 11, no. 9, September 2016 (2016-09-01), pages 1757 - 1774;;KESHISHIAN ET AL., MOL CELL PROTEOMICS, vol. 14, no. 9, September 2015 (2015-09-01), pages 2375 - 93;;GRASSL ET AL., GENOME MEDICINE, vol. 8, 2016, pages 44",PENDING
120,WO,A3,WO 2023/230578 A3,135-357-424-079-072,2024-02-01,2024,US 2023/0067505 W,2023-05-25,US 202263345771 P,2022-05-25,COMPOSITIONS AND METHODS FOR MODULATING CIRCULATING FACTORS,"The disclosure provides, in various embodiments, compositions, such as polypeptides, polynucleotides, gene editing system, small molecules, vectors or host cells, that comprises and/or modulate expression or activity of immune regulation-associated proteins. The disclosure also provides, in various embodiments, methods of treating aging, senescence, fibrosis, a metabolic disease, a cardiovascular disease, an endocrine-associated disorder, a genetic disease, cancer, an infection, an immunological disease, an indication treated with hormone, growth factor and/or protein replacement, or a combination thereof using an agent that comprises and/or modulates expression or activity of an immune regulation-associated protein and methods of identifying said agent.",FLAGSHIP PIONEERING INNOVATIONS VII LLC,MANI VINIDHRA;;WEINSTEIN ERICA;;ECHELARD YANN PAUL GUY;;KAHVEJIAN AVAK;;PENDERGRAST PATRICK;;OUSPENSKAIA TAMARA;;BILLINGS GABRIEL;;NICOD CHARLOTTE;;GRISHKEVICH VLAD;;BAEK SUNGMIN;;LABER SAMANTHA;;DAI SHUJIA;;ROSENBERGER GEORGE;;FANG TAO;;HAMSANATHAN SHURUTHI,,https://lens.org/135-357-424-079-072,Search Report,yes,8,0,2,2,0,C12Q1/6883;;C12Q1/6886;;C12Q2600/158;;A61K38/05;;A61K38/06;;G01N2500/00;;G01N33/57484;;G01N33/6893,C12Q1/6883;;A61K38/05;;A61K38/06;;C12Q1/6886;;G01N33/53;;G01N33/574,,1,1,011-543-438-498-879,pmc6409483;;30262890;;10.1038/nrd.2018.135,"CAMPBELL ADRIAN P. ET AL: ""Targeting G protein-coupled receptor signalling by blocking G proteins"", NATURE REVIEWS DRUG DISCOVERY, vol. 17, no. 11, 11 March 2019 (2019-03-11), GB, pages 789 - 803, XP093084090, ISSN: 1474-1776, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6409483/pdf/nihms-1010373.pdf> DOI: 10.1038/nrd.2018.135",PENDING
121,WO,A8,WO 2023/230578 A8,104-601-009-257-393,2024-03-07,2024,US US2023/067505,2023-05-25,"US 63/3/045,771",2022-05-25,COMPOSITIONS AND METHODS FOR MODULATING CIRCULATING FACTORS,"The disclosure provides, in various embodiments, compositions, such as polypeptides, polynucleotides, gene editing system, small molecules, vectors or host cells, that comprises and/or modulate expression or activity of immune regulation-associated proteins. The disclosure also provides, in various embodiments, methods of treating aging, senescence, fibrosis, a metabolic disease, a cardiovascular disease, an endocrine-associated disorder, a genetic disease, cancer, an infection, an immunological disease, an indication treated with hormone, growth factor and/or protein replacement, or a combination thereof using an agent that comprises and/or modulates expression or activity of an immune regulation-associated protein and methods of identifying said agent.","FLAGSHIP PIONEERING INNOVATIONS VII, LLC","MANI, Vinidhra;;WEINSTEIN, Erica, Gabrielle;;ECHELARD, Yann Paul Guy, Regis;;KAHVEJIAN, Avak;;PENDERGRAST, Patrick, Shannon;;OUSPENSKAIA, Tamara;;BILLINGS, Gabriel, Humphrey;;NICOD, Charlotte, Marie;;GRISHKEVICH, Vlad;;BAEK, Sungmin;;LABER, Samantha;;DAI, Shujia;;ROSENBERGER, George;;FANG, Tao;;HAMSANATHAN, Shruthi",,https://lens.org/104-601-009-257-393,Amended Application,yes,0,0,1,1,0,,C12Q1/6883;;A61K38/05;;A61K38/06;;C12Q1/6886;;G01N33/53;;G01N33/574,,0,0,,,,UNKNOWN
122,ES,T3,ES 2837431 T3,027-870-389-980-448,2021-06-30,2021,ES 17826629 T,2017-12-08,US 201662432537 P;;US 2017/0065425 W,2016-12-09,"Moduladores del regulador de la conductancia transmembrana de fibrosis quística, composiciones farmacéuticas, métodos de tratamiento, y procesos para elaborar el modulador","Un compuesto que tiene la fórmula siguiente: **(Ver fórmula)** una sal farmacéuticamente aceptable del mismo, o un derivado deuterado de cualquiera de los anteriores.",VERTEX PHARMA,ABELA ALEXANDER;;ALCACIO TIMOTHY;;ANDERSON COREY;;ANGELL PAUL;;BAEK MINSON;;CLEMENS JEREMY;;CLEVELAND THOMAS;;FERRIS LORI;;GROOTENHUIS PETER DIEDERIK;;GROSS RAYMOND;;GULEVICH ANTON;;HADIDA RUAH SARA;;HSIA CLARA;;HUGHES ROBERT;;JOSHI PRAMOD;;KANG PING;;KESHAVARZ-SHOKRI ALI;;KHATUYA HARIPADA;;KRENITSKY PAUL;;MCCARTNEY JASON;;MILLER MARK;;PARASELLI PRASUNA;;PIERRE FABRICE JEAN;;SHI YI;;SHRESTHA MUNA;;SIESEL DAVID;;STAVROPOULOS KATHY;;TERMIN ANDREAS;;UY JOHNNY;;VAN GOOR FREDRICK;;YOUNG TOMOTHY;;ZHOU JINGLAN,,https://lens.org/027-870-389-980-448,Granted Patent,no,0,0,63,63,0,A61K31/455;;C07D401/14;;C07D231/20;;A61P11/00;;C07D401/04;;C07D401/14;;A61P11/00;;C07D401/14;;C07D471/14;;C07B2200/13;;C07D231/20;;C07D498/14;;A61P11/00;;C07D401/04;;C07D401/14;;A61K31/4439;;A61K31/519;;A61K31/5365;;C07D231/20;;C07D401/04;;C07D471/14;;C07D498/14;;A61P11/00;;C07B2200/13;;C07D401/14;;C07D471/14;;C07B2200/13;;A61P11/00;;C07D498/14;;C07D401/04;;C07D231/20,C07D401/14;;A61K31/455;;A61P11/00;;C07D231/20;;C07D401/04,,0,0,,,,ACTIVE
123,WO,A1,WO 2018/107100 A1,075-874-666-813-904,2018-06-14,2018,US 2017/0065425 W,2017-12-08,US 201662432537 P,2016-12-09,"MODULATOR OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR","Compounds of Formula (I) pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed. Also disclosed are solid state forms of Compound 1 and salts and solvates thereof.",VERTEX PHARMA,ABELA ALEXANDER;;ALCACIO TIMOTHY;;ANDERSON COREY;;ANGELL PAUL;;BAEK MINSON;;CLEMENS JEREMY;;CLEVELAND THOMAS;;FERRIS LORI;;GROOTENHUIS PETER DIEDERIK;;GROSS RAYMOND;;GULEVICH ANTON;;HADIDA RUAH SARA;;HSIA CLARA;;HUGHES ROBERT;;JOSHI PRAMOD;;KANG PING;;KESHAVARZ-SHOKRI ALI;;KHATUYA HARIPADA;;KRENITSKY PAUL;;MCCARTNEY JASON;;MILLER MARK;;PARASELLI PRASUNA;;PIERRE FABRICE JEAN;;SHI YI;;SHRESTHA MUNA;;SIESEL DAVID;;STAVROPOULOS KATHY;;TERMIN ANDREAS;;UY JOHNNY;;VAN GOOR FREDRICK;;YOUNG TOMOTHY;;ZHOU JINGLAN,,https://lens.org/075-874-666-813-904,Patent Application,yes,16,44,63,63,0,A61K31/455;;C07D401/14;;C07D231/20;;A61P11/00;;C07D401/04;;C07D401/14;;A61P11/00;;C07D401/14;;C07D471/14;;C07B2200/13;;C07D231/20;;C07D498/14;;A61P11/00;;C07D401/04;;C07D401/14;;A61K31/4439;;A61K31/519;;A61K31/5365;;C07D231/20;;C07D401/04;;C07D471/14;;C07D498/14;;A61P11/00;;C07B2200/13;;C07D401/14;;C07D471/14;;C07B2200/13;;A61P11/00;;C07D498/14;;C07D401/04;;C07D231/20,C07D401/14;;A61K31/455;;A61P11/00;;C07D231/20;;C07D401/04,,15,9,027-495-322-764-618;;062-658-814-888-724;;115-252-470-991-090;;147-561-926-460-635;;059-603-579-320-605;;139-606-967-003-103;;009-491-011-950-586;;007-364-858-655-289;;002-186-545-851-173,1695717;;10.1038/346366a0;;10.1016/0092-8674(90)90196-l;;2344617;;10.1126/science.2570460;;2570460;;2236053;;pmc54973;;10.1073/pnas.87.21.8447;;10.1096/fasebj.4.10.2197151;;2197151;;10.1038/354526a0;;1722027;;7539001;;10.1074/jbc.270.21.12347;;10.1002/jps.2600660104;;833720;;10.1021/jm4007998;;24294889,"CUTTING, G. R. ET AL., NATURE, vol. 346, 1990, pages 366 - 369;;DEAN, M. ET AL., CELL, vol. 61, no. 863, 1990, pages 870;;KEREM, B-S. ET AL., SCIENCE, vol. 245, 1989, pages 1073 - 1080;;KEREM, B-S ET AL., PROC. NATL. ACAD. SCI., vol. 87, 1990, pages 8447 - 8451;;QUINTON, P. M., FASEB J., vol. 4, 1990, pages 2709 - 2727;;DALEMANS ET AL., NATURE LOND., vol. 354, 1991, pages 526 - 528;;PASYK; FOSKETT, J. CELL. BIOCHEM., vol. 270, 1995, pages 12347 - 12350;;LLOYD: ""The Art, Science and Technology of Pharmaceutical Compounding"", 1999;;S. M. BERGE ET AL., J. PHARMACEUTICAL SCIENCES, vol. 66, 1977, pages 1 - 19;;""Remington: The Science and Practice of Pharmacy. 21th ed."", 2005, LIPPINCOTT WILLIAMS & WILKINS;;""Encyclopedia of Pharmaceutical Technology"", 1988, MARCEL DEKKER;;S. L. HARBESON; R. D. TUNG: ""Deuterium In Drug Discovery and Development"", ANN. REP. MED. CHEM., vol. 46, 2011, pages 403 - 417, XP055422117, DOI: doi:10.1016/B978-0-12-386009-5.00003-5;;T.G. GANT: ""Using deuterium in drug discovery: leaving the label in the drug"", J. MED. CHEM., vol. 57, 2014, pages 3595 - 3611, XP055139522, DOI: doi:10.1021/jm4007998;;SHELDRICK, G.M., ACTA CRYST., vol. A64, 2008, pages 112 - 122;;MEIJERE ET AL., EUR. J. ORG. CHEM., 2002, pages 485 - 492",PENDING
124,HU,T2,HU E052205 T2,026-096-485-999-249,2021-04-28,2021,HU E17826629 A,2017-12-08,US 201662432537 P,2016-12-09,"MODULATOR OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR",,VERTEX PHARMA,ABELA ALEXANDER;;ALCACIO TIMOTHY;;ANDERSON COREY;;ANGELL PAUL;;BAEK MINSON;;CLEMENS JEREMY;;CLEVELAND THOMAS;;FERRIS LORI;;GROOTENHUIS PETER DIEDERIK;;GROSS RAYMOND;;GULEVICH ANTON;;HADIDA RUAH SARA;;HSIA CLARA;;HUGHES ROBERT;;JOSHI PRAMOD;;KANG PING;;KESHAVARZ-SHOKRI ALI;;KHATUYA HARIPADA;;KRENITSKY PAUL;;MCCARTNEY JASON;;MILLER MARK;;PARASELLI PRASUNA;;PIERRE FABRICE JEAN;;SHI YI;;SHRESTHA MUNA;;SIESEL DAVID;;STAVROPOULOS KATHY;;TERMIN ANDREAS;;UY JOHNNY;;VAN GOOR FREDRICK;;YOUNG TOMOTHY;;ZHOU JINGLAN,,https://lens.org/026-096-485-999-249,Amended Patent,no,0,0,63,63,0,A61K31/455;;C07D401/14;;C07D231/20;;A61P11/00;;C07D401/04;;C07D401/14;;A61P11/00;;C07D401/14;;C07D471/14;;C07B2200/13;;C07D231/20;;C07D498/14;;A61P11/00;;C07D401/04;;C07D401/14;;A61K31/4439;;A61K31/519;;A61K31/5365;;C07D231/20;;C07D401/04;;C07D471/14;;C07D498/14;;A61P11/00;;C07B2200/13;;C07D401/14;;C07D471/14;;C07B2200/13;;A61P11/00;;C07D498/14;;C07D401/04;;C07D231/20,A61P11/00,,0,0,,,,PENDING
125,LT,T,LT 3551622 T,153-902-376-223-44X,2021-02-25,2021,LT 17826629 T,2017-12-08,US 201662432537 P;;US 2017/0065425 W,2016-12-09,"MODULATOR OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR",,VERTEX PHARMA,ABELA ALEXANDER;;ALCACIO TIMOTHY;;ANDERSON COREY;;ANGELL PAUL;;BAEK MINSON;;CLEMENS JEREMY;;CLEVELAND THOMAS;;FERRIS LORI;;GROOTENHUIS PETER DIEDERIK;;GROSS RAYMOND;;GULEVICH ANTON;;HADIDA RUAH SARA;;HSIA CLARA;;HUGHES ROBERT;;JOSHI PRAMOD;;KANG PING;;KESHAVARZ-SHOKRI ALI;;KHATUYA HARIPADA;;KRENITSKY PAUL;;MCCARTNEY JASON;;MILLER MARK;;PARASELLI PRASUNA;;PIERRE FABRICE JEAN;;SHI YI;;SHRESTHA MUNA;;SIESEL DAVID;;STAVROPOULOS KATHY;;TERMIN ANDREAS;;UY JOHNNY;;VAN GOOR FREDRICK;;YOUNG TOMOTHY;;ZHOU JINGLAN,,https://lens.org/153-902-376-223-44X,Unknown,no,0,0,63,63,0,A61K31/455;;C07D401/14;;C07D231/20;;A61P11/00;;C07D401/04;;C07D401/14;;A61P11/00;;C07D401/14;;C07D471/14;;C07B2200/13;;C07D231/20;;C07D498/14;;A61P11/00;;C07D401/04;;C07D401/14;;A61K31/4439;;A61K31/519;;A61K31/5365;;C07D231/20;;C07D401/04;;C07D471/14;;C07D498/14;;A61P11/00;;C07B2200/13;;C07D401/14;;C07D471/14;;C07B2200/13;;A61P11/00;;C07D498/14;;C07D401/04;;C07D231/20,C07D401/14;;A61K31/455;;A61P11/00;;C07D231/20;;C07D401/04,,0,0,,,,PENDING
126,CN,A,CN 110267948 A,034-495-644-554-14X,2019-09-20,2019,CN 201780086007 A,2017-12-08,US 201662432537 P;;US 2017/0065425 W,2016-12-09,"MODULATOR OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR","Compounds of Formula (I) pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed. Also disclosed are solid state forms of Compound 1 and salts and solvates thereof.",VERTEX PHARMA,ABELA ALEXANDER;;ALCACIO TIMOTHY;;ANDERSON COREY;;ANGELL PAUL;;BAEK MINSON;;CLEMENS JEREMY;;CLEVELAND THOMAS;;FERRIS LORI;;GROOTENHUIS PETER DIEDERIK;;GROSS RAYMOND;;GULEVICH ANTON;;HADIDA RUAH SARA;;HSIA CLARA;;HUGHES ROBERT;;JOSHI PRAMOD;;KANG PING;;KESHAVARZ-SHOKRI ALI;;KHATUYA HARIPADA;;KRENITSKY PAUL;;MCCARTNEY JASON;;MILLER MARK;;PARASELLI PRASUNA;;PIERRE FABRICE JEAN;;SHI YI;;SHRESTHA MUNA;;SIESEL DAVID;;STAVROPOULOS KATHY;;TERMIN ANDREAS;;UY JOHNNY;;VAN GOOR FREDRICK;;YOUNG TOMOTHY;;ZHOU JINGLAN,,https://lens.org/034-495-644-554-14X,Patent Application,no,3,0,63,63,0,A61K31/455;;C07D401/14;;C07D231/20;;A61P11/00;;C07D401/04;;C07D401/14;;A61P11/00;;C07D401/14;;C07D471/14;;C07B2200/13;;C07D231/20;;C07D498/14;;A61P11/00;;C07D401/04;;C07D401/14;;A61K31/4439;;A61K31/519;;A61K31/5365;;C07D231/20;;C07D401/04;;C07D471/14;;C07D498/14;;A61P11/00;;C07B2200/13;;C07D401/14;;C07D471/14;;C07B2200/13;;A61P11/00;;C07D498/14;;C07D401/04;;C07D231/20,C07D401/14;;A61K31/455;;A61P11/00;;C07D231/20;;C07D401/04,,0,0,,,,ACTIVE
127,MA,B1,MA 49235 B1,085-569-062-939-102,2021-02-26,2021,MA 49235 A,2017-12-08,US 201662432537 P;;US 2017/0065425 W,2016-12-09,"Modulateur de régulateur de conductance transmembranaire de fibrose kystique, compositions pharmaceutiques, procédés de traitement et procédé de fabrication du modulateur","L'invention concerne des composés de formule (i) des sels pharmaceutiquement acceptables de ceux-ci, des dérivés deutérés et des métabolites de l'un quelconque des précédents. L'invention concerne également des compositions pharmaceutiques comprenant les composés de l'invention, des procédés de traitement de la fibrose kystique à l'aide de celles-ci, et des procédés de fabrication de celles-ci. L'invention concerne en outre des formes à l'état solide du composé 1, des sels et des solvates de celui-ci.",VERTEX PHARMA,FERRIS LORI;;ANDERSON COREY;;CLEVELAND THOMAS;;KHATUYA HARIPADA;;MCCARTNEY JASON;;UY JOHNNY;;ZHOU JINGLAN;;ALCACIO TIMOTHY;;BAEK MINSON;;HADIDA RUAH SARA;;HUGHES ROBERT;;KESHAVARZ-SHOKRI ALI;;MILLER MARK;;JOSHI PRAMOD;;KRENITSKY PAUL;;TERMIN ANDREAS;;ABELA ALEXANDER;;PARASELLI PRASUNA;;SIESEL DAVID;;ANGELL PAUL;;CLEMENS JEREMY;;GROOTENHUIS PETER DIEDERIK;;GROSS RAYMOND;;GULEVICH ANTON;;HSIA CLARA;;KANG PING;;PIERRE FABRICE JEAN;;SHI YI;;SHRESTHA MUNA;;STAVROPOULOS KATHY;;VAN GOOR FREDRICK;;YOUNG TOMOTHY,,https://lens.org/085-569-062-939-102,Granted Patent,no,0,0,63,63,0,A61K31/455;;C07D401/14;;C07D231/20;;A61P11/00;;C07D401/04;;C07D401/14;;A61P11/00;;C07D401/14;;C07D471/14;;C07B2200/13;;C07D231/20;;C07D498/14;;A61P11/00;;C07D401/04;;C07D401/14;;A61K31/4439;;A61K31/519;;A61K31/5365;;C07D231/20;;C07D401/04;;C07D471/14;;C07D498/14;;A61P11/00;;C07B2200/13;;C07D401/14;;C07D471/14;;C07B2200/13;;A61P11/00;;C07D498/14;;C07D401/04;;C07D231/20,A61K31/455;;A61P11/00;;C07D231/20;;C07D401/04;;C07D401/14,,0,0,,,,ACTIVE
128,SG,A,SG 10201913606V A,175-133-556-822-356,2020-02-27,2020,SG 10201913606V A,2017-12-08,US 201662432537 P,2016-12-09,"MODULATOR OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR",,VERTEX PHARMA,ABELA ALEXANDER;;ALCACIO TIMOTHY;;ANDERSON COREY;;ANGELL PAUL;;BAEK MINSON;;CLEMENS JEREMY;;CLEVELAND THOMAS;;FERRIS LORI;;GROOTENHUIS PETER DIEDERIK;;GROSS RAYMOND;;GULEVICH ANTON;;HADIDA RUAH SARA;;HSIA CLARA;;HUGHES ROBERT;;JOSHI PRAMOD;;KANG PING;;KESHAVARZ-SHOKRI ALI;;KHATUYA HARIPADA;;KRENITSKY PAUL;;MCCARTNEY JASON;;MILLER MARK;;PARASELLI PRASUNA;;PIERRE FABRICE JEAN;;SHI YI;;SHRESTHA MUNA;;SIESEL DAVID;;STAVROPOULOS KATHY;;TERMIN ANDREAS;;UY JOHNNY;;VAN GOOR FREDRICK;;YOUNG TOMOTHY;;ZHOU JINGLAN,,https://lens.org/175-133-556-822-356,Unknown,no,0,0,63,63,0,A61K31/455;;C07D401/14;;C07D231/20;;A61P11/00;;C07D401/04;;C07D401/14;;A61P11/00;;C07D401/14;;C07D471/14;;C07B2200/13;;C07D231/20;;C07D498/14;;A61P11/00;;C07D401/04;;C07D401/14;;A61K31/4439;;A61K31/519;;A61K31/5365;;C07D231/20;;C07D401/04;;C07D471/14;;C07D498/14;;A61P11/00;;C07B2200/13;;C07D401/14;;C07D471/14;;C07B2200/13;;A61P11/00;;C07D498/14;;C07D401/04;;C07D231/20,,,0,0,,,,PENDING
129,NZ,A,NZ 754805 A,119-800-208-798-236,2023-11-24,2023,NZ 75480517 A,2017-12-08,US 2017/0065425 W;;US 201662432537 P,2016-12-09,"Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator","Compounds of Formula (I) pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed. Also disclosed are solid state forms of Compound 1 and salts and solvates thereof.",VERTEX PHARMA,ALCACIO TIMOTHY;;BAEK MINSON;;HADIDA RUAH SARA SABINA;;HUGHES ROBERT M;;KESHAVARZ-SHOKRI ALI;;MCCARTNEY JASON;;MILLER MARK THOMAS;;ANDERSON COREY;;CLEVELAND THOMAS;;KHATUYA HARIPADA;;JOSHI PRAMOD VIRUPAX;;KRENITSKY PAUL JOHN;;PIERRE FABRICE JEAN DENIS;;TERMIN ANDREAS P;;UY JOHNNY;;ZHOU JINGLAN;;ABELA ALEXANDER RUSSELL;;PARASELLI PRASUNA;;SIESEL DAVID ANDREW;;ANGELL PAUL;;CLEMENS JEREMY;;FERRIS LORI;;GROOTENHUIS PETER DIEDERIK;;GROSS RAYMOND;;GULEVICH ANTON;;HSIA CLARA;;KANG PING;;SHI YI;;SHRESTHA MUNA;;STAVROPOULOS KATHY;;VAN GOOR FREDRICK;;YOUNG TIMOTHY,,https://lens.org/119-800-208-798-236,Patent Application,no,0,0,63,63,0,A61K31/455;;C07D401/14;;C07D231/20;;A61P11/00;;C07D401/04;;C07D401/14;;A61P11/00;;C07D401/14;;C07D471/14;;C07B2200/13;;C07D231/20;;C07D498/14;;A61P11/00;;C07D401/04;;C07D401/14;;A61K31/4439;;A61K31/519;;A61K31/5365;;C07D231/20;;C07D401/04;;C07D471/14;;C07D498/14;;A61P11/00;;C07B2200/13;;C07D401/14;;C07D471/14;;C07B2200/13;;A61P11/00;;C07D498/14;;C07D401/04;;C07D231/20,C07D401/14;;A61K31/455;;A61P11/00;;C07D231/20;;C07D401/04,,0,0,,,,PENDING
130,ES,T3,ES 2900263 T3,034-807-894-718-469,2022-03-16,2022,ES 17792230 T,2017-09-29,US 201662402838 P;;US 201662410353 P;;US 201662415409 P;;US 201662419935 P;;US 2017/0054611 W,2016-09-30,"Modulador de regulador de conductancia transmembrana de fibrosis quística, composiciones farmacéuticas, métodos de tratamiento y proceso de fabricación del modulador","Un compuesto de Fórmula I: **(Ver fórmula)** una sal farmacéuticamente aceptable del mismo, o un derivado deuterado de cualquiera de los anteriores, en donde: - uno de Y1 e Y2 es N y el otro es CH; - X se elige entre los grupos O, NH y N(C1-C4 alquilo); - R1 se elige entre grupos -(CR2)k-O-(CR2)m(CR)n(Anillo A)n+1, en donde cada Anillo A se elige independientemente entre grupos C3-C10 cicloalquilo opcionalmente sustituidos con uno o más sustituyentes elegidos cada uno independientemente entre grupos C1-C2 alquilo, grupos C1-C2 alquilo halogenados y halógenos, y en los que cada R se elige independientemente entre H, OH y grupos C1-C2 alquilo opcionalmente sustituidos con uno o más halógenos; - cada R2 se elige independientemente entre grupos C1-C2 alquilo, OH, grupos C1-C2 alcoxi, halógenos y ciano; - cada R3 se elige independientemente entre grupos C1-C2 alquilo opcionalmente sustituidos con uno o más grupos OH; - cada R4 se elige independientemente entre halógenos; - k es 0 o 1; - r es 0 o 1; - m es 0, 1, 2 o 3; - n es 0 o 1; - p es 0, 1, 2, 3, 4 o 5; y - q es 0, 1, 2, 3, 4, 5, 6, 7 u 8.",VERTEX PHARMA,ALCACIO TIMOTHY;;BAEK MINSON;;GROOTENHUIS PETER;;HADIDA RUAH SARA;;HUGHES ROBERT;;KESHAVARZ-SHOKRI ALI;;MCAULEY-AOKI RACHEL;;MCCARTNEY JASON;;MILLER MARK;;VAN GOOR FREDRICK;;ZHANG BEILI;;ANDERSON COREY;;CLEVELAND THOMAS;;FRIEMAN BRYAN;;KHATUYA HARIPADA;;JOSHI PRAMOD;;KRENITSKY PAUL;;MELILLO VITO;;PIERRE FABRICE;;TERMIN ANDREAS;;UY JOHNNY;;ZHOU JINGLAN;;ABELA ALEXANDER;;BUSCH BRETT;;PARASELLI PRASUNA;;SIESEL DAVID,,https://lens.org/034-807-894-718-469,Granted Patent,no,0,0,50,53,0,C07D471/14;;C07D498/14;;C07D401/14;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/12;;A61P43/00;;C07D401/14;;A61P11/00;;A61K31/4439;;A61P11/12;;A61K31/4439;;A61K31/519;;A61K31/5365;;C07B59/002;;C07D401/14;;C07D471/14;;C07D498/14;;C07B2200/05;;C07D471/14;;C07D498/14;;C07B59/002;;C07B2200/05;;C07D401/14,C07D401/14;;A61K31/4439;;A61P11/12;;C07D471/14;;C07D498/14,,0,0,,,,ACTIVE
131,HU,T2,HU E056716 T2,185-913-369-724-814,2022-03-28,2022,HU E17792230 A,2017-09-29,US 201662402838 P;;US 201662410353 P;;US 201662415409 P;;US 201662419935 P,2016-09-30,"MODULATOR OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR",,VERTEX PHARMA,ALCACIO TIMOTHY;;BAEK MINSON;;GROOTENHUIS PETER;;HADIDA RUAH SARA;;HUGHES ROBERT;;KESHAVARZ-SHOKRI ALI;;MCAULEY-AOKI RACHEL;;MCCARTNEY JASON;;MILLER MARK;;VAN GOOR FREDRICK;;ZHANG BEILI;;ANDERSON COREY;;CLEVELAND THOMAS;;FRIEMAN BRYAN;;KHATUYA HARIPADA;;JOSHI PRAMOD;;KRENITSKY PAUL;;MELILLO VITO;;PIERRE FABRICE;;TERMIN ANDREAS;;UY JOHNNY;;ZHOU JINGLAN;;ABELA ALEXANDER;;BUSCH BRETT;;PARASELLI PRASUNA;;SIESEL DAVID,,https://lens.org/185-913-369-724-814,Amended Patent,no,0,0,50,53,0,C07D471/14;;C07D498/14;;C07D401/14;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/12;;A61P43/00;;C07D401/14;;A61P11/00;;A61K31/4439;;A61P11/12;;A61K31/4439;;A61K31/519;;A61K31/5365;;C07B59/002;;C07D401/14;;C07D471/14;;C07D498/14;;C07B2200/05;;C07D471/14;;C07D498/14;;C07B59/002;;C07B2200/05;;C07D401/14,C07D401/14;;A61P11/12;;C07D471/14;;C07D498/14,,0,0,,,,PENDING
132,LT,T,LT 3519401 T,015-390-500-257-162,2021-11-25,2021,LT 17054611 T,2017-09-29,US 201662402838 P;;US 201662410353 P;;US 201662415409 P;;US 201662419935 P;;US 2017/0054611 W,2016-09-30,"MODULATOR OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR",,VERTEX PHARMA,ALCACIO TIMOTHY;;BAEK MINSON;;GROOTENHUIS PETER;;HADIDA RUAH SARA;;HUGHES ROBERT;;KESHAVARZ-SHOKRI ALI;;MCAULEY-AOKI RACHEL;;MCCARTNEY JASON;;MILLER MARK;;VAN GOOR FREDRICK;;ZHANG BEILI;;ANDERSON COREY;;CLEVELAND THOMAS;;FRIEMAN BRYAN;;KHATUYA HARIPADA;;JOSHI PRAMOD;;KRENITSKY PAUL;;MELILLO VITO;;PIERRE FABRICE;;TERMIN ANDREAS;;UY JOHNNY;;ZHOU JINGLAN;;ABELA ALEXANDER;;BUSCH BRETT;;PARASELLI PRASUNA;;SIESEL DAVID,,https://lens.org/015-390-500-257-162,Unknown,no,0,0,50,53,0,C07D471/14;;C07D498/14;;C07D401/14;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/12;;A61P43/00;;C07D401/14;;A61P11/00;;A61K31/4439;;A61P11/12;;A61K31/4439;;A61K31/519;;A61K31/5365;;C07B59/002;;C07D401/14;;C07D471/14;;C07D498/14;;C07B2200/05;;C07D471/14;;C07D498/14;;C07B59/002;;C07B2200/05;;C07D401/14,C07D401/14;;A61K31/4439;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/12;;A61P43/00;;C07D471/14;;C07D498/14,,0,0,,,,PENDING
133,MA,B1,MA 46357 B1,172-365-116-419-858,2021-10-29,2021,MA 46357 A,2017-09-29,US 201662402838 P;;US 201662410353 P;;US 201662415409 P;;US 201662419935 P;;US 2017/0054611 W,2016-09-30,"Modulateur de régulateur de conductance transmembranaire de fibrose kystique, compositions pharmaceutiques, procédés de traitement et procédé de fabrication du modulateur","L'invention concerne des composés de formule (i), des sels pharmaceutiquement acceptables de ceux-ci, des dérivés deutérés et des métabolites de l'un quelconque des précédents. L'invention concerne également des compositions pharmaceutiques les comprenant, des procédés de traitement de la fibrose kystique à l'aide de celles-ci, et des procédés de fabrication de celles-ci.",VERTEX PHARMA,ANDERSON COREY;;CLEVELAND THOMAS;;KHATUYA HARIPADA;;MELILLO VITO;;MCCARTNEY JASON;;UY JOHNNY;;ZHOU JINGLAN;;ALCACIO TIMOTHY;;BAEK MINSON;;GROOTENHUIS PETER;;HADIDA RUAH SARA;;HUGHES ROBERT;;KESHAVARZ-SHOKRI ALI;;MCAULEY-AOKI RACHEL;;MILLER MARK;;VAN GOOR FREDRICK;;ZHANG BEILI;;FRIEMAN BRYAN;;JOSHI PRAMOD;;KRENITSKY PAUL;;PIERRE FABRICE;;TERMIN ANDREAS;;ABELA ALEXANDER;;BUSCH BRETT;;PARASELLI PRASUNA;;SIESEL DAVID,,https://lens.org/172-365-116-419-858,Granted Patent,no,0,0,50,53,0,C07D471/14;;C07D498/14;;C07D401/14;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/12;;A61P43/00;;C07D401/14;;A61P11/00;;A61K31/4439;;A61P11/12;;A61K31/4439;;A61K31/519;;A61K31/5365;;C07B59/002;;C07D401/14;;C07D471/14;;C07D498/14;;C07B2200/05;;C07D471/14;;C07D498/14;;C07B59/002;;C07B2200/05;;C07D401/14,A61K31/4439;;A61P11/12;;C07D401/14;;C07D471/14;;C07D498/14,,0,0,,,,ACTIVE
134,SI,T1,SI 3551622 T1,113-083-616-442-59X,2021-02-26,2021,SI 201730537 T,2017-12-08,US 201662432537 P;;US 2017/0065425 W;;EP 17826629 A,2016-12-09,"MODULATOR OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR",,VERTEX PHARMA,ABELA ALEXANDER RUSSELL;;ALCACIO TIMOTHY;;ANDERSON COREY;;ANGELL PAUL TIMOTHY;;BAEK MINSON;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;FERRIS LORI ANN;;GROOTENHUIS PETER DIEDERIK JAN;;GROSS RAYMOND STANLEY;;GULEVICH ANTON;;HADIDA RUAH SARA SABINA;;HSIA CLARA KUANG-JU;;HUGHES ROBERT M;;JOSHI PRAMOD VIRUPAX;;KANG PING;;KESHAVARZ-SHOKRI ALI;;KHATUYA HARIPADA;;KRENITSKY PAUL JOHN;;MCCARTNEY JASON;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE JEAN DENIS;;SHI YI;;SHRESTHA MUNA;;SIESEL DAVID ANDREW;;STAVROPOULOS KATHY;;TERMIN ANDREAS P;;UY JOHNNY;;VAN GOOR FREDRICK F;;YOUNG TOMOTHY JOHN;;ZHOU JINGLAN,,https://lens.org/113-083-616-442-59X,Granted Patent,no,0,0,63,63,0,A61K31/455;;C07D401/14;;C07D231/20;;A61P11/00;;C07D401/04;;C07D401/14;;A61P11/00;;C07D401/14;;C07D471/14;;C07B2200/13;;C07D231/20;;C07D498/14;;A61P11/00;;C07D401/04;;C07D401/14;;A61K31/4439;;A61K31/519;;A61K31/5365;;C07D231/20;;C07D401/04;;C07D471/14;;C07D498/14;;A61P11/00;;C07B2200/13;;C07D401/14;;C07D471/14;;C07B2200/13;;A61P11/00;;C07D498/14;;C07D401/04;;C07D231/20,C07D401/00;;A61K31/00;;A61P11/00;;C07D231/00,,0,0,,,,ACTIVE
135,EP,A1,EP 3812379 A1,184-056-468-696-556,2021-04-28,2021,EP 20199562 A,2017-12-08,US 201662432537 P;;EP 17826629 A;;US 2017/0065425 W,2016-12-09,CRYSTALLINE FORM OF A N-(PYRAZOL-4-YL)SULFONYL-6-(PYRAZOL-1-YL)-2-(PYRROLIDIN-1-YL)PYRIDINE-3-CARBOXAMIDE FOR TREATING CYSTIC FIBROSIS,"Compounds of Formula (I):
  
pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed. Also disclosed are solid state forms of Compound 1 and salts and solvates thereof.",VERTEX PHARMA,ABELA ALEXANDER RUSSELL;;ALCACIO TIMOTHY;;ANDERSON COREY;;ANGELL PAUL TIMOTHY;;BAEK MINSON;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;FERRIS LORI ANN;;GROOTENHUIS PETER DIEDERIK JAN;;GROSS RAYMOND STANLEY;;GULEVICH ANTON;;HADIDA RUAH SARA SABINA;;HSIA CLARA KUANG-JU;;HUGHES ROBERT M;;JOSHI PRAMOD VIRUPAX;;KANG PING;;KESHAVARZ-SHOKRI ALI;;KHATUYA HARIPADA;;KRENITSKY PAUL JOHN;;MCCARTNEY JASON;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE JEAN DENIS;;SHI YI;;SHRESTHA MUNA;;SIESEL DAVID ANDREW;;STAVROPOULOS KATHY;;TERMIN ANDREAS P;;UY JOHNNY;;VAN GOOR FREDRICK F;;YOUNG TIMOTHY JOHN;;ZHOU JINGLAN,,https://lens.org/184-056-468-696-556,Patent Application,yes,17,0,63,63,0,A61K31/455;;C07D401/14;;C07D231/20;;A61P11/00;;C07D401/04;;C07D401/14;;A61P11/00;;C07D401/14;;C07D471/14;;C07B2200/13;;C07D231/20;;C07D498/14;;A61P11/00;;C07D401/04;;C07D401/14;;A61K31/4439;;A61K31/519;;A61K31/5365;;C07D231/20;;C07D401/04;;C07D471/14;;C07D498/14;;A61P11/00;;C07B2200/13;;C07D401/14;;C07D471/14;;C07B2200/13;;A61P11/00;;C07D498/14;;C07D401/04;;C07D231/20,C07D401/14;;A61K31/455;;A61P11/00,,16,11,027-495-322-764-618;;062-658-814-888-724;;115-252-470-991-090;;147-561-926-460-635;;059-603-579-320-605;;139-606-967-003-103;;009-491-011-950-586;;007-364-858-655-289;;007-364-858-655-289;;029-966-049-767-156;;002-186-545-851-173,1695717;;10.1038/346366a0;;10.1016/0092-8674(90)90196-l;;2344617;;10.1126/science.2570460;;2570460;;2236053;;pmc54973;;10.1073/pnas.87.21.8447;;10.1096/fasebj.4.10.2197151;;2197151;;10.1038/354526a0;;1722027;;7539001;;10.1074/jbc.270.21.12347;;10.1002/jps.2600660104;;833720;;10.1002/jps.2600660104;;833720;;10.1016/b978-0-12-386009-5.00003-5;;10.1021/jm4007998;;24294889,"CUTTING, G. R. ET AL., NATURE, vol. 346, 1990, pages 366 - 369;;DEAN, M. ET AL., CELL, vol. 61, no. 863, 1990, pages 870;;KEREM, B-S. ET AL., SCIENCE, vol. 245, 1989, pages 1073 - 1080;;KEREM, B-S ET AL., PROC. NATL. ACAD. SCI. USA, vol. 87, 1990, pages 8447 - 8451;;QUINTON, P. M., FASEB J, vol. 4, 1990, pages 2709 - 2727;;DALEMANS ET AL., NATURE LOND, vol. 354, 1991, pages 526 - 528;;PASYKFOSKETT, J. CELL. BIOCHEM., vol. 270, 1995, pages 12347 - 50;;S. M. BERGE ET AL.: ""pharmaceutically acceptable salts"", J. PHARMACEUTICAL SCIENCES, vol. 66, 1977, pages 1 - 19;;LLOYD, THE ART, SCIENCE AND TECHNOLOGY OF PHARMACEUTICAL COMPOUNDING, 1999;;S. M. BERGE ET AL., J. PHARMACEUTICAL SCIENCES, vol. 66, 1977, pages 1 - 19;;REMINGTON: ""The Science and Practice of Pharmacy"", 2005, LIPPINCOTT WILLIAMS & WILKINS;;""Encyclopedia of Pharmaceutical Technology"", 1988, MARCEL DEKKER;;S. L. HARBESONR. D. TUNG: ""Deuterium In Drug Discovery and Development"", ANN. REP. MED. CHEM., vol. 46, 2011, pages 403 - 417;;T.G. GANT: ""Using deuterium in drug discovery: leaving the label in the drug"", J. MED. CHEM., vol. 57, 2014, pages 3595 - 3611, XP055139522, DOI: 10.1021/jm4007998;;SHELDRICK, G.M., ACTA CRYST., vol. A64, 2008, pages 112 - 122;;MEIJERE ET AL., EUR. J. ORG. CHEM., 2002, pages 485 - 492",PENDING
136,KR,A,KR 20190101993 A,065-269-235-418-605,2019-09-02,2019,KR 20197019725 A,2017-12-08,US 201662432537 P;;US 2017/0065425 W,2016-12-09,"낭포성 섬유증 막관통 전도성 조절인자의 조절제, 약제학적 조성물, 치료 방법, 및 상기 조절제를 제조하는 방법","하기 화학식 (I)의 화합물:이의 약제학적으로 허용 가능한 염, 전술한 것들 중 임의의 것의 중수소화된 유도체, 및 전술한 것들 중 임의의 것의 대사산물이 개시된다. 이러한 화합물을 포함하는 약제학적 조성물, 상기 화합물을 사용하여 낭포성 섬유증을 치료하는 방법, 및 상기 화합물을 제조하는 방법이 또한 개시된다. 또한, 화합물 1 및 이의 염 및 용매화물의 고체 상태 형태가 개시된다.",VERTEX PHARMA,ABELA ALEXANDER RUSSELL;;ALCACIO TIMOTHY;;ANDERSON COREY;;ANGELL PAUL TIMOTHY;;BAEK MINSON;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;FERRIS LORI ANN;;GROOTENHUIS PETER DIEDERIK JAN;;GROSS RAYMOND STANLEY;;GULEVICH ANTON;;HADIDA RUAH SARA SABINA;;HSIA CLARA KUANG JU;;HUGHES ROBERT M;;JOSHI PRAMOD VIRUPAX;;KANG PING;;KESHAVARZ SHOKRI ALI;;KHATUYA HARIPADA;;KRENITSKY PAUL JOHN;;MCCARTNEY JASON;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE JEAN DENIS;;SHI YI;;SHRESTHA MUNA;;SIESEL DAVID ANDREW;;STAVROPOULOS KATHY;;TERMIN ANDREAS P;;UY JOHNNY;;VAN GOOR FREDRICK F;;YOUNG TOMOTHY JOHN;;ZHOU JINGLAN,,https://lens.org/065-269-235-418-605,Patent Application,no,1,0,63,63,0,A61K31/455;;C07D401/14;;C07D231/20;;A61P11/00;;C07D401/04;;C07D401/14;;A61P11/00;;C07D401/14;;C07D471/14;;C07B2200/13;;C07D231/20;;C07D498/14;;A61P11/00;;C07D401/04;;C07D401/14;;A61K31/4439;;A61K31/519;;A61K31/5365;;C07D231/20;;C07D401/04;;C07D471/14;;C07D498/14;;A61P11/00;;C07B2200/13;;C07D401/14;;C07D471/14;;C07B2200/13;;A61P11/00;;C07D498/14;;C07D401/04;;C07D231/20,C07D401/14;;A61K31/4439;;A61K31/519;;A61K31/5365;;A61P11/00;;C07D231/20;;C07D401/04;;C07D471/14;;C07D498/14,,0,0,,,,ACTIVE
137,EP,A1,EP 3551622 A1,024-617-518-353-814,2019-10-16,2019,EP 17826629 A,2017-12-08,US 201662432537 P;;US 2017/0065425 W,2016-12-09,"MODULATOR OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR",,VERTEX PHARMA,ABELA ALEXANDER RUSSELL;;ALCACIO TIMOTHY;;ANDERSON COREY;;ANGELL PAUL TIMOTHY;;BAEK MINSON;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;FERRIS LORI ANN;;GROOTENHUIS PETER DIEDERIK JAN;;GROSS RAYMOND STANLEY;;GULEVICH ANTON;;HADIDA RUAH SARA SABINA;;HSIA CLARA KUANG-JU;;HUGHES ROBERT M;;JOSHI PRAMOD VIRUPAX;;KANG PING;;KESHAVARZ-SHOKRI ALI;;KHATUYA HARIPADA;;KRENITSKY PAUL JOHN;;MCCARTNEY JASON;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE JEAN DENIS;;SHI YI;;SHRESTHA MUNA;;SIESEL DAVID ANDREW;;STAVROPOULOS KATHY;;TERMIN ANDREAS P;;UY JOHNNY;;VAN GOOR FREDRICK F;;YOUNG TOMOTHY JOHN;;ZHOU JINGLAN,,https://lens.org/024-617-518-353-814,Patent Application,yes,0,0,63,63,0,A61K31/455;;C07D401/14;;C07D231/20;;A61P11/00;;C07D401/04;;C07D401/14;;A61P11/00;;C07D401/14;;C07D471/14;;C07B2200/13;;C07D231/20;;C07D498/14;;A61P11/00;;C07D401/04;;C07D401/14;;A61K31/4439;;A61K31/519;;A61K31/5365;;C07D231/20;;C07D401/04;;C07D471/14;;C07D498/14;;A61P11/00;;C07B2200/13;;C07D401/14;;C07D471/14;;C07B2200/13;;A61P11/00;;C07D498/14;;C07D401/04;;C07D231/20,C07D401/14;;A61K31/455;;A61P11/00;;C07D231/20;;C07D401/04,,0,0,,,,ACTIVE
138,CL,A1,CL 2019001553 A1,090-057-913-853-764,2020-04-03,2020,CL 2019001553 A,2019-06-06,US 201662432537 P,2016-12-09,"Modulador del regulador de conductancia transmembrana de fibrosis quística, composiciones farmacéuticas, métodos de tratamiento y proceso para producir el modulador.",COMPUESTOS HETEROCÍCLICOS MODULADOR DEL REGULADOR DE CONDUCTANCIA TRANSMEMBRANA DE FIBROSIS QUÍSTICA; COMPOSICIONES FARMACÉUTICAS; PROCESO PARA PREPARAR EL MODULADOR; FORMAS CRISTALINAS Y USO EN EL TRATAMIENTO DE LA FIBROSIS QUÍSTICA.,VERTEX PHARMA,FERRIS LORI ANN;;ANDERSON COREY;;CLEVELAND THOMAS;;KHATUYA HARIPADA;;MCCARTNEY JASON;;UY JOHNNY;;ZHOU JINGLAN;;ALCACIO TIMOTHY;;BAEK MINSON;;KESHAVARZ-SHOKRI ALI;;PARASELLI PRASUNA;;GULEVICH ANTON;;HADIDA RUAH SARA SABINA;;HSIA CLARA KUANG-JU;;HUGHES ROBERT M;;JOSHI PRAMOD VIRUPAX;;KANG PING;;KRENITSKY PAUL JOHN;;MILLER MARK THOMAS;;PIERRE FABRICE JEAN DENIS;;SHI YI;;SHRESTHA MUNA;;SIESEL DAVID ANDREW;;STAVROPOULOS KATHY;;TERMIN ANDREAS P;;VAN GOOR FREDRICK F;;YOUNG TOMOTHY JOHN;;ABELA ALEXANDER RUSSELL;;ANGELL PAUL TIMOTHY;;CLEMENS JEREMY J;;GROOTENHUIS PETER DIEDERIK JAN;;GROSS RAYMOND STANLEY,,https://lens.org/090-057-913-853-764,Patent Application,no,0,2,63,63,0,A61K31/455;;C07D401/14;;C07D231/20;;A61P11/00;;C07D401/04;;C07D401/14;;A61P11/00;;C07D401/14;;C07D471/14;;C07B2200/13;;C07D231/20;;C07D498/14;;A61P11/00;;C07D401/04;;C07D401/14;;A61K31/4439;;A61K31/519;;A61K31/5365;;C07D231/20;;C07D401/04;;C07D471/14;;C07D498/14;;A61P11/00;;C07B2200/13;;C07D401/14;;C07D471/14;;C07B2200/13;;A61P11/00;;C07D498/14;;C07D401/04;;C07D231/20,C07D231/20;;A61K31/455;;A61P11/00;;C07D401/04;;C07D401/14,,0,0,,,,PENDING
139,MX,A,MX 2021013639 A,044-882-714-983-883,2022-09-30,2022,MX 2021013639 A,2017-12-08,US 201662432537 P;;US 2017/0065425 W,2016-12-09,"MODULATOR OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR.","Compounds of Formula (I) pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed. Also disclosed are solid state forms of Compound 1 and salts and solvates thereof.",VERTEX PHARMA,MILLER MARK THOMAS;;ZHOU JINGLAN;;GROOTENHUIS PETER DIEDERIK JAN;;VAN GOOR FREDRICK F;;SIESEL DAVID ANDREW;;SHI YI;;MCCARTNEY JASON;;ANDERSON COREY;;TERMIN ANDREAS P;;PIERRE FABRICE JEAN DENIS;;STAVROPOULOS KATHY;;KESHAVARZ-SHOKRI ALI;;FERRIS LORI ANN;;PARASELLI PRASUNA;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;GROSS RAYMOND STANLEY;;KHATUYA HARIPADA;;JOSHI PRAMOD VIRUPAX;;KRENITSKY PAUL JOHN;;ALCACIO TIMOTHY;;BAEK MINSON;;HADIDA RUAH SARA SABINA;;HUGHES ROBERT M;;ABELA ALEXANDER RUSSELL;;ANGELL PAUL TIMOTHY;;GULEVICH ANTON;;HSIA CLARA KUANG-JU;;KANG PING;;SHRESTHA MUNA;;UY JOHNNY;;YOUNG TOMOTHY JOHN,,https://lens.org/044-882-714-983-883,Patent Application,no,0,0,63,63,0,A61K31/455;;C07D401/14;;C07D231/20;;A61P11/00;;C07D401/04;;C07D401/14;;A61P11/00;;C07D401/14;;C07D471/14;;C07B2200/13;;C07D231/20;;C07D498/14;;A61P11/00;;C07D401/04;;C07D401/14;;A61K31/4439;;A61K31/519;;A61K31/5365;;C07D231/20;;C07D401/04;;C07D471/14;;C07D498/14;;A61P11/00;;C07B2200/13;;C07D401/14;;C07D471/14;;C07B2200/13;;A61P11/00;;C07D498/14;;C07D401/04;;C07D231/20,C07D401/14;;A61K31/455;;A61P11/00;;C07D231/20;;C07D401/04,,0,0,,,,PENDING
140,ZA,B,ZA 201904062 B,054-149-208-717-639,2022-12-21,2022,ZA 201904062 A,2019-06-21,US 201662432537 P;;US 2017/0065425 W,2016-12-09,"MODULATOR OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR",,VERTEX PHARMA,ALEXANDER RUSSELL ABELA;;TIMOTHY ALCACIO;;COREY ANDERSON;;PAUL TIMOTHY ANGELL;;MINSON BAEK;;JEREMY J CLEMENS;;THOMAS CLEVELAND;;LORI ANN FERRIS;;PETER DIEDERIK JAN GROOTENHUIS;;RAYMOND STANLEY GROSS;;ANTON GULEVICH;;SARA SABINA HADIDA RUAH;;CLARA KUANG-JU HSIA;;ROBERT M HUGHES;;PRAMOD VIRUPAX JOSHI;;PING KANG;;ALI KESHAVARZ-SHOKRI;;HARIPADA KHATUYA;;PAUL JOHN KRENITSKY;;JASON MCCARTNEY;;MARK THOMAS MILLER;;PRASUNA PARASELLI;;FABRICE JEAN DENIS PIERRE;;YI SHI;;MUNA SHRESTHA;;DAVID ANDREW SIESEL;;KATHY STAVROPOULOS;;ANDREAS P TERMIN;;JOHNNY UY;;FREDRICK F VAN GOOR;;TOMOTHY JOHN YOUNG;;JINGLAN ZHOU,,https://lens.org/054-149-208-717-639,Granted Patent,no,0,0,63,63,0,A61K31/455;;C07D401/14;;C07D231/20;;A61P11/00;;C07D401/04;;C07D401/14;;A61P11/00;;C07D401/14;;C07D471/14;;C07B2200/13;;C07D231/20;;C07D498/14;;A61P11/00;;C07D401/04;;C07D401/14;;A61K31/4439;;A61K31/519;;A61K31/5365;;C07D231/20;;C07D401/04;;C07D471/14;;C07D498/14;;A61P11/00;;C07B2200/13;;C07D401/14;;C07D471/14;;C07B2200/13;;A61P11/00;;C07D498/14;;C07D401/04;;C07D231/20,,,0,0,,,,ACTIVE
141,SA,B1,SA 519401947 B1,135-755-655-132-487,2022-06-19,2022,SA 519401947 A,2019-06-08,US 201662432537 P,2016-12-09,"Modulator of Cystic Fibrosis Transmembrane Conductance Regulator, Pharmaceutical Compositions, Methods of Treatment, and Process for Making the Modulator","Compounds of Formula (I): (I), pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed. Also disclosed are solid state forms of Compound 1 and salts and solvates thereof.",VERTEX PHARMA,ALEXANDER RUSSELL ABELA;;ANDREAS P TERMIN;;ANTON GULEVICH;;PRASUNA PARASELLI;;PRAMOD VIRUPAX JOSHI;;PAUL TIMOTHY ANGELL;;PAUL JOHN KRENITSKY;;PETER DIEDERIK JAN GROOTENHUIS;;PING KANG;;THOMAS CLEVELAND;;TOMOTHY JOHN YOUNG;;TIMOTHY ALCACIO;;JASON MCCARTNEY;;JOHNNY UY;;JEREMY J CLEMENS;;JINGLAN ZHOU;;DAVID ANDREW SIESEL;;RAYMOND STANLEY GROSS;;ROBERT M HUGHES;;SARA SABINA HADIDA RUAH;;ALI KESHAVARZ-SHOKRI;;FABRICE JEAN DENIS PIERRE;;FREDRICK F VAN GOOR;;KATHY STAVROPOULOS;;CLARA KUANG-JU HSIA;;COREY ANDERSON;;LORI ANN FERRIS;;MARK THOMAS MILLER;;MUNA SHRESTHA;;MINSON BAEK;;HARIPADA KHATUYA;;YI SHI,,https://lens.org/135-755-655-132-487,Granted Patent,no,0,0,63,63,0,A61K31/455;;C07D401/14;;C07D231/20;;A61P11/00;;C07D401/04;;C07D401/14;;A61P11/00;;C07D401/14;;C07D471/14;;C07B2200/13;;C07D231/20;;C07D498/14;;A61P11/00;;C07D401/04;;C07D401/14;;A61K31/4439;;A61K31/519;;A61K31/5365;;C07D231/20;;C07D401/04;;C07D471/14;;C07D498/14;;A61P11/00;;C07B2200/13;;C07D401/14;;C07D471/14;;C07B2200/13;;A61P11/00;;C07D498/14;;C07D401/04;;C07D231/20,,,0,0,,,,ACTIVE
142,MX,A,MX 2019006637 A,190-999-372-348-89X,2019-08-21,2019,MX 2019006637 A,2017-12-08,US 201662432537 P;;US 2017/0065425 W,2016-12-09,"MODULATOR OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR.","Compounds of Formula (I) pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed. Also disclosed are solid state forms of Compound 1 and salts and solvates thereof.",VERTEX PHARMA,MARK THOMAS MILLER;;JINGLAN ZHOU;;FREDRICK F VAN GOOR;;DAVID ANDREW SIESEL;;YI SHI;;JASON MCCARTNEY;;COREY ANDERSON;;ANDREAS P TERMIN;;FABRICE JEAN DENIS PIERRE;;ALI KESHAVARZ-SHOKRI;;KATHY STAVROPOULOS;;LORI ANN FERRIS;;PRASUNA PARASELLI;;JEREMY J CLEMENS;;THOMAS CLEVELAND;;RAYMOND STANLEY GROSS;;HARIPADA KHATUYA;;PRAMOD VIRUPAX JOSHI;;TIMOTHY ALCACIO;;MINSON BAEK;;SARA SABINA HADIDA RUAH;;ROBERT M HUGHES;;ALEXANDER RUSSELL ABELA;;PAUL TIMOTHY ANGELL;;PETER DIEDIERIK JAN GROOTENHUIS;;ANTON GULEVICH;;CLARA KUANG-JU HSIA;;PING KANG;;PAUL JHON KRENITSKY;;MUNA SHRESTHA;;JOHNNY UY;;TOMOTHY JOHN YOUNG,,https://lens.org/190-999-372-348-89X,Patent Application,no,0,0,63,63,0,A61K31/455;;C07D401/14;;C07D231/20;;A61P11/00;;C07D401/04;;C07D401/14;;A61P11/00;;C07D401/14;;C07D471/14;;C07B2200/13;;C07D231/20;;C07D498/14;;A61P11/00;;C07D401/04;;C07D401/14;;A61K31/4439;;A61K31/519;;A61K31/5365;;C07D231/20;;C07D401/04;;C07D471/14;;C07D498/14;;A61P11/00;;C07B2200/13;;C07D401/14;;C07D471/14;;C07B2200/13;;A61P11/00;;C07D498/14;;C07D401/04;;C07D231/20,C07D401/14;;A61K31/455;;A61P11/00;;C07D231/20;;C07D401/04,,0,0,,,,PENDING
143,MA,A,MA 54847 A,186-382-124-875-16X,2021-12-08,2021,MA 54847 A,2017-12-08,US 201662432537 P,2016-12-09,FORME CRYSTALLINE D'UN N-(PYRAZOL-4-YL)SULFONYL-6-(PYRAZOL-1-YL)-2-(PYRROLIDIN-1-YL)PYRIDINE-3-CARBOXAMIDE POUR TRAITER LA MUCOVISCIDOSE,,VERTEX PHARMA,ABELA ALEXANDER RUSSELL;;ALCACIO TIMOTHY;;ANDERSON COREY;;ANGELL PAUL TIMOTHY;;BAEK MINSON;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;FERRIS LORI ANN;;GROOTENHUIS PETER DIEDERIK JAN;;GROSS RAYMOND STANLEY;;GULEVICH ANTON;;HADIDA RUAH SARA SABINA;;HSIA CLARA KUANG-JU;;HUGHES ROBERT M;;JOSHI PRAMOD VIRUPAX;;KANG PING;;KESHAVARZ-SHOKRI ALI;;KHATUYA HARIPADA;;KRENITSKY PAUL JOHN;;MCCARTNEY JASON;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE JEAN DENIS;;SHI YI;;SHRESTHA MUNA;;SIESEL DAVID ANDREW;;STAVROPOULOS KATHY;;TERMIN ANDREAS P;;UY JOHNNY;;VAN GOOR FREDRICK F;;YOUNG TIMOTHY JOHN;;ZHOU JINGLAN,,https://lens.org/186-382-124-875-16X,Unknown,no,0,0,63,63,0,A61K31/455;;C07D401/14;;C07D231/20;;A61P11/00;;C07D401/04;;C07D401/14;;A61P11/00;;C07D401/14;;C07D471/14;;C07B2200/13;;C07D231/20;;C07D498/14;;A61P11/00;;C07D401/04;;C07D401/14;;A61K31/4439;;A61K31/519;;A61K31/5365;;C07D231/20;;C07D401/04;;C07D471/14;;C07D498/14;;A61P11/00;;C07B2200/13;;C07D401/14;;C07D471/14;;C07B2200/13;;A61P11/00;;C07D498/14;;C07D401/04;;C07D231/20,A61K31/455;;A61P11/00;;C07D401/14,,0,0,,,,PENDING
144,MD,T2,MD 3551622 T2,199-265-696-596-763,2021-03-31,2021,MD E20191168 T,2017-12-08,US 201662432537 P;;US 2017/0065425 W,2016-12-09,"Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator","Sunt divulgaţi compuşi cu Formula (I):săruri acceptabile farmaceutic ale acestora, derivaţi deuteraţi ai oricărora din cei anteriori, şi metaboliţi ai oricărora din cei anteriori. Sunt de asemenea divulgate compoziţii farmaceutice care îi cuprind pe aceştia, metode de tratare a fibrozei cistice care îi utilizează pe aceştia, şi metode de fabricare ale acestora. Sunt de asemenea divulgate forme ale stării solide a Compusului 1 şi săruri sau solvaţi ai acestuia.",VERTEX PHARMA,ABELA ALEXANDER RUSSELL;;ALCACIO TIMOTHY;;ANDERSON COREY;;ANGELL PAUL TIMOTHY;;BAEK MINSON;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;FERRIS LORI ANN;;GROOTENHUIS PETER DIEDERIK JAN;;GROSS RAYMOND STANLEY;;GULEVICH ANTON;;HADIDA RUAH SARA SABINA;;HSIA CLARA KUANG-JU;;HUGHES ROBERT M;;JOSHI PRAMOD VIRUPAX;;KANG PING;;KESHAVARZ-SHOKRI ALI;;KHATUYA HARIPADA;;KRENITSKY PAUL JOHN;;MCCARTNEY JASON;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE JEAN DENIS;;SHI YI;;SHRESTHA MUNA;;SIESEL DAVID ANDREW;;STAVROPOULOS KATHY;;TERMIN ANDREAS P;;UY JOHNNY;;VAN GOOR FREDRICK F;;YOUNG TOMOTHY JOHN;;ZHOU JINGLAN,,https://lens.org/199-265-696-596-763,Unknown,no,0,0,63,63,0,A61K31/455;;C07D401/14;;C07D231/20;;A61P11/00;;C07D401/04;;C07D401/14;;A61P11/00;;C07D401/14;;C07D471/14;;C07B2200/13;;C07D231/20;;C07D498/14;;A61P11/00;;C07D401/04;;C07D401/14;;A61K31/4439;;A61K31/519;;A61K31/5365;;C07D231/20;;C07D401/04;;C07D471/14;;C07D498/14;;A61P11/00;;C07B2200/13;;C07D401/14;;C07D471/14;;C07B2200/13;;A61P11/00;;C07D498/14;;C07D401/04;;C07D231/20,C07D401/14;;A61K31/455;;A61P11/00;;C07D231/20;;C07D401/04,,0,0,,,,PENDING
145,TW,B,TW I774712 B,069-902-056-764-998,2022-08-21,2022,TW 106143291 A,2017-12-08,US 201662432537 P,2016-12-09,"Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator",,VERTEX PHARMA,ABELA ALEXANDER RUSSELL;;ALCACIO TIMOTHY;;ANDERSON COREY;;ANGELL PAUL TIMOTHY;;BAEK MINSON;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;FERRIS LORI ANN;;GROOTENHUIS PETER DIEDERIK JAN;;GROSS RAYMOND STANLEY;;GULEVICH ANTON;;HADIDA RUAH SARA SABINA;;HSIA CLARA KUANG-JU;;HUGHES ROBERT M;;JOSHI PRAMOD VIRUPAX;;KANG PING;;KESHAVARZ-SHOKRI ALI;;KHATUYA HARIPADA;;KRENITSKY PAUL JOHN;;MCCARTNEY JASON;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE JEAN DENIS;;SHI YI;;SHRESTHA MUNA;;SIESEL DAVID ANDREW;;STAVROPOULOS KATHY;;TERMIN ANDREAS P;;UY JOHNNY;;VAN GOOR FREDRICK F;;YOUNG TIMOTHY JOHN;;ZHOU JINGLAN,,https://lens.org/069-902-056-764-998,Granted Patent,no,1,0,63,63,0,A61K31/455;;C07D401/14;;C07D231/20;;A61P11/00;;C07D401/04;;C07D401/14;;A61P11/00;;C07D401/14;;C07D471/14;;C07B2200/13;;C07D231/20;;C07D498/14;;A61P11/00;;C07D401/04;;C07D401/14;;A61K31/4439;;A61K31/519;;A61K31/5365;;C07D231/20;;C07D401/04;;C07D471/14;;C07D498/14;;A61P11/00;;C07B2200/13;;C07D401/14;;C07D471/14;;C07B2200/13;;A61P11/00;;C07D498/14;;C07D401/04;;C07D231/20,,,0,0,,,,ACTIVE
146,PE,A1,PE 20191304 A1,186-184-542-069-147,2019-09-23,2019,PE 2019001200 A,2017-12-08,US 201662432537 P,2016-12-09,"MODULADOR DEL REGULADOR DE CONDUCTANCIA DE TRANSMEMBRANA DE FIBROSIS QUISTICA, COMPOSICIONES FARMACEUTICAS, METODOS DE TRATAMIENTO Y PROCESO PARA PRODUCIR EL MODULADOR","Referido a un compuesto de formula I, su sal farmaceuticamente aceptable o un derivado deuterado del mismo, en donde: uno de Y1 e Y2 es N el otro es CH; X es N(alquilo C1-C4), O u NH; R1 es -(C(R2)2)k-O-(C(R2)2)mR7; cada R2 es H, halogeno, ente otros; cada R3 es alquilo C1-C4 sustituido opcionalmente, entre otros; K es 0 o 1; r es 0 o 1; m es 0, 1, 2 o 3; p es p, 1 o 2; y q es 0, 1, 2, 3, 4, 5, 6, 7 u 8. Estos compuestos modulan el regulador de conductancia transmembrana de fibrosis quistica (CFTR); tambien se refiere a metodos de preparacion de dichos compuestos, sus compuestos intermedios y una composicion farmaceutica que los contiene.",VERTEX PHARMA,ABELA ALEXANDER RUSSELL;;VAN GOOR FREDRICK;;YOUNG TOMOTHY JOHN;;ZHOU JINGLAN;;SIESEL DAVID ANDREW;;STAVROPOULOS KATHY;;TERMIN ANDREAS P;;UY JOHNNY;;PARASELLI PRASUNA;;PIERRE FABRICE JEAN DENIS;;SHI YI;;SHRESTHA MUNA;;KHATUYA HARIPADA;;KRENITSKY PAUL JOHN;;MCCARTNEY JASON;;MILLER MARK THOMAS;;HUGHES ROBERT M;;JOSHI PRAMOD VIRUPAX;;KANG PING;;KESHAVARZ-SHOKRI ALI;;GROOS RAYMOND STANLEY;;GULEVICH ANTON;;HADIDA RUAH SARA SABINA;;HSIA CLARA KUANG-JU;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;FERRIS LORI ANN;;GROOTENHUIS PETER DIEDERIK JAN;;ALCACIO TIMOTHY;;ANDERSON COREY;;ANGELL PAUL TIMOTHY;;BAEK MINSON,,https://lens.org/186-184-542-069-147,Patent Application,no,0,0,63,63,0,A61K31/455;;C07D401/14;;C07D231/20;;A61P11/00;;C07D401/04;;C07D401/14;;A61P11/00;;C07D401/14;;C07D471/14;;C07B2200/13;;C07D231/20;;C07D498/14;;A61P11/00;;C07D401/04;;C07D401/14;;A61K31/4439;;A61K31/519;;A61K31/5365;;C07D231/20;;C07D401/04;;C07D471/14;;C07D498/14;;A61P11/00;;C07B2200/13;;C07D401/14;;C07D471/14;;C07B2200/13;;A61P11/00;;C07D498/14;;C07D401/04;;C07D231/20,C07D401/14;;A61K31/455;;A61P11/00;;C07D231/20;;C07D401/04,,0,0,,,,PENDING
147,JO,B1,JO P20190125 B1,180-540-037-552-517,2022-03-14,2022,JO P20190125 A,2017-12-08,US 201662432537 P;;US 2017/0065425 W,2016-12-09,"Modulator of Cystic Fibrosis Transmembrane Conductance Regulator, Pharmaceutical Compositions, Methods of Treatment, and Process for Making the Modulator","Compounds of Formula (I): (I), pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed. Also disclosed are solid state forms of Compound 1 and salts and solvates thereof.",VERTEX PHARMA,ANDERSON COREY;;ALCACIO TIMOTHY;;PARASELLI PRASUNA;;BAEK MINSON;;ZHOU JINGLAN;;KHATUYA HARIPADA;;CLEVELAND THOMAS;;KESHAVARZ-SHOKRI ALI;;MCCARTNEY JASON;;ABELA ALEXANDER RUSSELL;;ANGELL PAUL TIMOTHY;;PIERRE FABRICE JEAN DENIS;;TERMIN ANDREAS P;;JOSHI PRAMOD VIRUPAX;;GULEVICH ANTON;;STAVROPOULOS KATHY;;SIESEL DAVID ANDREW;;SHRESTHA MUNA;;SHI YI;;GROOTENHUIS PETER DIEDERIK JAN;;GROSS RAYMOND STANLEY;;VAN GOOR FREDRICK F;;FERRIS LORI ANN;;KANG PING;;KRENITSKY PAUL JOHN;;CLEMENS JEREMY J;;MILLER MARK THOMAS;;HADIDA RUAH SARA SABINA;;HSIA CLARA KUANG-JU;;HUGHES ROBERT M;;UY JOHNNY;;YOUNG TOMOTHY JOHN,,https://lens.org/180-540-037-552-517,Granted Patent,no,0,0,63,63,0,A61K31/455;;C07D401/14;;C07D231/20;;A61P11/00;;C07D401/04;;C07D401/14;;A61P11/00;;C07D401/14;;C07D471/14;;C07B2200/13;;C07D231/20;;C07D498/14;;A61P11/00;;C07D401/04;;C07D401/14;;A61K31/4439;;A61K31/519;;A61K31/5365;;C07D231/20;;C07D401/04;;C07D471/14;;C07D498/14;;A61P11/00;;C07B2200/13;;C07D401/14;;C07D471/14;;C07B2200/13;;A61P11/00;;C07D498/14;;C07D401/04;;C07D231/20,C07D401/04;;A61K31/455;;A61P11/00;;C07D231/20;;C07D401/14,,0,0,,,,ACTIVE
148,CO,A2,CO 2019007129 A2,016-395-481-305-550,2019-07-31,2019,CO 2019007129 A,2019-07-03,US 2017/0065425 W;;US 201662432537 P,2016-12-09,"Modulador del regulador de conductancia transmembrana de fibrosis quística, composiciones farmacéuticas, métodos de tratamiento y proceso para producir el modulador","Se describen compuestos de Fórmula (I): (I), sales farmacéuticamente aceptables de este, derivados deuterados de cualquiera de los que anteceden y metabolitos de cualquiera de los anteceden. También se describen composiciones farmacéuticas que los comprenden, métodos para el tratamiento de la fibrosis quística mediante el uso de estos y métodos para confeccionarlos. Se describen además las formas en estado sólido del Compuesto 1 y sales y solvatos de este.",VERTEX PHARMA,ALCACIO TIMOTHY;;HADIDA RUAH SARA SABINA;;HUGHES ROBERT M;;KESHAVARZ-SHOKRI ALI;;MCCARTNEY JASON;;MILLER MARK THOMAS;;ANDERSON COREY;;CLEVELAND THOMAS;;KHATUYA HARIPADA;;JOSHI PRAMOD VIRUPAX;;KRENITSKY PAUL JOHN;;PIERRE FABRICE JEAN DENIS;;TERMIN ANDREAS P;;UY JOHNNY;;ZHOU JINGLAN;;ABELA ALEXANDER RUSSELL;;PARASELLI PRASUNA;;SIESEL DAVID ANDREW;;ANGELL PAUL TIMOTHY;;BAEK MINSON;;CLEMENS JEREMY J;;FERRIS LORI ANN;;GROOTENHUIS PETER DIEDERIK JAN;;GROSS RAYMOND STANLEY;;GULEVICH ANTON;;HSIA CLARA KUANG-JU;;KANG PING;;SHI YI;;SHRESTHA MUNA;;STAVROPOULOS KATHY;;VAN GOOR FREDRICK F;;YOUNG TIMOTHY JOHN,,https://lens.org/016-395-481-305-550,Patent Application,no,0,0,63,63,0,A61K31/455;;C07D401/14;;C07D231/20;;A61P11/00;;C07D401/04;;C07D401/14;;A61P11/00;;C07D401/14;;C07D471/14;;C07B2200/13;;C07D231/20;;C07D498/14;;A61P11/00;;C07D401/04;;C07D401/14;;A61K31/4439;;A61K31/519;;A61K31/5365;;C07D231/20;;C07D401/04;;C07D471/14;;C07D498/14;;A61P11/00;;C07B2200/13;;C07D401/14;;C07D471/14;;C07B2200/13;;A61P11/00;;C07D498/14;;C07D401/04;;C07D231/20,C07D401/14;;A61K31/455;;A61P11/00;;C07D231/20;;C07D401/04,,0,0,,,,PENDING
149,MA,A,MA 49235 A,139-734-647-038-493,2019-10-16,2019,MA 49235 A,2017-12-08,US 201662432537 P;;US 2017/0065425 W,2016-12-09,"MODULATEUR DE RÉGULATEUR DE CONDUCTANCE TRANSMEMBRANAIRE DE FIBROSE KYSTIQUE, COMPOSITIONS PHARMACEUTIQUES, PROCÉDÉS DE TRAITEMENT ET PROCÉDÉ DE FABRICATION DU MODULATEUR","L'invention concerne des composés de formule (i) des sels pharmaceutiquement acceptables de ceux-ci, des dérivés deutérés et des métabolites de l'un quelconque des précédents. L'invention concerne également des compositions pharmaceutiques comprenant les composés de l'invention, des procédés de traitement de la fibrose kystique à l'aide de celles-ci, et des procédés de fabrication de celles-ci. L'invention concerne en outre des formes à l'état solide du composé 1, des sels et des solvates de celui-ci.",VERTEX PHARMA,ABELA ALEXANDER RUSSELL;;ALCACIO TIMOTHY;;ANDERSON COREY;;ANGELL PAUL TIMOTHY;;BAEK MINSON;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;FERRIS LORI ANN;;GROOTENHUIS PETER DIEDERIK JAN;;GROSS RAYMOND STANLEY;;GULEVICH ANTON;;HADIDA RUAH SARA SABINA;;HSIA CLARA KUANG-JU;;HUGHES ROBERT M;;JOSHI PRAMOD VIRUPAX;;KANG PING;;KESHAVARZ-SHOKRI ALI;;KHATUYA HARIPADA;;KRENITSKY PAUL JOHN;;MCCARTNEY JASON;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE JEAN DENIS;;SHI YI;;SHRESTHA MUNA;;SIESEL DAVID ANDREW;;STAVROPOULOS KATHY;;TERMIN ANDREAS P;;UY JOHNNY;;VAN GOOR FREDRICK F;;YOUNG TOMOTHY JOHN;;ZHOU JINGLAN,,https://lens.org/139-734-647-038-493,Unknown,no,0,0,63,63,0,A61K31/455;;C07D401/14;;C07D231/20;;A61P11/00;;C07D401/04;;C07D401/14;;A61P11/00;;C07D401/14;;C07D471/14;;C07B2200/13;;C07D231/20;;C07D498/14;;A61P11/00;;C07D401/04;;C07D401/14;;A61K31/4439;;A61K31/519;;A61K31/5365;;C07D231/20;;C07D401/04;;C07D471/14;;C07D498/14;;A61P11/00;;C07B2200/13;;C07D401/14;;C07D471/14;;C07B2200/13;;A61P11/00;;C07D498/14;;C07D401/04;;C07D231/20,A61K31/455;;A61P11/00;;C07D231/20;;C07D401/04;;C07D401/14,,0,0,,,,ACTIVE
150,RS,B1,RS 61150 B1,011-760-159-328-798,2020-12-31,2020,RS P20201477 A,2017-12-08,US 201662432537 P;;US 2017/0065425 W;;EP 17826629 A,2016-12-09,"MODULATOR OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR",,VERTEX PHARMA,ABELA ALEXANDER RUSSELL;;ALCACIO TIMOTHY;;ANDERSON COREY;;ANGELL PAUL TIMOTHY;;BAEK MINSON;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;FERRIS LORI ANN;;GROOTENHUIS PETER DIEDERIK JAN;;GROSS RAYMOND STANLEY;;GULEVICH ANTON;;HADIDA RUAH SARA SABINA;;HSIA CLARA KUANG-JU;;HUGHES ROBERT M;;JOSHI PRAMOD VIRUPAX;;KANG PING;;KESHAVARZ-SHOKRI ALI;;KHATUYA HARIPADA;;KRENITSKY PAUL JOHN;;MCCARTNEY JASON;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE JEAN DENIS;;SHI YI;;SHRESTHA MUNA;;SIESEL DAVID ANDREW;;STAVROPOULOS KATHY;;TERMIN ANDREAS P;;UY JOHNNY;;VAN GOOR FREDRICK F;;YOUNG TOMOTHY JOHN;;ZHOU JINGLAN,,https://lens.org/011-760-159-328-798,Granted Patent,no,0,0,63,63,0,A61K31/455;;C07D401/14;;C07D231/20;;A61P11/00;;C07D401/04;;C07D401/14;;A61P11/00;;C07D401/14;;C07D471/14;;C07B2200/13;;C07D231/20;;C07D498/14;;A61P11/00;;C07D401/04;;C07D401/14;;A61K31/4439;;A61K31/519;;A61K31/5365;;C07D231/20;;C07D401/04;;C07D471/14;;C07D498/14;;A61P11/00;;C07B2200/13;;C07D401/14;;C07D471/14;;C07B2200/13;;A61P11/00;;C07D498/14;;C07D401/04;;C07D231/20,C07D401/14;;A61K31/455;;A61P11/00;;C07D231/20;;C07D401/04,,0,0,,,,ACTIVE
151,EP,B1,EP 3551622 B1,156-664-068-085-637,2020-10-07,2020,EP 17826629 A,2017-12-08,US 201662432537 P;;US 2017/0065425 W,2016-12-09,"MODULATOR OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR",,VERTEX PHARMA,ABELA ALEXANDER RUSSELL;;ALCACIO TIMOTHY;;ANDERSON COREY;;ANGELL PAUL TIMOTHY;;BAEK MINSON;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;FERRIS LORI ANN;;GROOTENHUIS PETER DIEDERIK JAN;;GROSS RAYMOND STANLEY;;GULEVICH ANTON;;HADIDA RUAH SARA SABINA;;HSIA CLARA KUANG-JU;;HUGHES ROBERT M;;JOSHI PRAMOD VIRUPAX;;KANG PING;;KESHAVARZ-SHOKRI ALI;;KHATUYA HARIPADA;;KRENITSKY PAUL JOHN;;MCCARTNEY JASON;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE JEAN DENIS;;SHI YI;;SHRESTHA MUNA;;SIESEL DAVID ANDREW;;STAVROPOULOS KATHY;;TERMIN ANDREAS P;;UY JOHNNY;;VAN GOOR FREDRICK F;;YOUNG TOMOTHY JOHN;;ZHOU JINGLAN,,https://lens.org/156-664-068-085-637,Granted Patent,yes,1,0,63,63,0,A61K31/455;;C07D401/14;;C07D231/20;;A61P11/00;;C07D401/04;;C07D401/14;;A61P11/00;;C07D401/14;;C07D471/14;;C07B2200/13;;C07D231/20;;C07D498/14;;A61P11/00;;C07D401/04;;C07D401/14;;A61K31/4439;;A61K31/519;;A61K31/5365;;C07D231/20;;C07D401/04;;C07D471/14;;C07D498/14;;A61P11/00;;C07B2200/13;;C07D401/14;;C07D471/14;;C07B2200/13;;A61P11/00;;C07D498/14;;C07D401/04;;C07D231/20,C07D401/14;;A61K31/455;;A61P11/00;;C07D231/20;;C07D401/04,,0,0,,,,ACTIVE
152,JO,A1,JO P20190125 A1,003-173-501-544-191,2019-05-28,2019,JO P20190125 A,2017-12-08,US 201662432537 P;;US 2017/0065425 W,2016-12-09,"Modulator of Cystic Fibrosis Transmembrane Conductance Regulator, Pharmaceutical Compositions, Methods of Treatment, and Process for Making the Modulator","<p>Compounds of Formula (I): (I), pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed. Also disclosed are solid state forms of Compound 1 and salts and solvates thereof.</p>",VERTEX PHARMA,ZHOU JINGLAN;;VAN GOOR FREDRICK F;;HADIDA RUAH SARA SABINA;;SIESEL DAVID ANDREW;;CLEVELAND THOMAS;;GULEVICH ANTON;;PIERRE FABRICE JEAN DENIS;;STAVROPOULOS KATHY;;GROOTENHUIS PETER DIEDERIK JAN;;KANG PING;;YOUNG TOMOTHY JOHN;;ANDERSON COREY;;ALCACIO TIMOTHY;;KESHAVARZ-SHOKRI ALI;;MCCARTNEY JASON;;ANGELL PAUL TIMOTHY;;GROSS RAYMOND STANLEY;;MILLER MARK THOMAS;;HUGHES ROBERT M;;ABELA ALEXANDER RUSSELL;;JOSHI PRAMOD VIRUPAX;;SHI YI;;CLEMENS JEREMY J;;UY JOHNNY;;BAEK MINSON;;KHATUYA HARIPADA;;KRENITSKY PAUL JOHN;;TERMIN ANDREAS P;;SHRESTHA MUNA;;FERRIS LORI ANN;;HSIA CLARA KUANG-JU;;PARASELLI PRASUNA,,https://lens.org/003-173-501-544-191,Granted Patent,no,0,0,63,63,0,A61K31/455;;C07D401/14;;C07D231/20;;A61P11/00;;C07D401/04;;C07D401/14;;A61P11/00;;C07D401/14;;C07D471/14;;C07B2200/13;;C07D231/20;;C07D498/14;;A61P11/00;;C07D401/04;;C07D401/14;;A61K31/4439;;A61K31/519;;A61K31/5365;;C07D231/20;;C07D401/04;;C07D471/14;;C07D498/14;;A61P11/00;;C07B2200/13;;C07D401/14;;C07D471/14;;C07B2200/13;;A61P11/00;;C07D498/14;;C07D401/04;;C07D231/20,,,0,0,,,,ACTIVE
153,DK,T3,DK 3551622 T3,131-251-105-657-76X,2020-11-23,2020,DK 17826629 T,2017-12-08,US 201662432537 P;;US 2017/0065425 W,2016-12-09,"MODULATOR AF TRANSMEMBRANKONDUKTANSREGULATOR AF CYSTISK FIBROSE, FARMACEUTISKE SAMMENSÆTNINGER, BEHANDLINGSFREMGANGSMÅDER OG FREMGANGSMÅDE TIL FREMSTILLING AF MODULATOREN",,VERTEX PHARMA,ABELA ALEXANDER RUSSELL;;ALCACIO TIMOTHY;;ANDERSON COREY;;ANGELL PAUL TIMOTHY;;BAEK MINSON;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;FERRIS LORI ANN;;GROOTENHUIS PETER DIEDERIK JAN;;GROSS RAYMOND STANLEY;;GULEVICH ANTON;;HADIDA RUAH SARA SABINA;;HSIA CLARA KUANG-JU;;HUGHES ROBERT M;;JOSHI PRAMOD VIRUPAX;;KANG PING;;KESHAVARZ-SHOKRI ALI;;KHATUYA HARIPADA;;KRENITSKY PAUL JOHN;;MCCARTNEY JASON;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE JEAN DENIS;;SHI YI;;SHRESTHA MUNA;;SIESEL DAVID ANDREW;;STAVROPOULOS KATHY;;TERMIN ANDREAS P;;UY JOHNNY;;VAN GOOR FREDRICK F;;YOUNG TOMOTHY JOHN;;ZHOU JINGLAN,,https://lens.org/131-251-105-657-76X,Granted Patent,no,0,0,63,63,0,A61K31/455;;C07D401/14;;C07D231/20;;A61P11/00;;C07D401/04;;C07D401/14;;A61P11/00;;C07D401/14;;C07D471/14;;C07B2200/13;;C07D231/20;;C07D498/14;;A61P11/00;;C07D401/04;;C07D401/14;;A61K31/4439;;A61K31/519;;A61K31/5365;;C07D231/20;;C07D401/04;;C07D471/14;;C07D498/14;;A61P11/00;;C07B2200/13;;C07D401/14;;C07D471/14;;C07B2200/13;;A61P11/00;;C07D498/14;;C07D401/04;;C07D231/20,C07D401/14;;A61K31/455;;A61P11/00;;C07D231/20;;C07D401/04,,0,0,,,,ACTIVE
154,UY,A,UY 39723 A,154-921-160-264-955,2022-05-31,2022,UY 39723 A,2022-04-08,UY 37513 A;;US 201662432537 P,2016-12-09,"MODULADOR DEL REGULADOR DE CONDUCTANCIA TRANSMEMBRANA DE FIBROSIS QUÍSTICA, COMPOSICIONES FARMACÉUTICAS, MÉTODOS DE TRATAMIENTO Y PROCESO PARA PRODUCIR EL MODULADOR","Se describen compuestos de Fórmula (I): sales farmacéuticamente aceptables de este, derivados deuterados de cualquiera de los que anteceden y metabolitos de cualquiera de los anteceden. También se describen composiciones farmacéuticas que los comprenden, métodos para el tratamiento de la fibrosis quistica mediante el uso de estos y métodos para confeccionarlos. Se describen además las formas en estado sólido del Compuesto 1 y sales y solvatos de este.",VERTEX PHARMA,ALCACIO TIMOTHY;;BAEK MINSON;;SARA SABINA HADIDA RUAH;;ALI KESHAVARZ-SHOKRI;;MCCARTNEY JASON;;ANDERSON COREY;;CLEVELAND THOMAS;;KHATUYA HARIPADA;;PRAMOD VIRUPAX JOSHI;;PAUL JOHN KRENITSKY;;FABRICE JEAN DENIS PIERRE;;ANDREAS P TERMIN;;ZHOU JINGLAN;;ALEXANDER RUSSELL ABELA;;PAUL TIMOTHY ANGELL;;JEREMY J CLEMENS;;LORI ANN FERRIS;;PETER DIEDERIK JAN GROOTENHUIS;;RAYMOND STANLEY GROSS;;GULEVICH ANTON;;CLARA KUANG-JU HSIA;;ROBERT M HUGHES;;KANG PING;;MARK THOMAS MILLER;;SHI YI;;SHRESTHA MUNA;;DAVID ANDREW SIESEL;;STAVROPOULOS KATHY;;UY JOHNNY;;FREDRICK F VAN GOOR;;TIMOTHY JOHN YOUNG;;PARASELLI PRASUNA,,https://lens.org/154-921-160-264-955,Patent Application,no,0,0,63,63,0,A61K31/455;;C07D401/14;;C07D231/20;;A61P11/00;;C07D401/04;;C07D401/14;;A61P11/00;;C07D401/14;;C07D471/14;;C07B2200/13;;C07D231/20;;C07D498/14;;A61P11/00;;C07D401/04;;C07D401/14;;A61K31/4439;;A61K31/519;;A61K31/5365;;C07D231/20;;C07D401/04;;C07D471/14;;C07D498/14;;A61P11/00;;C07B2200/13;;C07D401/14;;C07D471/14;;C07B2200/13;;A61P11/00;;C07D498/14;;C07D401/04;;C07D231/20,A61P11/00;;A61K31/44;;A61K31/4427;;A61K31/4439;;A61K31/455;;C07D401/14,,0,0,,,,ACTIVE
155,JP,A,JP 2023154048 A,188-421-628-049-306,2023-10-18,2023,JP 2023132080 A,2023-08-14,JP 2021075890 A;;US 201662432537 P;;JP 2019530713 A,2016-12-09,"MODULATOR OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING MODULATOR","To provide a modulator of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), pharmaceutical compositions containing the modulator, methods of treatment of cystic fibrosis, and a process for making the modulator.SOLUTION: The invention provides compounds of Formula (I) in the figure, where: one of Y1 and Y2 is N and the other is CH; X is selected from O, NH, and N(C1-C4 alkyl) groups; and R1 to R6 represent specific substituents.SELECTED DRAWING: Figure 1-1",VERTEX PHARMA,ALEXANDER RUSSELL ABELA;;TIMOTHY ALCACIO;;COREY ANDERSON;;PAUL TIMOTHY ANGEL;;BAEK MINSON;;JEREMY J CLEMENS;;THOMAS CLEVELAND;;LORI ANN FERRIS;;PETER DIEDERIK JAN GROOTENHUIS;;RAYMOND STANLEY GROSS;;ANTON GULEVICH;;SARA SABINA HADIDA RUAH;;CLARA KUANG-JU HSIA;;ROBERT M HUGHES;;PRAMOD VIRUPAX JOSHI;;KANG PING;;ALI KESHAVARZ-SHOKRI;;HARIPADA KATSUYA;;PAUL JOHN KRENITSKY;;MCCARTNEY JASON;;MARK THOMAS MILLER;;PRASUNA PARASELLI;;FABRICE JEAN DENIS PIERRE;;SHI YI;;MUNA SHRESTHA;;DAVID ANDREW SIESEL;;KATHY STAVROPOULOS;;TERMIN ANDREAS P;;JOHNNY UY;;FREDRICK F VAN GOOR;;TIMOTHY JOHN YOUNG;;ZHOU JINGLAN,,https://lens.org/188-421-628-049-306,Patent Application,no,0,0,63,63,0,A61K31/455;;C07D401/14;;C07D231/20;;A61P11/00;;C07D401/04;;C07D401/14;;A61P11/00;;C07D401/14;;C07D471/14;;C07B2200/13;;C07D231/20;;C07D498/14;;A61P11/00;;C07D401/04;;C07D401/14;;A61K31/4439;;A61K31/519;;A61K31/5365;;C07D231/20;;C07D401/04;;C07D471/14;;C07D498/14;;A61P11/00;;C07B2200/13;;C07D401/14;;C07D471/14;;C07B2200/13;;A61P11/00;;C07D498/14;;C07D401/04;;C07D231/20,C07D401/14;;A61K9/26;;A61K31/4439;;A61K31/519;;A61K31/5365;;A61K47/32;;A61K47/38;;A61P1/00;;A61P1/18;;A61P11/00;;A61P19/04;;A61P43/00;;C07D401/02;;C07D471/14;;C07D498/14,,0,0,,,,PENDING
156,AU,A1,AU 2021/211993 A1,023-504-912-506-711,2021-08-26,2021,AU 2021/211993 A,2021-08-03,AU 2021/211993 A;;AU 2017/371200 A;;US 201662432537 P;;US 2017/0065425 W,2016-12-09,"MODULATOR OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR","Abstract Compounds of Formula (I): )S 0 0 x y 1 N (R), R1 (R3 (R4)(, pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed. Also disclosed are solid state forms of Compound 1 and salts and solvates thereof.",VERTEX PHARMA,ABELA ALEXANDER RUSSELL;;ALCACIO TIMOTHY;;ANDERSON COREY;;ANGELL PAUL TIMOTHY;;BAEK MINSON;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;FERRIS LORI ANN;;GROOTENHUIS PETER DIEDERIK JAN;;GROSS RAYMOND STANLEY;;GULEVICH ANTON;;HADIDA RUAH SARA SABINA;;HSIA CLARA KUANG-JU;;HUGHES ROBERT M;;JOSHI PRAMOND VIRUPAX;;KANG PING;;KESHAVARZ-SHOKRI ALI;;KHATUYA HARIPADA;;KRENITSKY PAUL JOHN;;MCCARTNEY JASON;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE JEAN DENIS;;SHI YI;;SHRESTHA MUNA;;SIESEL DAVID ANDREW;;STAVROPOULOS KATHY;;TERMIN ANDREAS P;;UY JOHNNY;;VAN GOOR FREDRICK F;;YOUNG TOMOTHY JOHN;;ZHOU JINGLAN,,https://lens.org/023-504-912-506-711,Patent Application,no,0,0,63,63,0,A61K31/455;;C07D401/14;;C07D231/20;;A61P11/00;;C07D401/04;;C07D401/14;;A61P11/00;;C07D401/14;;C07D471/14;;C07B2200/13;;C07D231/20;;C07D498/14;;A61P11/00;;C07D401/04;;C07D401/14;;A61K31/4439;;A61K31/519;;A61K31/5365;;C07D231/20;;C07D401/04;;C07D471/14;;C07D498/14;;A61P11/00;;C07B2200/13;;C07D401/14;;C07D471/14;;C07B2200/13;;A61P11/00;;C07D498/14;;C07D401/04;;C07D231/20,C07D401/14;;A61K31/455;;A61P11/00;;C07D231/20;;C07D401/04,,0,0,,,,ACTIVE
157,AU,B2,AU 2017/371200 B2,059-873-438-055-588,2021-05-06,2021,AU 2017/371200 A,2017-12-08,US 201662432537 P;;US 2017/0065425 W,2016-12-09,"Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator","Compounds of Formula (I) pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed. Also disclosed are solid state forms of Compound 1 and salts and solvates thereof.",VERTEX PHARMA,ABELA ALEXANDER RUSSELL;;ALCACIO TIMOTHY;;ANDERSON COREY;;ANGELL PAUL TIMOTHY;;BAEK MINSON;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;FERRIS LORI ANN;;GROOTENHUIS PETER DIEDERIK JAN;;GROSS RAYMOND STANLEY;;GULEVICH ANTON;;HADIDA RUAH SARA SABINA;;HSIA CLARA KUANG-JU;;HUGHES ROBERT M;;JOSHI PRAMOD VIRUPAX;;KRENITSKY PAUL JOHN;;KANG PING;;KESHAVARZ-SHOKRI ALI;;KHATUYA HARIPADA;;MCCARTNEY JASON;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE JEAN DENIS;;SHI YI;;SHRESTHA MUNA;;SIESEL DAVID ANDREW;;STAVROPOULOS KATHY;;TERMIN ANDREAS P;;UY JOHNNY;;VAN GOOR FREDRICK F;;YOUNG TOMOTHY JOHN;;ZHOU JINGLAN,,https://lens.org/059-873-438-055-588,Granted Patent,no,1,0,63,63,0,A61K31/455;;C07D401/14;;C07D231/20;;A61P11/00;;C07D401/04;;C07D401/14;;A61P11/00;;C07D401/14;;C07D471/14;;C07B2200/13;;C07D231/20;;C07D498/14;;A61P11/00;;C07D401/04;;C07D401/14;;A61K31/4439;;A61K31/519;;A61K31/5365;;C07D231/20;;C07D401/04;;C07D471/14;;C07D498/14;;A61P11/00;;C07B2200/13;;C07D401/14;;C07D471/14;;C07B2200/13;;A61P11/00;;C07D498/14;;C07D401/04;;C07D231/20,C07D401/14;;A61K31/455;;A61P11/00;;C07D231/20;;C07D401/04,,0,0,,,,ACTIVE
158,EA,B1,EA 039280 B1,169-585-684-086-242,2021-12-28,2021,EA 201991403 A,2017-12-08,US 201662432537 P;;US 2017/0065425 W,2016-12-09,"MODULATOR OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR","Disclosed herein are a modulator of cystic fibrosis transmembrane conductance regulator (CFTR) of formula 1, and a deuterated derivative thereof, pharmaceutical compositions containing the modulator, and methods of treatment of cystic fibrosis.",VERTEX PHARMA,ABELA ALEXANDER RUSSELL;;ALCACIO TIMOTHY;;ANDERSON COREY;;ANGELL PAUL TIMOTHY;;BAEK MINSON;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;FERRIS LORI ANN;;GROOTENHUIS PETER DIEDERIK JAN;;GROSS RAYMOND STANLEY;;GULEVICH ANTON;;HADIDA RUAH SARA SABINA;;HSIA CLARA KUANG-JU;;HUGHES ROBERT M;;JOSHI PRAMOD VIRUPAX;;KANG PING;;KESHAVARZ-SHOKRI ALI;;KHATUYA HARIPADA;;KRENITSKY PAUL JOHN;;MCCARTNEY JASON;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE JEAN DENIS;;SHI YI;;SHRESTHA MUNA;;SIESEL DAVID ANDREW;;STAVROPOULOS KATHY;;TERMIN ANDREAS P;;UY JOHNNY;;VAN GOOR FREDRICK F;;YOUNG TIMOTHY JOHN;;ZHOU JINGLAN,,https://lens.org/169-585-684-086-242,Granted Patent,no,1,0,63,63,0,A61K31/455;;C07D401/14;;C07D231/20;;A61P11/00;;C07D401/04;;C07D401/14;;A61P11/00;;C07D401/14;;C07D471/14;;C07B2200/13;;C07D231/20;;C07D498/14;;A61P11/00;;C07D401/04;;C07D401/14;;A61K31/4439;;A61K31/519;;A61K31/5365;;C07D231/20;;C07D401/04;;C07D471/14;;C07D498/14;;A61P11/00;;C07B2200/13;;C07D401/14;;C07D471/14;;C07B2200/13;;A61P11/00;;C07D498/14;;C07D401/04;;C07D231/20,,,0,0,,,,ACTIVE
159,AU,A1,AU 2023/203944 A1,134-262-937-625-069,2023-07-13,2023,AU 2023/203944 A,2023-06-22,AU 2023/203944 A;;AU 2021/211993 A;;AU 2017/371200 A;;US 201662432537 P;;US 2017/0065425 W,2016-12-09,"MODULATOR OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR","Abstract Compounds of Formula (I): Y 1 N (R6 ) R N Y2 N NR5 L (R 3)q (R4)(, pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed. Also disclosed are solid state forms of Compound 1 and salts and solvates thereof.",VERTEX PHARMA,ABELA ALEXANDER RUSSELL;;ALCACIO TIMOTHY;;ANDERSON COREY;;ANGELL PAUL TIMOTHY;;BAEK MINSON;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;FERRIS LORI ANN;;GROOTENHUIS PETER DIEDERIK JAN;;GROSS RAYMOND STANLEY;;GULEVICH ANTON;;HADIDA RUAH SARA SABINA;;HSIA CLARA KUANG-JU;;HUGHES ROBERT M;;JOSHI PRAMOND VIRUPAX;;KANG PING;;KESHAVARZ-SHOKRI ALI;;KHATUYA HARIPADA;;KRENITSKY PAUL JOHN;;MCCARTNEY JASON;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE JEAN DENIS;;SHI YI;;SHRESTHA MUNA;;SIESEL DAVID ANDREW;;STAVROPOULOS KATHY;;TERMIN ANDREAS P;;UY JOHNNY;;VAN GOOR FREDRICK F;;YOUNG TIMOTHY JOHN;;ZHOU JINGLAN,,https://lens.org/134-262-937-625-069,Patent Application,no,0,0,63,63,0,A61K31/455;;C07D401/14;;C07D231/20;;A61P11/00;;C07D401/04;;C07D401/14;;A61P11/00;;C07D401/14;;C07D471/14;;C07B2200/13;;C07D231/20;;C07D498/14;;A61P11/00;;C07D401/04;;C07D401/14;;A61K31/4439;;A61K31/519;;A61K31/5365;;C07D231/20;;C07D401/04;;C07D471/14;;C07D498/14;;A61P11/00;;C07B2200/13;;C07D401/14;;C07D471/14;;C07B2200/13;;A61P11/00;;C07D498/14;;C07D401/04;;C07D231/20,C07D401/14;;A61K31/455;;A61P11/00;;C07D231/20;;C07D401/04,,0,0,,,,PENDING
160,EC,A,EC SP19048759 A,142-169-287-698-234,2019-07-31,2019,EC DI201948759 A,2019-07-09,US 201662432537 P;;US 2017/0065425 W,2016-12-09,"MODULADOR DEL REGULADOR DE CONDUCTANCIA DE TRANSMEMBRANA DE FIBROSIS QUÍSTICA, COMPOSICIONES FARMACÉUTICAS, Y PROCESO PARA PRODUCIR EL MODULADOR","Se describen compuestos de Fórmula (I): (VER FÓRMULA EN LA DESCRIPCION) sales farmacéuticamente aceptables de este, derivados deuterados de cualquiera de los que anteceden y metabolitos de cualquiera de los anteceden. También se describen composiciones farmacéuticas que los comprenden, métodos para el tratamiento de la fibrosis quística mediante el uso de estos y métodos para confeccionarlos. Se describen además las formas en estado sólido del Compuesto 1 y sales y solvatos de este.",VERTEX PHARMA,JASON MCCARTNEY;;PAUL JOHN KRENITSKY;;SHI YI;;FABRICE JEAN DENIS PIERRE;;HARIPADA KHATUYA;;TIMOTHY ALCACIO;;ANGELL PAUL TIMOTHY;;ROBERT M HUGHES;;THOMAS CLEVELAND;;FERRIS LORI ANN;;SARA SABINA HADIDA RUAH;;JOHNNY UY;;DAVID ANDREW SIESEL;;GULEVICH ANTON;;MINSON BAEK;;GROSS RAYMOND STANLEY;;PRAMOD VIRUPAX JOSHI;;ALI KESHAVARZ-SHOKRI;;STAVROPOULOS KATHY;;PRASUNA PARASELLI;;ALEXANDER RUSSELL ABELA;;MARK THOMAS MILLER;;HSIA CLARA KUANG-JU;;ANDREAS P TERMIN;;YOUNG TOMOTHY JOHN;;VAN GOOR FREDRICK F;;SHRESTHA MUNA;;KANG PING;;CLEMENS JEREMY J;;JINGLAN ZHOU;;GROOTENHUIS PETER DIEDERIK JAN;;COREY ANDERSON,,https://lens.org/142-169-287-698-234,Patent Application,no,0,2,63,63,0,A61K31/455;;C07D401/14;;C07D231/20;;A61P11/00;;C07D401/04;;C07D401/14;;A61P11/00;;C07D401/14;;C07D471/14;;C07B2200/13;;C07D231/20;;C07D498/14;;A61P11/00;;C07D401/04;;C07D401/14;;A61K31/4439;;A61K31/519;;A61K31/5365;;C07D231/20;;C07D401/04;;C07D471/14;;C07D498/14;;A61P11/00;;C07B2200/13;;C07D401/14;;C07D471/14;;C07B2200/13;;A61P11/00;;C07D498/14;;C07D401/04;;C07D231/20,A61K31/455;;C07D231/20,,0,0,,,,PENDING
161,JP,A,JP 2021119172 A,104-830-346-583-906,2021-08-12,2021,JP 2021075890 A,2021-04-28,JP 2019530713 A;;US 201662432537 P,2016-12-09,"MODULATOR OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING MODULATOR","To provide a modulator of the cystic fibrosis transmembrane conductance regulator (CFTR), pharmaceutical compositions comprising the modulator, methods of treating cystic fibrosis, and a process for making the modulator.SOLUTION: The invention provides a crystalline form A of a compound 1 in the figure.SELECTED DRAWING: Figure 2",VERTEX PHARMA,ALEXANDER RUSSELL ABELA;;TIMOTHY ALCACIO;;COREY ANDERSON;;PAUL TIMOTHY ANGEL;;BAEK MINSON;;JEREMY J CLEMENS;;THOMAS CLEVELAND;;LORI ANN FERRIS;;PETER DIEDERIK JAN GROOTENHUIS;;RAYMOND STANLEY GROSS;;ANTON GULEVICH;;SARA SABINA HADIDA RUAH;;CLARA KUANG-JU HSIA;;ROBERT M HUGHES;;PRAMOD VIRUPAX JOSHI;;KANG PING;;ALI KESHAVARZ-SHOKRI;;HARIPADA KATSUYA;;PAUL JOHN KRENITSKY;;MCCARTNEY JASON;;MARK THOMAS MILLER;;PRASUNA PARASELLI;;FABRICE JEAN DENIS PIERRE;;SHI YI;;MUNA SHRESTHA;;DAVID ANDREW SIESEL;;KATHY STAVROPOULOS;;TERMIN ANDREAS P;;JOHNNY UY;;FREDRICK F VAN GOOR;;TIMOTHY JOHN YOUNG;;ZHOU JINGLAN,,https://lens.org/104-830-346-583-906,Patent Application,no,5,0,63,63,0,A61K31/455;;C07D401/14;;C07D231/20;;A61P11/00;;C07D401/04;;C07D401/14;;A61P11/00;;C07D401/14;;C07D471/14;;C07B2200/13;;C07D231/20;;C07D498/14;;A61P11/00;;C07D401/04;;C07D401/14;;A61K31/4439;;A61K31/519;;A61K31/5365;;C07D231/20;;C07D401/04;;C07D471/14;;C07D498/14;;A61P11/00;;C07B2200/13;;C07D401/14;;C07D471/14;;C07B2200/13;;A61P11/00;;C07D498/14;;C07D401/04;;C07D231/20,C07D401/10;;A61K31/4439;;A61P43/00,,0,0,,,,ACTIVE
162,AU,A1,AU 2017/371200 A1,120-741-602-525-883,2019-07-11,2019,AU 2017/371200 A,2017-12-08,US 201662432537 P;;US 2017/0065425 W,2016-12-09,"Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator","Compounds of Formula (I) pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed. Also disclosed are solid state forms of Compound 1 and salts and solvates thereof.",VERTEX PHARMA,ABELA ALEXANDER RUSSELL;;ALCACIO TIMOTHY;;ANDERSON COREY;;ANGELL PAUL TIMOTHY;;BAEK MINSON;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;FERRIS LORI ANN;;GROOTENHUIS PETER DIEDERIK JAN;;GROSS RAYMOND STANLEY;;GULEVICH ANTON;;HADIDA RUAH SARA SABINA;;HSIA CLARA KUANG-JU;;HUGHES ROBERT M;;JOSHI PRAMOD VIRUPAX;;KANG PING;;KESHAVARZ-SHOKRI ALI;;KHATUYA HARIPADA;;KRENITSKY PAUL JOHN;;MCCARTNEY JASON;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE JEAN DENIS;;SHI YI;;SHRESTHA MUNA;;SIESEL DAVID ANDREW;;STAVROPOULOS KATHY;;TERMIN ANDREAS P;;UY JOHNNY;;VAN GOOR FREDRICK F;;YOUNG TOMOTHY JOHN;;ZHOU JINGLAN,,https://lens.org/120-741-602-525-883,Patent Application,no,0,0,63,63,0,A61K31/455;;C07D401/14;;C07D231/20;;A61P11/00;;C07D401/04;;C07D401/14;;A61P11/00;;C07D401/14;;C07D471/14;;C07B2200/13;;C07D231/20;;C07D498/14;;A61P11/00;;C07D401/04;;C07D401/14;;A61K31/4439;;A61K31/519;;A61K31/5365;;C07D231/20;;C07D401/04;;C07D471/14;;C07D498/14;;A61P11/00;;C07B2200/13;;C07D401/14;;C07D471/14;;C07B2200/13;;A61P11/00;;C07D498/14;;C07D401/04;;C07D231/20,C07D401/14;;A61K31/455;;A61P11/00;;C07D231/20;;C07D401/04,,0,0,,,,ACTIVE
163,AU,B2,AU 2021/211993 B2,175-247-061-625-030,2023-04-06,2023,AU 2021/211993 A,2021-08-03,AU 2021/211993 A;;AU 2017/371200 A;;US 201662432537 P;;US 2017/0065425 W,2016-12-09,"MODULATOR OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR","Abstract Compounds of Formula (I): )S 0 0 x y 1 N (R), R1 (R3 (R4)(, pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed. Also disclosed are solid state forms of Compound 1 and salts and solvates thereof.",VERTEX PHARMA,ABELA ALEXANDER RUSSELL;;ALCACIO TIMOTHY;;ANDERSON COREY;;ANGELL PAUL TIMOTHY;;BAEK MINSON;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;FERRIS LORI ANN;;GROOTENHUIS PETER DIEDERIK JAN;;GROSS RAYMOND STANLEY;;GULEVICH ANTON;;HADIDA RUAH SARA SABINA;;HSIA CLARA KUANG-JU;;HUGHES ROBERT M;;JOSHI PRAMOND VIRUPAX;;KANG PING;;KESHAVARZ-SHOKRI ALI;;KHATUYA HARIPADA;;KRENITSKY PAUL JOHN;;MCCARTNEY JASON;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE JEAN DENIS;;SHI YI;;SHRESTHA MUNA;;SIESEL DAVID ANDREW;;STAVROPOULOS KATHY;;TERMIN ANDREAS P;;UY JOHNNY;;VAN GOOR FREDRICK F;;YOUNG TIMOTHY JOHN;;ZHOU JINGLAN,,https://lens.org/175-247-061-625-030,Granted Patent,no,1,0,63,63,0,A61K31/455;;C07D401/14;;C07D231/20;;A61P11/00;;C07D401/04;;C07D401/14;;A61P11/00;;C07D401/14;;C07D471/14;;C07B2200/13;;C07D231/20;;C07D498/14;;A61P11/00;;C07D401/04;;C07D401/14;;A61K31/4439;;A61K31/519;;A61K31/5365;;C07D231/20;;C07D401/04;;C07D471/14;;C07D498/14;;A61P11/00;;C07B2200/13;;C07D401/14;;C07D471/14;;C07B2200/13;;A61P11/00;;C07D498/14;;C07D401/04;;C07D231/20,C07D401/14;;A61K31/455;;A61P11/00;;C07D231/20;;C07D401/04,,0,0,,,,ACTIVE
164,CY,T1,CY 1123736 T1,082-226-974-211-09X,2022-03-24,2022,CY 201101200 T,2020-12-18,US 201662432537 P;;US 2017/0065425 W,2016-12-09,"ΤΡΟΠΟΠΟΙΗΤΗΣ ΤΟΥ ΡΥΘΜΙΣΤΗ ΔΙΑΜΕΜΒΡΑΝΙΚΗΣ ΑΓΩΓΙΜΟΤΗΤΑΣ ΚΥΣΤΙΚΗΣ ΙΝΩΣΗΣ, ΦΑΡΜΑΚΕΥΤΙΚΕΣ ΣΥΝΘΕΣΕΙΣ, ΜΕΘΟΔΟΙ ΘΕΡΑΠΕΙΑΣ, ΚΑΙ ΜΕΘΟΔΟΣ ΓΙΑ ΠΑΡΑΣΚΕΥΗ ΤΟΥ ΤΡΟΠΟΠΟΙΗΤΗ","Αποκαλύπτονται ενώσεις του Τύπου (Ι) φαρμακευτικώς αποδεκτά άλατα αυτών, δευτεριωμένα παράγωγα οιουδήποτε από τα προαναφερθέντα, και μεταβολίτες οιουδήποτε από τα προαναφερθέντα. Αποκαλύπτονται επίσης φαρμακευτικές συνθέσεις που περιλαμβάνουν αυτά, μέθοδοι θεραπείας κυστικής ίνωσης χρησιμοποιώντας αυτά, και μέθοδοι για παρασκευή αυτών. Επίσης αποκαλύπτονται μορφές στερεάς κατάστασης της Ένωσης 1 και αλάτων και διαλυτωμάτων αυτής.",VERTEX PHARMA,ABELA ALEXANDER RUSSELL;;ALCACIO TIMOTHY;;ANDERSON COREY;;ANGELL PAUL TIMOTHY;;BAEK MINSON;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;FERRIS LORI ANN;;GROOTENHUIS PETER DIEDERIK JAN;;GROSS RAYMOND STANLEY;;GULEVICH ANTON;;HADIDA-RUAH SARA SABINA;;HSIA CLARA KUANG-JU;;HUGHES ROBERT M;;JOSHI PRAMOD VIRUPAX;;KANG PING;;KESHAVARZ-SHOKRI ALI;;KHATUYA HARIPADA;;KRENITSKY PAUL JOHN;;MCCARTNEY JASON;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE JEAN DENIS;;SHI YI;;SHRESTHA MUNA;;SIESEL DAVID ANDREW;;STAVROPOULOS KATHY;;TERMIN ANDREAS P;;UY JOHNNY;;VAN GOOR FREDRICK F;;YOUNG TOMOTHY JOHN;;ZHOU JINGLAN,,https://lens.org/082-226-974-211-09X,Granted Patent,no,0,0,63,63,0,A61K31/455;;C07D401/14;;C07D231/20;;A61P11/00;;C07D401/04;;C07D401/14;;A61P11/00;;C07D401/14;;C07D471/14;;C07B2200/13;;C07D231/20;;C07D498/14;;A61P11/00;;C07D401/04;;C07D401/14;;A61K31/4439;;A61K31/519;;A61K31/5365;;C07D231/20;;C07D401/04;;C07D471/14;;C07D498/14;;A61P11/00;;C07B2200/13;;C07D401/14;;C07D471/14;;C07B2200/13;;A61P11/00;;C07D498/14;;C07D401/04;;C07D231/20,C07D401/14;;A61K31/455;;A61P11/00;;C07D231/20;;C07D401/04,,0,0,,,,ACTIVE
165,CA,A1,CA 3046086 A1,016-905-295-364-28X,2018-06-14,2018,CA 3046086 A,2017-12-08,US 201662432537 P;;US 2017/0065425 W,2016-12-09,"MODULATOR OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR","Compounds of Formula (I) pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed. Also disclosed are solid state forms of Compound 1 and salts and solvates thereof.",VERTEX PHARMA,ABELA ALEXANDER RUSSELL;;ALCACIO TIMOTHY;;ANDERSON COREY;;ANGELL PAUL TIMOTHY;;BAEK MINSON;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;FERRIS LORI ANN;;GROOTENHUIS PETER DIEDERIK JAN;;GROSS RAYMOND STANLEY;;GULEVICH ANTON;;HADIDA RUAH SARA SABINA;;HSIA CLARA KUANG-JU;;HUGHES ROBERT M;;JOSHI PRAMOD VIRUPAX;;KANG PING;;KESHAVARZ-SHOKRI ALI;;KHATUYA HARIPADA;;KRENITSKY PAUL JOHN;;MCCARTNEY JASON;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE JEAN DENIS;;SHI YI;;SHRESTHA MUNA;;SIESEL DAVID ANDREW;;STAVROPOULOS KATHY;;TERMIN ANDREAS P;;UY JOHNNY;;VAN GOOR FREDRICK F;;YOUNG TOMOTHY JOHN;;ZHOU JINGLAN,,https://lens.org/016-905-295-364-28X,Patent Application,no,0,0,63,63,0,A61K31/455;;C07D401/14;;C07D231/20;;A61P11/00;;C07D401/04;;C07D401/14;;A61P11/00;;C07D401/14;;C07D471/14;;C07B2200/13;;C07D231/20;;C07D498/14;;A61P11/00;;C07D401/04;;C07D401/14;;A61K31/4439;;A61K31/519;;A61K31/5365;;C07D231/20;;C07D401/04;;C07D471/14;;C07D498/14;;A61P11/00;;C07B2200/13;;C07D401/14;;C07D471/14;;C07B2200/13;;A61P11/00;;C07D498/14;;C07D401/04;;C07D231/20,C07D401/14;;A61K31/455;;A61P11/00;;C07D231/20;;C07D401/04,,0,0,,,,PENDING
166,AR,A1,AR 110346 A1,187-567-101-689-193,2019-03-20,2019,AR P170103464 A,2017-12-12,US 201662432537 P,2016-12-09,"MODULADOR DEL REGULADOR DE CONDUCTANCIA TRANSMEMBRANA DE FIBROSIS QUÍSTICA, COMPOSICIONES FARMACÉUTICAS, MÉTODOS DE TRATAMIENTO Y PROCESO PARA PRODUCIR EL MODULADOR","También se describen composiciones farmacéuticas que los comprenden, su uso para el tratamiento de la fibrosis quística para confeccionarlos. Se describen además las formas en estado sólido del compuesto de fórmula (7) y sales y solvatos de este. Reivindicación 1: Un compuesto de fórmula (1), una sal farmacéuticamente aceptable de este o un derivado deuterado de cualquiera de los que anteceden, donde: uno de Y¹ e Y² es N el otro es CH; X se selecciona de grupos N(alquilo C₁₋₄), O y NH; R¹ es -(C(R²)₂)ₖ-O-(C(R²)₂)ₘR⁷; cada R² se selecciona independientemente de hidrógeno; halógenos; ciano; hidroxi; grupos alcoxi C₁₋₂; y grupos alquilo C₁₋₂ sustituidos opcionalmente con uno o más sustituyentes, donde cada uno se selecciona independientemente de halógenos, hidroxi y grupos cicloalquilo C₃₋₅ sustituidos opcionalmente con uno o más sustituyentes, donde cada uno se selecciona independientemente de grupos alquilo C₁₋₂, grupos alquilo C₁₋₂ halogenados y halógenos; cada R³ se selecciona independientemente de grupos alquilo C₁₋₄ sustituidos opcionalmente con uno o más grupos hidroxi, u opcionalmente, dos R³ germinales, junto con el átomo de carbono al cual se acoplan, forman un cicloalquilo C₃₋₄; cada R⁴ se selecciona independientemente de halógenos; R⁵ se selecciona de grupos alquilo C₁₋₄ e hidrógeno; cada R⁶ se selecciona independientemente de halógenos, ciano, hidroxi, hidroximetilo, grupos alcoxi C₁₋₂, grupos alquilo C₁₋₂ y grupos alquilo C₁₋₂ halogenados; R⁷ se selecciona de hidrógeno; halógenos; ciano; grupos alquilo C₁₋₂ sustituidos opcionalmente con uno o más sustituyentes, donde cada uno se selecciona independientemente de halógenos e hidroxi; y grupos cicloalquilo C₃₋₁₀ sustituidos opcionalmente con uno o más sustituyentes, donde cada uno se selecciona independientemente de grupos alquilo C₁₋₂, grupos alquilo C₁₋₂ halogenados y halógenos; k es 0 ó 1; r es 0 ó 1; m es 0, 1, 2 ó 3; p es 0, 1 ó 2; y q es 0, 1, 2, 3, 4, 5, 6, 7 u 8. Reivindicación 64: Un compuesto de fórmula (2) o una sal de este, o un derivado deuterado de cualquiera de los que anteceden, donde Xᵃ es F o Cl. Reivindicación 65: Un compuesto de fórmula (3) ó (4), o una sal de este, o un derivado deuterado de cualquiera de los que anteceden, donde, en cada una de dichas fórmulas: uno de Y¹ e Y² es independientemente N y el otro es independientemente CH; R¹ es -(C(R²)₂)ₖ-O-(C(R²)₂)ₘR⁷; cada R² se selecciona independientemente de hidrógeno; halógenos; ciano; hidroxi; grupos alcoxi C₁₋₂; y grupos alquilo C₁₋₂ sustituidos opcionalmente con uno o más sustituyentes, donde cada uno se selecciona independientemente de halógenos, hidroxi y grupos cicloalquilo C₃₋₅ sustituidos opcionalmente con uno o más sustituyentes, donde cada uno se selecciona independientemente de grupos alquilo C₁₋₂, grupos alquilo C₁₋₂ halogenados y halógenos; cada R⁴ se selecciona independientemente de halógenos; R⁷ se selecciona de hidrógeno, halógenos, ciano, grupos alquilo C₁₋₂ sustituidos opcionalmente con uno o más sustituyentes, donde cada uno se selecciona independientemente de halógenos e hidroxi, y grupos cicloalquilo C₃₋₁₀ sustituidos opcionalmente con uno o más sustituyentes, donde cada uno se selecciona independientemente de grupos alquilo C₁₋₂, grupos alquilo C₁₋₂ halogenados y halógenos; Rᵃ es alquilo C₁₋₄; Xᵃ es F o Cl; k es 0 ó 1; r es 0 ó 1; y m es 0, 1, 2 ó 3. Reivindicación 68: Un compuesto de fórmula (5) ó (6), o una sal de este, o un derivado deuterado de cualquiera de los que anteceden, donde Rᵃ es alquilo C₁₋₄; y cada Xᵃ es independientemente F o Cl. Reivindicación 72: Una Forma cristalina A del compuesto de fórmula (7). Reivindicación 74: La Forma cristalina A de acuerdo con la reivindicación 72, caracterizada por un difractograma en polvo de rayos X que posee una señal a al menos tres valores 2-q que se seleccionan de 6.6 ± 0.2, 7.6 ± 0.2, 9.6 ± 0.2, 12.4 ± 0.2, 13.1 ± 0.2, 15.2 ± 0.2, 16.4 ± 0.2, 18.2 ± 0.2 y 18.6 ± 0.2. Reivindicación 83: Una Forma cristalina M del compuesto de fórmula (7). Reivindicación 85: La Forma cristalina M de acuerdo con la reivindicación 83, caracterizada por un difractograma en polvo de rayos X que posee una señal a al menos tres valores 2-q que se seleccionan de 7.0 ± 0.2, 11.6 ± 0.2, 13.1 ± 0.2, 13.7 ± 0.2, 15.2 ± 0.2, 15.9 ± 0.2, 16.4 ± 0.2, 17.8 ± 0.2 y 19.3 ± 0.2. Reivindicación 90: Una Forma cristalina E del compuesto de fórmula (7). Reivindicación 92: La Forma cristalina E de acuerdo con la reivindicación 90, caracterizada por un difractograma en polvo de rayos X que posee una señal a al menos tres valores 2-q que se seleccionan de 7.0 ± 0.2, 11.2 ± 0.2, 12.8 ± 0.2, 13.2 ± 0.2, 14.1 ± 0.2, 15.1 ± 0.2, 16.1 ± 0.2, 17.8 ± 0.2 y 18.9 ± 0.2. Reivindicación 99: Una Forma cristalina X de una sal de potasio del compuesto de fórmula (7). Reivindicación 101: La Forma cristalina X de acuerdo con la reivindicación 99, caracterizada por un difractograma en polvo de rayos X que posee una señal a al menos tres valores 2-q que se seleccionan de 4.9 ± 0.2, 5.9 ± 0.2, 8.1 ± 0.2, 8.5 ± 0.2, 10.3 ± 0.2, 13.0 ± 0.2, 13.9 ± 0.2, 14.6 ± 0.2 y 17.0 ± 0.2. Reivindicación 106: Una Forma cristalina Y de una sal de sodio del compuesto de fórmula (7). Reivindicación 108: La Forma cristalina Y de acuerdo con la reivindicación 106, caracterizada por un difractograma en polvo de rayos X que posee una señal a al menos tres valores 2-q que se seleccionan de 3.5 ± 0.2, 7.0 ± 0.2, 11.7 ± 0.2, 12.8 ± 0.2, 13.2 ± 0.2, 14.2 ± 0.2, 15.4 ± 0.2, 16.6 ± 0.2 y 18.0 ± 0.2. Reivindicación 119: Una Forma cristalina P2 del compuesto de fórmula (7). Reivindicación 121: La Forma cristalina P2 de acuerdo con la reivindicación 119, caracterizada por un difractograma en polvo de rayos X que posee una señal a al menos tres valores 2-q que se seleccionan de 10.2 ± 0.2, 10.9 ± 0.2, 12.6 ± 0.2, 12.9 ± 0.2, 15.0 ± 0.2, 15.9 ± 0.2, 16.2 ± 0.2, 16.5 ± 0.2 y 17.6 ± 0.2.",VERTEX PHARMA,SIESEL DAVID A;;SHRESTHA MUNA;;SHI YI;;PIERRE FABRICE J D;;PARASELLI PRASUNA;;MILLER MARK T;;MCARTNEY JASON;;KRENITSKY PAUL J;;KHATUYA HARIPADA;;KESHAVARZ-SHOKRI ALI;;KANG PING;;JOSHI PRAMOD V;;HUGHES ROBERT M;;HSIA CLARA KUANG;;JU - HADIDA RUAH SARA S;;GULEVICH ANTON;;GROSS RAYMOND S;;GROOTENHUIS PETER D J;;FERRIS LORI ANN;;CLEVELAND THOMAS;;CLEMENS JEREMY J;;BAEK MINSON;;ANGELL PAUL T;;ANDERSOY COREY;;ALCACIO TIMOTHY;;ABELA ALEXANDER R;;ZHOU JINGLAN;;YOUNG TIMOTHY JOHN;;VAN GOOR FREDRICK F;;UY JOHNNY;;TERMIN ANDREAS P;;STAVROPOULOS KATHY,,https://lens.org/187-567-101-689-193,Patent Application,no,0,0,63,63,0,A61K31/455;;C07D401/14;;C07D231/20;;A61P11/00;;C07D401/04;;C07D401/14;;A61P11/00;;C07D401/14;;C07D471/14;;C07B2200/13;;C07D231/20;;C07D498/14;;A61P11/00;;C07D401/04;;C07D401/14;;A61K31/4439;;A61K31/519;;A61K31/5365;;C07D231/20;;C07D401/04;;C07D471/14;;C07D498/14;;A61P11/00;;C07B2200/13;;C07D401/14;;C07D471/14;;C07B2200/13;;A61P11/00;;C07D498/14;;C07D401/04;;C07D231/20,C07D401/14;;A61K31/465;;A61P11/00,,0,0,,,,PENDING
167,HR,T1,HR P20201946 T1,050-417-622-913-814,2021-01-22,2021,HR P20201946 T,2020-12-04,US 201662432537 P;;EP 17826629 A;;US 2017/0065425 W,2016-12-09,"MODULATOR OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR",,VERTEX PHARMA,ABELA ALEXANDER RUSSELL;;ALCACIO TIMOTHY;;ANDERSON COREY;;ANGELL PAUL TIMOTHY;;BAEK MINSON;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;FERRIS LORI ANN;;GROOTENHUIS PETER DIEDERIK JAN;;GROSS RAYMOND STANLEY;;GULEVICH ANTON;;HADIDA RUAH SARA SABINA;;HSIA CLARA KUANG-JU;;HUGHES ROBERT M;;JOSHI PRAMOD VIRUPAX;;KANG PING;;KESHAVARZ-SHOKRI ALI;;KHATUYA HARIPADA;;KRENITSKY PAUL JOHN;;MCCARTNEY JASON;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE JEAN DENIS;;SHI YI;;SHRESTHA MUNA;;SIESEL DAVID ANDREW;;STAVROPOULOS KATHY;;TERMIN ANDREAS P;;UY JOHNNY;;VAN GOOR FREDRICK F;;YOUNG TOMOTHY JOHN;;ZHOU JINGLAN,,https://lens.org/050-417-622-913-814,Granted Patent,no,0,0,63,63,0,A61K31/455;;C07D401/14;;C07D231/20;;A61P11/00;;C07D401/04;;C07D401/14;;A61P11/00;;C07D401/14;;C07D471/14;;C07B2200/13;;C07D231/20;;C07D498/14;;A61P11/00;;C07D401/04;;C07D401/14;;A61K31/4439;;A61K31/519;;A61K31/5365;;C07D231/20;;C07D401/04;;C07D471/14;;C07D498/14;;A61P11/00;;C07B2200/13;;C07D401/14;;C07D471/14;;C07B2200/13;;A61P11/00;;C07D498/14;;C07D401/04;;C07D231/20,C07D401/14;;A61K31/455;;A61P11/00;;C07D231/20;;C07D401/04,,0,0,,,,ACTIVE
168,TW,A,TW 201835065 A,089-047-468-068-148,2018-10-01,2018,TW 106143291 A,2017-12-08,US 201662432537 P,2016-12-09,"Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator","Compounds of Formula (I): pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed. Also disclosed are solid state forms of Compound 1 and salts and solvates thereof.",VERTEX PHARMA,ABELA ALEXANDER RUSSELL;;ALCACIO TIMOTHY;;ANDERSON COREY;;ANGELL PAUL TIMOTHY;;BAEK MINSON;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;FERRIS LORI ANN;;GROOTENHUIS PETER DIEDERIK JAN;;GROSS RAYMOND STANLEY;;GULEVICH ANTON;;HADIDA RUAH SARA SABINA;;HSIA CLARA KUANG-JU;;HUGHES ROBERT M;;JOSHI PRAMOD VIRUPAX;;KANG PING;;KESHAVARZ-SHOKRI ALI;;KHATUYA HARIPADA;;KRENITSKY PAUL JOHN;;MCCARTNEY JASON;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE JEAN DENIS;;SHI YI;;SHRESTHA MUNA;;SIESEL DAVID ANDREW;;STAVROPOULOS KATHY;;TERMIN ANDREAS P;;UY JOHNNY;;VAN GOOR FREDRICK F;;YOUNG TIMOTHY JOHN;;ZHOU JINGLAN,,https://lens.org/089-047-468-068-148,Patent of Addition,no,0,0,63,63,0,A61K31/455;;C07D401/14;;C07D231/20;;A61P11/00;;C07D401/04;;C07D401/14;;A61P11/00;;C07D401/14;;C07D471/14;;C07B2200/13;;C07D231/20;;C07D498/14;;A61P11/00;;C07D401/04;;C07D401/14;;A61K31/4439;;A61K31/519;;A61K31/5365;;C07D231/20;;C07D401/04;;C07D471/14;;C07D498/14;;A61P11/00;;C07B2200/13;;C07D401/14;;C07D471/14;;C07B2200/13;;A61P11/00;;C07D498/14;;C07D401/04;;C07D231/20,C07D401/14;;A61K31/4439;;A61K31/519;;A61K31/5383;;C07D471/14;;C07D498/14,,0,0,,,,ACTIVE
169,BR,A2,BR 112019011626 A2,128-034-444-568-738,2019-10-22,2019,BR 112019011626 A,2017-12-08,US 2017/0065425 W;;US 201662432537 P,2016-12-09,"modulador de regulador de condutância transmembrana na fibrose cística, composições farmacêuticas, métodos de tratamento e processo para a produção do modulador","a presente invenção refere-se a compostos de fórmula (i), (i), sais farmaceuticamente aceitáveis deles, derivados deuterados de qualquer um dos acima expostos, e metabólitos de qualquer um dos acima expostos. são também divulgadas composições farmacêuticas compreendendo os mesmos, métodos de tratamento de fibrose cística usando os mesmos, e métodos para a sua produção. são também divulgadas as formas de estado sólido do composto 1 e sais e solvatos do mesmo.",VERTEX PHARMA,ALEXANDER RUSSELL ABELA;;ALI KESHAVARZ-SHOKRI;;ANDREAS P TERMIN;;ANTON GULEVICH;;CLARA KUANG-JU HSIA;;COREY ANDERSON;;DAVID ANDREW SIESEL;;FABRICE JEAN DENIS PIERRE;;FREDRICK F VAN GOOR;;HARIPADA KHATUYA;;JASON MCCARTNEY;;JEREMY J CLEMENS;;JINGLAN ZHOU;;JOHNNY UY;;KATHY STAVROPOULOS;;LORI ANN FERRIS;;MARK THOMAS MILLER;;MINSON BAEK;;MUNA SHRESTHA;;PAUL JOHN KRENITSKY;;PAUL TIMOTHY ANGELL;;PETER DIEDERIK JAN GROOTENHUIS;;PING KANG;;PRAMOD VIRUPAX JOSHI;;PRASUNA PARASELLI;;RAYMOND STANLEY GROSS;;ROBERT M HUGHES;;SARA SABINA HADIDA RUAH;;THOMAS CLEVELAND;;TIMOTHY ALCACIO;;TOMOTHY JOHN YOUNG;;YI SHI,,https://lens.org/128-034-444-568-738,Patent Application,no,0,0,63,63,0,A61K31/455;;C07D401/14;;C07D231/20;;A61P11/00;;C07D401/04;;C07D401/14;;A61P11/00;;C07D401/14;;C07D471/14;;C07B2200/13;;C07D231/20;;C07D498/14;;A61P11/00;;C07D401/04;;C07D401/14;;A61K31/4439;;A61K31/519;;A61K31/5365;;C07D231/20;;C07D401/04;;C07D471/14;;C07D498/14;;A61P11/00;;C07B2200/13;;C07D401/14;;C07D471/14;;C07B2200/13;;A61P11/00;;C07D498/14;;C07D401/04;;C07D231/20,A61K31/455;;A61P11/00;;C07D231/20;;C07D401/04;;C07D401/14,,0,0,,,,PENDING
170,UY,A,UY 37513 A,143-101-899-446-180,2018-07-31,2018,UY 37513 A,2017-12-08,US 201662432537 P,2016-12-09,"MODULADOR DEL REGULADOR DE CONDUCTANCIA TRANSMEMBRANA DE FIBROSIS QUÍSTICA, COMPOSICIONES FARMACÉUTICAS, MÉTODOS DE TRATAMIENTO Y PROCESO PARA PRODUCIR EL MODULADOR","Se describen compuestos de Fórmula (I): sales farmacéuticamente aceptables de este, derivados deuterados de cualquiera de los que anteceden y metabolitos de cualquiera de los anteceden. También se describen composiciones farmacéuticas que los comprenden, métodos para el tratamiento de la fibrosis quística mediante el uso de estos y métodos para confeccionarlos. Se describen además las formas en estado sólido del Compuesto 1 y sales y solvatos de este.",VERTEX PHARMA,ALCACIO TIMOTHY;;BAEK MINSON;;SARA SABINA HADIDA RUAH;;ALI KESHAVARZ-SHOKRI;;MCCARTNEY JASON;;ANDERSON COREY;;CLEVELAND THOMAS;;KHATUYA HARIPADA;;PRAMOD VIRUPAX JOSHI;;PAUL JOHN KRENITSKY;;FABRICE JEAN DENIS PIERRE;;ANDREAS P TERMIN;;ZHOU JINGLAN;;ALEXANDER RUSSELL ABELA;;PAUL TIMOTHY ANGELL;;JEREMY J CLEMENS;;LORI ANN FERRIS;;PETER DIEDERIK JAN GROOTENHUIS;;RAYMOND STANLEY GROSS;;GULEVICH ANTON;;CLARA KUANG-JU HSIA;;ROBERT M HUGHES;;KANG PING;;MARK THOMAS MILLER;;SHI YI;;SHRESTHA MUNA;;DAVID ANDREW SIESEL;;STAVROPOULOS KATHY;;UY JOHNNY;;FREDRICK F VAN GOOR;;TIMOTHY JOHN YOUNG;;PARASELLI PRASUNA,,https://lens.org/143-101-899-446-180,Patent Application,no,0,0,63,63,0,A61K31/455;;C07D401/14;;C07D231/20;;A61P11/00;;C07D401/04;;C07D401/14;;A61P11/00;;C07D401/14;;C07D471/14;;C07B2200/13;;C07D231/20;;C07D498/14;;A61P11/00;;C07D401/04;;C07D401/14;;A61K31/4439;;A61K31/519;;A61K31/5365;;C07D231/20;;C07D401/04;;C07D471/14;;C07D498/14;;A61P11/00;;C07B2200/13;;C07D401/14;;C07D471/14;;C07B2200/13;;A61P11/00;;C07D498/14;;C07D401/04;;C07D231/20,A61K31/44,,0,0,,,,ACTIVE
171,US,B2,US 10793547 B2,157-515-534-655-770,2020-10-06,2020,US 201715836627 A,2017-12-08,US 201715836627 A;;US 201662432537 P,2016-12-09,"Modulator of the cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator","Compounds of Formula (I): pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed. Also disclosed are solid state forms of Compound 1 and salts and solvates thereof.",VERTEX PHARMA,ABELA ALEXANDER RUSSELL;;ALCACIO TIMOTHY;;ANDERSON COREY;;ANGELL PAUL TIMOTHY;;BAEK MINSON;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;FERRIS LORI ANN;;GROOTENHUIS PETER DIEDERIK JAN;;GROSS RAYMOND STANLEY;;GULEVICH ANTON V;;HADIDA RUAH SARA SABINA;;HSIA CLARA KUANG-JU;;HUGHES ROBERT M;;JOSHI PRAMOD VIRUPAX;;KANG PING;;KESHAVARZ-SHOKRI ALI;;KHATUYA HARIPADA;;KRENITSKY PAUL JOHN;;MCCARTNEY JASON;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE JEAN DENIS;;SHI YI;;SHRESTHA MUNA;;SIESEL DAVID ANDREW;;STAVROPOULOS KATHY;;TERMIN ANDREAS P;;VAN GOOR FREDRICK F;;UY JOHNNY;;YOUNG TIMOTHY JOHN;;ZHOU JINGLAN,VERTEX PHARMACEUTICALS (SAN DIEGO) LLC (2017-12-20);;VERTEX PHARMACEUTICALS INCORPORATED (2017-12-07),https://lens.org/157-515-534-655-770,Granted Patent,yes,220,12,63,63,0,A61K31/455;;C07D401/14;;C07D231/20;;A61P11/00;;C07D401/04;;C07D401/14;;A61P11/00;;C07D401/14;;C07D471/14;;C07B2200/13;;C07D231/20;;C07D498/14;;A61P11/00;;C07D401/04;;C07D401/14;;A61K31/4439;;A61K31/519;;A61K31/5365;;C07D231/20;;C07D401/04;;C07D471/14;;C07D498/14;;A61P11/00;;C07B2200/13;;C07D401/14;;C07D471/14;;C07B2200/13;;A61P11/00;;C07D498/14;;C07D401/04;;C07D231/20,C07D401/14;;A61P11/00;;C07D231/20;;C07D401/04;;C07D471/14;;C07D498/14,,72,25,045-406-285-588-795;;034-587-611-086-755;;013-937-078-602-349;;096-312-557-325-378;;078-417-508-507-333;;012-371-996-064-723;;103-052-069-575-996;;039-573-265-223-407;;064-116-226-667-307;;009-891-282-676-18X;;006-026-497-014-33X;;010-718-962-322-429;;061-669-166-608-882;;019-580-410-758-652;;102-930-132-246-061;;011-850-681-025-027;;119-132-751-946-922;;063-867-427-592-138;;002-186-545-851-173;;181-512-135-393-079;;022-265-272-874-951;;042-420-274-722-532;;030-350-705-205-427;;040-107-243-792-147;;118-007-112-303-323,10.1002/(sici)1520-6017(200002)89:2<145::aid-jps2>3.0.co;2-6;;10688744;;22104146;;10.1016/j.bmcl.2011.10.041;;23394148;;10.1021/ol400049m;;10.1055/s-0035-1561339;;10.1016/j.bmcl.2006.08.003;;16919947;;10.1016/j.bmcl.2003.10.049;;14698169;;10.1021/jo01296a034;;10.1021/jm0111346;;12061878;;24392786;;10.1517/13543776.2014.876412;;10.1039/b009154p;;10.1016/s1569-1993(16)30138-2;;25981758;;pmc4764353;;10.1056/nejmoa1409547;;10.1021/jm00070a012;;8410980;;10.1002/anie.200700039;;17886815;;10.1002/anie.201708903;;29024330;;10.4155/fmc-2019-0183;;31538524;;31034626;;10.1002/jlcr.3743;;10.1021/jacs.5b05144;;pmc4490774;;26088401;;10.1021/jm4007998;;24294889;;10.1021/cen-09427-cover;;27169762;;10.1002/jlcr.3383;;10.1021/acs.jmedchem.8b01808;;30640460;;28591114;;10.1038/nbt0617-493;;10.1007/978-1-4939-1598-9_9;;10.1021/cen-v087n025.p036,"Veraldo Synthesis (1), 74-79, 1999.;;Dorwald F. A. Side Reactions in Organic Synthesis, 2005, Wiley: VCH, Weinheim p. IX of Preface p. 1-15.;;Venkatesh, J. Pharm. Sci. 89, 145-54 (2000).;;U.S. Appl. No. 10/118,916, filed Nov. 6, 2018, Altenbach et al.;;U.S. Appl. No. 10/208,053, filed Feb. 19, 2019, Strohbach et al.;;U.S. Appl. No. 10/138,227, filed Nov. 27, 2018, Altenbach et al.;;U.S. Appl. No. 10/131,670, filed Nov. 20, 2018, Strohbach et al.;;U.S. Appl. No. 10/258,624, filed Apr. 16, 2019, Miller et al.;;Anilkumar, G.N. et al. (2011) “II. Novel HCV NS5B polymerase inhibitors: Discovery of indole C2 acyl sulfonamides” Biogranic & Medicinal Chemistry Letters, 22(1):713-717.;;Borhade, S.R. et al. (2013) “Synthesis of Novel Aryl and Heteroaryl Acyl Sulfonimidamides via Pd-Catalyzed Carbonylation Using a Nongaseous Precursor” Organic Lett, 15(5):1056-1059.;;Chen, Y. (Jan. 26, 2016) “N-Monoacylation of Sulfonimidamides” Synthesis, 48(7):1019-1028.;;Database Caplus, Accession No. 1965:51408. Abstract of French Patent No. FR M2868, filed Nov. 23, 1964, by Roussel-UCLAF [online]. Retrieved Jan. 6, 2017 (1 page).;;Database Caplus, Accession No. 1965:51409. Abstract of German Patent No. DE 1182243, filed Nov. 26, 1964, by Badische Anilin & Soda-Fabrik A.G. [online]. Retrieved Jan. 6, 2017 (2 pages).;;Database Pubchem, CID: 2545578. Compound Summary, T5339296. NIH, U.S. National Library of Medicine, National Center for Biotechnology Information; Modify Date: Jan. 16, 2016. [online]. Retrieved from https://pubchem.ncbi.nlm.nih.gov/compound/2545578, on Jan. 22, 2016 (9 pages).;;Database Pubchem, CID: 44419393. Compound Summary, CHEMBL374189. NIH, U.S. National Library of Medicine, National Center for Biotechnology Information; Modify Date: Jan. 16, 2016. [online]. Retrieved from https://pubchem.ncbi.nlm.nih.gov/compound/44419393, on Jan. 22, 2016 (11 pages).;;Database Pubchem, CID: 49774135. Compound Summary, SCHEMBL13395127. NIH, U.S. National Library of Medicine, National Center for Biotechnology Information; Modify Date: Jan. 16, 2016 [online]. Retrieved from https://pubchem.ncbi.nlm.nih.gov/compound/49774135, on Jan. 22, 2016 (10 pages).;;Database Pubchem, CID: 58132855. Compound Summary, SCHEMBL831192. NIH, U.S. National Library of Medicine, National Center for Biotechnology Information, PubChem Open Chemistry Database; Modify Date: Jan. 16, 2016 [online]. Retrieved from: https://pubchem.ncbi.nlm.nih.gov/compound/58132855, on Jan. 22, 2016 (10 pages).;;Hopkins, C.R. et al. (2006) “Design and synthesis of novel N-sulfonyl-2-indole carboxamides as potent PPAR-gamma binding agents with potential application to the treatment of osteoporosis” Bioorganic & Medicinal Chemistry Letters, 16(21):5659-5663.;;International Patent Application No. PCT/US2015/54316: International Search Report and Written Opinion, dated Feb. 5, 2016 (11 pages).;;International Patent Application No. PCT/US2017/025381: International Search Report and Written Opinion, dated Jun. 6, 2017 (11 pages).;;International Patent Application No. PCT/US2017/054611: International Search Report and Written Opinion, dated Jan. 3, 2018 (10 pages).;;International Patent Application No. PCT/US2017/065425: International Search Report and Written Opinion, dated Feb. 27, 2018 (10 pages).;;International Patent Application No. PCT/US2018/036610: International Search Report and Written Opinion, dated Sep. 19, 2018 (9 pages).;;International Patent Application No. PCT/US2018/040427: International Search Report and Written Opinion, dated Oct. 9, 2018 (15 pages).;;International Patent Application No. PCT/US2018/042415: International Search Report and Written Opinion, dated Oct. 31, 2018 (12 pages).;;International Patent Application No. PCT/US2018/042486: International Search Report and Written Opinion, dated Nov. 7, 2018 (13 pages).;;International Patent Application No. PCT/US2018/044963: International Search Report and Written Opinion, dated Sep. 25, 2018 (15 pages).;;International Patent Application No. PCT/US2018/056772: International Search Report and Written Opinion, dated Jan. 29, 2019 (13 pages).;;Jain, B.C. et al. (1947) “Studies in Sulphanilamides. Part XIII. Reaction With Dicarboxylic Acids. Some New N1- and N4-Acyl and Heterocycic Derivatives” Journal of the Indian Chemical Society, 24:173-176.;;Kettle, J.G. et al. (2004) “N-Benzylindole-2-carboxylic acids: potent functional antagonists of the CCR2b chemokine receptor” Bioorganic & Medicinal Chemistry Letters, 14(2): 405-408.;;Lai, J.T. et al. (1980) “Rearrangement of 2,2,6,6-tetramethyl-4-piperidone in phase-transfer catalyzed reactions,” Journal of Organic Chemistry, 45(8):1513-1514.;;Matter, H. et al. (2002) “Design and Quantitative Structure-Activity Relationship of 3-Amidinobenzy1-1H-indole-2-carboxamides as Potent, Nonchiral, and Selective Inhibitors of Blood Coagulation Factor Xa” Journal of Medicinal Chemistry, 45(13):2749-2769.;;Norman, P. (2014) “Novel picolinamide-based cystic fibrosis transmembrane regulator modulators: evaluation of WO2013038373, WO2013038376, WO2013038381, WO2013038386, and WO2013038390,” Expert Opinion on Therapeutic Patents, 24(7):829-837.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 15/721,390, dated Sep. 4, 2019.;;Notman, N. (2016) “2Heavy drugs gaining momentum” [online] Retrieved from the internet: https://www.chemistryworld.com/features/2heavy-drugs-gaining-momentum/1010186.article, on Oct. 7, 2019.;;Passarella, D. et al. (2001) “Cyclodimerization of indol-2-ylacetylenes. An example of intermolecular enyne-alkyne cycloaddition” Journal of the Chemical Society, Perkin Transactions 1, 127-129.;;Rosebraugh, C.J. (2015) “Highlights of Presecribing Information for Orkambi,” [online] Retrieved from the Internet: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206038Orig1s000lbl.pdf, on Aug. 24, 2017.;;Silverman, R. (2004) The Organic Chemistry of Drug Design and Drug Action, Elsevier, pp. 29-32.;;Soloducho, J. (1989) “Synthesis of Some Pyrido [2,3-c][1,2,6]triazinone Derivatives” Journal far Pracktische Chemie, 331(3):503-506.;;Tullis, E. et al. (2018) “Preliminary safety and efficacy of triple-combination CFTR modulator regimens,” Respirology, 23(51):33.;;Uttamsingh, V. et al. (2016) “WS13.6 CTP-656 tablet confirmed superiority of pharmacokinetic profile relative to Kalydeco in Phase I clinical studies” Journal of Cystic Fibrosis, 15:S22.;;Wainwright, C.E. et al. (2015) “Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR,” The New England Journal of Medicine, 373(3):220-231.;;Winn, M. et al. (1993) “2-(Alkylamino)nicotinic Acid and Analogs. Potent Angiotensin II Antagonists” Journal of Medicinal Chemistry, 36(18):2676-2688.;;Vertex Pharmaceuticals, Inc. (Mar. 28, 2017) “Two Phase 3 Studies of the Tezacaftor/Ivacaftor Combination Treatment Met Primary Endpoints with Statistically Significant Improvements in Lung Function (FEV1) in People With Cystic Fibrosis” [online] Retrieved from the Internet: http://investors.vrtx.com/static-files/f15217ac-4a8b-436a-9215-79144ec2e59b, on Oct. 10, 2019.;;Atzrodt J, Derdau V, Fey T, Zimmermann J. “The Renaissance of H/D Exchange” Angew. Chem. Int. Ed. 2007: 46, 7744-7765.;;Atzrodt J, Derdau V, Kerr W, Reid M. “C-H functionalization for hydrogen isotope exchange” Angew. Chem. Int. Ed. 2018: 57, 3022-3047.;;Braman, V.; Liu, J. F.; Harbeson, S.; Uttamsingh, V.; Bridson, G.; Wu, L.; Shipley, J. E. “Preliminary Clinical Outcomes for CTP-354, a Novel Subtype-Selective GABA(A) Modulator” Presented at the American Neurological Association (ANA) 2014 Annual Meeting, Baltimore, MD, Oct. 12-14, 2014.;;Cargnin S, Serafini M, Pirali T. “A primer of deuterium in drug design” Future Med. Chem. 2019; 11(16): 2039-2042.;;Czeskis B, Elmore, CS, Haight A, Hesk D, Maxwell BD, Miller SA, Raglione T, Schildknegt K, Traverse JF, Wang P. “Deuterated active pharmaceutical ingredients: A science-based proposal for synthesis, analysis, and control. Part 1: Framing the problem” J. Label. Compd. Radiopharm. 2019, 62: 690-694. DOI: 10.1002/jlcr.3743.;;Dao HT, Li C, Michaudel Q, Maxwell BD, Baran PS. J. Am. Chem. Soc. 2015; 137, 8046-8049.;;Database Pubchem, CID: 20050716. Compound Summary, 1-[2-[[2-[(2-Amino-3-methylbutanoyl)amino]-3-methylpentanoyl]amino]-3-phenylpropancy[pyrrolidine-2-carboxylic acid. NIH, U.S. National Library of Medicine, National Center for Biotechnology Information; Modify Date: Nov. 30, 2019. [online]. Retrieved from https://pubchem.ncbi.nlm.nih.gov/compound/20050716, on Dec. 3, 2019 (7 pages).;;Database Pubchem, CID: 20091118. Compound Summary, [4-(5-Hexylpyrimidin-2-yl)phenyl] 2-methoxypropanoate. NIH, U.S. National Library of Medicine, National Center for Biotechnology Information; Modify Date: Nov. 30, 2019. [online]. Retrieved from https://pubchem.ncbi.nlm.nih.gov/compound/20091118, on Dec. 3, 2019 (9 pages).;;Database Pubchem, CID: 20120819. Compound Summary, 4-(Cyclopentyloxy)-3-fluorobenzene-1-sulfonyl chloride. NIH, U.S. National Library of Medicine, National Center for Biotechnology Information; Modify Date: Nov. 30, 2019. [online]. Retrieved from https://pubchem.ncbi.nlm.nih.gov/compound/20120819, on Dec. 3, 2019 (8 pages).;;Gant TG. “Using Deuterium in Drug Discovery: Leaving the Label in the Drug” J Med. Chem. 2014; 57(9): 3595-3611.;;Halford B. “The deuterium switcheroo” Chemical & Engineering News 2016; 94(27), 32-36.;;International Patent Application No. PCT/US2019/016537: International Search Report and Written Opinion, dated Apr. 23, 2019 (13 pages).;;International Patent Application No. PCT/US2018/065522: International Search Report and Written Opinion, dated Jun. 25, 2019 (21 pages).;;Liu, J. F. et al. “CTP-354: A Novel Deuterated Subtype-Selective GABA(A) Modulator for Treatment of Neuropathic Pain, Spasticity and Anxiety Disorders” Presented at the American College of Neuropsychopharmacology (ACNP) 51st Annual Meeting, Hollywood, FL, Dec. 2-6, 2012.;;Maxwell BD, Tran SB, Lago M, Li J, and Bonacorsi Jr SJ. “The syntheses of [14C]BMS-823778 for use in a human ADME clinical study and of [13CD313CD2]BMT-094817, a stable-isotope labeled standard of a newly detected human metabolite” J. Label. Compd. Radiopharm. 2016; 59, 255-259.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 16/165,849, dated Jan. 27, 2020.;;Vertex Pharmaceuticals, Inc. (Nov. 3, 2017) “Vertex announces presentations of data at North American Cystic Fibrosis Conference that Demonstrate Important Progress Toward Goal of Helping All People with CF,” Health and Medicine Week, vol. 3, p. 196.;;Pirali T, Serafini M, Cargnin S, Genazzani AA. “Applications of Deuterium in Medicinal Chemistry” J Med. Chem. 2019; 62(11): 5276-5297.;;Schmidt, C. “First deuterated drug approved” Nat. Biotechnol. 2017, 35, 493-494.;;U.S. Appl. No. 16/620,265, filed Dec. 6, 2019, by Chen et al.;;U.S. Appl. No. 16/625,028, filed Dec. 20, 2019, by Chu et al.;;U.S. Appl. No. 16/631,989, filed Jan. 17, 2020, by Haseltine et al.;;U.S. Appl. No. 16/629,472, filed Jan. 8, 2020, by Chen et al.;;U.S. Appl. No. 16/635,346, filed Jan. 30, 2020, by Angell et al.;;U.S. Appl. No. 16/836,155, filed Mar. 31, 2020, by Miller et al.;;Vertex Pharmaceuticals, Inc. (Jul. 18, 2017) “Vertex Announces Positive Phase 1 & Phase 2 Data from Three Different Triple Combination Regimins in People with Cystic Fibrosis Who Have One F508del Mutation and One Minimal Function Mutation (F508del/Min)”, Retrieved from the Internet: URL: http://investors.vrtx.com/news-releases/news-release-details/vertex/announces-positive-phase-1-phase-2-data-three-different [retrieved on Mar. 27, 2019].;;Vodak, D. (2014) “Design and Development of HPMCAS-Based Spray-Dried Dispersions,” 303-322.;;Yarnell, AT. “Heavy-Hydrogen Drugs Turn Heads, Again” Chemical & Engineering News 2009; 87(25), 36-39.",ACTIVE
172,US,B2,US 11453655 B2,179-890-427-602-115,2022-09-27,2022,US 202016994875 A,2020-08-17,US 202016994875 A;;US 201715836627 A;;US 201662432537 P,2016-12-09,"Modulator of the cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator","Compounds of Formula (I): pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed. Also disclosed are solid state forms of Compound 1 and salts and solvates thereof.",VERTEX PHARMA,ABELA ALEXANDER RUSSELL;;ALCACIO TIMOTHY;;ANDERSON COREY;;ANGELL PAUL TIMOTHY;;BAEK MINSON;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;FERRIS LORI ANN;;GROOTENHUIS PETER DIEDERIK JAN;;GROSS RAYMOND STANLEY;;GULEVICH ANTON V;;HADIDA RUAH SARA SABINA;;HSIA CLARA KUANG-JU;;HUGHES ROBERT M;;JOSHI PRAMOD VIRUPAX;;KANG PING;;KESHAVARZ-SHOKRI ALI;;KHATUYA HARIPADA;;KRENITSKY PAUL JOHN;;MCCARTNEY JASON;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE JEAN DENIS;;SHI YI;;SHRESTHA MUNA;;SIESEL DAVID ANDREW;;STAVROPOULOS KATHY;;TERMIN ANDREAS P;;VAN GOOR FREDRICK F;;UY JOHNNY;;YOUNG TIMOTHY JOHN;;ZHOU JINGLAN,VERTEX PHARMACEUTICALS (SAN DIEGO) LLC (2017-12-20);;VERTEX PHARMACEUTICALS INCOPORATED (2017-12-14);;VERTEX PHARMACEUTICALS INCORPORATED (2017-12-07),https://lens.org/179-890-427-602-115,Granted Patent,yes,264,1,63,63,0,A61K31/455;;C07D401/14;;C07D231/20;;A61P11/00;;C07D401/04;;C07D401/14;;A61P11/00;;C07D401/14;;C07D471/14;;C07B2200/13;;C07D231/20;;C07D498/14;;A61P11/00;;C07D401/04;;C07D401/14;;A61K31/4439;;A61K31/519;;A61K31/5365;;C07D231/20;;C07D401/04;;C07D471/14;;C07D498/14;;A61P11/00;;C07B2200/13;;C07D401/14;;C07D471/14;;C07B2200/13;;A61P11/00;;C07D498/14;;C07D401/04;;C07D231/20,C07D401/04;;A61P11/00;;C07D231/20;;C07D401/14;;C07D471/14;;C07D498/14,,100,39,030-344-533-512-103;;011-459-178-850-597;;016-315-186-852-575;;029-362-218-879-507;;067-187-844-310-10X;;034-587-611-086-755;;019-580-410-758-652;;102-930-132-246-061;;013-937-078-602-349;;009-214-187-079-899;;104-949-654-022-72X;;011-850-681-025-027;;096-312-557-325-378;;119-132-751-946-922;;063-867-427-592-138;;002-186-545-851-173;;181-512-135-393-079;;078-417-508-507-333;;012-371-996-064-723;;103-052-069-575-996;;039-573-265-223-407;;022-265-272-874-951;;064-116-226-667-307;;009-891-282-676-18X;;042-420-274-722-532;;030-350-705-205-427;;006-026-497-014-33X;;045-406-285-588-795;;079-362-981-419-890;;040-107-243-792-147;;010-718-962-322-429;;061-669-166-608-882;;118-007-112-303-323;;087-626-907-619-006;;144-170-754-278-61X;;170-189-696-205-940;;115-350-648-150-731;;038-005-480-898-683;;001-641-923-364-301,24973281;;10.1016/s2213-2600(14)70132-8;;10.3410/f.725446625.793506150;;pmc6510372;;10.1111/cts.12610;;30694595;;10.2533/chimia.2008.260;;31987762;;10.1016/j.jcf.2020.01.005;;pmc10657649;;25650311;;10.1016/j.bmc.2014.12.056;;22104146;;10.1016/j.bmcl.2011.10.041;;10.1002/anie.200700039;;17886815;;10.1002/anie.201708903;;29024330;;23394148;;10.1021/ol400049m;;10.1023/a:1016241927429;;7494814;;10.1007/3-540-69178-2_5;;10.4155/fmc-2019-0183;;31538524;;10.1055/s-0035-1561339;;31034626;;10.1002/jlcr.3743;;10.1021/jacs.5b05144;;pmc4490774;;26088401;;10.1021/jm4007998;;24294889;;10.1021/cen-09427-cover;;10.1016/j.bmcl.2006.08.003;;16919947;;10.1016/j.bmcl.2003.10.049;;14698169;;10.1021/jo01296a034;;10.1021/jm0111346;;12061878;;27169762;;10.1002/jlcr.3383;;24392786;;10.1517/13543776.2014.876412;;10.1039/b009154p;;10.1021/acs.jmedchem.8b01808;;30640460;;28591114;;10.1038/nbt0617-493;;10.1016/s1569-1993(16)30138-2;;10.1002/(sici)1520-6017(200002)89:2<145::aid-jps2>3.0.co;2-6;;10688744;;10.1055/s-1999-3685;;10.1007/978-1-4939-1598-9_9;;25981758;;pmc4764353;;10.1056/nejmoa1409547;;10.1021/jm00070a012;;8410980;;10.1021/cen-v087n025.p036;;17100633;;10.2174/138955706778742768;;10.1021/cc9800071;;10746014;;10.1002/9780470571224.pse414;;15286737;;10.1038/nrd1470;;pmc2838761;;20178582;;10.1186/1423-0127-17-13;;10.1016/s0169-409x(02)00003-0;;11922947,"“A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial”, Boyle, M., The Lancet Respiratory Medicine (Jul. 1, 2014) Retrieved from the Internet: https://www-clinicalkeycom-ez03.infotrieve.com/#!/content/playContent/1-s2.0S2213260014701328?returnurl=null&referrer=null.;;VARUN GARG, JINSHAN SHEN, CHONGHUA LI, SAGAR AGARWAL, ASFIHA GEBRE, SARAH ROBERTSON, JIAYIN HUANG, LINDA HAN, LICONG JIANG, KRISTI: ""Pharmacokinetic and Drug–Drug Interaction Profiles of the Combination of Tezacaftor/Ivacaftor"", CTS - CLINICAL AND TRANSLATIONAL SCIENCE, WILEYBLACKWELL PUB., US, vol. 12, no. 3, 1 May 2019 (2019-05-01), US , pages 267 - 275, XP055719490, ISSN: 1752-8054, DOI: 10.1111/cts.12610;;International Patent Application No. PCT/US2020/028699: International Search Report and Written Opinion, dated Jul. 20, 2020 (9 pages).;;International Patent Application No. PCT/US2020/034199: International Search Report and Written Opinion, dated Aug. 11, 2020 (15 pages).;;IRIS KIELTSCH, PATRICK EISENBERGER, KYRILL STANEK, ANTONIO TO: ""LAUREATES: AWARDS AND HONORS SCS FALL MEETING 2007 260 Recent Advances in Electrophilic CF 3 -Transfer Using Hypervalent Iodine(III) Reagents"", CHIMIA CHIMIA SCHWEIZERISCHE CHEMISCHE GESELLSCHAFT ISSN, vol. 62, no. 62, 1 January 2008 (2008-01-01), pages 260 - 263, XP055591571, DOI: 10.2533/chimia.2008.260;;MONTEMAYOR KRISTINA; CLAUDIO ABIGAIL T.; CARSON SARA; LECHTZIN NOAH; CHRISTIANSON MINDY S.; WEST NATALIE E.: ""Unmasking catamenial hemoptysis in the era of CFTR modulator therapy"", JOURNAL OF CYSTIC FIBROSIS, ELSEVIER, NL, vol. 19, no. 4, 24 January 2020 (2020-01-24), NL , XP086202454, ISSN: 1569-1993, DOI: 10.1016/j.jcf.2020.01.005;;NCT03029455 “A Study to Evaluate Safety and Pharmacokinetics of VX-659 in Healthy Subjects and in Adults With Cystic Fibrosis”. Vertex Pharmaceuticals Incorporated, Retrieved from the Internet: https://clinicaltrials.gov/ct2/show/study/NCT03029455.;;CHEN, QUN; ZHU, GUO-BIAO: ""Synthesis of 3,3,3-trifluoro-2,2-dimethylpropionic acid"", HUAXUE SHIJI - CHEMICAL REAGENTS, BEIJING : HUAXUE HUAXUE SHIJI KEJI QINGBAO ZHONGXINZHAN, CN, vol. 38, no. 4, 1 January 2016 (2016-01-01), CN , pages 386 - 388, XP009513488, ISSN: 0258-3283, DOI: 10.13822/j.cnki.hxsj.2016.04.026;;HWANG TSONG-LONG; WANG WEN-HUI; WANG TING-YI; YU HUANG-PING; HSIEH PEI-WEN: ""Synthesis and pharmacological characterization of 2-aminobenzaldehyde oxime analogs as dual inhibitors of neutrophil elastase and proteinase 3"", BIOORGANIC & MEDICINAL CHEMISTRY, ELSEVIER, AMSTERDAM, NL, vol. 23, no. 5, 16 January 2015 (2015-01-16), AMSTERDAM, NL, pages 1123 - 1134, XP029199003, ISSN: 0968-0896, DOI: 10.1016/j.bmc.2014.12.056;;“Vertex Provides Update on Ongoing Phase 3 Program for VX-661 in Combination with Ivacaftor for the Treatment of Cystic Fibrosis” (Aug. 15, 2016) Retrieved from the Internet: https://www.businesswire.com/news/home/20160815006099/en/Vertex-Update-Ongoing-Phase-3-Program-VX-661.;;Anilkumar, G.N. et al. (2011) “II. Novel HCV NS5B polymerase inhibitors: Discovery of indole C2 acyl sulfonamides” Biogranic & Medicinal Chemistry Letters, 22(1):713-717.;;Atzrodt J, Derdau V, Fey T, Zimmermann J. “The Renaissance of H/D Exchange” Angew. Chem. Int. Ed. 2007: 46, 7744-7765.;;Atzrodt J, Derdau V, Kerr W, Reid M. “C—H functionalization for hydrogen isotope exchange” Angew. Chem. Int. Ed. 2018: 57, 3022-3047.;;Belikov, V.G., (2007) Farmatsevticheskaya khimiya (Pharmaceutical Chemistry), Moscow: MEDpress-inform, pp. 27-29.;;Borhade, S.R. et al. (2013) “Synthesis of Novel Aryl and Heteroaryl Acyl Sulfonimidamides via Pd-Catalyzed Carbonylation Using a Nongaseous Precursor” Organic Lett, 15(5):1056-1059.;;Braman, V.; Liu, J. F.; Harbeson, S.; Uttamsingh, V.; Bridson, G.; Wu, L.; Shipley, J. E. “Preliminary Clinical Outcomes for CTP-354, a Novel Subtype-Selective GABA(A) Modulator” Presented at the American Neurological Association (ANA) 2014 Annual Meeting, Baltimore, MD, Oct. 12-14, 2014.;;Byrn, S. et al. (1995) “Pharmaceutical solids: A strategic approach to regulatory considerations,” (12): 945-954.;;Caira, M. R. (1998) “Crystalline Polymorphism of Organic Compounds,” Topics in Current Chemistry, 163-208.;;Cargnin S, Serafini M, Pirali T. “A primer of deuterium in drug design” Future Med. Chem. 2019; 11(16): 2039-2042.;;Chen, Y. (Jan. 26, 2016) “N-Monoacylation of Sulfonimidamides” Synthesis, 48(7):1019-1028.;;Czeskis B, Elmore, CS, Haight A, Hesk D, Maxwell BD, Miller SA, Raglione T, Schildknegt K, Traverse JF, Wang P. “Deuterated active pharmaceutical ingredients: A science-based proposal for synthesis, analysis, and control. Part 1: Framing the problem” J. Label. Compd. Radiopharm. 2019, 62: 690-694. DOI: 10.1002/jlcr.3743.;;Dao HT, Li C, Michaudel Q, Maxwell BD, Baran PS. J. Am. Chem. Soc. 2015; 137, 8046-8049.;;Database Caplus, Accession No. 1965:51408. Abstract of French Patent No. FR M2868, filed Nov. 23, 1964, by Roussel-UCLAF [online]. Retrieved Jan. 6, 2017 (1 page).;;Database Caplus, Accession No. 1965:51409. Abstract of German Patent No. DE 1182243, filed Nov. 26, 1964, by Badische Anilin & Soda-Fabrik A.G. [online]. Retrieved Jan. 6, 2017 (2 pages).;;Database Pubchem, CID: 20050716. Compound Summary, 1-[2-[[2-[(2-Amino-3-methylbutanoyl)amino]-3-methylpentanoyl]amino]-3-phenylpropanoyl]pyrrolidine-2-carboxylic acid. NIH, U.S. National Library of Medicine, National Center for Biotechnology Information; Modify Date: Nov. 30, 2019. [online]. Retrieved from https://pubchem.ncbi.nlm.nih.gov/compound/20050716, on Dec. 3, 2019 (7 pages).;;Database Pubchem, CID: 20091118. Compound Summary, [4-(5-Hexylpyrimidin-2-yl)phenyl] 2-methoxypropanoate. NIH, U.S. National Library of Medicine, National Center for Biotechnology Information; Modify Date: Nov. 30, 2019. [online]. Retrieved from https://pubchem.ncbi.nlm.nih.gov/compound/20091118, on Dec. 3, 2019 (9 pages).;;Database Pubchem, CID: 20120819. Compound Summary, 4-(Cyclopentyloxy)-3-fluorobenzene-1-sulfonyl chloride. NIH, U.S. National Library of Medicine, National Center for Biotechnology Information; Modify Date: Nov. 30, 2019. [online]. Retrieved from https://pubchem.ncbi.nlm.nih.gov/compound/20120819, on Dec. 3, 2019 (8 pages).;;Database Pubchem, CID: 2545578. Compound Summary, T5339296. NIH, U.S. National Library of Medicine, National Center for Biotechnology Information; Modify Date: Jan. 16, 2016. [online]. Retrieved from https://pubchem.ncbi.nlm.nih.gov/compound/2545578, on Jan. 22, 2016 (9 pages).;;Database Pubchem, CID: 44419393. Compound Summary, CHEMBL374189. NIH, U.S. National Library of Medicine, National Center for Biotechnology Information; Modify Date: Jan. 16, 2016. [online]. Retrieved from https://pubchem.ncbi.nlm.nih.gov/compound/44419393, on Jan. 22, 2016 (11 pages).;;Database Pubchem, CID: 49774135. Compound Summary, SCHEMBL13395127. NIH, U.S. National Library of Medicine, National Center for Biotechnology Information; Modify Date: Jan. 16, 2016 [online], Retrieved from https://pubchem.ncbi.nlm.nih.gov/compound/49774135, on Jan. 22, 2016 (10 pages).;;Database Pubchem, CID: 58132855. Compound Summary, SCHEMBL831192. NIH, U.S. National Library of Medicine, National Center for Biotechnology Information, PubChem Open Chemistry Database; Modify Date: Jan. 16, 2016 [online]. Retrieved from: https://pubchem.ncbi.nlm.nih.gov/compound/58132855, on Jan. 22, 2016 (10 pages).;;Dorwald, F. A. (2006) “Side Reactions in Organic Synthesis” Wiley: VCH, Weinheim p. IX of Preface p. 1-15.;;Gant TG. “Using Deuterium in Drug Discovery: Leaving the Label in the Drug” J Med. Chem. 2014; 57(9): 3595-3611.;;Halford B. “The deuterium switcheroo” Chemical & Engineering News 2016; 94(27), 32-36.;;Hopkins, C.R. et al. (2006) “Design and synthesis of novel N-sulfonyl-2-indole carboxamides as potent PPAR-gamma binding agents with potential application to the treatment of osteoporosis” Bioorganic & Medicinal Chemistry Letters, 16(21):5659-5663.;;International Patent Application No. PCT/US2015/54316: International Search Report and Written Opinion, dated Feb. 5, 2016 (11 pages).;;International Patent Application No. PCT/US2017/025381: International Search Report and Written Opinion, dated Jun. 6, 2017 (11 pages).;;International Patent Application No. PCT/US2017/054611: International Search Report and Written Opinion, dated Jan. 3, 2018 (10 pages).;;International Patent Application No. PCT/US2017/065425: International Search Report and Written Opinion, dated Feb. 27, 2018 (10 pages).;;International Patent Application No. PCT/US2018/036610: International Search Report and Written Opinion, dated Sep. 19, 2018 (9 pages).;;International Patent Application No. PCT/US2018/040427: International Search Report and Written Opinion, dated Oct. 9, 2018 (15 pages).;;International Patent Application No. PCT/US2018/042415: International Search Report and Written Opinion, dated Oct. 31, 2018 (12 pages).;;International Patent Application No. PCT/US2018/042486: International Search Report and Written Opinion, dated Nov. 7, 2018 (13 pages).;;International Patent Application No. PCT/US2018/044963: International Search Report and Written Opinion, dated Sep. 25, 2018 (15 pages).;;International Patent Application No. PCT/US2018/056772: International Search Report and Written Opinion, dated Jan. 29, 2019 (13 pages).;;International Patent Application No. PCT/US2018/063871: International Search Report and Written Opinion, dated Feb. 25, 2019 (16 pages).;;International Patent Application No. PCT/US2019/016537: International Search Report and Written Opinion, dated Apr. 23, 2019 (13 pages).;;International Patent Application No. PCT/US2018/064522: International Search Report and Written Opinion, dated Jun. 25, 2019 (21 pages).;;International Patent Application No. PCT/US2019/018042: International Search Report and Written Opinion, dated Apr. 17, 2019 (10 pages).;;International Patent Application No. PCT/US2019/024890: International Search Report and Written Opinion, dated Jun. 17, 2019 (13 pages).;;International Patent Application No. PCT/US2019/026075: International Search Report and Written Opinion, dated Jun. 17, 2019 (13 pages).;;International Patent Application No. PCT/US2019/027202: International Search Report and Written Opinion, dated Jun. 17, 2019 (10 pages).;;Jain, B.C. et al. (1947) “Studies in Sulphanilamides. Part XIII. Reaction With Dicarboxylic Acids. Some New N1- and N4-Acyl and Heterocycic Derivatives” Journal of the Indian Chemical Society, 24:173-176.;;Kettle, J.G. et al. (2004) “N-Benzylindole-2-carboxylic acids: potent functional antagonists of the CCR2b chemokine receptor” Bioorganic & Medicinal Chemistry Letters, 14(2): 405-408.;;Lai, J.T. et al. (1980) “Rearrangement of 2,2,6,6-tetramethyl-4-piperidone in phase-transfer catalyzed reactions,” Journal of Organic Chemistry, 45(8):1513-1514.;;Liu, J. F. et al. “CTP-354: A Novel Deuterated Subtype-Selective GABA(A) Modulator for Treatment of Neuropathic Pain, Spasticity and Anxiety Disorders” Presented at the American College of Neuropsychopharmacology (ACNP) 51st Annual Meeting, Hollywood, FL, Dec. 2-6, 2012.;;Matter, H. et al. (2002) “Design and Quantitative Structure-Activity Relationship of 3-Amidinobenzyl-1H-indole-2-carboxamides as Potent, Nonchiral, and Selective Inhibitors of Blood Coagulation Factor Xa” Journal of Medicinal Chemistry, 45(13):2749-2769.;;Maxwell BD, Tran SB, Lago M, Li J, and Bonacorsi Jr SJ. “The syntheses of [14C]BMS-823778 for use in a human ADME clinical study and of [13CD313CD2]BMT-094817, a stable-isotope labeled standard of a newly detected human metabolite” J. Label. Compd. Radiopharm. 2016; 59, 255-259.;;Norman, P. (2014) “Novel picolinamide-based cystic fibrosis transmembrane regulator modulators: evaluation of WO2013038373, WO2013038376, WO2013038381, WO2013038386, and WO2013038390,” Expert Opinion on Therapeutic Patents, 24(7):829-837.;;Notman, N. (2016) “2Heavy drugs gaining momentum” [online] Retrieved from the internet: https://www.chemistryworld.com/features/2heavy-drugs-gaining-momentum/1010186.article, on Oct. 7, 2019.;;Passarella, D. et al. (2001) “Cyclodimerization of indol-2-ylacetylenes. An example of intermolecular enyne-alkyne cycloaddition” Journal of the Chemical Society, Perkin Transactions 1, 127-129.;;Pirali T, Serafini M, Cargnin S, Genazzani AA. “Applications of Deuterium in Medicinal Chemistry” J Med. Chem. 2019; 62(11): 5276-5297.;;Rosebraugh, C.J. (2015) “Highlights of Presecribing Information for Orkambi,” [online] Retrieved from the Internet: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206038Orig1s000lbl.pdf, on Aug. 24, 2017.;;Schmidt C. “First deuterated drug approved” Nat. Biotechnol. 2017, 35, 493-494.;;Silverman, R. (2004) The Organic Chemistry of Drug Design and Drug Action, Elsevier, pp. 29-32.;;Soloducho, J. (1989) “Synthesis of Some Pyrido [2,3-c][1,2,6]triazinone Derivatives” Journal für Pracktische Chemie, 331(3):503-506.;;Tullis, E. et al. (2018) “Preliminary safety and efficacy of triple-combination CFTR modulator regimens,” Respirology, 23(51):33.;;U.S. Appl. No. 16/620,265, filed Dec. 6, 2019, by Chen et al.;;U.S. Appl. No. 16/625,028, filed Dec. 20, 2019, by Chu et al.;;U.S. Appl. No. 16/625,028, filed Jan. 17, 2020, by Haseltine et al.;;U.S. Appl. No. 16/635,346, filed Jan. 30, 2020, by Angell et al.;;U.S. Appl. No. 16/836,155, filed Mar. 31, 2020, by Miller et al.;;Uttamsingh, V. et al. (2016) “WS13.6 CTP-656 tablet confirmed superiority of pharmacokinetic profile relative to Kalydeco in Phase I clinical studies” Journal of Cystic Fibrosis, 15:S22.;;Venkatesh, S. et al. (2000) “Role of the development scientist in compound lead selection and optimization” J. Pharm. Sci. 89(2), 145-154.;;Verado, G. et al. (1999) “Reductive One Batch Synthesis of N-Substituted Pyrrolidines from Primary Amines and 2,5-Dimethoxytetrahydrofuran” Synthesis, (1):74-79.;;Vertex Pharmaceuticals, Inc. (Mar. 28, 2017) “Two Phase 3 Studies of the Tezacaftor/Ivacaftor Combination Treatment Met Primary Endpoints with Statistically Significant Improvements in Lung Function (FEV1) in People With Cystic Fibrosis” [online] Retrieved from the Internet: http://investors.vrtx.com/static-files/f15217ac-4a8b-436a-9215-79144ec2e59b, on Oct. 10, 2019.;;Vertex Pharmaceuticals, Inc. (Jul. 18, 2017) “Vertex Announces Positive Phase 1 & Phase 2 Data from Three Different Triple Combination Regimens in People with Cystic Fibrosis Who Have One F508del Mutation and One Minimal Function Mutation (F508del/Min)”, Retrieved from the Internet: URL: http://investors.vrtx.com/news-releases/news-release-details/vertex/announces-positive-phase-1-phase-2-data-three-different [retrieved on Mar. 27, 2019].;;Vertex Pharmaceuticals, Inc. (Nov. 3, 2017) “Vertex announces presentations of data at North American Cystic Fibrosis Conference that Demonstrate Important Progress Toward Goal of Helping All People with CF,” Health and Medicine Week, vol. 3, p. 196.;;Vodak, D. (2014) “Design and Development of HPMCAS-Based Spray-Dried Dispersions,” 303-322.;;Wainwright, C.E. et al. (2015) “Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR,” The New England Journal of Medicine, 373(3):220-231.;;Winn, M. et al. (1993) “2-(Alkylamino)nicotinic Acid and Analogs. Potent Angiotensin II Antagonists” Journal of Medicinal Chemistry, 36(18):2676-2688.;;Yarnell AT. “Heavy-Hydrogen Drugs Turn Heads, Again” Chemical & Engineering News 2009; 87(25), 36-39.;;Bhattacharya, S. et al. (2009) Polymorphism in Pharmaceutical Solids: Thermoanalytical and Crystallographic Methods (Brittain H. ed., 2d ed. Informa Healthcare USA, Inc. 2009) 318-335.;;Brown et al. (2006) “On scaffolds and hopping in medicinal Chemistry,” Mini-reviews in medicinal chemistry, vol. 6, 11(13), 1217-1229.;;Chemical Abstracts Service, CAS Registry No. 204017-11-8. CA Index Name: 1H-Indole-2-carboxamide, 1-[[2,4-bis(trifluoromethyl)phenyl]methyl]-2,3-dihydro-N-(phenylsulfonyl)-. Entered STN: Apr. 12, 1998.;;Chemical Abstracts Service, CAS Registry No. 220678-97-7. CA Index Name: 1H-Indole-2-carboxamide, 1-[(3,4-dichlorophenyl)methyl]-N-(phenylsulfonyl)-. Entered STN: Mar. 24, 1999.;;Chemical Abstracts Service, CAS Registry No. 220678-99-9. CA Index Name: 1H-Indole-2-carboxamide, 1-[(3,4-dichlorophenyl)methyl]-N-[(3,5-dimethyl-4-isoxazolyl)sulfonyl]-. Entered STN: Mar. 24, 1999.;;Chemical Abstracts Service, CAS Registry No. 412005-98-2. CA Index Name: 1H-Indole-2-carboxamide, 3-(4-methoxyphenyl)-N-(phenylsulfonyl)-1-[[3-(trifluoromethyl)phenyl]methyl]-. Entered STN: May 7, 2002.;;Chemical Abstracts Service, CAS Registry No. 895575-67-4. CA Index Name: 1H-Indole-2-carboxamide,1-[(3-chlorophenyl)methyl]-4-nitro-N-(2-thienylsulfonyl)-. Jun. 30, 2006.;;Chemical Abstracts Service, CAS Registry No. 895575-68-5. CA Index Name: 1H-Indole-2-carboxamide,4-amino-1-[(3-chlorophenyl)methyl]-N-(2-thienylsulfonyl)-. Jul. 23, 2006.;;European Patent Application No. 15849396.5 (Patent No. 3203840): Notice of Opposition by Elkington and Fife, LLP, May 5, 2021 (19 pages).;;Ghose et al. (1999) Knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery—qualitive and quantitative characterization of known drug databases, J. Comb. Chem. 1(1), 55-68.;;Ivanisevic, I. (2011) “Uses of X-Ray Powder Diffraction in the Pharmaceutical Industry,” Pharm. Form. Qual. 30-33.;;Kola et al. (2004) “Can the pharmaceutical industry reduce attrition rates?” Nature Reviews Drug Discovery, 3(8), 711-715.;;Shih et al. (2010) “Pyrazole compound BPR1P0034 with potent and selective anti-influenza virus activity” Journal of Biomedical Science, 17:13.;;Soloducho, J. et al. “Synthesis of Some Pyrido[3,2g][1,2,5]triazocine Derivatives,” Polish Journal of Chemistry, vol. 59, No. 10-12, Jan. 1, 1985, pp. 1115-1120.;;Table 2 : List of the mutations or SNP tested in this study (https://www.jmdjournal.org/cms/10.2353/jmoldx.2008.080056/attachment/2286a276-d0b2-4a8a-83f8-8273bef9a761/mmc1.doc). Accessed Jan. 25, 2021.;;U.S. Appl. No. 17/475,606, filed Sep. 15, 2021, by Chu et al.;;U.S. Appl. No. 17/505,699, filed Oct. 20, 2021, by Alcacio et al.;;Walters et al. (2002) “Prediction of ‘drug-likeness’,” Advanced Drug Delivery Reviews, 54(3), 255-271.",ACTIVE
173,US,A1,US 2021/0047295 A1,046-945-158-208-234,2021-02-18,2021,US 202016994875 A,2020-08-17,US 202016994875 A;;US 201715836627 A;;US 201662432537 P,2016-12-09,"MODULATOR OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR","Compounds of Formula (I): pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed. Also disclosed are solid state forms of Compound 1 and salts and solvates thereof.",VERTEX PHARMA,ABELA ALEXANDER RUSSELL;;ALCACIO TIMOTHY;;ANDERSON COREY;;ANGELL PAUL TIMOTHY;;BAEK MINSON;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;FERRIS LORI ANN;;GROOTENHUIS PETER DIEDERIK JAN;;GROSS RAYMOND STANLEY;;GULEVICH ANTON V;;HADIDA RUAH SARA SABINA;;HSIA CLARA KUANG-JU;;HUGHES ROBERT M;;JOSHI PRAMOD VIRUPAX;;KANG PING;;KESHAVARZ-SHOKRI ALI;;KHATUYA HARIPADA;;KRENITSKY PAUL JOHN;;MCCARTNEY JASON;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE JEAN DENIS;;SHI YI;;SHRESTHA MUNA;;SIESEL DAVID ANDREW;;STAVROPOULOS KATHY;;TERMIN ANDREAS P;;VAN GOOR FREDRICK F;;UY JOHNNY;;YOUNG TIMOTHY JOHN;;ZHOU JINGLAN,VERTEX PHARMACEUTICALS (SAN DIEGO) LLC (2017-12-20);;VERTEX PHARMACEUTICALS INCOPORATED (2017-12-14);;VERTEX PHARMACEUTICALS INCORPORATED (2017-12-07),https://lens.org/046-945-158-208-234,Patent Application,yes,0,7,63,63,0,A61K31/455;;C07D401/14;;C07D231/20;;A61P11/00;;C07D401/04;;C07D401/14;;A61P11/00;;C07D401/14;;C07D471/14;;C07B2200/13;;C07D231/20;;C07D498/14;;A61P11/00;;C07D401/04;;C07D401/14;;A61K31/4439;;A61K31/519;;A61K31/5365;;C07D231/20;;C07D401/04;;C07D471/14;;C07D498/14;;A61P11/00;;C07B2200/13;;C07D401/14;;C07D471/14;;C07B2200/13;;A61P11/00;;C07D498/14;;C07D401/04;;C07D231/20,C07D401/14;;A61P11/00;;C07D231/20;;C07D401/04;;C07D471/14;;C07D498/14,,0,0,,,,ACTIVE
174,US,A1,US 2018/0162839 A1,157-804-718-184-492,2018-06-14,2018,US 201715836627 A,2017-12-08,US 201715836627 A;;US 201662432537 P,2016-12-09,"Modulator of the Cystic Fibrosis Transmembrane Conductance Regulator, Pharmaceutical Compositions, Methods of Treatment, and Process for Making the Modulator","Compounds of Formula (I): pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed. Also disclosed are solid state forms of Compound 1 and salts and solvates thereof.",VERTEX PHARMA,ABELA ALEXANDER RUSSELL;;ALCACIO TIMOTHY;;ANDERSON COREY;;ANGELL PAUL TIMOTHY;;BAEK MINSON;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;FERRIS LORI ANN;;GROOTENHUIS PETER DIEDERIK JAN;;GROSS RAYMOND STANLEY;;GULEVICH ANTON V;;HADIDA RUAH SARA SABINA;;HSIA CLARA KUANG-JU;;HUGHES ROBERT M;;JOSHI PRAMOD VIRUPAX;;KANG PING;;KESHAVARZ-SHOKRI ALI;;KHATUYA HARIPADA;;KRENITSKY PAUL JOHN;;MCCARTNEY JASON;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE JEAN DENIS;;SHI YI;;SHRESTHA MUNA;;SIESEL DAVID ANDREW;;STAVROPOULOS KATHY;;TERMIN ANDREAS P;;VAN GOOR FREDRICK F;;UY JOHNNY;;YOUNG TIMOTHY JOHN;;ZHOU JINGLAN,VERTEX PHARMACEUTICALS (SAN DIEGO) LLC (2017-12-20);;VERTEX PHARMACEUTICALS INCORPORATED (2017-12-07),https://lens.org/157-804-718-184-492,Patent Application,yes,0,18,63,63,0,A61K31/455;;C07D401/14;;C07D231/20;;A61P11/00;;C07D401/04;;C07D401/14;;A61P11/00;;C07D401/14;;C07D471/14;;C07B2200/13;;C07D231/20;;C07D498/14;;A61P11/00;;C07D401/04;;C07D401/14;;A61K31/4439;;A61K31/519;;A61K31/5365;;C07D231/20;;C07D401/04;;C07D471/14;;C07D498/14;;A61P11/00;;C07B2200/13;;C07D401/14;;C07D471/14;;C07B2200/13;;A61P11/00;;C07D498/14;;C07D401/04;;C07D231/20,C07D401/14;;A61P11/00;;C07D471/14;;C07D498/14,,4,1,045-406-285-588-795,10.1002/(sici)1520-6017(200002)89:2<145::aid-jps2>3.0.co;2-6;;10688744,"Dorwald F. A. Side Reactions in Organic Synthesis, 2005, Wiley: VCH, Weinheim pg. IX of Preface pg. 1-15;;Venkatesh, J. Pharm. Sci. 89, 145-54 (2000);;Veraldo Synthesis (1), 74-79, 1999.;;Veraldo Synthesis (1), 74-79, 1999",ACTIVE
175,US,A1,US 2023/0357191 A1,194-255-079-504-746,2023-11-09,2023,US 202217880720 A,2022-08-04,US 202217880720 A;;US 202016994875 A;;US 201715836627 A;;US 201662432537 P,2016-12-09,"MODULATOR OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR","Compounds of Formula (I): pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed. Also disclosed are solid state forms of Compound 1 and salts and solvates thereof.",VERTEX PHARMA,ABELA ALEXANDER RUSSELL;;ALCACIO TIMOTHY;;ANDERSON COREY;;ANGELL PAUL TIMOTHY;;BAEK MINSON;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;FERRIS LORI ANN;;GROOTENHUIS PETER DIEDERIK JAN;;GROSS RAYMOND STANLEY;;GULEVICH ANTON V;;HADIDA RUAH SARA SABINA;;HSIA CLARA KUANG-JU;;HUGHES ROBERT M;;JOSHI PRAMOD VIRUPAX;;KANG PING;;KESHAVARZ-SHOKRI ALI;;KHATUYA HARIPADA;;KRENITSKY PAUL JOHN;;MCCARTNEY JASON;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE JEAN DENIS;;SHI YI;;SHRESTHA MUNA;;SIESEL DAVID ANDREW;;STAVROPOULOS KATHY;;TERMIN ANDREAS P;;VAN GOOR FREDRICK F;;UY JOHNNY;;YOUNG TIMOTHY JOHN;;ZHOU JINGLAN,VERTEX PHARMACEUTICALS (SAN DIEGO) LLC (2017-12-20);;VERTEX PHARMACEUTICALS INCORPORATED (2017-12-07),https://lens.org/194-255-079-504-746,Patent Application,yes,2,0,63,63,0,A61K31/455;;C07D401/14;;C07D231/20;;A61P11/00;;C07D401/04;;C07D401/14;;A61P11/00;;C07D401/14;;C07D471/14;;C07B2200/13;;C07D231/20;;C07D498/14;;A61P11/00;;C07D401/04;;C07D401/14;;A61K31/4439;;A61K31/519;;A61K31/5365;;C07D231/20;;C07D401/04;;C07D471/14;;C07D498/14;;A61P11/00;;C07B2200/13;;C07D401/14;;C07D471/14;;C07B2200/13;;A61P11/00;;C07D498/14;;C07D401/04;;C07D231/20,C07D401/14;;A61P11/00;;C07D231/20;;C07D401/04;;C07D471/14;;C07D498/14,,0,0,,,,PENDING
176,BR,A2,BR 112019006213 A2,173-682-386-696-623,2019-06-18,2019,BR 112019006213 A,2017-09-29,US 2017/0054611 W;;US 201662402838 P;;US 201662410353 P;;US 201662415409 P;;US 201662419935 P,2016-09-30,"modulador de regulador de condutância transmembranar de fibrose cística, composições farmacêuticas, métodos de tratamento e processo para fazer o modulador","a presente invenção refere-se a compostos de fórmula (i) , sais farmaceuticamente aceitáveis dos mesmos, derivados deuterados de qualquer um dos anteriores e metabólitos de qualquer um dos anteriores são divulgados. composições farmacêuticas compreendendo os mesmos, métodos de tratamento de fibrose cística usando os mesmos e métodos para fazer os mesmos são também divulgados.",VERTEX PHARMA,ALEXANDER RUSSELL ABELA;;ALI KESHAVARZSHOKRI;;ANDREAS P TERMIN;;BEILI ZHANG;;BRETT BRADLEY BUSCH;;BRYAN A FRIEMAN;;COREY ANDERSON;;DAVID ANDREW SIESEL;;FABRICE JEAN DENIS PIERRE;;FREDRICK VAN GOOR;;HARIPADA KHATUYA;;JASON MCCARTNEY;;JINGLAN ZHOU;;JOHNNY UY;;MARK THOMAS MILLER;;MINSON BAEK;;PAUL JOHN KRENITSKY;;PETER GROOTENHUIS;;PRAMOD VIRUPAX JOSHI;;PRASUNA PARASELLI;;RACHEL MCAULEY-AOKI;;ROBERT M HUGHES;;SARA SABINA HADIDA RUAH;;THOMAS CLEVELAND;;TIMOTHY ALCACIO;;VITO MELILLO,,https://lens.org/173-682-386-696-623,Patent Application,no,0,0,50,53,0,C07D471/14;;C07D498/14;;C07D401/14;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/12;;A61P43/00;;C07D401/14;;A61P11/00;;A61K31/4439;;A61P11/12;;A61K31/4439;;A61K31/519;;A61K31/5365;;C07B59/002;;C07D401/14;;C07D471/14;;C07D498/14;;C07B2200/05;;C07D471/14;;C07D498/14;;C07B59/002;;C07B2200/05;;C07D401/14,C07D401/14;;A61K31/4439;;A61P11/12;;C07D471/14;;C07D498/14,,0,0,,,,PENDING
177,US,A1,US 2022/0306606 A1,042-200-065-369-272,2022-09-29,2022,US 202117505699 A,2021-10-20,US 202117505699 A;;US 201916702891 A;;US 201715721390 A;;US 201662419935 P;;US 201662415409 P;;US 201662410353 P;;US 201662402838 P,2016-09-30,"MODULATOR OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR","Compounds of Formula I: pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.",VERTEX PHARMA,ALCACIO TIMOTHY;;BAEK MINSON;;GROOTENHUIS PETER;;HADIDA RUAH SARA SABINA;;HUGHES ROBERT M;;KESHAVARZ-SHOKRI ALI;;MCAULEY-AOKI RACHEL;;MCCARTNEY JASON;;MILLER MARK THOMAS;;VAN GOOR FREDRICK;;ZHANG BEILI;;ANDERSON COREY;;CLEVELAND THOMAS;;FRIEMAN BRYAN A;;KHATUYA HARIPADA;;JOSHI PRAMOD VIRUPAX;;KRENITSKY PAUL JOHN;;MELILLO VITO;;PIERRE FABRICE JEAN DENIS;;TERMIN ANDREAS P;;UY JOHNNY;;ZHOU JINGLAN;;ABELA ALEXANDER RUSSELL;;BUSCH BRETT BRADLEY;;PARASELLI PRASUNA,VERTEX PHARMACEUTICALS (SAN DIEGO) LLC (2017-10-02);;VERTEX PHARMACEUTICALS INCORPORATED (2017-09-29),https://lens.org/042-200-065-369-272,Patent Application,yes,1,0,50,53,0,C07D471/14;;C07D498/14;;C07D401/14;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/12;;A61P43/00;;C07D401/14;;A61P11/00;;A61K31/4439;;A61P11/12;;A61K31/4439;;A61K31/519;;A61K31/5365;;C07B59/002;;C07D401/14;;C07D471/14;;C07D498/14;;C07B2200/05;;C07D471/14;;C07D498/14;;C07B59/002;;C07B2200/05;;C07D401/14,C07D401/14;;C07B59/00;;C07D471/14;;C07D498/14,,1,0,,,"Vertex Pharmaceuticals Inc., ""A Study Evaluating the Safety and Efficacy of VX-659 Combination Therapy in Subjects With Cystic Fibrosis"", Study NCT03224351, ClinicalTrials.gov, publicly available July 18, 2017 (Year: 2017)",PENDING
178,US,B2,US 11186566 B2,174-990-351-061-020,2021-11-30,2021,US 201916702891 A,2019-12-04,US 201916702891 A;;US 201715721390 A;;US 201662419935 P;;US 201662415409 P;;US 201662410353 P;;US 201662402838 P,2016-09-30,"Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator","Compounds of Formula I: pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.",VERTEX PHARMA,ALCACIO TIMOTHY;;BAEK MINSON;;GROOTENHUIS PETER;;HADIDA RUAH SARA SABINA;;HUGHES ROBERT M;;KESHAVARZ-SHOKRI ALI;;MCAULEY-AOKI RACHEL;;MCCARTNEY JASON;;MILLER MARK THOMAS;;VAN GOOR FREDRICK;;ZHANG BEILI;;ANDERSON COREY;;CLEVELAND THOMAS;;FRIEMAN BRYAN A;;KHATUYA HARIPADA;;JOSHI PRAMOD VIRUPAX;;KRENITSKY PAUL JOHN;;MELILLO VITO;;PIERRE FABRICE JEAN DENIS;;TERMIN ANDREAS P;;UY JOHNNY;;ZHOU JINGLAN;;ABELA ALEXANDER RUSSELL;;BUSCH BRETT BRADLEY;;PARASELLI PRASUNA,VERTEX PHARMACEUTICALS (SAN DIEGO) LLC (2017-10-02);;VERTEX PHARMACEUTICALS INCORPORATED (2017-09-29),https://lens.org/174-990-351-061-020,Granted Patent,yes,229,4,50,53,0,C07D471/14;;C07D498/14;;C07D401/14;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/12;;A61P43/00;;C07D401/14;;A61P11/00;;A61K31/4439;;A61P11/12;;A61K31/4439;;A61K31/519;;A61K31/5365;;C07B59/002;;C07D401/14;;C07D471/14;;C07D498/14;;C07B2200/05;;C07D471/14;;C07D498/14;;C07B59/002;;C07B2200/05;;C07D401/14,C07D401/14;;C07B59/00;;C07D471/14;;C07D498/14,,72,27,034-587-611-086-755;;013-937-078-602-349;;096-312-557-325-378;;078-417-508-507-333;;012-371-996-064-723;;103-052-069-575-996;;039-573-265-223-407;;064-116-226-667-307;;009-891-282-676-18X;;006-026-497-014-33X;;010-718-962-322-429;;061-669-166-608-882;;045-406-285-588-795;;079-362-981-419-890;;019-580-410-758-652;;102-930-132-246-061;;009-214-187-079-899;;104-949-654-022-72X;;011-850-681-025-027;;119-132-751-946-922;;063-867-427-592-138;;002-186-545-851-173;;181-512-135-393-079;;022-265-272-874-951;;042-420-274-722-532;;030-350-705-205-427;;118-007-112-303-323,22104146;;10.1016/j.bmcl.2011.10.041;;23394148;;10.1021/ol400049m;;10.1055/s-0035-1561339;;10.1016/j.bmcl.2006.08.003;;16919947;;10.1016/j.bmcl.2003.10.049;;14698169;;10.1021/jo01296a034;;10.1021/jm0111346;;12061878;;24392786;;10.1517/13543776.2014.876412;;10.1039/b009154p;;10.1016/s1569-1993(16)30138-2;;25981758;;pmc4764353;;10.1056/nejmoa1409547;;10.1021/jm00070a012;;8410980;;10.1002/(sici)1520-6017(200002)89:2<145::aid-jps2>3.0.co;2-6;;10688744;;10.1055/s-1999-3685;;10.1002/anie.200700039;;17886815;;10.1002/anie.201708903;;29024330;;10.1023/a:1016241927429;;7494814;;10.1007/3-540-69178-2_5;;10.4155/fmc-2019-0183;;31538524;;31034626;;10.1002/jlcr.3743;;10.1021/jacs.5b05144;;pmc4490774;;26088401;;10.1021/jm4007998;;24294889;;10.1021/cen-09427-cover;;27169762;;10.1002/jlcr.3383;;10.1021/acs.jmedchem.8b01808;;30640460;;28591114;;10.1038/nbt0617-493;;10.1021/cen-v087n025.p036,"Anilkumar, G.N. et al. (2011) “II. Novel HCV NS5B polymerase inhibitors: Discovery of indole C2 acyl sulfonamides” Biogranic & Medicinal Chemistry Letters, 22(1):713-717.;;Borhade, S.R. et al. (2013) “Synthesis of Novel Aryl and Heteroaryl Acyl Sulfonimidamides via Pd-Catalyzed Carbonylation Using a Nongaseous Precursor” Organic Lett, 15(5):1056-1059.;;Chen, Y. (Jan. 26, 2016) “N-Monoacylation of Sulfonimidamides” Synthesis, 48(7):1019-1028.;;Database Caplus, Accession No. 1965:51408. Abstract of French Patent No. FR M2868, filed Nov. 23, 1964, by Roussel-UCLAF [online]. Retrieved Jan. 6, 2017 (1 page).;;Database Caplus, Accession No. 1965:51409. Abstract of German Patent No. DE 1182243, filed Nov. 26, 1964, by Badische Anilin & Soda-Fabrik A.G. [online]. Retrieved Jan. 6, 2017 (2 pages).;;Database Pubchem, CID: 2545578. Compound Summary, T5339296. NIH, U.S. National Library of Medicine, National Center for Biotechnology Information; Modify Date: Jan. 16, 2016. [online]. Retrieved from https://pubchem.ncbi.nlm.nih.gov/compound/2545578, on Jan. 22, 2016 (9 pages).;;Database Pubchem, CID: 44419393. Compound Summary, CHEMBL374189. NIH, U.S. National Library of Medicine, National Center for Biotechnology Information; Modify Date: Jan. 16, 2016. [online]. Retrieved from https://pubchem.ncbi.nlm.nih.gov/compound/44419393, on Jan. 22, 2016 (11 pages).;;Database Pubchem, CID: 49774135. Compound Summary, SCHEMBL13395127. NIH, U.S. National Library of Medicine, National Center for Biotechnology Information; Modify Date: Jan. 16, 2016 [online], Retrieved from https://pubchem.ncbi.nlm.nih.gov/compound/49774135, on Jan. 22, 2016 (10 pages).;;Database Pubchem, CID: 58132855. Compound Summary, SCHEMBL831192. NIH, U.S. National Library of Medicine, National Center for Biotechnology Information, PubChem Open Chemistry Database; Modify Date: Jan. 16, 2016 [online]. Retrieved from: https://pubchem.ncbi.nlm.nih.gov/compound/58132855, on Jan. 22, 2016 (10 pages).;;Dorwald, F. A. (2006) “Side Reactions in Organic Synthesis” Wiley: VCH, Weinheim p. IX of Preface p. 1-15.;;Hopkins, C.R. et al. (2006) “Design and synthesis of novel N-sulfonyl-2-indole carboxamides as potent PPAR-gamma binding agents with potential application to the treatment of osteoporosis” Bioorganic & Medicinal Chemistry Letters, 16(21):5659-5663.;;International Patent Application No. PCT/US2015/54316: International Search Report and Written Opinion, dated Feb. 5, 2016 (11 pages).;;International Patent Application No. PCT/US2017/025381: International Search Report and Written Opinion, dated Jun. 6, 2017 (11 pages).;;International Patent Application No. PCT/US2017/054611: International Search Report and Written Opinion, dated Jan. 3, 2018 (10 pages).;;International Patent Application No. PCT/US2017/065425: International Search Report and Written Opinion, dated Feb. 27, 2018 (10 pages).;;International Patent Application No. PCT/US2018/036610: International Search Report and Written Opinion, dated Sep. 19, 2018 (9 pages).;;International Patent Application No. PCT/US2018/040427: International Search Report and Written Opinion, dated Oct. 9, 2018 (15 pages).;;International Patent Application No. PCT/US2018/042415: International Search Report and Written Opinion, dated Oct. 31, 2018 (12 pages).;;International Patent Application No. PCT/US2018/042486: International Search Report and Written Opinion, dated Nov. 7, 2018 (13 pages).;;International Patent Application No. PCT/US2018/044963: International Search Report and Written Opinion, dated Sep. 25, 2018 (15 pages).;;International Patent Application No. PCT/US2018/056772: International Search Report and Written Opinion, dated Jan. 29, 2019 (13 pages).;;Jain, B.C. et al. (1947) “Studies in Sulphanilamides. Part XIII. Reaction With Dicarboxylic Acids. Some New N1- and N4-ACYL and Heterocycic Derivatives” Journal of the Indian Chemical Society, 24:173-176.;;Kettle, J.G. et al. (2004) “N-Benzylindole-2-carboxylic acids: potent functional antagonists of the CCR2b chemokine receptor” Bioorganic & Medicinal Chemistry Letters, 14(2): 405-408.;;Lai, J.T. et al. (1980) “Rearrangement of 2,2,6,6-tetramethyl-4-piperidone in phase-transfer catalyzed reactions,” Journal of Organic Chemistry, 45(8): 1513-1514.;;Matter, H. et al. (2002) “Design and Quantitative Structure-Activity Relationship of 3-Amidinobenzyl-1H-indole-2-carboxamides as Potent, Nonchiral, and Selective Inhibitors of Blood Coagulation Factor Xa” Journal of Medicinal Chemistry, 45(13):2749-2769.;;Norman, P. (2014) “Novel picolinamide-based cystic fibrosis transmembrane regulator modulators: evaluation of WO2013038373, WO2013038376, WO2013038381, WO2013038386, and WO2013038390,” Expert Opinion on Therapeutic Patents, 24(7):829-837.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 15/721,390, dated Sep. 4, 2019.;;Notman, N. (2016) “2Heavy drugs gaining momentum” [online] Retrieved from the internet: https://www.chemistryworld.com/features/2heavy-drugs-gaining-momentum/1010186.article, on Oct. 7, 2019.;;Passarella, D. et al. (2001) “Cyclodimerization of indol-2-ylacetylenes. An example of intermolecular enyne-alkyne cycloaddition” Journal of the Chemical Society, Perkin Transactions 1, 127-129.;;Rosebraugh, C.J. (2015) “Highlights of Presecribing Information for Orkambi,” [online] Retrieved from the Internet: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206038Orig1s000lbl.pdf, on Aug. 24, 2017.;;Silverman, R. (2004) The Organic Chemistry of Drug Design and Drug Action, Elsevier, pp. 29-32.;;Soloducho, J. (1989) “Synthesis of Some Pyrido [2,3-c][1,2,6]triazinone Derivatives” Journal für Pracktische Chemie, 331(3):503-506.;;Tullis, E. et al. (2018) “Preliminary safety and efficacy of triple-combination CFTR modulator regimens,” Respirology, 23(51):33.;;Uttamsingh, V. et al. (2016) “WS13.6 CTP-656 tablet confirmed superiority of pharmacokinetic profile relative to Kalydeco in Phase I clinical studies” Journal of Cystic Fibrosis, 15:S22.;;Wainwright, C.E. et al. (2015) “Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR,” The New England Journal of Medicine, 373(3):220-231.;;Winn, M. et al. (1993) “2-(Alkylamino)nicotinic Acid and Analogs. Potent Angiotensin II Antagonists” Journal of Medicinal Chemistry, 36(18):2676-2688.;;Venkatesh, S. et al. (2000) “Role of the development scientist in compound lead selection and optimization” J. Pharm. Sci. 89(2), 145-154.;;Verado, G. et al. (1999) “Reductive One Batch Synthesis of N-Substituted Pyrrolidines from Primary Amines and 2,5-Dimethoxytetrahydrofuran” Synthesis, (1):74-79.;;Vertex Pharmaceuticals, Inc. (Mar. 28, 2017) “Two Phase 3 Studies of the Tezacaftor/Ivacaftor Combination Treatment Met Primary Endpoints with Statistically Significant Improvements in Lung Function (FEV1) in People With Cystic Fibrosis” [online] Retrieved from the Internet: http://investors.vrtx.com/static-files/f15217ac-4a8b-436a-9215-79144ec2e59b, on Oct. 10, 2019.;;Atzrodt J, Derdau V, Fey T, Zimmermann J. “The Renaissance of H/D Exchange” Angew. Chem. Int. Ed. 2007: 46, 7744-7765.;;Atzrodt J, Derdau V, Kerr W, Reid M. “C—H functionalization for hydrogen isotope exchange” Angew. Chem. Int. Ed. 2018:57, 3022-3047.;;Braman, V.; Liu, J. F.; Harbeson, S.; Uttamsingh, V.; Bridson, G.; Wu, L.; Shipley, J. E. “Preliminary Clinical Outcomes for CTP-354, a Novel Subtype-Selective GABA(A) Modulator” Presented at the American Neurological Association (ANA) 2014 Annual Meeting, Baltimore, MD, Oct. 12-14, 2014.;;Byrn, S. et al. (1995) “Pharmaceutical solids: A strategic approach to regulatory considerations,” (12): 945-954.;;Caira, M. R. (1998) “Crystalline Polymorphism of Organic Compounds,” Topics in Current Chemistry, 163-208.;;Cargnin S, Serafini M, Pirali T. “A primer of deuterium in drug design” Future Med. Chem. 2019; 11(16): 2039-2042.;;Czeskis B, Elmore, CS, Haight A, Hesk D, Maxwell BD, Miller SA, Raglione T, Schildknegt K, Traverse JF, Wang P. “Deuterated active pharmaceutical ingredients: A science-based proposal for synthesis, analysis, and control. Part 1: Framing the problem” J. Label. Compd. Radiopharm. 2019, 62: 690-694. DOI: 10.1002/jlcr.3743.;;Dao HT, Li C, Michaudel Q, Maxwell BD, Baran PS. J. Am. Chem. Soc. 2015; 137, 8046-8049.;;Database Pubchem, CID: 20050716. Compound Summary, 1-[2-[[2-[(2-Amino-3-methylbutanoyl)amino]-3-methylpentanoyl]amino]-3-phenylpropanoyl]pyrrolidine-2-carboxylic acid. NIH, U.S. National Library of Medicine, National Center for Biotechnology Information; Modify Date: Nov. 30, 2019. [online]. Retrieved from https://pubchem.ncbi.nlm.nih.gov/compound/20050716, on Dec. 3, 2019 (7 pages).;;Database Pubchem, CID: 20091118. Compound Summary, [4-(5-Hexylpyrimidin-2-yl)phenyl] 2-methoxypropanoate. NIH, U.S. National Library of Medicine, National Center for Biotechnology Information; Modify Date: Nov. 30, 2019. [online]. Retrieved from https://pubchem.ncbi.nlm.nih.gov/compound/20091118, on Dec. 3, 2019 (9 pages).;;Database Pubchem, CID: 20120819. Compound Summary, 4-(Cyclopentyloxy)-3-fluorobenzene-1-sulfonylchloride. NIH, U.S. National Library of Medicine, National Center for Biotechnology Information; Modify Date: Nov. 30, 2019. [online]. Retrieved from https://pubchem.ncbi.nlm.nih.gov/compound/20120819, on Dec. 3, 2019 (8 pages).;;Gant TG. “Using Deuterium in Drug Discovery: Leaving the Label in the Drug” J Med. Chem. 2014; 57(9): 3595-3611.;;Halford B. “The deuterium switcheroo” Chemical & Engineering News 2016; 94(27), 32-36.;;International Patent Application No. PCT/US2018/063871: International Search Report and Written Opinion, dated Feb. 25, 2019 (16 pages).;;International Patent Application No. PCT/US2019/016537: International Search Report and Written Opinion, dated Apr. 23, 2019 (13 pages).;;International Patent Application No. PCT/US2018/065522: International Search Report and Written Opinion, dated Jun. 25, 2019 (21 pages).;;International Patent Application No. PCT/US2019/018042: International Search Report and Written Opinion, dated Apr. 17, 2019 (10 pages).;;International Patent Application No. PCT/US2019/024890: International Search Report and Written Opinion, dated Jun. 17, 2019 (13 pages).;;International Patent Application No. PCT/US2019/026075: International Search Report and Written Opinion, dated Jun. 17, 2019 (13 pages).;;International Patent Application No. PCT/US2019/027202: International Search Report and Written Opinion, dated Jun. 17, 2019 (10 pages).;;Liu, J. F. et al. “CTP-354: A Novel Deuterated Subtype-Selective GABA(A) Modulator for Treatment of Neuropathic Pain, Spasticity and Anxiety Disorders” Presented at the American College of Neuropsychopharmacology (ACNP) 51st Annual Meeting, Hollywood, FL, Dec. 2-6, 2012.;;Maxwell BD, Tran SB, Lago M, Li J, and Bonacorsi Jr SJ. “The syntheses of [14C]BMS-823778 for use in a human ADME clinical study and of [13CD313CD2]BMT-094817, a stable-isotope labeled standard of a newly detected human metabolite” J. Label. Compd. Radiopharm. 2016; 59, 255-259.;;Pirali T, Serafini M, Cargnin S, Genazzani AA. “Applications of Deuterium in Medicinal Chemistry” J Med. Chem. 2019; 62(11): 5276-5297.;;Schmidt, C. “First deuterated drug approved” Nat. Biotechnol. 2017, 35, 493-494.;;U.S. Appl. No. 16/620,265, filed Dec. 6, 2019, by Chen et al.;;U.S. Appl. No. 16/625,028, filed Dec. 20, 2019, by Chu et al.;;U.S. Appl. No. 16/631,989, filed Jan. 17, 2020, by Haseltine et al.;;U.S. Appl. No. 16/635,346, filed Jan. 30, 2020, by Angell et al.;;U.S. Appl. No. 16/836,155, filed Mar. 31, 2020, by Miller et al.;;Vertex Pharmaceuticals, Inc. (Jul. 18, 2017) “Vertex Announces Positive Phase 1 & Phase 2 Data from Three Different Triple Combination Regimens in People with Cystic Fibrosis Who Have One F508del Mutation and One Minimal Function Mutation (F508del/Min)”, Retrieved from the Internet: URL: http://investors.vrtx.com/news-releases/news-release-details/vertex/announces-positive-phase-1-phase-2-data-three-different [retrieved on Mar. 27, 2019].;;Vertex Pharmaceuticals, Inc. (Nov. 3, 2017) “Vertex announces presentations of data at North American Cystic Fibrosis Conference that Demonstrate Important Progress Toward Goal of Helping All People with CF,” Health and Medicine Week, vol. 3, p. 196.;;Willson T. M. et al. (1996) “Bone targeted drugs 2. Synthesis of estrogens with hydroxyapatite affinity,” Bioorg. & Med. Chem. Lett., (6): 1047-1050.;;Yarnell, AT. “Heavy-Hydrogen Drugs Turn Heads, Again” Chemical & Engineering News 2009; 87(25), 36-39.",ACTIVE
179,US,A1,US 2020/0283405 A1,084-115-759-604-246,2020-09-10,2020,US 201916702891 A,2019-12-04,US 201916702891 A;;US 201715721390 A;;US 201662419935 P;;US 201662415409 P;;US 201662410353 P;;US 201662402838 P,2016-09-30,"MODULATOR OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR","Compounds of Formula I: pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.",VERTEX PHARMA,ALCACIO TIMOTHY;;BAEK MINSON;;GROOTENHUIS PETER;;HADIDA RUAH SARA SABINA;;HUGHES ROBERT M;;KESHAVARZ-SHOKRI ALI;;MCAULEY-AOKI RACHEL;;MCCARTNEY JASON;;MILLER MARK THOMAS;;VAN GOOR FREDRICK;;ZHANG BEILI;;ANDERSON COREY;;CLEVELAND THOMAS;;FRIEMAN BRYAN A;;KHATUYA HARIPADA;;JOSHI PRAMOD VIRUPAX;;KRENITSKY PAUL JOHN;;MELILLO VITO;;PIERRE FABRICE JEAN DENIS;;TERMIN ANDREAS P;;UY JOHNNY;;ZHOU JINGLAN;;ABELA ALEXANDER RUSSELL;;BUSCH BRETT BRADLEY;;PARASELLI PRASUNA,VERTEX PHARMACEUTICALS (SAN DIEGO) LLC (2017-10-02);;VERTEX PHARMACEUTICALS INCORPORATED (2017-09-29),https://lens.org/084-115-759-604-246,Patent Application,yes,0,8,50,53,0,C07D471/14;;C07D498/14;;C07D401/14;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/12;;A61P43/00;;C07D401/14;;A61P11/00;;A61K31/4439;;A61P11/12;;A61K31/4439;;A61K31/519;;A61K31/5365;;C07B59/002;;C07D401/14;;C07D471/14;;C07D498/14;;C07B2200/05;;C07D471/14;;C07D498/14;;C07B59/002;;C07B2200/05;;C07D401/14,C07D401/14;;C07B59/00;;C07D471/14;;C07D498/14,,0,0,,,,ACTIVE
180,PE,A1,PE 20191147 A1,196-419-153-479-050,2019-09-02,2019,PE 2019000737 A,2017-09-29,US 201662402838 P;;US 201662410353 P;;US 201662415409 P;;US 201662419935 P,2016-09-30,"MODULADOR DE REGULADOR DE CONDUCTANCIA DE TRANSMEMBRANA DE FIBROSIS QUISTICA, COMPOSICIONES FARMACEUTICAS, METODOS DE TRATAMIENTO Y PROCESO PARA PRODUCIR EL MODULADOR","Se refiere a un compuesto de Formula (I), una sal farmaceuticamente aceptable en donde: uno de Y1 y Y2 es N y el otro es CH; X puede ser O, NH y N(alquilo de C1-C4); R1 puede ser -(CR2)K-O-(CR2)m (CR)n(ANILLO A)n+1, en donde cada anillo A pueden ser grupos cicloalquilo de C3-C10 opcionalmente sustituidos con uno o mas sustituyentes elegidos cada uno independientemente de grupos alquilo de C1-C2, grupos alquilo de C1-C2 halogenados y halogenos H, OH y alquilo de C1-C2 opcionalmente sustituidos con uno o mas halogenos; y en donde cada R puede ser H, OH y alquilo de C1-C2, opcionalmente sustituidos con uno o mas halogenos; R2 puede ser un grupo alquilo de C1-C2, OH, grupos alcoxi de C1-C2, halogenos y ciano; R3 puede ser un grupo alquilo de C1-C2 opcionalmente sustituidos con uno o mas grupos OH; R4 pueden ser halogenos; k es 0 o 1; r es 0 o 1; m es 0, 1, 2 o 3; n es 0 o 1; p es 0, 1, 2, 3, 4 o 5; q es 0, 1, 2, 3, 4, entre otros. Son compuestos preferidos N-(2,4-di-terc-butil-5-hidroxifenil)-4-oxo-1,4-dihidroquinolina-3-carboxamida; N-(bencenosulfonil)-6-[3-[2-[1-(trifluorometil)ciclopropil]etoxi]pirazol-1-il]-2-[(4S)-2,2,4-trimetilpirrolidin-1-il]piridina-3-carboxamida; 2, (R)-N-(fenilsulfonil)-6-(3-(2-(1-(trifuorometil)ciclopropil)etoxi)-1H-pirazol-1-il)-2-(2,2,4-trimetilpirrolidin-1-il)nicotinamida. Dicho compuesto es un modulador del regulador de conductancia de transmembrana de fibrosis quistica.",VERTEX PHARMA,ALCACIO TIMOTHY;;BAEK MINSON;;GROOTENHUIS PETER;;HADIDA RUAH SARA SABINA;;HUGHES ROBERT M;;KESHAVARZSHOKRI ALI;;MCAULEY-AOKI RACHEL;;MCCARTNEY JASON;;MILLER MARK THOMAS;;VAN GOOR FREDRICK;;ZHANG BEILI;;ANDERSON COREY;;CLEVELAND THOMAS;;FRIEMAN BRYAN A;;KHATUYA HARIPADA;;JOSHI PRAMOD VIRUPAX;;KRENITSKY PAUL JOHN;;MELILLO VITO;;PIERRE FABRICE JEAN DENIS;;TERMIN ANDREAS P;;UY JOHNNY;;ZHOU JINGLAN;;ABELA ALEXANDER RUSSELL;;BUSCH BRETT BRADLEY;;PARASELLI PRASUNA;;SIESEL DAVID ANDREW,,https://lens.org/196-419-153-479-050,Patent Application,no,0,0,50,53,0,C07D471/14;;C07D498/14;;C07D401/14;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/12;;A61P43/00;;C07D401/14;;A61P11/00;;A61K31/4439;;A61P11/12;;A61K31/4439;;A61K31/519;;A61K31/5365;;C07B59/002;;C07D401/14;;C07D471/14;;C07D498/14;;C07B2200/05;;C07D471/14;;C07D498/14;;C07B59/002;;C07B2200/05;;C07D401/14,C07D401/14;;A61K31/4439;;A61P11/12;;C07D471/14;;C07D498/14,,0,0,,,,PENDING
181,AU,A1,AU 2017/336156 A1,000-613-421-090-393,2019-05-02,2019,AU 2017/336156 A,2017-09-29,US 201662415409 P;;US 201662419935 P;;US 201662402838 P;;US 201662410353 P;;US 2017/0054611 W,2016-09-30,"Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator","Compounds of Formula (I), pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.",VERTEX PHARMA,ALCACIO TIMOTHY;;BAEK MINSON;;GROOTENHUIS PETER;;HADIDA RUAH SARA SABINA;;HUGHES ROBERT M;;KESHAVARZ-SHOKRI ALI;;MCAULEY-AOKI RACHEL;;MCCARTNEY JASON;;MILLER MARK THOMAS;;VAN GOOR FREDRICK;;ZHANG BEILI;;ANDERSON COREY;;CLEVELAND THOMAS;;FRIEMAN BRYAN A;;KHATUYA HARIPADA;;JOSHI PRAMOD VIRUPAX;;KRENITSKY PAUL JOHN;;MELILLO VITO;;PIERRE FABRICE JEAN DENIS;;TERMIN ANDREAS P;;UY JOHNNY;;ZHOU JINGLAN;;ABELA ALEXANDER RUSSELL;;BUSCH BRETT BRADLEY;;PARASELLI PRASUNA;;SIESEL DAVID ANDREW,,https://lens.org/000-613-421-090-393,Patent Application,no,0,0,50,53,0,C07D471/14;;C07D498/14;;C07D401/14;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/12;;A61P43/00;;C07D401/14;;A61P11/00;;A61K31/4439;;A61P11/12;;A61K31/4439;;A61K31/519;;A61K31/5365;;C07B59/002;;C07D401/14;;C07D471/14;;C07D498/14;;C07B2200/05;;C07D471/14;;C07D498/14;;C07B59/002;;C07B2200/05;;C07D401/14,C07D401/14;;A61K31/4439;;A61P11/12;;C07D471/14;;C07D498/14,,0,0,,,,ACTIVE
182,EP,A1,EP 3519401 A1,100-599-374-855-10X,2019-08-07,2019,EP 17792230 A,2017-09-29,US 201662402838 P;;US 201662410353 P;;US 201662415409 P;;US 201662419935 P;;US 2017/0054611 W,2016-09-30,"MODULATOR OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR",,VERTEX PHARMA,ALCACIO TIMOTHY;;BAEK MINSON;;GROOTENHUIS PETER;;HADIDA RUAH SARA SABINA;;HUGHES ROBERT M;;KESHAVARZ-SHOKRI ALI;;MCAULEY-AOKI RACHEL;;MCCARTNEY JASON;;MILLER MARK THOMAS;;VAN GOOR FREDRICK;;ZHANG BEILI;;ANDERSON COREY;;CLEVELAND THOMAS;;FRIEMAN BRYAN A;;KHATUYA HARIPADA;;JOSHI PRAMOD VIRUPAX;;KRENITSKY PAUL JOHN;;MELILLO VITO;;PIERRE FABRICE JEAN DENIS;;TERMIN ANDREAS P;;UY JOHNNY;;ZHOU JINGLAN;;ABELA ALEXANDER RUSSELL;;BUSCH BRETT BRADLEY;;PARASELLI PRASUNA;;SIESEL DAVID ANDREW,,https://lens.org/100-599-374-855-10X,Patent Application,yes,0,0,50,53,0,C07D471/14;;C07D498/14;;C07D401/14;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/12;;A61P43/00;;C07D401/14;;A61P11/00;;A61K31/4439;;A61P11/12;;A61K31/4439;;A61K31/519;;A61K31/5365;;C07B59/002;;C07D401/14;;C07D471/14;;C07D498/14;;C07B2200/05;;C07D471/14;;C07D498/14;;C07B59/002;;C07B2200/05;;C07D401/14,C07D401/14;;A61K31/4439;;A61P11/12;;C07D471/14;;C07D498/14,,0,0,,,,ACTIVE
183,GE,B,GE P20217329 B,065-595-949-171-978,2021-12-10,2021,GE AP2017015057 A,2017-09-29,US 201662419935 P;;US 201662402838 P;;US 201662410353 P;;US 201662415409 P,2016-09-30,"MODULATOR OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR","Compounds of Formula (I), (I), wherein values of Y1, Y2, X, R1, R2, R3, R4 substitudes and k, r, m, n, p, q variabels are provided in the claims, pharmaceutically acceptable salt and deuterated derivative thereof, and pharmaceutical usage therefor the treatment of mucoviscidose. s Table: 9",VERTEX PHARMA,MCCARTNEY JASON;;VAN GOOR FREDRICK;;ANDRESON COREY;;FRIEMAN BRYAN A;;KRENITSKY PAUL JOHN;;MELILLO VITO;;KHATUYA HARIPADA;;CLEVELAND THOMAS;;ZHANG BEILI;;HUGHES ROBERT M;;ALI KESHAVARZ-SHOKRI ALI;;MCAULEY-AOKI RACHEL;;TERMIN ANDREAS P;;PIERRE FABRICE JEAN DENIS;;UY JOHNNY;;ABELA ALEXANDER RUSSELL;;BUSCH BRETT BRADLEY;;SIESEL DAVID ANDREW;;ZHOU JINGLAN;;HADIDA RUAH SARA SABINA;;BAEK MINSON;;GROOTENHUIS PETER;;MILLER MARK THOMAS;;ALCACIO TIMOTHY;;JOSHI PRAMOD VIRUPAX;;PARASELLI PRASUNA,,https://lens.org/065-595-949-171-978,Granted Patent,no,0,0,50,53,0,C07D471/14;;C07D498/14;;C07D401/14;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/12;;A61P43/00;;C07D401/14;;A61P11/00;;A61K31/4439;;A61P11/12;;A61K31/4439;;A61K31/519;;A61K31/5365;;C07B59/002;;C07D401/14;;C07D471/14;;C07D498/14;;C07B2200/05;;C07D471/14;;C07D498/14;;C07B59/002;;C07B2200/05;;C07D401/14,C07D401/14;;A61K31/4439;;A61P11/12;;C07D471/14;;C07D498/14,,0,0,,,,ACTIVE
184,CN,A,CN 109803962 A,044-781-813-844-536,2019-05-24,2019,CN 201780061062 A,2017-09-29,US 201662402838 P;;US 201662410353 P;;US 201662415409 P;;US 201662419935 P;;US 2017/0054611 W,2016-09-30,"MODULATOR OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR","Compounds of Formula (I) shown in description, pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.",VERTEX PHARMA,ALCACIO TIMOTHY;;BAEK MINSON;;GROOTENHUIS PETER;;HADIDA RUAH SARA SABINA;;HUGHES ROBERT M;;KESHAVARZ-SHOKRI ALI;;MCAULEY-AOKI RACHEL;;MCCARTNEY JASON;;MILLER MARK THOMAS;;VAN GOOR FREDRICK;;ZHANG BEILI;;ANDRESON COREY;;CLEVELAND THOMAS;;FRIEMAN BRYAN A;;KHATUYA HARIPADA;;JOSHI PRAMOD VIRUPAX;;KRENITSKY PAUL JOHN;;MELILLO VITO;;PIERRE FABRICE JEAN DENIS;;TERMIN ANDREAS P;;UY JOHNNY;;ZHOU JINGLAN;;ABELA ALEXANDER RUSSELL;;BUSCH BRETT BRADLEY;;PARASELLI PRASUNA;;SIESEL DAVID ANDREW,,https://lens.org/044-781-813-844-536,Patent Application,no,3,0,50,53,0,C07D471/14;;C07D498/14;;C07D401/14;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/12;;A61P43/00;;C07D401/14;;A61P11/00;;A61K31/4439;;A61P11/12;;A61K31/4439;;A61K31/519;;A61K31/5365;;C07B59/002;;C07D401/14;;C07D471/14;;C07D498/14;;C07B2200/05;;C07D471/14;;C07D498/14;;C07B59/002;;C07B2200/05;;C07D401/14,C07D401/14;;A61K31/4439;;A61P11/12;;C07D471/14;;C07D498/14,,0,0,,,,ACTIVE
185,CA,A1,CA 3037986 A1,171-292-236-205-087,2018-04-05,2018,CA 3037986 A,2017-09-29,US 201662402838 P;;US 201662410353 P;;US 201662415409 P;;US 201662419935 P;;US 2017/0054611 W,2016-09-30,"MODULATOR OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR","Compounds of Formula (I), pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.",VERTEX PHARMA,ALCACIO TIMOTHY;;BAEK MINSON;;GROOTENHUIS PETER;;KESHAVARZ-SHOKRI ALI;;MCAULEY-AOKI RACHEL;;MCCARTNEY JASON;;VAN GOOR FREDRICK;;ZHANG BEILI;;CLEVELAND THOMAS;;KHATUYA HARIPADA;;MELILLO VITO;;UY JOHNNY;;ZHOU JINGLAN;;PARASELLI PRASUNA;;HADIDA RUAH SARA SABINA;;HUGHES ROBERT M;;MILLER MARK THOMAS;;ANDERSON COREY;;FRIEMAN BRYAN A;;JOSHI PRAMOD VIRUPAX;;KRENITSKY PAUL JOHN;;PIERRE FABRICE JEAN DENIS;;TERMIN ANDREAS P;;ABELA ALEXANDER RUSSELL;;BUSCH BRETT BRADLEY;;SIESEL DAVID ANDREW,,https://lens.org/171-292-236-205-087,Patent Application,no,0,0,50,53,0,C07D471/14;;C07D498/14;;C07D401/14;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/12;;A61P43/00;;C07D401/14;;A61P11/00;;A61K31/4439;;A61P11/12;;A61K31/4439;;A61K31/519;;A61K31/5365;;C07B59/002;;C07D401/14;;C07D471/14;;C07D498/14;;C07B2200/05;;C07D471/14;;C07D498/14;;C07B59/002;;C07B2200/05;;C07D401/14,C07D401/14;;A61K31/4439;;A61P11/12;;C07D471/14;;C07D498/14,,0,0,,,,PENDING
186,DK,T3,DK 3519401 T3,194-279-116-197-041,2021-11-22,2021,DK 17792230 T,2017-09-29,US 201662402838 P;;US 201662410353 P;;US 201662415409 P;;US 201662419935 P;;US 2017/0054611 W,2016-09-30,"MODULATOR AF CYSTISK FIBROSETRANSMEMBRANKONDUKTANSREGULATOR, FARMACEUTISKE SAMMENSÆTNINGER, FREMGANGSMÅDER TIL BEHANDLING OG FREMGANGSMÅDE TIL FREMSTILLING AF MODULATOREN",,VERTEX PHARMA,ALCACIO TIMOTHY;;BAEK MINSON;;GROOTENHUIS PETER;;HADIDA RUAH SARA SABINA;;HUGHES ROBERT M;;KESHAVARZ-SHOKRI ALI;;MCAULEY-AOKI RACHEL;;MCCARTNEY JASON;;MILLER MARK THOMAS;;VAN GOOR FREDRICK;;ZHANG BEILI;;ANDERSON COREY;;CLEVELAND THOMAS;;FRIEMAN BRYAN A;;KHATUYA HARIPADA;;JOSHI PRAMOD VIRUPAX;;KRENITSKY PAUL JOHN;;MELILLO VITO;;PIERRE FABRICE JEAN DENIS;;TERMIN ANDREAS P;;UY JOHNNY;;ZHOU JINGLAN;;ABELA ALEXANDER RUSSELL;;BUSCH BRETT BRADLEY;;PARASELLI PRASUNA;;SIESEL DAVID ANDREW,,https://lens.org/194-279-116-197-041,Granted Patent,no,0,0,50,53,0,C07D471/14;;C07D498/14;;C07D401/14;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/12;;A61P43/00;;C07D401/14;;A61P11/00;;A61K31/4439;;A61P11/12;;A61K31/4439;;A61K31/519;;A61K31/5365;;C07B59/002;;C07D401/14;;C07D471/14;;C07D498/14;;C07B2200/05;;C07D471/14;;C07D498/14;;C07B59/002;;C07B2200/05;;C07D401/14,C07D401/14;;A61K31/4439;;A61P11/12;;C07D471/14;;C07D498/14,,0,0,,,,ACTIVE
187,TW,A,TW 201827405 A,155-894-672-822-40X,2018-08-01,2018,TW 106133964 A,2017-09-30,US 201662402838 P;;US 201662410353 P;;US 201662415409 P;;US 201662419935 P,2016-09-30,"Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator","Compounds of Formula I: (I), pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.",VERTEX PHARMA,ALCACIO TIMOTHY;;BAEK MINSON;;GROOTENHUIS PETER;;HADIDA RUAH SARA SABINA;;HUGHES ROBERT M;;KESHAVARZ-SHOKRI ALI;;MCAULEY-AOKI RACHEL;;MCCARTNEY JASON;;MILLER MARK THOMAS;;VAN GOOR FREDRICK;;ZHANG BEILI;;ANDERSON COREY;;CLEVELAND THOMAS;;FRIEMAN BRYAN A;;KHATUYA HARIPADA;;JOSHI PRAMOD VIRUPAX;;KRENITSKY PAUL JOHN;;MELILLO VITO;;PIERRE FABRICE JEAN DENIS;;TERMIN ANDREAS P;;UY JOHNNY;;ZHOU JINGLAN;;ABELA ALEXANDER RUSSELL;;BUSCH BRETT BRADLEY;;PARASELLI PRASUNA;;SIESEL DAVID ANDREW,,https://lens.org/155-894-672-822-40X,Patent of Addition,no,0,0,50,53,0,C07D471/14;;C07D498/14;;C07D401/14;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/12;;A61P43/00;;C07D401/14;;A61P11/00;;A61K31/4439;;A61P11/12;;A61K31/4439;;A61K31/519;;A61K31/5365;;C07B59/002;;C07D401/14;;C07D471/14;;C07D498/14;;C07B2200/05;;C07D471/14;;C07D498/14;;C07B59/002;;C07B2200/05;;C07D401/14,C07D215/233;;A61K31/404;;A61K31/4439;;A61K31/47;;A61K31/519;;A61P43/00;;C07B59/00;;C07D401/04;;C07D405/12;;C07D471/14,,0,0,,,,ACTIVE
188,TN,A1,TN 2019000079 A1,011-716-940-680-505,2020-07-15,2020,TN 2019000079 A,2017-09-29,US 201662402838 P;;US 201662410353 P;;US 201662415409 P;;US 201662419935 P;;US 2017/0054611 W,2016-09-30,"MODULATOR OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR","Compounds of Formula (I), pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.",VERTEX PHARMA,ABELA ALEXANDER RUSSELL;;ALCACIO TIMOTHY;;ANDERSON COREY;;BAEK MINSON;;BUSCH BRETT BRADLEY;;CLEVELAND THOMAS;;FRIEMAN BRYAN A;;GROOTENHUIS PETER;;HADIDA RUAH SARA SABINA;;HUGHES ROBERT M;;JOSHI PRAMOD VIRUPAX;;KESHAVARZ-SHOKRI ALI;;KHATUYA HARIPADA;;KRENITSKY PAUL JOHN;;MCAULEY-AOKI RACHEL;;MCCARTNEY JASON;;MELILLO VITO;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE JEAN DENIS;;SIESEL DAVID ANDREW;;TERMIN ANDREAS P;;UY JOHNNY;;VAN GOOR FREDRICK;;ZHANG BEILI;;ZHOU JINGLAN,,https://lens.org/011-716-940-680-505,Patent Application,no,0,0,50,53,0,C07D471/14;;C07D498/14;;C07D401/14;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/12;;A61P43/00;;C07D401/14;;A61P11/00;;A61K31/4439;;A61P11/12;;A61K31/4439;;A61K31/519;;A61K31/5365;;C07B59/002;;C07D401/14;;C07D471/14;;C07D498/14;;C07B2200/05;;C07D471/14;;C07D498/14;;C07B59/002;;C07B2200/05;;C07D401/14,A61P11/12;;C07D498/14,,0,0,,,,PENDING
189,WO,A8,WO 2018/064632 A8,041-827-182-394-998,2018-05-17,2018,US 2017/0054611 W,2017-09-29,US 201662402838 P;;US 201662410353 P;;US 201662415409 P;;US 201662419935 P,2016-09-30,"MODULATOR OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR","Compounds of Formula (I), pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.",VERTEX PHARMA,ALCACIO TIMOTHY;;BAEK MINSON;;GROOTENHUIS PETER;;HADIDA RUAH SARA SABINA;;HUGHES ROBERT M;;KESHAVARZ-SHOKRI ALI;;MCAULEY-AOKI RACHEL;;MCCARTNEY JASON;;MILLER MARK THOMAS;;VAN GOOR FREDRICK;;ZHANG BEILI;;ANDERSON COREY;;CLEVELAND THOMAS;;FRIEMAN BRYAN A;;KHATUYA HARIPADA;;JOSHI PRAMOD VIRUPAX;;KRENITSKY PAUL JOHN;;MELILLO VITO;;PIERRE FABRICE JEAN DENIS;;TERMIN ANDREAS P;;UY JOHNNY;;ZHOU JINGLAN;;ABELA ALEXANDER RUSSELL;;BUSCH BRETT BRADLEY;;PARASELLI PRASUNA;;SIESEL DAVID ANDREW,,https://lens.org/041-827-182-394-998,Amended Application,yes,0,0,50,53,0,C07D471/14;;C07D498/14;;C07D401/14;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/12;;A61P43/00;;C07D401/14;;A61P11/00;;A61K31/4439;;A61P11/12;;A61K31/4439;;A61K31/519;;A61K31/5365;;C07B59/002;;C07D401/14;;C07D471/14;;C07D498/14;;C07B2200/05;;C07D471/14;;C07D498/14;;C07B59/002;;C07B2200/05;;C07D401/14,C07D401/14;;A61K31/4439;;A61P11/12;;C07D471/14;;C07D498/14,,0,0,,,,PENDING
190,RS,B1,RS 62670 B1,094-800-366-042-148,2021-12-31,2021,RS P20211432 A,2017-09-29,US 201662402838 P;;US 201662410353 P;;US 201662415409 P;;US 201662419935 P;;US 2017/0054611 W;;EP 17792230 A,2016-09-30,"MODULATOR OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR",,VERTEX PHARMA,ALCACIO TIMOTHY;;BAEK MINSON;;GROOTENHUIS PETER;;HADIDA RUAH SARA SABINA;;HUGHES ROBERT M;;KESHAVARZ-SHOKRI ALI;;MCAULEY-AOKI RACHEL;;MCCARTNEY JASON;;MILLER MARK THOMAS;;VAN GOOR FREDRICK;;ZHANG BEILI;;ANDERSON COREY;;CLEVELAND THOMAS;;FRIEMAN BRYAN A;;KHATUYA HARIPADA;;JOSHI PRAMOD VIRUPAX;;KRENITSKY PAUL JOHN;;MELILLO VITO;;PIERRE FABRICE JEAN DENIS;;TERMIN ANDREAS P;;UY JOHNNY;;ZHOU JINGLAN;;ABELA ALEXANDER RUSSELL;;BUSCH BRETT BRADLEY;;PARASELLI PRASUNA;;SIESEL DAVID ANDREW,,https://lens.org/094-800-366-042-148,Granted Patent,no,0,0,50,53,0,C07D471/14;;C07D498/14;;C07D401/14;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/12;;A61P43/00;;C07D401/14;;A61P11/00;;A61K31/4439;;A61P11/12;;A61K31/4439;;A61K31/519;;A61K31/5365;;C07B59/002;;C07D401/14;;C07D471/14;;C07D498/14;;C07B2200/05;;C07D471/14;;C07D498/14;;C07B59/002;;C07B2200/05;;C07D401/14,C07D401/14;;A61K31/4439;;A61P11/12;;C07D471/14;;C07D498/14,,0,0,,,,ACTIVE
191,KR,A,KR 20190067827 A,087-824-214-586-624,2019-06-17,2019,KR 20197012347 A,2017-09-29,US 201662402838 P;;US 201662410353 P;;US 201662415409 P;;US 201662419935 P;;US 2017/0054611 W,2016-09-30,"낭포성 섬유증 막횡단 전도 조절자의 조절제, 제약 조성물, 치료 방법, 및 상기 조절제의 제조 방법","식 I의 화합물:이의 약제학적으로 허용가능한 염, 전술한 것들 중 임의의 것의 중수소화된 유도체, 및 전술한 것들 중 임의의 것의 대사물이 개시된다. 상기 화합물을 포함하는 약제학적 조성물, 상기 화합물을 사용하여 낭포성 섬유증을 치료하는 방법, 및 상기 화합물을 제조하는 방법이 또한 개시된다.",VERTEX PHARMA,ALCACIO TIMOTHY;;BAEK MINSON;;GROOTENHUIS PETER;;HADIDA RUAH SARA SABINA;;HUGHES ROBERT M;;KESHAVARZ SHOKRI ALI;;MCAULEY AOKI RACHEL;;MCCARTNEY JASON;;MILLER MARK THOMAS;;VAN GOOR FREDRICK;;ZHANG BEILI;;ANDERSON COREY;;CLEVELAND THOMAS;;FRIEMAN BRYAN A;;KHATUYA HARIPADA;;JOSHI PRAMOD VIRUPAX;;KRENITSKY PAUL JOHN;;MELILLO VITO;;PIERRE FABRICE JEAN DENIS;;TERMIN ANDREAS P;;UY JOHNNY;;ZHOU JINGLAN;;ABELA ALEXANDER RUSSELL;;BUSCH BRETT BRADLEY;;PARASELLI PRASUNA;;SIESEL DAVID ANDREW,,https://lens.org/087-824-214-586-624,Patent Application,no,3,0,50,53,0,C07D471/14;;C07D498/14;;C07D401/14;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/12;;A61P43/00;;C07D401/14;;A61P11/00;;A61K31/4439;;A61P11/12;;A61K31/4439;;A61K31/519;;A61K31/5365;;C07B59/002;;C07D401/14;;C07D471/14;;C07D498/14;;C07B2200/05;;C07D471/14;;C07D498/14;;C07B59/002;;C07B2200/05;;C07D401/14,C07D401/14;;A61K31/4439;;A61K31/519;;A61K31/5365;;A61P11/12;;C07B59/00;;C07D471/14;;C07D498/14,,0,0,,,,ACTIVE
192,JO,A1,JO P20190042 A1,128-888-642-932-413,2019-03-11,2019,JO P20190042 A,2017-09-29,US 201662410353 P;;US 201662402838 P;;US 201662419935 P;;US 201662415409 P;;US 2017/0054611 W,2016-09-30,"Modulator of Cystic Fibrosis Transmembrane Conductance Regulator, Pharmaceutical Compositions, Methods of Treatment, and Process for Making the Modulator","<p>Compounds of Formula I: (I), pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed. Please check accompanying specification fro the full abstract.</p>",VERTEX PHARMA,ABELA ALEXANDER RUSSELL;;BAEK MINSON;;ZHANG BEILI;;UY JOHNNY;;ZHOU JINGLAN;;JOSHI PRAMOD VIRUPAX;;SIESEL DAVID ANDREW;;BUSCH BRETT BRADLEY;;GROOTENHUIS PETER;;VAN GOOR FREDRICK;;KESHAVARZ-SHOKRI ALI;;MELILLO VITO;;HUGHES ROBERT M;;ANDERSON COREY;;ALCACIO TIMOTHY;;PARASELLI PRASUNA;;KHATUYA HARIPADA;;FRIEMAN BRYAN A;;CLEVELAND THOMAS;;PIERRE FABRICE JEAN DENIS;;KRENITSKY PAUL JOHN;;MCCARTNEY JASON;;TERMIN ANDREAS P;;MCAULEY-AOKI RACHEL;;MILLER MARK THOMAS;;HADIDA RUAH SARA SABINA,,https://lens.org/128-888-642-932-413,Granted Patent,no,0,0,50,53,0,C07D471/14;;C07D498/14;;C07D401/14;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/12;;A61P43/00;;C07D401/14;;A61P11/00;;A61K31/4439;;A61P11/12;;A61K31/4439;;A61K31/519;;A61K31/5365;;C07B59/002;;C07D401/14;;C07D471/14;;C07D498/14;;C07B2200/05;;C07D471/14;;C07D498/14;;C07B59/002;;C07B2200/05;;C07D401/14,,,0,0,,,,ACTIVE
193,MA,A,MA 46357 A,152-709-462-256-490,2021-05-05,2021,MA 46357 A,2017-09-29,US 201662402838 P;;US 201662410353 P;;US 201662415409 P;;US 201662419935 P;;US 2017/0054611 W,2016-09-30,"MODULATEUR DE RÉGULATEUR DE CONDUCTANCE TRANSMEMBRANAIRE DE FIBROSE KYSTIQUE, COMPOSITIONS PHARMACEUTIQUES, PROCÉDÉS DE TRAITEMENT ET PROCÉDÉ DE FABRICATION DU MODULATEUR",,VERTEX PHARMA,ABELA ALEXANDER RUSSELL;;ALCACIO TIMOTHY;;ANDERSON COREY;;BAEK MINSON;;BUSCH BRETT BRADLEY;;CLEVELAND THOMAS;;FRIEMAN BRYAN A;;GROOTENHUIS PETER;;HADIDA RUAH SARA SABINA;;HUGHES ROBERT M;;JOSHI PRAMOD VIRUPAX;;KESHAVARZ-SHOKRI ALI;;KHATUYA HARIPADA;;KRENITSKY PAUL JOHN;;MCAULEY-AOKI RACHEL;;MCCARTNEY JASON;;MELILLO VITO;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE JEAN DENIS;;SIESEL DAVID ANDREW;;TERMIN ANDREAS P;;UY JOHNNY;;VAN GOOR FREDRICK;;ZHANG BEILI;;ZHOU JINGLAN,,https://lens.org/152-709-462-256-490,Unknown,no,0,0,50,53,0,C07D471/14;;C07D498/14;;C07D401/14;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/12;;A61P43/00;;C07D401/14;;A61P11/00;;A61K31/4439;;A61P11/12;;A61K31/4439;;A61K31/519;;A61K31/5365;;C07B59/002;;C07D401/14;;C07D471/14;;C07D498/14;;C07B2200/05;;C07D471/14;;C07D498/14;;C07B59/002;;C07B2200/05;;C07D401/14,A61K31/4439;;A61P11/12;;C07D401/14;;C07D471/14;;C07D498/14,,0,0,,,,ACTIVE
194,AR,A1,AR 109787 A1,001-371-834-524-88X,2019-01-23,2019,AR P170102750 A,2017-10-02,US 201662402838 P,2016-09-30,"MODULADOR DEL REGULADOR DE CONDUCTANCIA DE TRANSMEMBRANA DE FIBROSIS QUÍSTICA, COMPOSICIONES FARMACÉUTICAS, MÉTODOS DE TRATAMIENTO Y PROCESO PARA PRODUCIR EL MODULADOR","Reivindicación 1: Un compuesto de la fórmula (1), una sal farmacéuticamente aceptable de este o un derivado deuterado de cualquiera de los precedentes, en donde: uno de Y¹ e Y² es N y el otro es CH; X se elige de grupos O, NH y N(alquilo C₁₋₄); R¹ se elige de los grupos -(CR₂)ₖ-O-(CR₂)ₘ(CR)ₙ(Anillo A)ₙ₊₁, en donde cada Anillo A se elige independientemente de grupos cicloalquilo C₃₋₁₀ opcionalmente sustituidos con uno o más sustituyentes elegidos cada uno independientemente de grupos alquilo C₁₋₂, grupos alquilo C₁₋₂ halogenados y halógenos, y en donde cada R se elige independientemente de grupos H, OH y alquilo C₁₋₂ opcionalmente sustituidos con uno o más halógenos; cada R² se elige independientemente de grupos alquilo C₁₋₂, OH, grupos alcoxi C₁₋₂, halógenos y ciano; cada R³ se elige independientemente de grupos alquilo C₁₋₂ opcionalmente sustituidos con uno o más grupos OH; cada R⁴ se elige independientemente de halógenos; k es 0 ó 1; r es 0 ó 1; m es 0, 1, 2 ó 3; n es 0 ó 1; p es 0, 1, 2, 3, 4 ó 5; y q es 0, 1, 2, 3, 4, 5, 6, 7 u 8.",VERTEX PHARMA,SIESEL DAVID ANDREW;;BUSCH BRETT BRADLEY;;ABELA ALEXANDER RUSSELL;;UY JOHNNY;;PARASELLI PRASUNA;;ZHOU JINGLAN;;TERMIN ANDREAS P;;PIERRE FABRICE JEAN DENIS;;MELILLO VITO;;KRENITSKY PAUL JOHN;;JOSHI PRAMOD VIRUPAX;;KHATUYA HARIPADA;;FRIEMAN BRIAN A;;CLEVELAND THOMAS;;ANDERSON COREY;;ZHANG BEILI;;VAN GOOR FREDRICK;;MILLER MARK THOMAS;;MCARTNEY JASON;;MAULEY-AOKI RACHEL;;KESHAVARZ-SHOKRI ALI;;HUGHES ROBERT M;;HADIDA RUAH SARA SABINA;;GROOTENHUIS PETER;;BAEK MINSON;;ALCACIO TIMOTHY,,https://lens.org/001-371-834-524-88X,Patent Application,no,0,0,1,53,0,,C07D401/04;;A61P11/00;;C07D401/14;;C07D487/04,,0,0,,,,PENDING
195,CO,A2,CO 2019004065 A2,024-953-391-102-243,2019-04-30,2019,CO 2019004065 A,2019-04-24,US 2017/0054611 W;;US 201662402838 P;;US 201662410353 P;;US 201662415409 P;;US 201662419935 P,2016-09-30,"Modulador del regulador de conductancia de transmembrana de fibrosis quística, composiciones farmacéuticas, métodos de tratamiento y proceso para producir el modulador","Compuestos de Fórmula I: sales farmacéuticamente aceptables de este, derivados deuterados de cualquiera de los precedentes y metabolitos de cualquiera de los precedentes se describen. También se describen composiciones farmacéuticas que los comprenden, métodos para tratar la fibrosis quística usándolos y métodos para producirlos.",VERTEX PHARMA,ALCACIO TIMOTHY;;BAEK MINSON;;GROOTENHUIS PETER;;HADIDA RUAH SARA SABINA;;HUGHES ROBERT M;;KESHAVARZ-SHOKRI ALI;;MCAULEY-AOKI RACHEL;;MCCARTNEY JASON;;MILLER MARK THOMAS;;VAN GOOR FREDRICK;;ZHANG BEILI;;ANDERSON COREY;;CLEVELAND THOMAS;;FRIEMAN BRYAN A;;KHATUYA HARIPADA;;JOSHI PRAMOD VIRUPAX;;KRENITSKY PAUL JOHN;;MELILLO VITO;;PIERRE FABRICE JEAN DENIS;;TERMIN ANDREAS P;;UY JOHNNY;;ZHOU JINGLAN;;ABELA ALEXANDER RUSSELL;;BUSCH BRETT BRADLEY;;PARASELLI PRASUNA;;SIESEL DAVID ANDREW,,https://lens.org/024-953-391-102-243,Patent Application,no,0,0,50,53,0,C07D471/14;;C07D498/14;;C07D401/14;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/12;;A61P43/00;;C07D401/14;;A61P11/00;;A61K31/4439;;A61P11/12;;A61K31/4439;;A61K31/519;;A61K31/5365;;C07B59/002;;C07D401/14;;C07D471/14;;C07D498/14;;C07B2200/05;;C07D471/14;;C07D498/14;;C07B59/002;;C07B2200/05;;C07D401/14,C07D401/14;;A61K31/4439;;A61P11/12;;C07D471/14;;C07D498/14,,0,0,,,,PENDING
196,DO,A,DO P2019000081 A,126-331-442-915-044,2019-07-15,2019,DO 2019000081 A,2019-03-28,US 201662402838 P;;US 201662410353 P;;US 201662415409 P;;US 201662419935 P,2016-09-30,"MODULADOR DEL REGULADOR DE CONDUCTANCIA DE TRANSMEMBRANA DE FIBROSIS QUÍSTICA, COMPOSICIONES FARMACÉUTICAS, MÉTODOS DE TRATAMIENTO Y PROCESO PARA PRODUCIR EL MODULADOR","Compuestos de Fórmula I: (I), sales farmacéuticamente aceptables de este, derivados deuterados de cualquiera de los precedentes y metabolitos de cualquiera de los precedentes se describen. También se describen composiciones farmacéuticas que los comprenden, métodos para tratar la fibrosis quística usándolos y métodos para producirlos.",VERTEX PHARMA,TIMOTHY ALCACIO;;MINSON BAEK;;PETER GROOTENHUIS;;SARA SABRINA HADIDA RUAH;;ROBERT M HUGHES;;ALI KESHAVARZ-SHOKRI;;RACHEL MCAULEY-AOKI;;JASON MCCARTNEY;;MARK THOMAS MILLER;;FREDRICK VAN GOOR;;BEILI ZHANG;;COREY ANDERSON;;THOMAS CLEVELAND;;BRYAN A FRIEMAN;;HARIPADA KHATUYA;;PRAMOD VIRUPAX JOSHI;;PAUL JOHN KRENITSKY;;VITO MELILLO;;FABRICE JEAN DENIS PIERRE;;ANDREAS P TERMIN;;JOHNNY UY;;JINGLAN ZHOU;;ALEXANDER RUSSELL ABELA;;BRETT BRADLEY BUSCH;;PRASUNA PARASELLI;;DAVID ANDREW SIESEL,,https://lens.org/126-331-442-915-044,Patent Application,no,0,0,50,53,0,C07D471/14;;C07D498/14;;C07D401/14;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/12;;A61P43/00;;C07D401/14;;A61P11/00;;A61K31/4439;;A61P11/12;;A61K31/4439;;A61K31/519;;A61K31/5365;;C07B59/002;;C07D401/14;;C07D471/14;;C07D498/14;;C07B2200/05;;C07D471/14;;C07D498/14;;C07B59/002;;C07B2200/05;;C07D401/14,A61K31/4439;;A61P11/12;;C07D401/14;;C07D471/14,,0,0,,,,PENDING
197,EP,B1,EP 3519401 B1,133-621-936-842-411,2021-09-29,2021,EP 17792230 A,2017-09-29,US 201662402838 P;;US 201662410353 P;;US 201662415409 P;;US 201662419935 P;;US 2017/0054611 W,2016-09-30,"MODULATOR OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR",,VERTEX PHARMA,ALCACIO TIMOTHY;;BAEK MINSON;;GROOTENHUIS PETER;;HADIDA RUAH SARA SABINA;;HUGHES ROBERT M;;KESHAVARZ-SHOKRI ALI;;MCAULEY-AOKI RACHEL;;MCCARTNEY JASON;;MILLER MARK THOMAS;;VAN GOOR FREDRICK;;ZHANG BEILI;;ANDERSON COREY;;CLEVELAND THOMAS;;FRIEMAN BRYAN A;;KHATUYA HARIPADA;;JOSHI PRAMOD VIRUPAX;;KRENITSKY PAUL JOHN;;MELILLO VITO;;PIERRE FABRICE JEAN DENIS;;TERMIN ANDREAS P;;UY JOHNNY;;ZHOU JINGLAN;;ABELA ALEXANDER RUSSELL;;BUSCH BRETT BRADLEY;;PARASELLI PRASUNA;;SIESEL DAVID ANDREW,,https://lens.org/133-621-936-842-411,Granted Patent,yes,1,0,50,53,0,C07D471/14;;C07D498/14;;C07D401/14;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/12;;A61P43/00;;C07D401/14;;A61P11/00;;A61K31/4439;;A61P11/12;;A61K31/4439;;A61K31/519;;A61K31/5365;;C07B59/002;;C07D401/14;;C07D471/14;;C07D498/14;;C07B2200/05;;C07D471/14;;C07D498/14;;C07B59/002;;C07B2200/05;;C07D401/14,C07D401/14;;A61K31/4439;;A61P11/12;;C07D471/14;;C07D498/14,,0,0,,,,ACTIVE
198,AU,B2,AU 2017/336156 B2,157-088-988-841-021,2021-10-21,2021,AU 2017/336156 A,2017-09-29,US 201662415409 P;;US 201662419935 P;;US 201662402838 P;;US 201662410353 P;;US 2017/0054611 W,2016-09-30,"Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator","Compounds of Formula (I), pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.",VERTEX PHARMA,ALCACIO TIMOTHY;;BAEK MINSON;;GROOTENHUIS PETER;;HADIDA RUAH SARA SABINA;;HUGHES ROBERT M;;KESHAVARZ-SHOKRI ALI;;MCAULEY-AOKI RACHEL;;MCCARTNEY JASON;;MILLER MARK THOMAS;;VAN GOOR FREDRICK;;ZHANG BEILI;;ANDERSON COREY;;CLEVELAND THOMAS;;FRIEMAN BRYAN A;;KHATUYA HARIPADA;;JOSHI PRAMOD VIRUPAX;;KRENITSKY PAUL JOHN;;MELILLO VITO;;PIERRE FABRICE JEAN DENIS;;TERMIN ANDREAS P;;UY JOHNNY;;ZHOU JINGLAN;;ABELA ALEXANDER RUSSELL;;BUSCH BRETT BRADLEY;;PARASELLI PRASUNA;;SIESEL DAVID ANDREW,,https://lens.org/157-088-988-841-021,Granted Patent,no,1,0,50,53,0,C07D471/14;;C07D498/14;;C07D401/14;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/12;;A61P43/00;;C07D401/14;;A61P11/00;;A61K31/4439;;A61P11/12;;A61K31/4439;;A61K31/519;;A61K31/5365;;C07B59/002;;C07D401/14;;C07D471/14;;C07D498/14;;C07B2200/05;;C07D471/14;;C07D498/14;;C07B59/002;;C07B2200/05;;C07D401/14,C07D401/14;;A61K31/4439;;A61P11/12;;C07D471/14;;C07D498/14,,0,0,,,,ACTIVE
199,KR,A,KR 20220139189 A,166-353-143-521-908,2022-10-14,2022,KR 20210045526 A,2021-04-07,KR 20210045526 A,2021-04-07,METHOD AND SYSTEM FOR PROVIDING SPEECH-TO-TEXT RECORDING GENERATED BASED ON INFORMATION AFTER SPEECH RECORDING,"The present disclosure relates to a method for providing a generated speech record based on the information after speech recording, performed by at least one computing device. The method for providing the speech record comprises: a step of receiving the information associated with the speech data after speech recording; a step of receiving a speech-to-text conversion request for the speech data; and a step of outputting the generated speech record, in response to the speech-to-text conversion request, based on at least one part of the speech included in the speech data and the information associated with the speech data received after the speech recording. Therefore, the present invention is capable of providing a text wherein the speech data is more accurately converted.",NAVER CORP;;LINE CORP,LEE SUMEE;;SHIN JIEUN;;JEONG YE LIM;;HWANG GILHWAN;;CHOI JONG PHIL;;JEON YUJIN;;KANG MYUNG HUN;;LEE JIN MYOUNG;;KIM DEOK SU;;CHOI JONGMIN;;KIM HYUNJIN;;SONG YEON SOO;;SOHN DAIGEUN;;LIM DAI HYUN;;BAEK SEOL KI;;LEE DONGYEOL;;AN GIBAEK;;YI JAEHONG;;CHOI JIN HYEON;;LEE CHAN KYU;;JANG JUNGHOON;;LEE BONG JIN;;HEO HEE SOO;;JUNG NAMKYU;;KWON YOUNGKI;;KIM GEONMIN;;JANG DONG HAN;;LEE PAUL,,https://lens.org/166-353-143-521-908,Patent Application,no,0,0,3,3,0,G06F16/68;;G10L15/26;;G10L17/00;;G10L15/26;;G10L17/00;;G06F16/686,G10L15/26;;G06F16/68;;G10L17/00,,0,0,,,,PENDING
200,HR,T1,HR P20211683 T1,009-349-452-300-178,2022-03-04,2022,HR P20211683 T,2017-09-29,US 201662402838 P;;US 201662410353 P;;US 201662415409 P;;US 201662419935 P;;EP 17792230 A;;US 2017/0054611 W,2016-09-30,"MODULATOR OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR",,VERTEX PHARMA,ALCACIO TIMOTHY;;BAEK MINSON;;GROOTENHUIS PETER;;HADIDA RUAH SARA SABINA;;HUGHES ROBERT M;;KESHAVARZ-SHOKRI ALI;;MCAULEY-AOKI RACHEL;;MCCARTNEY JASON;;MILLER MARK THOMAS;;VAN GOOR FREDRICK;;ZHANG BEILI;;ANDERSON COREY;;CLEVELAND THOMAS;;FRIEMAN BRYAN A;;KHATUYA HARIPADA;;JOSHI PRAMOD VIRUPAX;;KRENITSKY PAUL JOHN;;MELILLO VITO;;PIERRE FABRICE JEAN DENIS;;TERMIN ANDREAS P;;UY JOHNNY;;ZHOU JINGLAN;;ABELA ALEXANDER RUSSELL;;BUSCH BRETT BRADLEY;;PARASELLI PRASUNA;;SIESEL DAVID ANDREW,,https://lens.org/009-349-452-300-178,Granted Patent,no,0,0,50,53,0,C07D471/14;;C07D498/14;;C07D401/14;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/12;;A61P43/00;;C07D401/14;;A61P11/00;;A61K31/4439;;A61P11/12;;A61K31/4439;;A61K31/519;;A61K31/5365;;C07B59/002;;C07D401/14;;C07D471/14;;C07D498/14;;C07B2200/05;;C07D471/14;;C07D498/14;;C07B59/002;;C07B2200/05;;C07D401/14,C07D401/14;;A61K31/4439;;A61P11/12;;C07D471/14;;C07D498/14,,0,0,,,,ACTIVE
201,PL,T3,PL 3519401 T3,003-516-323-250-458,2022-01-31,2022,PL 17792230 T,2017-09-29,US 201662402838 P;;US 201662410353 P;;US 201662415409 P;;US 201662419935 P;;EP 17792230 A;;US 2017/0054611 W,2016-09-30,"MODULATOR OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR",,VERTEX PHARMA,ALCACIO TIMOTHY;;BAEK MINSON;;GROOTENHUIS PETER;;HADIDA RUAH SARA SABINA;;HUGHES ROBERT M;;KESHAVARZ-SHOKRI ALI;;MCAULEY-AOKI RACHEL;;MCCARTNEY JASON;;MILLER MARK THOMAS;;VAN GOOR FREDRICK;;ZHANG BEILI;;ANDERSON COREY;;CLEVELAND THOMAS;;FRIEMAN BRYAN A;;KHATUYA HARIPADA;;JOSHI PRAMOD VIRUPAX;;KRENITSKY PAUL JOHN;;MELILLO VITO;;PIERRE FABRICE JEAN DENIS;;TERMIN ANDREAS P;;UY JOHNNY;;ZHOU JINGLAN;;ABELA ALEXANDER RUSSELL;;BUSCH BRETT BRADLEY;;PARASELLI PRASUNA;;SIESEL DAVID ANDREW,,https://lens.org/003-516-323-250-458,Patent Application,no,0,0,50,53,0,C07D471/14;;C07D498/14;;C07D401/14;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/12;;A61P43/00;;C07D401/14;;A61P11/00;;A61K31/4439;;A61P11/12;;A61K31/4439;;A61K31/519;;A61K31/5365;;C07B59/002;;C07D401/14;;C07D471/14;;C07D498/14;;C07B2200/05;;C07D471/14;;C07D498/14;;C07B59/002;;C07B2200/05;;C07D401/14,C07D401/14;;A61K31/4439;;A61P11/12;;C07D471/14;;C07D498/14,,0,0,,,,PENDING
202,ZA,B,ZA 201902124 B,058-603-046-828-004,2022-11-30,2022,ZA 201902124 A,2019-04-04,US 201662402838 P;;US 201662410353 P;;US 201662415409 P;;US 201662419935 P;;US 2017/0054611 W,2016-09-30,"MODULATOR OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR",,VERTEX PHARMA,TIMOTHY ALCACIO;;MINSON BAEK;;PETER GROOTENHUIS;;SARA SABINA HADIDA RUAH;;ROBERT M HUGHES;;ALI KESHAVARZ-SHOKRI;;RACHEL MCAULEY-AOKI;;JASON MCCARTNEY;;MARK THOMAS MILLER;;FREDRICK VAN GOOR;;BEILI ZHANG;;COREY ANDERSON;;THOMAS CLEVELAND;;BRYAN A FRIEMAN;;HARIPADA KHATUYA;;PRAMOD VIRUPAX JOSHI;;PAUL JOHN KRENITSKY;;VITO MELILLO;;FABRICE JEAN DENIS PIERRE;;ANDREAS P TERMIN;;JOHNNY UY;;JINGLAN ZHOU;;ALEXANDER RUSSELL ABELA;;BRETT BRADLEY BUSCH;;PRASUNA PARASELLI;;DAVID ANDREW SIESEL,,https://lens.org/058-603-046-828-004,Granted Patent,no,0,0,50,53,0,C07D471/14;;C07D498/14;;C07D401/14;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/12;;A61P43/00;;C07D401/14;;A61P11/00;;A61K31/4439;;A61P11/12;;A61K31/4439;;A61K31/519;;A61K31/5365;;C07B59/002;;C07D401/14;;C07D471/14;;C07D498/14;;C07B2200/05;;C07D471/14;;C07D498/14;;C07B59/002;;C07B2200/05;;C07D401/14,,,0,0,,,,ACTIVE
203,SG,A,SG 10201913595Y A,059-917-636-663-172,2020-02-27,2020,SG 10201913595Y A,2017-09-29,US 201662402838 P;;US 201662410353 P;;US 201662415409 P;;US 201662419935 P,2016-09-30,"MODULATOR OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR",,VERTEX PHARMA,ALCACIO TIMOTHY;;BAEK MINSON;;GROOTENHUIS PETER;;HADIDA RUAH SARA SABINA;;HUGHES ROBERT M;;KESHAVARZ-SHOKRI ALI;;MCAULEY-AOKI RACHEL;;MCCARTNEY JASON;;MILLER MARK THOMAS;;VAN GOOR FREDRICK;;ZHANG BEILI;;ANDERSON COREY;;CLEVELAND THOMAS;;FRIEMAN BRYAN A;;KHATUYA HARIPADA;;JOSHI PRAMOD VIRUPAX;;KRENITSKY PAUL JOHN;;MELILLO VITO;;PIERRE FABRICE JEAN DENIS;;TERMIN ANDREAS P;;UY JOHNNY;;ZHOU JINGLAN;;ABELA ALEXANDER RUSSELL;;BUSCH BRETT BRADLEY;;PARASELLI PRASUNA;;SIESEL DAVID ANDREW,,https://lens.org/059-917-636-663-172,Unknown,no,0,0,50,53,0,C07D471/14;;C07D498/14;;C07D401/14;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/12;;A61P43/00;;C07D401/14;;A61P11/00;;A61K31/4439;;A61P11/12;;A61K31/4439;;A61K31/519;;A61K31/5365;;C07B59/002;;C07D401/14;;C07D471/14;;C07D498/14;;C07B2200/05;;C07D471/14;;C07D498/14;;C07B59/002;;C07B2200/05;;C07D401/14,,,0,0,,,,PENDING
204,CY,T1,CY 1124862 T1,122-704-194-668-534,2022-11-25,2022,CY 211101083 T,2021-12-09,US 201662402838 P;;US 201662410353 P;;US 201662415409 P;;US 201662419935 P;;US 2017/0054611 W,2016-09-30,"ΔΙΑΜΟΡΦΩΤΗΣ ΡΥΘΜΙΣΤΗ ΔΙΑΜΕΜΒΡΑΝΙΚΗΣ ΑΓΩΓΙΜΟΤΗΤΑΣ ΚΥΣΤΙΚΗΣ ΙΝΩΣΗΣ, ΦΑΡΜΑΚΕΥΤΙΚΕΣ ΣΥΝΘΕΣΕΙΣ, ΜΕΘΟΔΟΙ ΘΕΡΑΠΕΙΑΣ, ΚΑΙ ΔΙΕΡΓΑΣΙΑ ΓΙΑ ΚΑΤΑΣΚΕΥΗ ΤΟΥ ΔΙΑΜΟΡΦΩΤΗ","Αποκαλύπτονται οι ενώσεις του Τύπου (Ι), φαρμακευτικώς αποδεκτά άλατα αυτών, δευτεριωμένα παράγωγα οιουδήποτε από τα προαναφερθέντα, και μεταβολίτες οιουδήποτε από τα προαναφερθέντα. Επίσης αποκαλύπτονται φαρμακευτικές συνθέσεις που περιλαμβάνουν αυτές, μέθοδοι θεραπείας κυστικής ίνωσης χρησιμοποιώντας αυτές και μέθοδοι για κατασκευή αυτών.",VERTEX PHARMA,ALCACIO TIMOTHY;;BAEK MINSON;;GROOTENHUIS PETER;;HADIDA-RUAH SARA SABINA;;HUGHES ROBERT M;;KESHAVARZ-SHOKRI ALI;;MCAULEY-AOKI RACHEL;;MCCARTNEY JASON;;MILLER MARK THOMAS;;VAN GOOR FREDRICK;;ZHANG BEILI;;ANDERSON COREY;;CLEVELAND THOMAS;;FRIEMAN BRYAN A;;KHATUYA HARIPADA;;JOSHI PRAMOD VIRUPAX;;KRENITSKY PAUL JOHN;;MELILLO VITO;;PIERRE FABRICE JEAN DENIS;;TERMIN ANDREAS P;;UY JOHNNY;;ZHOU JINGLAN;;ABELA ALEXANDER RUSSELL;;BUSCH BRETT BRADLEY;;PARASELLI PRASUNA;;SIESEL DAVID ANDREW,,https://lens.org/122-704-194-668-534,Granted Patent,no,0,0,50,53,0,C07D471/14;;C07D498/14;;C07D401/14;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/12;;A61P43/00;;C07D401/14;;A61P11/00;;A61K31/4439;;A61P11/12;;A61K31/4439;;A61K31/519;;A61K31/5365;;C07B59/002;;C07D401/14;;C07D471/14;;C07D498/14;;C07B2200/05;;C07D471/14;;C07D498/14;;C07B59/002;;C07B2200/05;;C07D401/14,C07D401/14;;A61K31/4439;;A61P11/12;;C07D471/14;;C07D498/14,,0,0,,,,ACTIVE
205,UY,A,UY 37428 A,151-389-964-070-286,2018-05-31,2018,UY 37428 A,2017-10-02,US 201662402838 P;;US 201662410353 P;;US 201662415409 P;;US 201662419935 P,2016-09-30,"MODULADOR DEL REGULADOR DE CONDUCTANCIA DE TRANSMEMBRANA DE FIBROSIS QUÍSTICA, COMPOSICIONES FARMACÉUTICAS, MÉTODOS DE TRATAMIENTO Y PROCESO PARA PRODUCIR EL MODULADOR","Compuestos de Fórmula I: sales farmacéuticamente aceptables de este, derivados deuterados de cualquiera de los precedentes y metabolitos de cualquiera de los precedentes se describen. También se describen composiciones farmacéuticas que los comprenden, métodos para tratar la fibrosis quística usándolos y métodos para producirlos.",VERTEX PHARMA,ALCACIO TIMOTHY;;BAEK MINSON;;GROOTENHUIS PETER;;SARA SABINA HADIDA RUAH;;ALI KESHAVARZ-SHOKRI;;RACHEL MCAULEY-AOKI;;MCCARTNEY JASON;;FREDRICK VAN GOOR;;ZHANG BEILI;;ANDERSON COREY;;CLEVELAND THOMAS;;BRYAN A FRIEMAN;;KHATUYA HARIPADA;;PRAMOD VIRUPAX JOSHI;;PAUL JOHN KRENITSKY;;MELILLO VITO;;FABRICE JEAN DENIS PIERRE;;ANDREAS P TERMIN;;ZHOU JINGLAN;;MARK THOMAS MILLER;;JOHNNY U Y;;BRETT BRADLEY BUSCH;;DAVID ANDREW SIESEL;;ROBERT M HUGHES;;ALEXANDER RUSSELL ABELA;;PARASELLI PRASUNA,,https://lens.org/151-389-964-070-286,Patent Application,no,0,0,50,53,0,C07D471/14;;C07D498/14;;C07D401/14;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/12;;A61P43/00;;C07D401/14;;A61P11/00;;A61K31/4439;;A61P11/12;;A61K31/4439;;A61K31/519;;A61K31/5365;;C07B59/002;;C07D401/14;;C07D471/14;;C07D498/14;;C07B2200/05;;C07D471/14;;C07D498/14;;C07B59/002;;C07B2200/05;;C07D401/14,A61P1/16;;A61K31/404;;A61K31/4439;;A61K31/47;;A61K31/519;;A61K31/5365;;A61P1/18;;A61P11/00;;C07D215/54;;C07D215/56;;C07D401/04;;C07D401/14;;C07D405/12;;C07D471/04;;C07D471/14;;C07D498/04,,0,0,,,,PENDING
206,WO,A1,WO 2018/064632 A1,103-776-826-517-747,2018-04-05,2018,US 2017/0054611 W,2017-09-29,US 201662402838 P;;US 201662410353 P;;US 201662415409 P;;US 201662419935 P,2016-09-30,"MODULATOR OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR","Compounds of Formula (I), pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.",VERTEX PHARMA,ALCACIO TIMOTHY;;BAEK MINSON;;GROOTENHUIS PETER;;HADIDA RUAH SARA SABINA;;HUGHES ROBERT M;;KESHAVARZ-SHOKRI ALI;;MCAULEY-AOKI RACHEL;;MCCARTNEY JASON;;MILLER MARK THOMAS;;VAN GOOR FREDRICK;;ZHANG BEILI;;ANDRESON COREY;;CLEVELAND THOMAS;;FRIEMAN BRYAN A;;KHATUYA HARIPADA;;JOSHI PRAMOD VIRUPAX;;KRENITSKY PAUL JOHN;;MELILLO VITO;;PIERRE FABRICE JEAN DENIS;;TERMIN ANDREAS P;;UY JOHNNY;;ZHOU JINGLAN;;ABELA ALEXANDER RUSSELL;;BUSCH BRETT BRADLEY;;PARASELLI PRASUNA;;SIESEL DAVID ANDREW,,https://lens.org/103-776-826-517-747,Patent Application,yes,1,44,50,53,0,C07D471/14;;C07D498/14;;C07D401/14;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/12;;A61P43/00;;C07D401/14;;A61P11/00;;A61K31/4439;;A61P11/12;;A61K31/4439;;A61K31/519;;A61K31/5365;;C07B59/002;;C07D401/14;;C07D471/14;;C07D498/14;;C07B2200/05;;C07D471/14;;C07D498/14;;C07B59/002;;C07B2200/05;;C07D401/14,C07D401/14;;A61K31/4439;;A61P11/12;;C07D471/14;;C07D498/14,,0,0,,,,PENDING
207,CR,A,CR 20190211 A,178-542-137-241-617,2019-07-11,2019,CR 20190211 A,2017-09-29,US 201662402838 P;;US 201662410353 P;;US 201662415409 P;;US 2017/0054611 W,2016-09-30,"MODULATOR OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR","Compounds of Formula (I), pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.Compuestos de Fórmula I: sales farmacéuticamente aceptables de este, derivados deuterados de cualquiera de los precedentes y metabolitos de cualquiera de los precedentes se describen. También se describen composiciones farmacéuticas que los comprenden, métodos para tratar la fibrosis quística usándolos y métodos para producirlos.",VERTEX PHARMA,MCCARTNEY JASON;;ANDERSON COREY;;CLEVELAND THOMAS;;JOSHI PRAMOD VIRUPAX;;ZHOU JINGLAN;;BAEK MINSON;;FRIEMAN BRYAN A;;BUSCH BRETT BRADLEY;;SIESEL DAVID ANDREW;;KESHAVARZ-SHOKRI ALI;;MCAULEY-AOKI RACHEL;;VAN GOOR FREDRICK;;TERMIN ANDREAS P;;PARASELLI PRASUNA;;GROOTENHUIS PETER;;HUGHES ROBERT M;;ALCACIO TIMOTHY;;HADIDA RUAH SARA SABINA;;ZHANG BEILI;;KRENITSKY PAUL JOHN;;UY JOHNNY;;KHATUYA HARIPADA;;MELILLO VITO;;MILLER MARK THOMAS;;PIERRE FABRICE JEAN DENIS;;ABELA ALEXANDER RUSSELL,,https://lens.org/178-542-137-241-617,Patent Application,no,0,0,1,53,0,,C07D471/14;;A61K31/4439;;A61P11/12;;C07B59/00;;C07D401/14;;C07D498/14,,0,0,,,,PENDING
208,NZ,A,NZ 752486 A,013-352-930-743-873,2023-04-28,2023,NZ 75248617 A,2017-09-29,US 2017/0054611 W;;US 201662402838 P;;US 201662410353 P;;US 201662415409 P;;US 201662419935 P,2016-09-30,"Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator","Compounds of Formula (I), pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.",VERTEX PHARMA,ALCACIO TIMOTHY;;BAEK MINSON;;GROOTENHUIS PETER;;HADIDA RUAH SARA SABINA;;HUGHES ROBERT M;;KESHAVARZ-SHOKRI ALI;;MCAULEY-AOKI RACHEL;;MCCARTNEY JASON;;MILLER MARK THOMAS;;VAN GOOR FREDRICK;;ZHANG BEILI;;ANDERSON COREY;;CLEVELAND THOMAS;;FRIEMAN BRYAN A;;KHATUYA HARIPADA;;JOSHI PRAMOD VIRUPAX;;KRENITSKY PAUL JOHN;;MELILLO VITO;;PIERRE FABRICE JEAN DENIS;;TERMIN ANDREAS P;;UY JOHNNY;;ZHOU JINGLAN;;ABELA ALEXANDER RUSSELL;;BUSCH BRETT BRADLEY;;PARASELLI PRASUNA;;SIESEL DAVID ANDREW,,https://lens.org/013-352-930-743-873,Patent Application,no,0,0,50,53,0,C07D471/14;;C07D498/14;;C07D401/14;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/12;;A61P43/00;;C07D401/14;;A61P11/00;;A61K31/4439;;A61P11/12;;A61K31/4439;;A61K31/519;;A61K31/5365;;C07B59/002;;C07D401/14;;C07D471/14;;C07D498/14;;C07B2200/05;;C07D471/14;;C07D498/14;;C07B59/002;;C07B2200/05;;C07D401/14,C07D401/14;;A61K31/4439;;A61P11/12;;C07D471/14;;C07D498/14,,0,0,,,,PENDING
209,MX,A,MX 2019003620 A,026-040-042-990-832,2019-08-01,2019,MX 2019003620 A,2017-09-29,US 201662402838 P;;US 201662410353 P;;US 201662415409 P;;US 201662419935 P;;US 2017/0054611 W,2016-09-30,"MODULATOR OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR.","Compounds of Formula (I), pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.",VERTEX PHARMA,MARK THOMAS MILLER;;JINGLAN ZHOU;;JOHNNY UY;;BRYAN A FRIEMAN;;BEILI ZHANG;;DAVID ANDREW SIESEL;;JASON MCCARTNEY;;COREY ANDERSON;;ANDREAS P TERMIN;;FABRICE JEAN DENIS PIERRE;;ALI KESHAVARZ-SHOKRI;;PRASUNA PARASELLI;;THOMAS CLEVELAND;;HARIPADA KHATUYA;;PRAMOD VIRUPAX JOSHI;;PAUL JOHN KRENITSKY;;VITO MELILLO;;TIMOTHY ALCACIO;;MINSON BAEK;;PETER GROOTENHUIS;;SARA SABINA HADIDA RUAH;;ROBERT M HUGHES;;RACHEL MCAULEY-AOKI;;FREDRICK VAN GOOR;;ALEXANDER RUSSELL ABELA;;BRETT BRADLEY BUSCH,,https://lens.org/026-040-042-990-832,Patent Application,no,0,0,50,53,0,C07D471/14;;C07D498/14;;C07D401/14;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/12;;A61P43/00;;C07D401/14;;A61P11/00;;A61K31/4439;;A61P11/12;;A61K31/4439;;A61K31/519;;A61K31/5365;;C07B59/002;;C07D401/14;;C07D471/14;;C07D498/14;;C07B2200/05;;C07D471/14;;C07D498/14;;C07B59/002;;C07B2200/05;;C07D401/14,A61K31/4439;;A61P11/12;;C07D401/14;;C07D471/14;;C07D498/14,,0,0,,,,PENDING
210,TW,B,TW I766886 B,169-797-924-096-314,2022-06-11,2022,TW 106133964 A,2017-09-30,US 201662402838 P;;US 201662410353 P;;US 201662415409 P;;US 201662419935 P,2016-09-30,"Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator",,VERTEX PHARMA,ALCACIO TIMOTHY;;BAEK MINSON;;GROOTENHUIS PETER;;HADIDA RUAH SARA SABINA;;HUGHES ROBERT M;;KESHAVARZ-SHOKRI ALI;;MCAULEY-AOKI RACHEL;;MCCARTNEY JASON;;MILLER MARK THOMAS;;VAN GOOR FREDRICK;;ZHANG BEILI;;ANDERSON COREY;;CLEVELAND THOMAS;;FRIEMAN BRYAN A;;KHATUYA HARIPADA;;JOSHI PRAMOD VIRUPAX;;KRENITSKY PAUL JOHN;;MELILLO VITO;;PIERRE FABRICE JEAN DENIS;;TERMIN ANDREAS P;;UY JOHNNY;;ZHOU JINGLAN;;ABELA ALEXANDER RUSSELL;;BUSCH BRETT BRADLEY;;PARASELLI PRASUNA;;SIESEL DAVID ANDREW,,https://lens.org/169-797-924-096-314,Granted Patent,no,1,0,50,53,0,C07D471/14;;C07D498/14;;C07D401/14;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/12;;A61P43/00;;C07D401/14;;A61P11/00;;A61K31/4439;;A61P11/12;;A61K31/4439;;A61K31/519;;A61K31/5365;;C07B59/002;;C07D401/14;;C07D471/14;;C07D498/14;;C07B2200/05;;C07D471/14;;C07D498/14;;C07B59/002;;C07B2200/05;;C07D401/14,,,0,0,,,,ACTIVE
211,US,B2,US 10570115 B2,079-166-337-133-746,2020-02-25,2020,US 201715721390 A,2017-09-29,US 201715721390 A;;US 201662402838 P;;US 201662410353 P;;US 201662415409 P;;US 201662419935 P,2016-09-30,"Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator","Compounds of Formula I: pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.",VERTEX PHARMA,ALCACIO TIMOTHY;;BAEK MINSON;;GROOTENHUIS PETER;;HADIDA RUAH SARA SABINA;;HUGHES ROBERT M;;KESHAVARZ-SHOKRI ALI;;MCAULEY-AOKI RACHEL;;MCCARTNEY JASON;;MILLER MARK THOMAS;;VAN GOOR FREDRICK;;ZHANG BEILI;;ANDERSON COREY;;CLEVELAND THOMAS;;FRIEMAN BRYAN A;;KHATUYA HARIPADA;;JOSHI PRAMOD VIRUPAX;;KRENITSKY PAUL JOHN;;MELILLO VITO;;PIERRE FABRICE JEAN DENIS;;TERMIN ANDREAS P;;UY JOHNNY;;ZHOU JINGLAN;;ABELA ALEXANDER RUSSELL;;BUSCH BRETT BRADLEY;;PARASELLI PRASUNA;;SIESEL DAVID ANDREW,VERTEX PHARMACEUTICALS (SAN DIEGO) LLC (2017-10-02);;VERTEX PHARMACEUTICALS INCORPORATED (2017-09-29),https://lens.org/079-166-337-133-746,Granted Patent,yes,171,12,50,53,0,C07D471/14;;C07D498/14;;C07D401/14;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/12;;A61P43/00;;C07D401/14;;A61P11/00;;A61K31/4439;;A61P11/12;;A61K31/4439;;A61K31/519;;A61K31/5365;;C07B59/002;;C07D401/14;;C07D471/14;;C07D498/14;;C07B2200/05;;C07D471/14;;C07D498/14;;C07B59/002;;C07B2200/05;;C07D401/14,C07D401/14;;A61K31/4025;;A61K31/4155;;A61K31/455;;A61K31/465;;C07B59/00;;C07D471/14;;C07D498/14,,40,13,013-937-078-602-349;;096-312-557-325-378;;034-587-611-086-755;;078-417-508-507-333;;012-371-996-064-723;;103-052-069-575-996;;039-573-265-223-407;;064-116-226-667-307;;009-891-282-676-18X;;006-026-497-014-33X;;010-718-962-322-429;;061-669-166-608-882;;079-362-981-419-890,23394148;;10.1021/ol400049m;;10.1055/s-0035-1561339;;22104146;;10.1016/j.bmcl.2011.10.041;;10.1016/j.bmcl.2006.08.003;;16919947;;10.1016/j.bmcl.2003.10.049;;14698169;;10.1021/jo01296a034;;10.1021/jm0111346;;12061878;;24392786;;10.1517/13543776.2014.876412;;10.1039/b009154p;;10.1016/s1569-1993(16)30138-2;;25981758;;pmc4764353;;10.1056/nejmoa1409547;;10.1021/jm00070a012;;8410980;;10.1055/s-1999-3685,"Borhade, S.R. et al. (2013) “Synthesis of Novel Aryl and Heteroaryl Acyl Sulfonimidamides via Pd-Catalyzed Carbonylation Using a Nongaseous Precursor” Organic Lett, 15(5):1056-1059.;;Chen, Y. (Jan. 26, 2016) “N-Monoacylation of Sulfonimidamides” Synthesis, 48(7):1019-1028.;;Database Caplus, Accession No. 1965:51408. Abstract of French Patent No. FR M2868, filed Nov. 23, 1964, by Roussel-Uclaf [online]. Retrieved Jan. 6, 2017 (1 page).;;Database Caplus, Accession No. 1965:51409. Abstract of German Patent No. DE 1182243, filed Nov. 26, 1964, by Badische Anilin & Soda-Fabrik A.G. [online]. Retrieved Jan. 6, 2017 (2 pages).;;Database Pubchem, CID: 2545578. Compound Summary, T5339296. NIH, U.S. National Library of Medicine, National Center for Biotechnology Information; Modify Date: Jan. 16, 2016. [online]. Retrieved from https://pubchem.ncbi.nlm.nih.gov/compound/2545578, on Jan. 22, 2016 (9 pages).;;Database Pubchem, CID: 44419393. Compound Summary, CHEMBL374189. NIH, U.S. National Library of Medicine, National Center for Biotechnology Information; Modify Date: Jan. 16, 2016. [online]. Retrieved from https://pubchem.ncbi.nlm.nih.gov/compound/44419393, on Jan. 22, 2016 (11 pages).;;Database Pubchem, CID: 49774135. Compound Summary, SCHEMBL13395127. NIH, U.S. National Library of Medicine, National Center for Biotechnology Information; Modify Date: Jan. 16, 2016 [online]. Retrieved from https://pubchem.ncbi.nlm.nih.gov/compound/49774135, on Jan. 22, 2016 (10 pages).;;Database Pubchem, CID: 58132855. Compound Summary, SCHEMBL831192. Nih, U.S. National Library of Medicine, National Center for Biotechnology Information, PubChem Open Chemistry Database; Modify Date: Jan. 16, 2016 [online]. Retrieved from: https://pubchem.ncbi.nlm.nih.gov/compound/58132855, on Jan. 22, 2016 (10 pages).;;International Patent Application No. PCT/US2015/54316: International Search Report and Written Opinion, dated Feb. 5, 2016 (11 pages).;;International Patent Application No. PCT/US2017/025381: International Search Report and Written Opinion, dated Jun. 6, 2017 (11 pages).;;International Patent Application No. PCT/US2017/054611: International Search Report and Written Opinion, dated Jan. 3, 2018 (10 pages).;;International Patent Application No. PCT/US2017/065425: International Search Report and Written Opinion, dated Feb. 27, 2018 (10 pages).;;U.S. Appl. No. 15/836,627, filed Dec. 8, 2017, by Abela et al.;;Anilkumar, G.N. et al. (2011) “II. Novel HCV NS5B polymerase inhibitors: Discovery of indole C2 acyl sulfonamides” Biogranic & Medicinal Chemistry Letters, 22(1):713-717.;;Hopkins, C.R. et al. (2006) “Design and synthesis of novel N-sulfonyl-2-indole carboxamides as potent PPAR-gamma binding agents with potential application to the treatment of osteoporosis” Bioorganic & Medicinal Chemistry Letters, 16(21):5659-5663.;;International Patent Application No. PCT/US2018/036610: International Search Report and Written Opinion, dated Sep. 19, 2018 (9 pages).;;International Patent Application No. PCT/US2018/040427: International Search Report and Written Opinion, dated Oct. 9, 2018 (15 pages).;;International Patent Application No. PCT/US2018/042415: International Search Report and Written Opinion, dated Oct. 31, 2018 (12 pages).;;International Patent Application No. PCT/US2018/042486: International Search Report and Written Opinion, dated Nov. 7, 2018 (13 pages).;;International Patent Application No. PCT/US2018/044963: International Search Report and Written Opinion, dated Sep. 25, 2018 (15 pages).;;International Patent Application No. PCT/US2018/056772: International Search Report and Written Opinion, dated Jan. 29, 2019 (13 pages).;;Jain, B.C. et al. (1947) “Studies in Sulphanilamides. Part XIII. Reaction With Dicarboxylic Acids. Some NEWN1- and N4-Acyl and Heterocycic Derivatives” Journal of the Indian Chemical Society, 24:173-176.;;Kettle, J.G. et al. (2004) “N-Benzylindole-2-carboxylic acids: potent functional antagonists of the CCR2b chemokine receptor” Bioorganic & Medicinal Chemistry Letters, 14(2): 405-408.;;Lai, J.T. et al. (1980) “Rearrangement of 2,2,6,6-tetramethyl-4-piperidone in phase-transfer catalyzed reactions,” Journal of Organic Chemistry, 45(8):1513-1514.;;Matter, H. et al. (2002) “Design and Quantitative Structure-Activity Relationship of 3-Amidinobenzyl-1H-indole-2-carboxamides as Potent, Nonchiral, and Selective Inhibitors of Blood Coagulation Factor Xa” Journal of Medicinal Chemistry, 45(13):2749-2769.;;Norman, P. (2014) “Novel picolinamide-based cystic fibrosis transmembrane regulator modulators: evaluation of WO2013038373, WO2013038376, WO2013038381, WO2013038386, and WO2013038390,” Expert Opinion on Therapeutic Patents, 24(7):829-837.;;Passarella, D. et al. (2001) “Cyclodimerization of indol-2-ylacetylenes. An example of intermolecular enyne-alkyne cycloaddition” Journal of the Chemical Society, Perkin Transactions 1, 127-129.;;Rosebraugh, C.J. (2015) “Highlights of Presecribing Information for Orkambi,” [online] Retrieved from the Internet: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206038Orig1s000lbl.pdf, on Aug. 24, 2017.;;Silverman, R. (2004) The Organic Chemistry of Drug Design and Drug Action, Elsevier, pp. 29-32.;;Soloducho, J. (1989) “Synthesis of Some Pyrido [2,3-c][1,2,6]triazinone Derivatives” Journal far Pracktische Chemie, 331(3):503-506.;;Tullis, E. et al. (2018) “Preliminary safety and efficacy of triple-combination CFTR modulator regimens,” Respirology, 23(51):33.;;U.S. Appl. No. 16/258,024, filed Jan. 25, 2019, by Miller et al.;;U.S. Appl. No. 16/165,849, filed Oct. 19, 2018, by Dhamankar et al.;;U.S. Appl. No. 16/267,222, filed Feb. 4, 2019, by Chu et al.;;U.S. Appl. No. 16/267,350, filed Feb. 14, 2019, by Clemens et al.;;Uttamsingh, V. et al. (2016) “WS13.6 CTP-656 tablet confirmed superiority of pharmacokinetic profile relative to Kalydeco in Phase I clinical studies” Journal of Cystic Fibrosis, 15:S22.;;Wainwright, C.E. et al. (2015) “Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR,” The New England Journal of Medicine, 373(3):220-231.;;Winn, M. et al. (1993) “2-(Alkylamino)nicotinic Acid and Analogs. Potent Angiotensin II Antagonists” Journal of Medicinal Chemistry, 36(18):2676-2688.;;Vertex Pharmaceuticals, Inc. (Mar. 28, 2017) “Two Phase 3 Studies of the Tezacaftor/Ivacaftor Combination Treatment Met Primary Endpoints with Statistically Significant Improvements in Lung Function (FEV1) in People With Cystic Fibrosis” [online] Retrieved from the Internet: http://investors.vrtx.com/static-files/f15217ac-4a8b-436a-9215-79144ec2e59b, on Oct. 10, 2019.;;Verardo, G. et al. (1999) “Reductive One Batch Synthesis of N-Substituted Pyrrolidines from Primary Amines and 2,5-Dimethoxytetrahydrofuran” Synthesis, (1):74-79.",ACTIVE
212,JO,B1,JO P20190042 B1,105-917-340-931-04X,2021-08-17,2021,JO P20190042 A,2017-09-29,US 201662410353 P;;US 201662402838 P;;US 201662419935 P;;US 201662415409 P;;US 2017/0054611 W,2016-09-30,"Modulator of Cystic Fibrosis Transmembrane Conductance Regulator, Pharmaceutical Compositions, Methods of Treatment, and Process for Making the Modulator","Compounds of Formula I: (I), pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed. Please check accompanying specification fro the full abstract.",VERTEX PHARMA,ABELA ALEXANDER RUSSELL;;ANDERSON COREY;;ALCACIO TIMOTHY;;PARASELLI PRASUNA;;BAEK MINSON;;BUSCH BRETT BRADLEY;;PIERRE FABRICE JEAN DENIS;;ZHANG BEILI;;ZHOU JINGLAN;;TERMIN ANDREAS P;;GROOTENHUIS PETER;;JOSHI PRAMOD VIRUPAX;;KHATUYA HARIPADA;;SIESEL DAVID ANDREW;;VAN GOOR FREDRICK;;FRIEMAN BRYAN A;;KRENITSKY PAUL JOHN;;CLEVELAND THOMAS;;KESHAVARZ-SHOKRI ALI;;MCCARTNEY JASON;;MCAULEY-AOKI RACHEL;;MILLER MARK THOMAS;;MELILLO VITO;;HADIDA RUAH SARA SABINA;;HUGHES ROBERT M;;UY JOHNNY,,https://lens.org/105-917-340-931-04X,Granted Patent,no,0,0,50,53,0,C07D471/14;;C07D498/14;;C07D401/14;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/12;;A61P43/00;;C07D401/14;;A61P11/00;;A61K31/4439;;A61P11/12;;A61K31/4439;;A61K31/519;;A61K31/5365;;C07B59/002;;C07D401/14;;C07D471/14;;C07D498/14;;C07B2200/05;;C07D471/14;;C07D498/14;;C07B59/002;;C07B2200/05;;C07D401/14,C07D401/14;;A61K31/4439;;A61P11/12;;C07D471/14;;C07D498/14,,0,0,,,,ACTIVE
213,EC,A,EC SP19028690 A,165-130-127-385-200,2019-05-31,2019,EC DI201928690 A,2019-04-24,US 201662402838 P;;US 201662410353 P;;US 201662415409 P;;US 201662419935 P;;US 2017/0054611 W,2016-09-30,"MODULADOR DEL REGULADOR DE CONDUCTANCIA DE TRANSMEMBRANA DE FIBROSIS QUÍSTICA, COMPOSICIONES FARMACÉUTICAS, Y PROCESO PARA PRODUCIR EL MODULADOR","Compuestos de Fórmula I: (VER LA FORMULA EN LA DESCRIPCION) (I), sales farmacéuticamente aceptables de este, derivados deuterados de cualquiera de los precedentes y metabolitos de cualquiera de los precedentes se describen. También se describen composiciones farmacéuticas que los comprenden, métodos para tratar la fibrosis quística usándolos y métodos para producirlos.",VERTEX PHARMA,THOMAS CLEVELAND;;ROBERT M HUGHES;;SARA SABINA HADIDA RUAH;;RACHEL MCAULEY-AOKI;;HARIPADA KHATUYA;;TIMOTHY ALCACIO;;ALEXANDER RUSSELL ABELA;;JASON MCCARTNEY;;BEILI ZHANG;;MINSON BAEK;;JINGLAN ZHOU;;COREY ANDERSON;;JOHNNY UY;;BRETT BRADLEY BUSCH;;PRAMOD VIRUPAX JOSHI;;PAUL JOHN KRENITSKY;;VITO MELILLO;;FREDRICK VAN GOOR;;PRASUNA PARASELLI;;BRYAN A FRIEMAN;;DAVID ANDREW SIESEL;;ANDREAS P TERMIN;;PETER GROOTENHUIS;;ALI KESHAVARZ-SHOKRI;;MARK THOMAS MILLER;;FABRICE JEAN DENIS PIERRE,,https://lens.org/165-130-127-385-200,Patent Application,no,0,2,50,53,0,C07D471/14;;C07D498/14;;C07D401/14;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/12;;A61P43/00;;C07D401/14;;A61P11/00;;A61K31/4439;;A61P11/12;;A61K31/4439;;A61K31/519;;A61K31/5365;;C07B59/002;;C07D401/14;;C07D471/14;;C07D498/14;;C07B2200/05;;C07D471/14;;C07D498/14;;C07B59/002;;C07B2200/05;;C07D401/14,A61K31/4439;;A61P11/12;;C07D401/14,,0,0,,,,PENDING
214,US,A1,US 2018/0093969 A1,088-421-476-582-463,2018-04-05,2018,US 201715721390 A,2017-09-29,US 201715721390 A;;US 201662402838 P;;US 201662410353 P;;US 201662415409 P;;US 201662419935 P,2016-09-30,"Modulator of Cystic Fibrosis Transmembrane Conductance Regulator, Pharmaceutical Compositions, Methods of Treatment, and Process for Making the Modulator","Compounds of Formula I: pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.",VERTEX PHARMA,ALCACIO TIMOTHY;;BAEK MINSON;;GROOTENHUIS PETER;;HADIDA RUAH SARA SABINA;;HUGHES ROBERT M;;KESHAVARZ-SHOKRI ALI;;MCAULEY-AOKI RACHEL;;MCCARTNEY JASON;;MILLER MARK THOMAS;;VAN GOOR FREDRICK;;ZHANG BEILI;;ANDERSON COREY;;CLEVELAND THOMAS;;FRIEMAN BRYAN A;;KHATUYA HARIPADA;;JOSHI PRAMOD VIRUPAX;;KRENITSKY PAUL JOHN;;MELILLO VITO;;PIERRE FABRICE JEAN DENIS;;TERMIN ANDREAS P;;UY JOHNNY;;ZHOU JINGLAN;;ABELA ALEXANDER RUSSELL;;BUSCH BRETT BRADLEY;;PARASELLI PRASUNA;;SIESEL DAVID ANDREW,VERTEX PHARMACEUTICALS (SAN DIEGO) LLC (2017-10-02);;VERTEX PHARMACEUTICALS INCORPORATED (2017-09-29),https://lens.org/088-421-476-582-463,Patent Application,yes,0,7,50,53,0,C07D471/14;;C07D498/14;;C07D401/14;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/12;;A61P43/00;;C07D401/14;;A61P11/00;;A61K31/4439;;A61P11/12;;A61K31/4439;;A61K31/519;;A61K31/5365;;C07B59/002;;C07D401/14;;C07D471/14;;C07D498/14;;C07B2200/05;;C07D471/14;;C07D498/14;;C07B59/002;;C07B2200/05;;C07D401/14,C07D401/14;;C07B59/00,,0,0,,,,ACTIVE
215,MD,T2,MD 3519401 T2,093-473-125-767-736,2022-02-28,2022,MD E20190875 T,2017-09-29,US 201662402838 P;;US 201662410353 P;;US 201662415409 P;;US 201662419935 P;;US 2017/0054611 W,2016-09-30,"Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator","Compuşii cu Formula I:sărurile acceptabile farmaceutic ale acestora, derivaţii deuteraţi ai oricărora dintre cei anteriori, şi metaboliţii oricărora dintre cei anteriori sunt divulgaţi. Compoziţiile farmaceutice care-i cuprind pe aceştia, metodele de tratare a fibrozei chistice utilizȃndu-i pe aceştia, şi metodele pentru fabricarea acestora sunt de asemenea divulgate.",VERTEX PHARMA,ALCACIO TIMOTHY;;BAEK MINSON;;GROOTENHUIS PETER;;HADIDA RUAH SARA SABINA;;HUGHES ROBERT M;;KESHAVARZ-SHOKRI ALI;;MCAULEY-AOKI RACHEL;;MCCARTNEY JASON;;MILLER MARK THOMAS;;VAN GOOR FREDRICK;;ZHANG BEILI;;ANDERSON COREY;;CLEVELAND THOMAS;;FRIEMAN BRYAN A;;KHATUYA HARIPADA;;JOSHI PRAMOD VIRUPAX;;KRENITSKY PAUL JOHN;;MELILLO VITO;;PIERRE FABRICE JEAN DENIS;;TERMIN ANDREAS P;;UY JOHNNY;;ZHOU JINGLAN;;ABELA ALEXANDER RUSSELL;;BUSCH BRETT BRADLEY;;PARASELLI PRASUNA;;SIESEL DAVID ANDREW,,https://lens.org/093-473-125-767-736,Unknown,no,0,0,50,53,0,C07D471/14;;C07D498/14;;C07D401/14;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/12;;A61P43/00;;C07D401/14;;A61P11/00;;A61K31/4439;;A61P11/12;;A61K31/4439;;A61K31/519;;A61K31/5365;;C07B59/002;;C07D401/14;;C07D471/14;;C07D498/14;;C07B2200/05;;C07D471/14;;C07D498/14;;C07B59/002;;C07B2200/05;;C07D401/14,C07D401/14;;A61K31/4439;;A61P11/12;;C07D471/14;;C07D498/14,,0,0,,,,PENDING
216,SI,T1,SI 3519401 T1,111-912-836-148-344,2022-01-31,2022,SI 201731014 T,2017-09-29,US 201662402838 P;;US 201662410353 P;;US 201662415409 P;;US 201662419935 P;;US 2017/0054611 W;;EP 17792230 A,2016-09-30,"MODULATOR OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR",,VERTEX PHARMA,ALCACIO TIMOTHY;;BAEK MINSON;;GROOTENHUIS PETER;;HADIDA RUAH SARA SABINA;;HUGHES ROBERT M;;KESHAVARZ-SHOKRI ALI;;MCAULEY-AOKI RACHEL;;MCCARTNEY JASON;;MILLER MARK THOMAS;;VAN GOOR FREDRICK;;ZHANG BEILI;;ANDERSON COREY;;CLEVELAND THOMAS;;FRIEMAN BRYAN A;;KHATUYA HARIPADA;;JOSHI PRAMOD VIRUPAX;;KRENITSKY PAUL JOHN;;MELILLO VITO;;PIERRE FABRICE JEAN DENIS;;TERMIN ANDREAS P;;UY JOHNNY;;ZHOU JINGLAN;;ABELA ALEXANDER RUSSELL;;BUSCH BRETT BRADLEY;;PARASELLI PRASUNA;;SIESEL DAVID ANDREW,,https://lens.org/111-912-836-148-344,Granted Patent,no,0,0,50,53,0,C07D471/14;;C07D498/14;;C07D401/14;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/12;;A61P43/00;;C07D401/14;;A61P11/00;;A61K31/4439;;A61P11/12;;A61K31/4439;;A61K31/519;;A61K31/5365;;C07B59/002;;C07D401/14;;C07D471/14;;C07D498/14;;C07B2200/05;;C07D471/14;;C07D498/14;;C07B59/002;;C07B2200/05;;C07D401/14,C07D401/00;;A61K31/00;;A61P11/00;;C07D471/00;;C07D498/00,,0,0,,,,ACTIVE
217,CL,A1,CL 2019000827 A1,140-518-511-967-524,2019-08-09,2019,CL 2019000827 A,2019-03-28,US 201662402838 P;;US 201662410353 P;;US 201662415409 P;;US 201662419935 P,2016-09-30,"Modulador del regulador de conductancia de transmembrana de fibrosis quística, composiciones farmacéuticas, métodos de tratamiento y proceso para producir el modulador.","COMPUESTOS DE FÓRMULA I, SALES FARMACÉUTICAMENTE ACEPTABLES DE ESTE, DERIVADOS DEUTERADOS DE CUALQUIERA DE LOS PRECEDENTES Y METABOLITOS DE CUALQUIERA DE LOS PRECEDENTES SE DESCRIBEN. TAMBIÉN SE DESCRIBEN COMPOSICIONES FARMACÉUTICAS QUE LOS COMPRENDEN, MÉTODOS PARA TRATAR LA FIBROSIS QUÍSTICA USÁNDOLOS Y MÉTODOS PARA PRODUCIRLOS.",VERTEX PHARMA,MILLER MARK THOMAS;;ANDERSON COREY;;CLEVELAND THOMAS;;FRIEMAN BRYAN A;;KHATUYA HARIPADA;;JOSHI PRAMOD VIRUPAX;;KRENITSKY PAUL JOHN;;MELILLO VITO;;MCCARTNEY JASON;;PIERRE FABRICE JEAN DENIS;;TERMIN ANDREAS P;;UY JOHNNY;;ZHOU JINGLAN;;ALCACIO TIMOTHY;;BAEK MINSON;;GROOTENHUIS PETER;;HADIDA RUAH SARA SABINA;;HUGHES ROBERT M;;KESHAVARZ-SHOKRI ALI;;MCAULEY-AOKI RACHEL;;VAN GOOR FREDRICK;;ZHANG BEILI;;ABELA ALEXANDER RUSSELL;;BUSCH BRETT BRADLEY;;PARASELLI PRASUNA;;SIESEL DAVID ANDREW,,https://lens.org/140-518-511-967-524,Patent Application,no,0,0,50,53,0,C07D471/14;;C07D498/14;;C07D401/14;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/12;;A61P43/00;;C07D401/14;;A61P11/00;;A61K31/4439;;A61P11/12;;A61K31/4439;;A61K31/519;;A61K31/5365;;C07B59/002;;C07D401/14;;C07D471/14;;C07D498/14;;C07B2200/05;;C07D471/14;;C07D498/14;;C07B59/002;;C07B2200/05;;C07D401/14,A61K31/4439;;A61P11/12;;C07D401/14;;C07D471/14;;C07D498/14,,0,0,,,,PENDING
